var title_f36_49_37648="Tetracaine: Pediatric drug information";
var content_f36_49_37648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetracaine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/18/13603?source=see_link\">",
"       Tetracaine (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/8/43138?source=see_link\">",
"       Tetracaine (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/31/2547?source=see_link\">",
"       Tetracaine (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12828 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37648=[""].join("\n");
var outline_f36_49_37648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/18/13603?source=related_link\">",
"      Tetracaine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/8/43138?source=related_link\">",
"      Tetracaine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/31/2547?source=related_link\">",
"      Tetracaine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_49_37649="Rosacea erythema";
var content_f36_49_37649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema and telangiectasias are present on the nose, chin, and cheeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37649=[""].join("\n");
var outline_f36_49_37649=null;
var title_f36_49_37650="Prednisolone (ophthalmic): Pediatric drug information";
var content_f36_49_37650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prednisolone (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?30/0/30723?source=see_link\">",
"    see \"Prednisolone (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/13/43220?source=see_link\">",
"    see \"Prednisolone (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9505541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Omnipred&trade;;",
"     </li>",
"     <li>",
"      Pred Forte&reg;;",
"     </li>",
"     <li>",
"      Pred Mild&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9505548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diopred&reg;;",
"     </li>",
"     <li>",
"      Ophtho-Tate&reg;;",
"     </li>",
"     <li>",
"      Pred Forte&reg;;",
"     </li>",
"     <li>",
"      Pred Mild&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10507854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10507859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/0/30723?source=see_link\">",
"      see \"Prednisolone (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Ophthalmic suspension: Instill 1-2 drops into conjunctival sac every hour during the day and every 2 hours at night until favorable response is obtained, then use 1 drop every 4 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9506894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as sodium phosphate [drops]: 1% (5 mL [DSC], 10 mL, 15 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic, as acetate [drops]: 1% (5 mL, 10 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnipred&trade;: 1% (5 mL, 10 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pred Forte&reg;: 1% (1 mL, 5 mL, 10 mL, 15 mL) [contains benzalkonium chloride, sodium bisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pred Mild&reg;: 0.12% (5 mL, 10 mL) [contains benzalkonium chloride, sodium bisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9505550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10507860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake suspension well before use; instill drops into affected eye(s); avoid contact of container tip with skin or eye; apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10507855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of palpebral and bulbar conjunctivitis; corneal injury from chemical, radiation, thermal burns, or foreign body penetration",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9505496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       PrednisoLONE may be confused with predniSONE",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9505604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ocular: Conjunctival hyperemia, conjunctivitis, corneal ulcers, delayed wound healing, glaucoma, intraocular pressure increased, keratitis, loss of accommodation, optic nerve damage, mydriasis, posterior subcapsular cataract formation, ptosis, secondary ocular infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10507856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to prednisolone or any component; viral diseases of the cornea and conjunctiva (eg, acute superficial herpes simplex keratitis); mycobacterial or fungal infections of the eye",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10892704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Corticosteroids should not be used in active ocular herpes simplex.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10507857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunosuppression may occur; patients may be more susceptible to infection. Suspension may contain sodium bisulfite which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9505606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9505607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9505561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9505562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ophthalmic prednisolone was shown to be teratogenic in animal studies The amount of prednisolone available systemically following topical application of the ophthalmic drops is not known; refer to the PrednisoLONE, Systemic monograph for additional information.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16044 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-218.7.204.202-34378B5ED4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37650=[""].join("\n");
var outline_f36_49_37650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505541\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505548\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507854\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507859\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9506894\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505550\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507860\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507855\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505496\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505604\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507856\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10892704\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507857\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505606\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505607\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505561\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505562\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16044\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16044|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/0/30723?source=related_link\">",
"      Prednisolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/13/43220?source=related_link\">",
"      Prednisolone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40376?source=related_link\">",
"      Prednisolone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/12/29894?source=related_link\">",
"      Prednisolone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/54/1896?source=related_link\">",
"      Prednisolone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_49_37651="Pyogenic granuloma lip";
var content_f36_49_37651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma of the lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37651=[""].join("\n");
var outline_f36_49_37651=null;
var title_f36_49_37652="Eflornithine: Drug information";
var content_f36_49_37652=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Eflornithine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/14/1252?source=see_link\">",
"    see \"Eflornithine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vaniqa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3011945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vaniqa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F164459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiprotozoal;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F164445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Unwanted facial hair (females):",
"     </b>",
"     Topical: Apply thin layer of cream to affected areas of face and areas under the chin twice daily, at least 8 hours apart.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of infections caused by",
"     </b>",
"     <i>",
"      Trypanosoma brucei gambiense",
"     </i>",
"     <b>",
"      infection (sleeping sickness; unlabeled use):",
"     </b>",
"     I.V. infusion: 100 mg/kg/dose given every 6 hours for 14 days (Kappagoda, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F164454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Unwanted facial hair (females):",
"     </b>",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F164446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F164447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection: Dose should be adjusted although no specific guidelines are available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vaniqa&reg;: 13.9% (30 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F15837501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injectable eflornithine is donated to World Health Organization (WHO) by the manufacturer. Further information may be found on WHO website at file://www.who.int/trypanosomiasis_african/diagnosis/en/index.html or by contacting the CDC Drug Service (404-639-3670).",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F164428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: For external use only. Rub in thoroughly. Hair removal techniques must still be continued; wait at least 5 minutes after removing hair to apply cream. Do not wash affected area for at least 8 hours following application. Makeup and sunscreen may be used over treated area(s) after cream has dried.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Administered I.V. only; dilute prior to use and infuse over 45-120 minutes. Not for I.M. administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F164427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce unwanted hair from face and adjacent areas under the chin",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F15837502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Injection: Treatment of meningoencephalitic stage of",
"     <i>",
"      Trypanosoma brucei gambiense",
"     </i>",
"     infection (sleeping sickness).",
"     <b>",
"      Note:",
"     </b>",
"     Eflornithine has specific activity against",
"     <i>",
"      T.b. gambiense",
"     </i>",
"     in early and late stages (not effective for",
"     <i>",
"      T.b. rhodesiense",
"     </i>",
"     ).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F164466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vaniqa&reg; may be confused with Viagra&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F164457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection (Priotto, 2009):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia (22%), hypertension (13%), chest pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (46%), fever (43%), dizziness (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (19%), rash (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (30%), diarrhea (29%), nausea (20%), vomiting (20%), anorexia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia/arthralgia (30%), weakness (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (2% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (4%), hypotension/shock (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (10%), seizure (9%), anxiety (8%), coma (2%), amnesia (1%), ataxia (1%), confusion (1%), depression (1%), hallucination (1%), lethargy (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dysphagia (9%), xerostomia (5%), constipation (4%), taste disturbance (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary frequency/urgency (4%), urinary incontinence (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (9%), leukopenia (4%), thrombocytopenia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Extravasation (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (1% to 4%), tremor (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Inner ear disturbance (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Bilirubin altered (5%), ALT altered (3%), creatinine altered (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (10%), epistaxis (2%), dyspnea (1%), respiratory distress (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hiccups (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Topical:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Dermatologic: Acne (11% to 21%), pseudofolliculitis barbae (5% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (4%), dizziness (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Stinging (4% to 8%), burning skin (4%), pruritus (3% to 4%), tingling skin (2% to 4%), dry skin (2% to 3%), rash (2% to 3%), erythema (1% to 3%), alopecia (1% to 2%), skin irritation (1% to 2%), folliculitis (&le;1%), ingrown hair (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (2% to 3%), anorexia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Bleeding skin, cheilitis, contact dermatitis, facial edema, herpes simplex, lip swelling, nausea, numbness, rosacea, vertigo, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F164431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to eflornithine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F164415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cream: For topical use by females only; discontinue if hypersensitivity occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: For I.V. use only; not for I.M. administration. Must be diluted before use; frequent monitoring for myelosuppression should be done; use with caution in patients with a history of seizures and in patients with renal impairment; serial audiograms should be obtained; due to the potential for relapse, patients should be followed up for at least 24 months.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered topically, teratogenic effects were not observed in animal reproduction studies. Discontinuation or not initiating therapy should be considered since information related to topical use in pregnancy is limited.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F164450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F164433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Vaniqa External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     13.9% (30 g): $106.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F164424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with platelet counts",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F164435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Vaniqa (AU, BE, CZ, DE, ES, FR, GB, IE, IL, IT, NL, NZ, PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F164414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Eflornithine inhibits the enzyme ornithine decarboxylase (ODC) which inhibits cell division and synthetic functions and thereby affects the rate of hair growth.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Eflornithine exerts antitumor and antiprotozoal effects through specific, irreversible (&ldquo;suicide&rdquo;) inhibition of the enzyme ornithine decarboxylase (ODC). ODC is the rate-limiting enzyme in the biosynthesis of putrescine, spermine, and spermidine, the major polyamines in nucleated cells. Polyamines are necessary for the synthesis of DNA, RNA, and proteins and are, therefore, necessary for cell growth and differentiation. Although many microorganisms and higher plants are able to produce polyamines from alternate biochemical pathways, all mammalian cells depend on ornithine decarboxylase to produce polyamines. Eflornithine inhibits ODC and rapidly depletes animal cells of putrescine and spermidine; the concentration of spermine remains the same or may even increase. Rapidly dividing cells appear to be most susceptible to the effects of eflornithine.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F164430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Decreased hair growth: 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: &lt;1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: 3-3.5 hours; Topical: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1993, 35(911):111-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37652/abstract-text/8246830/pubmed\" id=\"8246830\" target=\"_blank\">",
"        8246830",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haegele KD, Alken RG, Grove J, et al, &ldquo;Kinetics of &alpha;-Difluoromethylornithine: An Irreversible Inhibitor of Ornithine Decarboxylase,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1981, 30(2):210-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37652/abstract-text/6788425/pubmed\" id=\"6788425\" target=\"_blank\">",
"        6788425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kappagoda S, Singh U, and Blackburn BG, \"Antiparasitic Therapy,\"",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2011, 86(6):561-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37652/abstract-text/21628620/pubmed\" id=\"21628620\" target=\"_blank\">",
"        21628620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lapidoth M, Dierickx C, Lanigan S, et al, \"Best Practice Options for Hair Removal in Patients With Unwanted Facial Hair Using Combination Therapy With Laser: Guidelines Drawn Up by an Expert Working Group,\"",
"      <i>",
"       Dermatology",
"      </i>",
"      , 2010, 221(1):34-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37652/abstract-text/20587996/pubmed\" id=\"20587996\" target=\"_blank\">",
"        20587996",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Priotto G, Kasparian S, Mutombo W, et al, \"Nifurtimox-Eflornithine Combination Therapy for Second-Stage African",
"      <i>",
"       Trypanosoma brucei gambiense",
"      </i>",
"      Trypanosomiasis: A Multicenter, Randomized, Phase III, Non-Inferiority Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9683):56-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37652/abstract-text/19559476/pubmed\" id=\"19559476\" target=\"_blank\">",
"        19559476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steverding D, \"The Development of Drugs for Treatment of Sleeping Sickness: A Historical Review,\"",
"      <i>",
"       Parasit Vectors",
"      </i>",
"      , 2010, 3(1):15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37652/abstract-text/20219092/pubmed\" id=\"20219092\" target=\"_blank\">",
"        20219092",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9404 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37652=[""].join("\n");
var outline_f36_49_37652=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164442\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3011945\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164459\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164445\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164454\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164446\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164447\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164426\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164411\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837501\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164428\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164427\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837502\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164466\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164457\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164431\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164415\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299255\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164420\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164422\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164434\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164450\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164433\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164424\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164435\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164414\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164430\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9404\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9404|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/14/1252?source=related_link\">",
"      Eflornithine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_49_37653="Rosacea in dark skin";
var content_f36_49_37653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Papulopustular rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDRWF2m2yRSdPlO3OMnv7VNHbOsitNAsaBtrozYBHvjmty3nguopTEGUM370feZU7bRTdttPcC3laW4DtwQfLKEDg1zcqO3nexi2+ntLNKVcoi53RZwcexqeCyWJ0khtYnD9HmOSCfT6VoW/nRswnikmMJONpAZkH97PUU13W9jhaCJoreQ7gJm4BJ4x7UWQXbZWulmuEGT5zYwAmdy0gsEuEgW1VA/3ZHwRtPr6itYiWwu2DRW80hXCTQnaM9Mk1NLapErypL5qOuHQdUccg561XKQ59jCtLYxyyJI/mSnJaMkgNj0PpVu3Fmly0q6c7QMByi8xn1GfetGLUFt7fyNTFud8W77RsG+QemexFRi88yNLezu2FpKQUV1ww9ceoNUoroEpMddXtr5zDUg8cgQmPZH88gPTA7026SEWS3MSLHchVaPy48gkjo/bNWjZMieZbXdo9ygLjzPuxJ7ntVmJILtgl9uhPkb4G5IZvX8TVJGTaKunS/8truzQTSDbEy425zzx/WsqXTLuWWScXbRQyz7I4tuDJ/e+gFXJ5LmGz+zvPDHJB8kkhXJ5P3R6GkurhdPaaW2uWYRIoIYBgqf7PuTRcFdbdRbry0+0TrFBHHakqHUfec4+QY/nWfqd81paT35aJbq5ARLXHK++KravqkH2eeCVmdo9vlKh2jf1LMKzUubexuob++82a8kZnETHhF7frUuVtjSMOrGXcUm9IUM9zqd0BnzWyEQ+/p7UmpXNxKkNhYBFiiwXZADznjLdxmpJrqCJY1JmDyyGSa4AwxGOij09KgUtPIy28DW1kjBjvOCQPVqzZvDuxsrGEC3tZgZpv8AWyYPyAf7VS2+yG3guDGDCA2xWBxKf7x9ear28U/kI6KWWdiSOmVHb3rXm+0aldIjxpEIxtCKPlhXuTUt6FpEGnW883llJG+0SA4XZ/BjnFdFY6Wkkduk+I1ckpk44H8TVW0rT2uL8RWLNM4baGHQ+/0rtrCwXTIm80mW7zhy4+VMn7o9TSir6sKk1HRFW9vFW3t9M0uX5iAs06qV2e3vWvJaixsEfZHNsUrvGPmyPU96ltdKtrbTHlmWEzSZ2Fvvkdse9Zk9uy28ck0TSSrIXIZ/kQenua0sc909F0KdrA/2NA0TZJzMeOQDz+AqppsqTXs3mNCy2wPk4I2jPcn2rduGezitpJRD83OC+AFPRSBXHXVuLa9lR1BaUMBtOQrE8fQc1ElZXNab5rmlcTNPbQLMBHLknn+Lvuz3zTZZkFndFyTJNFiMnB596gtxO0MVisYeWEl1ZuuB1HvUc0ctxFcSqNkaLlwQOBnGfz9KnXc0SWzM0RgSQkK7seiqvb1FUld5rpIoEHzNjB65q5MrmFCGw4U7MdcZ7VmIxjYNnaUP3h3rI6N00StAyXF7G0uYosjcBwTV6W3WPRkmyVkwoAA6knnP4VTEKLYwTRSs0zylXXGR7VYmuZJkKTvuCHoOMHFUrLcTu2UGnVGixksOckfKtEQ33RZCdrHjAxnNV7wCOMNksRy/p+NP0YiSeJWLb2cc9QPSs0m3Y0eiuam8s4QKNsfX3x1qyABuabzDbn5QwP3e4FUrmAQvKsq4MbESKDja1RGTZAySDPO4EHjOKewlrsXpXV8NsHHyg+1QOxDRoh245z6VJEw+zByFZicDJ6/hUSEZOMFx0yP50ikXNMvHsrzzojglSh3DP1qKRyNz7gWPbNRsCFwBkEckdSagaRhuBHNF9AVm7luKVQCXXKH09asTXAdUEfyjHQelZ0ErJgcAZB9cVeYxPt8p8ux+fcMYPtTWopKzHec7t8rY45/wpzOET5UZWHOe/uKdaoLmSRigyn8I4H5U4RqrxrOfLU87wM5H0p2JvZkGZlCp5Z2ucg45xWtr1jFp01l+8d96qGHQgEZqC4O4YVH64VmPWp9M+zjzBes01zGAU3c9O3NawRlKXUufZbc2trbyXF0wBLxrGcbfw7Gu00OwstNsRcW8jtLGu1snqT2IrkbW5hGqxzOBtjc4Cjhs+9aVrql3NJNlMKc8xfeA/rW8Zo5KkJS0udFuQrIkkssvmt82E4z6A1BcaDIwZ7G4MUmMYLZP0zWFBdNAogS7WV1OERHIyeuTWnFqd7feXCY1R1ycK+CxHvT5kzNwlHYpahDcXVmJZIgskR2lkOctXLNLJHdM7gMOn4+9dTc3CwQsX82FmbDBuQT71zFwY3cEAiNqyqI6aPU055o59NjkBLMjZdSfu+gHtWReOkq7zkkcfQUiKzTsgcLkevFUrokMT0fnOO9Q27XNIxs9CC7iDAFXy4/hrGlcK3lnO/PWteS5ZTD5sYynGcdRWHqgU3nmRZ27s4pPVG0d7MjLkOQWzg4p8gDJll474pkm4KG4IJ4oJYoynKtRZDlsAcC0ZM4KkMKyjL5TkyDcprTkjIjOAG4wTWLc8OFOM5xT6GSjchnjSZmZPkOM47Z9qzbuEggNkE+orQKhw6d16e9VL+CYRRyuGw4wjHkGmjOSsc3qUYQKIwT2bjqawpWbLgDBxgiuluRtLZyT0OayZ5o4oJI2tY2dhhZeQQM+laR1MppowpNjQFJEJbqCP60VauCu8yQRgKAAVzn8aK1RzuKPo9lZbxmWMwuynep4ycZJFdDaQLqelB7kCKQR5W4x9xscKB1rNhmuIdMRbmKKSHPltIxyVHpjr3qutjJFqUdtFOTE5J++VHTisL2N2r6GnZ+a6yNBNG1xHHidpBgqp4/KqU1jJcwSi1jUyW6BiDn5x9K044obnR5ZoUSK4iyv3vmkI7H1qLzbySES2z/ZZEAErMMhmI7GrVmZ3a2KVzMIYIWkSJ3lIwM8qR/CR71bCl5klaGERzHaVIx5Z7e9QahGtz5N0gWC6SXaQfvhh6+uaiSb/SvtY/eblAMfO4P6/hTvrYLaXLkGnq0snnBJlQjbFJ1LHqM+tXNSs5boJNbaaIhgIyZA8oDuD61nxX06yGe8JaEZjtygGHb+LPfNWYroSQStlor6WTEVq5yAOm9s/XNWmjOSle5UeKO9uw8KC1aDCmOU8zAdFI7nNXJ5r2e+trW4HlWyjzp5EADRgfw57CqU8ONTkxcqWsxv3ysCsr46g+lMsrm4uLfVS9zDFZbw105X55DjovtST11Kaurks6wTalbNpdu72kBeRvNbcZn7ZP8AjWRdaiI792bynkRjPLCi5Td2DH0HpTiiul3NH5v2rpAI/uKpHJb0qA3SWtlDb20MLXly4O1BkkZ4yfwNS31KUehSnlnjP2V4CkZxc3MhXBGemfQe1Miha51SMWdqmMFFlmGcnqSaZLLqM11O0Uo815DJKWGQMevrirYh1DT7WERsiyTKcP13Kc5NTuzW1l5kEdtNcao0Sot4YDh5M4APt7Ulza3MhImmWVEjJKK21QM96m0rT5pFWKLMZbBDBvvD6dPep7e2S8ubhDORbwnLMVJMhB5zUFrcXT0eKAGJYZHkQorNk+Sp64HrWtaW2LMWdgWUyLm4kIxtH93nqadbyf2nqK3HlLBZxqxVFAyV9TXQ6QIJTHfTE29nGCdh++//ANc9qLCu47lywsYrayKrGYbS3i8y4lH8bY4UVc0Ca51i8W6nRVtrZh8rDHy/T1rSt4mu7DyzCILKR96qxy2OOtWRbrJFdPYXBt1ZiWyMdOD+Fa8pzOd733IJ0F9dNIyiC3WTYWfGSe2Pasu6unthLE6IbQZDSbiQD2P0rbhWWKz+1Bizk7dzHBP+0O34VkeIFnvrO4VSIgigqDgs56kDHA47U2hL4rPYx5wb+2W4iQtEmVV4wDvIHBqjqVnD/YcTOxNwiliiZBDHufXmpNF06W1t1RmLORvPlnhe/J9ah1CWBltbZZGYMAzSE8sM/cxUPVG8dJaFWy48mMhvOZSY3zzuJxgD261BNeu9nNDKRiMjATAJ55z61p39lFDfQQwyGQ/KQx4IXHJ/pWLe24VWdRhWyV2jO7npnt61lJNG8ZRkypbAtOvl+Yjh+4zgVFrNusV1kbhEW25x1psbTRSsdxLEg7s/pW3LfRXdhFbTsAyg8DpnHU1C1TuattNNHPwlgSkbDg7qcwby22At8pLHvU0ZCuiuF2ngMB2qsm4XjxxsSuSOmc4rM080Ubo5XaoOWxWpYW8SWTXcNwsc0LrmMg5+v07VSvgJp2cKy5wMVMkTeVHvCkIDiReePQ1cdGKeqViW5nlnneW4yZJjufJ60w487arFlAzzUSggHPp0FPhIYLvBLHtUNlrQsQx+duO7a5OQD39qUR8EKGAzg59agBKPsAxIvTBqZArK0jEZHT5sFjRuHqNl/dxsFb5ieuaTy28rziwxgbjQYtkhSfI9CvSo2TCspyTjoKLDTXQLTfcMyxqSQOo549asqW8nKOhb7wIOfwqrpNy9ncBkwdysuOgPHerGmLDCZftBUyMpK8Zw1VFKyJk3qya2mlif923zdct71o2FxGk6SXSCfaCAGOAvpVCGMlHZB+7OA5POKmWNTEfnLKDtGOpFCRLsy47uGURsAyPuyORntUqGeOS4luNjtMgVnYdM96rxTMlnIiou48Fm7Y9D60XDsLaISNvVh0PGKt6IztqSadci3kMWAx+6Gc5X64rQ3W8FwIBcNMx6iM4BHpVGXT/sdpFcvKpDAMsanJFbGh+Hpbq3OpufLijy6fLksauEWRNwSu3oX9MsZvNfKGR0UlOmUX60+8+YRmGJ5gPv7Dhgfb0p7Ti1lTYk/LDzJJVCqPYVel1ZYLWaS0cQ+Y2cBNwPrtreySscjk7mJdXkjbBfIXOdpJrGnfdlFcBN2FBrQa7k84SPG88G/wCZWIBf8e1Zl1/x8yAx+Wu7oT0FYyR0QdiKGQxzBXCllOQc1C+2SVpmwR0I+tF5GPMIBB44wapyv5Y4IyOvPX2qTZK+qGToB8quCCeCe1ULyE7DwCRzkelSSyhlBPHpioDcYcEqSMEHnrQjRJopgF1C5yMcCpbeLeH+Zdy/wk8mp5I0EJlQgAjBXPNVQjBQc4x0NJ7hLVBIMHBLAjsB/OsG/Ro7lX5KA966CaeS4xuXJRcFgOoqheeXKGXnkcHpVGUW0ZLLiVpEI2nnircd0rae9ndLuty4kQDgg9wD2qBUMY+vFMkTzICufxPaiLswqRUjHuol88oE3ICcBj2+tYN3b5zhwcfpXSOQ2AeHAwazJpjE7CMrtkG1srmqRjJHLTnaW+XD9D9KKnv1ClxjDdz7UVomYuOp9P2QinkuVXrFk7H9+9V57c/bUuUP7thtTdnarj3qzeqkSpexQqk+S2/JIYY4GKhSZjoRRnZCAJPKx0yf4R6+9R5D8yJJo/t8kd6DGFCsXPABI7U+yMkWo3KxjfH5Ymg3tgJzycGpxKmoW8m5ljghPmCMjJLDjLHtVK1vbaS0iS4BN5K5EsknZewHtilcbu7ok1Fyb+RWZVupSolkYZRc/wAQPoKRrs6FbT2VuZLiWQ4jl8vG5e7etNtLb+1LhrSObyLZl27v4Tg8Ln1q3qurS3SCAKpnsz5cbqPv+p+lWk7XJlb4StI8Et1BHbQ+QsOJnRiWBYc4J7E1Rul1PxJdNdQQbFkl2FshSUHVanuJG0mzk0+0nae3uWDyu3DYzzimahfRaWDBYblR3ChMkhB/ER7mmGvQZqUtnY5kgjEgi/dqhOQTjGc98Gm3WotDFHbS2i+SY9uAhwzHGXI68VVnjH2i3FxDiGQBvs5HAx0yfU9aW1uTbPc308LERg+Uc5IOMcH0pXuUopFe7vJbhY7G0UW0b4RpOckep9aJJpLe0ldJIwFPkQlQBz3bPUim2UF7eXAMA+zB13Akj92nc1A8tnLqjypA7W9ouFjY5Xd059eam5XL0C1ikt7YwGUKXBw7L82OpI+tSwpcapqTyX8kiKIwBtbAVfT8qc8Fzd3qSzDYgQJHGDgrn0HatSSxRfIVsSXAz5hzkFvf6UivPqU44oppmlijmjtYh5cUkbHLn+nFbWnWXmwqAvl2rZdkBwcL6n3p+i2cqrcKubpouUhXoSep9K2xYzNKn2kIgd1Cshyq4/hHrjvT5epLl0K1jpyhY7qRlXzvl8pRkxoO5FaCWyv9nllZpraJi0aoRgY7sO+ats1vH58Zl23Kx7Qqjg9qu6PA0UEkaIGaRNpjYAEDsc9qaj0M3NrVj2ummlU/vEZuZgo5Rc8AVrMhuh5hikWAAbUXgsc9fpWbpiSwaqftMsUUoBCxlCcr35q5qWsGC9gtPljikAPmr0GD+gq1ojGSu9BLy3F4bcvDIVjHzRh+OvX3xWVq1k3l72lEbvIIvLXkMx/i9AOlbd1MVjllmki/dAhmJwHU9QMe1c497ptzc3EdxJNFpvlluCcM317U3YS5tzKERgNwmxYyOMI/cdQF9T2qte6hYi5gu0h8lgvlYnHdeTjHT0p/iVHiimm2PHIUSODad2D1BLDvjjFU0uYboLcTfvLxohGxwFUL3OKl6G8dbMhmlifUknh3NJLkKGBwGz2P0qK1y2mRSCEKVkMZZpO47D0yDStYS3SH7NcS4hDGNSw655I9qy7aW3NsIJSwcsCwUEbMH9TWMtGbpXH7WjgELqiuJCUbqdpPQ/SiSEJGzLtBQF/p7Cornfa6kzQkeWpyGY57U4zrMWDhfMwFwR2xWba2NknpYRoXLRkfOxXDIByDVaMyW1xFcWxGSfTIH1q0Y9zKdp2nJDdCT3pkv7smHfgf8s2PHBGamxfNbQp3kuL5ioUENng5Ge+ParFvMczJj7wGCvG01UmCTKDFnKdR6D61LpfL/Kx80ZAPZvShasH8Ish+ZgRhhwCKaZd0aA5ITJHbmiQMpaOSMpICGUn0pjPgHBG4noO4pMaYNNlApwSOhHWiO4VSVACs3I39jVW4L+QWjXKg4JrPadklQknaTQVa5vQSbs78suQSPWpJCdwkHU9B6CoRtFur9GlXAVTyv1qJZm37CAF7t6U2rEpk5G7IIGW6c1KEC4ycEDgjv9ahZsgAYJ9e1KzleDnaO1Iou2rlFdVLgt1x/WpVk2MoDLgjv0qrATKryblRkGMdM1JiKW13ZbzV+UADgCmk2KSsWo2AclQDsGQWHyn6VMhmunE0dq0gjHzbTkfU+lQXlzbQizjgkaY+X8/ybQpPb3q7Y3dxDG8FqxhW6PlttXOcjpVxWtmQ3pdF3RLGXUDLEYlZEHKhuTXXalc7NFgs7JvKYIobjBx3zXPeGh/Z8NzDCz/bJMoHJACD60kXnaleeRaZT+F13kg+pOfWt4+6rdTlqJzlfojSNz9n09zdypMAVC5OTk9/wrAvrotcbi6nzOMHgY+lauq2CWYlS4yJFIAwcCsC/DSy/O21UGHZQDge1KV9ioRT1IptUYR7DKGAJGwDG3FVxevIv7zBx0zVLVY1M4GlLcT2yEK0rAAhj7dxVMOdxVmZmHTtWclJHRGMbaGtDKkskhdgAoyKr3LLklxtPYY61QVmV949ceuKuRuXmVJRgN3A/lQiuWxTvw0cKlB154qu0rOg3rgdgBVyUGNSjjPzZAPUU2V1kbCRbQewpNpFXsVlXcwG8DOPmPapE2suCc9s0rIFhyM5Pao4sOQ3YcAdOaDOWoSI0fKccfhWRLKBNjGFYZIPatO/ZyctkkenBrLvrcs/zDB7YNPoKIxQNpBOR1+lRDCZDdGFLsBTazEbu1PeJVA6sen0oFIz54wxLJyBWNqEKKm7seoA5rpvL+TjscfjWZe7BG+4bfU4qjNnI3UIkBZup4ye47UVbuIiTgDKDoxoqkzJxuz6Nu0k/fxAhTKctjkIOox71lXJlkt45I1KLC2WIPzdMACrxQz6fK6kh3fYIx3weuahtrkRw3cMyBZ434RhzxSb1El2I9HfyLG6tn+YRgucjl89AfaqVvBF5MsU07LtXBYDOQTxV67jZHiliZhNMuHXOd469KqzSxS2uAWWZirAkYGc8/yoRT7l8hvNgtiHMCkNKqDChQOCPqaz2IFkb7YfLDmBI92CB3qxqVyzfbZvOMczKhK54LZxjH61UltwdPVFVMyyfeLZbdjkgVVyLFAB/sjxhWdmZVR2/iA5OPatWWMxS/aj5P2meMJDGDlR/tH0OBUk2psuiJAqq+xDbgjAJ5/T61UsYY/s9xdXsaLFE4Zctypxxx3pqyDV6sgUTpM93dmOQbi2wH5s46D2rPMwn8ma5/doW4jA4HfAFaMd6buEzRhVW4dmmkVcsqjv7Z9Kgjt2lIcK846JJIMKp+n0qW+xaXRlW9AmknnmJ3zKCu5uUUdBxVi1tEtIYkCMxIEr4HIYjgH271eFvA+oGa4wtqqAFxyMjsKu6bGiWN/cyxuQBzg/wnpS0bB7Fe2gmsY/MU77yRdyZ5ZWPfHtWnbaLcwWluSgF5dggITx/vE+9WvDscd8f7Qe12tZ25wD0bP8Rz/nip7G/nBlmnXfGEKxKw/I5p6bkXldpBZW/wDZ8KW8RUGJhJLIOhPb8B0rY09/tENr5GfMYfuzxgFm5PPFc34cmFxcvBdOyTyAqFmO1VXr+NdfDHP9itbd7eJlLNhguNg9QRVR1JqaMyjpVy00zWqPLJIzASMR0XrW7o812sx+0gueAylMMxA469hTSZYpm8ja8YTaEBztJ7n0pTeXOGhvGd3iZdsYx+8/EU0kjNycka0FhMl+s7T7tqYG8DIz1rKuUh/tp5JU835SkYbjkd/wpFle5njf97bxPwY3O4jHoe1TpdhYZJGQSJGQqAr/AB92Hrx3pt3ErozLi1DhjdwzBwd6lT09/f6VoPJb20Swrguy/caPIYnoWB71HqciX/2NoWkJUFnY/eU9RntVcWDXkhuLqUF872IPK9gB70a9B+phh7mRrq3ys8QVvKMjhAhB5YL3PpWTPC1xfBzCss5Xenlp8gboF/Kt8WVtfWmoQQJHEYskyMcys3oo/rVCFpbPTLeKB0BbORIPnTJzuPvUt33NV5blKf7JFZxXVm7Q3CS7JrcklgfQCsnV7Z/t73SxrubD7SNu0N3wKv67FFLercBnSWQj94sZQZA6j1rPS8LXUyToXlf5S0h5AxisZO+jN4LqiKAHyQJOVk6tjgHvUTpvc5wSflXBxSRTPbykR4IddrA+3GRTriIIg2NjoWwucHsaztoa3swZ3jgWNwNoOUweVx/OoLidZ02S/Pg/KSOQaazyRhi0eO24jpVGa6PJKjcD6UmWtR8hZZEKLnb1PTJp92iBFYHY7dVHP40yC9DAIXBxwOcfhSGREDNuIkBxjsRTSuTJ6jriSWR97kF9o5HpSooKYXJbuf61RvGjFyvlM5j29+vNSWV2YpSxUFSMFc5yKElfUbemg+ZAuVyCQe3Q1SkUHCjAx2qV5PMcsnAznHpTchpckfWhopFi1uSGB6MOmegqdG81SOMjJz61nsweQAEYU84qYzIj4GeBjmkFi1vwwHBxUplTerAggfwNWPLdCKVCThc80xL5ZbpggOwtnJppXLUWb7DDFZBtPenIS8RG/aqjoO9ZiTq9wpd34PXNSi4DEjf+ND0WgtTSOCijoQeSeuK1kuJPNicBmTOQw4yR39q5oTEHdknoOtbDyC3YbJlZ8DhDkLVoiUTYF0IpJHwrTMmV5ztNWdHlukZRCcSO2N3cGucid5HAILDqQOK1LB2UH51XzTwSeaqLuRKNkaF7bTxyhb+Uu7NyN2T7mprqRbmdLa0iRbWJcHjLH1J9adbwwiLbuLzOQCzPgY+tWraxKyrJbNEgRSzN5nSrStsYOQrHTVtHtYYl3vt2FhhkYfxVjah4YltJjsu4pmkBIYY5B7VbvIkaVSkrGZlJ4YEVLJb3lvb/AG28VjtxGu1RgD3962vdakxfJqmcHaiW0uZUYbWPHNWLe6ESGKdFaNm3K/cH0HtXWXNrFP5jyweYHj/duvHI9ax7TSoNQF0PtAikiGQjHgn0HvWLj2OmNZSWpl6hJbvhoVZCp6k5zVaaM7gU6fWmzQyrM8DqVdTgqeMGnoojhQ/dB4+Y96y3NGrDCSG2k8GlaNo8GMAZPANPCCYf6wAjgrinqQjKJB8o9KLEsZOAcPxkjBHpVG4VQnPPvnpV24hDlw+47DkdsismdwAVUEEdRRqSlcqug8xgWymKijk+fa7YLe1E0u3Axx60iKS6k4OOhzTTKktBU3fNgZqlqKsUAIG3tVu5kAdXX6EVWuw0gyckYpmbRiXYwd+0ADqKKkuUXyuT35NFO5nY94Z40u4YowFG04OcDjPWo/sIurG7nzlXXPmMcfMOOPb3qjPcxrJOs65kkHyk8bc/yq5LZGHSYVFwCruVMbNyo9R7UXIa2MW1kaKSzZyZJNxEiu/yqMVan2FwsYwNwyDycnkAVCiCO31CEqDKjqd3cg+lKkSyTyq8uXi2FSx6juP6UlpoaSV3cqSLPK12djMg5O4YYDtVnZcXkyyhVWGKMyMXPyq5HUVNqUxj0zzWUo91gIq9EAPert08NhbiC2USS3cIG3qqZ68Vat1MnfoYtvayyJAyk+RFkytHgscnk0pVNTtbxISFgU5DMeXPQfjVkSC2H2OAvvZSjbupz6/hS2cEFlOLdyEhGHwRkkVL8i9ba/IqxRSLphsoiiozDzAo5Az3PrWh/ZUt60EUcfk21qnPzf6xh/Eafp1tNdanJMrFLc/LGGHUeppVuWjjura2diJMp5ueN2cUA229CGaDzbW0tIWJhb940YPVj/KtaWwNpKtjJIsjTqrFIz8oHYGiza0gifYGYwKsbgc7ufXtV9IfNupJ2LK7KFUA9B2A/CqSREmNjhMM8trCytGGG6Fedwzzz2rUuobdrd5bchGicKkD9VzWHqKS2tqIoUVZpMfMqkkt/St6NI3EK3D7bhFEhDcblHqe5zTiyJLqU9Ojjy11PGZp4gwAKg5PpWlY3d0LNJiVULkKg+Vc4xTY7pLi7MESou7AKrztHcmpLjZv2RIBCCCiO/HoeP1pol6vUjkb7JC80rPEjAKu1sk/UVOvkn5HuUSNQDMyZJkPYVbktluvsltHFIPmJeRl+Ugdqke0iikZkwsUHyAMOWb2HpVWIcl1EspI9kpm+WzAWOEsMsc9eff0pwt9kIksw0yINgWVOcE/w1HbOEKQSMGkwSIgAQuB1x689aWW6aWYRkKXhUhtgwBnsKNhWuynqOq3NrNPb2kVutsTtViuee/PfvVWK8lguBNLGZSigKoT5VAP3/qas/YIIkR50EhkcqGL8DnPI7UQ2UEFvJPdSbi8+0fN8p9D6/hSaZd422MURG0klnV8XPmlkdfnPIzz71lXVw0ULlWuHWQDex4JPpn1rTuXkfUp8zvHbRD5THGBkHgnHbPNNupolht7cRF7ZP3iIAASM9WPf2rN6my+8zL2b+0YtlxcxpEnCRKmWzjue1YGqWb203mK33l24jPPGDnNbdxcwzTxedA6QkExRQ4Dn6tWNdbHszi4ljljOfLUfcTtk+tZvVam0NHoZ+JfJbcih1O7kdVPuaR5g0i+c208Ehe9S3MMeI/NmnZ/lxnnAqnJjLDAOSTuHBqbM0vcb9oOHDkuQTksazpmY5ONyjt0qcIxDR4Y87gB1qtKGbBU5xwx7UrNj5iJmELMyL1HRh096db3rQAiSPzY5Fw2RwPQ5qGU4kdXQZ7HPApqLKgdCcxsB07itIxJk7j7i42llxlwep7CmySqIRIrENu24HpjrVe/O3dKAeh/HHeufe5aYxneAB1APWhlx2OnhmJ3c5IHSpDMVbLkqPfqazLORlnVeTn7tWbkyFlklXCMcFu1DgNO5oMPLBBUcDdjHaoluY2OJSRkcUqQhnlPmkgqNi+tZ9yZXCIQMKeDjio5dS46ly5iLx4bBXqCOvvWeZXRljjXc2OM1qhs4Q4KkYPtWFqUzWtzkYx2PcVVi46ktneO0jxzNtdeNtats5Z8Dp9KytOtzqN+m1CzEdf8a6G0hkiidXAVVIxx0NWoXIcuXctl3ktxB5QByTkD5jWtpsKQ2KPJ8jkZ5HLVWuU+zSxyFyXdQ3A+77Vea+fb+6jTZ5ZjztzgH+tU0kZ3uPt8fMAitkYyT933Falq1rDbuDEkryJt3Ecx47j61HofhufUdKm1AzeVBESAD1Y1Y0HTjqLP9mdTcRsFeHJz+VEYyZnKcNddiAG4khKxRHbnBPpWrpdrAsri7Em0LnYehPpXT6Zpsts0UV3GnlZbcWHQ+tOeGy025kuEhluDL8qF+RWqpW1ZyzrX0RU0/wAPRXkcN7bkKImJAI6fSo/EsLxWkghkkYMoMkcuBj3FDC/hVY1inWWR8gbiF2Htj196XULaZbz95FIWI53E4/Gr6WM9ebVnPfbYftKhGlNvtGVxyDjmsy/sPLunlt5OG+bG7v2roZNOjl0+W9jY2txGxRCB8snriuSnluUt2EZO8H7x7VlLTdHXDW/KS38Ru41ulYCUx/N6kjr+NYEjNGqpLliDn5q0xLKX4cbiv7wgY3GovLInENwgYsflLelQ/e1No3WjKFuAbgNubbnt05q6jRnzVd8MvTI4qjdxLFcbbd2ZGORj1p9kj3n2ghhviGSvdqmzHJLcuTTszZmbcdoRSR2HSsfUIiqtszlhkEVdDmVWUemMnsaoTuRFtZsbTyf6VIkrGBGvQM2WySRVmPmME9qmeEBwyjHPfvUdw3lxYA/KiyuaMpXh2Sdck1XNwcnOc/WpLxgingnj0qlOdsA4IYDJqrCcdBbsBnUY4HOKKh8xpCsiAFcfjRVL0OdrU9hmgaK38hlBlxlS3X15q5DOv2dm3MzpHtR+ucj7prGeWWUXUrEZVQJMHBIqWxlJ06UynBIDIo4Jx0rO4OOhYiLTW7gqqNkRlV5bI70x/Lj0+F0cfaJHC7h098mprS8EQkmdgkqIWXjkk8UaWlmo3XqsYCXclG5DY6Y+tAWsTXE0c8YtyFRoyArHgHuSah12Vo7iI2LD/V/eI7Y5A9qr6dbvNaXBJGZAxAPP4+2K1LZ4Wihjmt0SJE8tyDktg5zz0NO/MrMm3K9CpbBJ4mnO0XKpuJcdO2MetVY7KdfLuzvePcEZ2PUdwK1lt0bXGaJR5VziNVzwg9T71YsYZW1mey3j+z1fbu25OKaVyeayZpbU/s51s7ddoKrIzHO0nutJbyWlvpsalUdJImZ0/wBscZrDa5u9M1SXTx88YO5wnO4dRir7xQm4ijhADEeZIoOQM9FHvVKdyXTSW+jKulWEkkhG6JVeYbo5DjI9/StlLSRtVeeZv3EZIZFOAcdlpLURJcQyOpaY5JAHGc4FXlYCGdHXMiMHfH8Jz6U1YJSdwSOSS4jLTI0IyUU9V57e4q1qaIUW0wWSQgoVGWz17+tQ6hc24urSOJPMDhXwDje2On+NadpaB4jKBveTO7acbfQD6Vdk9jFtrUqS2cVjdSXUURBlIDgA5HHOKWC3WW5SaGNIyoYiNzkg/wD16df27iVreVmnA2kbHOdx7AVWuHX7OrKzQEScS9+vTHtSY1qat5eXCw2yKdrytudOrAA+vvSXdwo1CJLdxHGy7cMvLEnmqdpMrSI0yzTNGdoc/KGXrxV2GdbjadqCUK2+UjGF/wBknvTV2TaxLqGqJbTyRCzzMExKxXoMcc+lV10qKHbcmRGLgEIzEhhjqfpVVIVhZ3kEixBxIQ3zFyD0z3qG9kdrN5YUVEmyh3Nk4z046D1ouNR6JjL+4EtuzwzFY4iZFAGFkI449aie7mSzDfZGaVxvRmwFjGMZ+tPjeZ3igxE0Swc45JHoT2FVtRvBcyPbxTYOwKxA2rj0Ge1ZNrdmqXRFGG5Ro5Li7U72IWRegZOnH1qLek947JsEccXyoD90Z4ye9Rahcm1jjtQWcOwUbBkOgPTP1qG/uISCIomWctsaPOcfT+VTsbJdTN1G5eW6bywEEagk5xg+tZUtvIUM5lTKgFlbOeT39c1q3EZdJn2j7wjXHUn6Vj6gNzpHG2IwOdxyRWTNlbZEc1011mSTbnbgYHygD+tUWuPJXLKJFIwA/pUrxtCXIHy4BwB1qrdu+Qwi/wCA1Wom0NWXB+VlG4cc9R9ar3D+WC2Qq5AAB6/hUqRsylkAG87SAOgqrPaxgr5MpZiDlWHTFaJaGLkMupJDFGJCGQnIIHSp4bgR5ZsEY4B6CqyS8sjjP+z3xVeSYx7o+Bu45HSqvbUtarUsanKj2E2ecKeR1/8A1VzMMYdYSqb9vTFaF5N5cLDJbecDPf2p/gyx+1astrcAYUnK5wB+NFrsd1GLudN4ts1hnsJgnlwS20ZDxnjdjnpU/kQ3mrJaSKI7UW4UOnKs+OGP17mqOrSGG4hsbpiYbdiVAIPWrEF4YYHhB+dl2Af7PXrVtrUlRbiikM28uAehKk9aiOcMTggHilBYu52/hUElwEyG288DPasGdEb2CYMzjaxA/iX1qtciKceW2Gwe9WU3bQAeMZDGqNzHumZy2Hb0pdTaOhfsI1s5VkR0A+7sJx2610trcSRW0kXGyRAHBGfpzWDYwefbpuIBHynjmtWMFBsByq4Aq+axlNFl2KrGxYsQMfhU6z7oAFI2nqOmaqNhsk9CMfhU1tGI5FGCUqLsEkd7YC+TwqttaSQZeWOVYXXDOWPAx3Fbvw2077Nd6rc3oEeoPMVZBwqj2FcdbyXEd5bzJLIQqjYzfwgdq62e+EtoJIf3d2zndIp5Zj0rqi1Y86rF6rudzJawecJ2B3pk/e4/KuOn1nbfTsBbrAsoYoWyWrG1PVbu5khsTMUYnZIwPb1+ldE/hzTLTTInmQuqDzJ5N33s96uLcnozFxjTtz63LMWuR3aTLasz3C9oxlT9CaQ30t1dE3cLxAYCoRyPel0+zkso4DZJ5lm/zgqoyPxrZuLdNy3DSukzAAHG4D8Kq3czbSbsjkp9OlRbuFZhux5nlduf7voaxLnSN0Hn27JNuyWj7qPcV3l3bsZQ7iMTtmInkA5HBrkYoLzTJzHcKvlJlC6n73uRUyib05nHvD5VwJUAxnkEcVc1aGO9tYJWAJK5+T+H61NqKMkz7drQSE8kfyqqFS3s1bzFmMynAXrER2P1rHbQ6eZuzMS3h8u8t1f5dkgUsfTNVr21ay1a4RSQokblT+Wa0LhW+ztLtJGc5Hei4gdoY7g4d5E3Mc8EVHkbX1MdUMu1CxBPIx61FdIyyuZiSQemK0Una3lZo9gJBXkZwD6VBqKp8sgJbK5PPepKvqYskjBnYoStVJZVdAoJANXbmPBZmB5GcZqjMzB8oAFIxyKEiyrOoljZAc96ydU/cwhcMzGtSNyk2zcFbB7VQvx9oQbc8Dn1qtxXsZtvMY4xvYA54GOlFMIAfA5A7miiOiM2lc9cj3StC/MjDONvHC96kuFDW0DLKrSTN/q14ZTmoJkeJ7VCTtG5iF+8PakkEUc8EwyQfmIHb0FYXaKtfY0rnMd80oG6NYwuCeMkc0x4iL1ZbDmOFMOG5GSKSI7ZxA0wEDIWMmO5FRW888LzwxPiOYgFsffUU/UheXQnt5ZIJY4XjlWQgj5hj8vWteyQXGqLFEPlifAZuCRjkGqhvI5dT85VwqKEWNuSvfP51Zt4A0FzdxXBM7Alx0zntVK3Qid92LDbs0eqtE7KID5kJzyG9M96ntL29sSl0HH2rYRyvXPc1l6QkaSNBeXJgjb7xfOFxzV27sZZLy3WG4DWxiMocjqR2NNXauJxSfKy/ptzbW929xJJi+/569QV7n61r6bbLfx3WonBkQCSKRcBQAO4rGt4LaeyeCRQLkEKqqcbs85rQhhfT9PuFtm2FZBC/wDe+YYOPUVabRnOz2HWMNzdzQrDJuuHlLKQeCo5zmrNtGI9SnifcZJZdzOBnd9KgVmtrKRrNxhAEyBznpmpAWht0upHVjkFir9G9D6GgT1L1ukfmTTGQLOiBE9eT1AqWMqNTcRszxsmZN3GD6596riVZYUuRJl1BdQRkD0ArNkkUyu1xPMqTJhmTnj0P41pczUb7mxey7b2O4sFJgXlyMg9OcVOl1ZXUC3FuF2Y2MrKSwP97FZWlzPDA9tAnmSo+DK7c7e2fpVuV5Ibcgwx4VwZJYz972ob6g420ZdtLyWa4hto4tiA8Fk5Y9SR6Uks1st48BWQbmLPvycr9Pas1LieaX7TaM0MoBxIzfJj+npT7K+CXk5uAjSMfmkbPNJyDlGwiS4vbl90kcSZZFJ5UZ4OO1S3DXSxQ3N0FSIKERCwBHPLkVblljFoYvLMaSndK45c98AHoKo2r2t9J9quEmVUfKKOeB0BH9aGNN9iNZgsU2Fk2uSN+cBU9/rWPcPBcy+XGyAIPLXA49Sc961NZdGs7mIEpvy5ZeTkdF9hWUipFaQJb2qyuYM5PUE/xVm30NYrS5AxMs8MhAjjjibynA+U9uPf3qotzJHMlxIiSy7NqIq4EeOPxPvSXcV0Yrd7ycTTdI4yflRfp3qpHETbzzMzHL7Q4bnb9KzbNox0uMvZTGimLdliWYg5wD/I1mFSYlHl5LEnJ7mrss5+zhVQpEBznqzepqhLMqJhTux68Kam92aWsinPL5SFkAZeuW5OfrVeO9jCuJVDKRjaDkmpGmAwv8I+8Kg+zxqHcsCuc5Azz6VcNTOb7iR3YmsinR0zgds1n6ld/aJEEZRSigBlH61pX1qrR7E2quN5x2NYDDbE/lhS2cE9q36anOrXBXLyu+TgCp5QTErOBk81XhZEZs5GR1Hc0spcgA4AHH1qJG8UV7iITRsEPyqM9OlWPBsBgkvbppDFIiFo2bncSen0p1tCQoGBz0yKtzOttZskShG5zx1qou2pUo3VjEL3VxqRMuTGT1POPeugS3d0gBABdQVUdxXPWT3LXS7ud52qB1PtXWwQeTcwr5bK0eGYP3Pp9KmOqKaszPuswsQGGVHPPQ1m3EakyeY53dV963b6LzGeRlUliW29qotYpIpmPG042+lZ9TWD0ILYsLVGb5s8AU8YO0MoLdcioXdo5fLTLMegrSs4d4+Vds2M7T3qlqynoWreEmASr0J+b/61XUzuBx8pHWobFDFbMJsnzGBUfSrYVi77QQhPftSnoZt3Y5SxOFUfMvJxVyyiPmIRg4+bb6H0NQj92uI0HIxmta0j4QoDvCZbn86mLuKTsi4l0GVGbcpRCo2nvWtBPH9rsFeQDcqpjHDE9Sa5Ni6MXGVQkkZ5qzpt3O15bMozIrgoAO9aKbMpU00dX4n05rbWQ1oPMCrvYD+VdUmpWuoWUMFxvXdGA8YGVPHU+1UvDd7BqGoTQ324akwbd6EelaM1mNLvfPBMkBXgMOh9K6o73RwTeijJbGtZrGLWO0iLBUQDcowPwqe7SYwbbYqsnQM3b3pLSeK5RZ4WyuMY6AVFNPc/2lHAkY8hly0meRVHO0QaonmWShuJ1+YHHBIrIEbz+HbqS7hzJv8AlbqTXS3YJgceUJF2/dzyay4GkGj3M00e1SpwlBSZ51qgAt1iaIARufnHXB9axTKsQmjPzREjk8d+MVrarcSENA7bWY5z6CsW9jWcnyQWjjX7x71jNHoQ2swvodkbQmQhwPTiqaTskCwTBdoJwQOxrRtoWns90vLFtijqSPWsaedUm2OBgAgVErL3jSDvoQ3ETRvlm+VulV0WTYS2NgNWri6WRIAQNw446kVTmYiUxq+Yx0FZPuaJNjLwKVGSGB5yfWsiYNu2gDk9c9K1HYFdpGe+Kzbpl25JG4dqaY0Zk4YyDOA2ep9ao6jMIYgMfPnk+taMwVUJOevXsKwdWllcDZ0BKnHpVLYZWRlkJAPGcnsRRVKAFJTv4BbrRTitCJOzPXTcSRyRSEH5jwCMnPelmkChMY+duR7VWmuppoYodiEozOGUfMxPvVaPebYNKjKckZNcrNUtTalgePT7WWFwfNdkdc8inW85sdSEVyrGNRlTwSB61SspnkWBXX92h5Iq3EIWuikoB25Ic9xj7tUtSHpozd0ddOuYroXG5bkozkn+Js8Y+tVlZrR41t2BdiC6N6jtWWodZbcRCQOTvDYJ29wMVqPexmI3c0aI4UgHPOe5qk76EONnp1LOqJKLiVJh80qDBx3z0I/rVqxmS1t4zM8m0uCyjnGOwrJsdQ8+WSe8EkhYbUIP3PTj6VtR6gUvYmtQE+QqY8A5yMc571atuZyUvhaLryJdqiW0IzGzTK4GTjsCfSkN9NdQwC4+SR+SexwPSokZLeSZoUfykUo8TttJY/zrUtbi3Z4wQGtNpCqRtKZHII6/jVbkbbEVvKJLLDxkJFJuC9yB15qSAWep/aWimEQ/iDjG4+n1qLT7wp5hS2MwRmEWTxk9QatwRwJpyT7WiuPMJlbhlJ9MUCe1x9qkRjjaNlxGMCEnp9TTYvLnBiO1UDZbI5T6UQzQTuymEqGAVpcc+/Hp0qpe2N3aXsbyq3lD5Y8EDB96H3QJX3JsbZxCiMI48kSL1H4dxV+CFLq3uN4V4xtbB479MVUikd4TEFk3OTiU8Bj349KjgWSKwJmQgOx+fackegqkyXG5duokhT/RmWREIUsRlV79O9LJ5ZRDANwU7mLcAfj71RSKcENIHQHlVbsPU0aZBLcPdXlw7sjthI1XO/6UCsS3E87amFSHEWNpAbjP+z/jTdXvpo7ZxZwtEoPlFc5JxTnuFtpJmKuqvhCowSgA5AP+FZ8ckhZZ71WKbspBs2+YvbJqH5Fx1FKTzxLbyPFGsjB5Npw2B2rM1G6Bdo7YyLCGAZx1VemKtzXYe8/ewgSPlY1Q5wP8KqK8DTx/aUWO1SQ4VDySO5qG1sbRTKt+8bHbGWDq2FUHJYHv+NV7iFrdzFNhWzyAcnNWIpRHKJVRWJJdWbsB0NZ12zTysxO8ltxbpWbNkuhWd2LsBuAHIz2qncHex3qCc54q1KuASq8Y61UjCbyzEgAUkNsr+SDJnaSM/MoPYUajcMbVoIQMFtwAqWaZFJLAjBzxULvHsLucEjIx/Wummkc03rdkV1LE1p5j8lFKlf61zcZ3EYwFOfrWhqOqJeW0CY2svysw7jt9azs+XJtVSCRg46Vo9jOCsxoct9047ZHarUZOANvA/Wo5ovLYLwrAYwD0qfB8sBMEdDis2dMUT27CRvmBCgZBzVh4/NBzzniksrQgCTdn2PatGC2BmVdpw5xUl2S1KWi2UdtqMM7AMsbh8deQc1v+LNTXW9ba4it47aIDnb3qFIGRLobQyghN3cU14w4QgcMMD8KpysrEOKlLme5TvV2xFIz8qnAI6GqclwixAkEAccDqa1J7MC0kcEBwQAvX61iy+e0CRbQMPnNZs1j5Fa8gaOVTuKyLyDjpT7K8ls7tGuNzhmyc9xV+8Sa7IZ2UmNRu45I9qyrtptqxlcr2PtTWhotVY7q4td9hb3acJIduewzUcSnJjYcjsaqaXqM6+HotPZMBJDIrDoR6VZkkeQ+YeJMYJpz5ehzxi1uWbR1SYMwD4H3T0HvViV3gmaSJly3AA9D6VQgCnHByOc+9WYXcSiRcBs+nFZJ2KaLKymZFRCFIP3W5zVm61GaTULa4WGNZLYKFCLgHHrVOWGR5N7MHB+9g4xUkd0it5U8ZaQEbSp7Vp6ktLc318QvJ4gXUliVZeAyoOMd663+07e8jS5DkpJIUERzt6dz61wht1MgjikXc4yinsfSrVvfzW0BtJnMSKd2VXIU1vCTW5y1aalblO/s1ELKYZVjtXPzRu3zE+1aiypzKY5GVM7W6j6VwrXcDCOXzJZhjAk28E1tx67eNbobK1ZkBw0hHUeuK2UrnJOmzdnS7Rp7lrkeVtG2Pb0rOurk2miz7BIZJBiJcZ4NZd3rxU5upwIhgnaOC3pVtNWtXU75jPLIuMMP9XVKxPK1ucNfWr3BM4yZgQpXsKzZpJYEWAAGJjyvvXeSqIo3KlHJ56cEiuP8AEFunmRpEfLuUYllJ+9molCx1U6l9CNZmtIHMuBIitnHXNcbfOTOJAR83JNX9Z1Qb3MrqXA2isb7T52DkZY5z3rnqPodlODWoXUwCs6ja55PtTo4kESGN2JAzz61FMnmA4PfOfWpYSFw248elZo1ei0HXA2Rqw+8R3rLuVdpRsXDEdKt3cgHzMe/fvWbfsEQyFshedoFNJEozLm4jCspb5QckCs++dFYLAdyEZBp92yugKKR3b6VTU7t425U/dPemn0CStqVmy0bNuXAbBAPJ9xRUZCrE0Z5kJ4NFWk2ZNnpS7YoWROX9fXipbcnhdxaMfMFY8A1FFIyyIhXPbPXJp6xuty0Mkm0DoR/KuM6EXmkislgl3KwJyyZ7+9KJEUnC7Dvzu7LnrVURxuqJ5e8g5Yjgn2qeGdoHkDIrAjGW6D3qrkNF+G5Blm3SYc4KMD0AqS41a2ltp7eOJRNtCBhzx3NZlkZLi8hjhiWSZgQvIrM3SQ31w8qgFMo23nkd6qL0E4Js6/w1JGL6GJosxBgGwOfbFaEOlRP4julE7LZAn95J1H5e9cjoupql2jecFUnO412OhXAmnLwHzZljZjk4B9x6n2rWFmrGNS8HdGnLaxrqDyzSAt8qq7DcCKheyFrriICS7/e3nA3Hv7CnKJFEMlwcFyd0TJygNXLuaCAKEkSV3XJL9QB/D7/WqkkYxk0VzLJpt6PKcmK4Ys8brjDegq6ilL0NImxZFOcg/MajTypLBPNj3Tscq7cgAdMelPOqXqwq9zxHGMooOSOfWltqO99iwIgiyeaxX5eNx7/Spt7TxNIjDyYQqnI+8e2fWsrVzLNDDL5oMssmXLDBPqPoKt6VcBTI09yIUBw0aDIOKFvYGrq5Evmuyy3cUrN5hyEPy7fb3q08jx2gmMwaUEukIGdmD0x9KzrjUNlqVBkk8v5l4PBqslyZUAlkCMSGUdPl75PrRezHyt2Zq6XPNqFzJcSyhEcbWAGWxjjrxVaSQxxL5Mpi6pgHkD2H9azb+5aVJYt7KzchAPlT6H1pumFrYu1zPmRABtK8sp9DS5ugKC3JYrm7nvibVWiEeY+RnAI5P1qdp5ElEQuZJiVIckDIz2omu42tYobCMSSH93sC8yMeSx9cVAlyYrx2aJA+OAnY+tLYu1+hKscHlXDOj/aiiwwjuq9yfSsSVhDt+QkIDjJ+83erMks376V5PmbjaTy1ZoZguJsNtHC9cVnJo2hFrUtvut4oldYzNIoc852r6D61VuZ87mCqFdeF/u0rfNIEmwp27ix5xntUVzG+TlUURpkgHt/Wo3KWjuUiTtBZuCcnHpVdyGY5Jwf1xUmDt+bjPH0pcZz0IHv1prcJFWKJnfOQzA96r6gpilfeQ3IDAdBmrgUhztGB1yOpqvqkeyzkDkGQkEknrW9M55u7MDxFbLaXAB2hOAuznP1qmqmOOXO4f3FB/nV/Xfn8vH7wIuX3nAz7VkqCrkkMAB8xNbzRlTv1NK3t2dSzDJAHBNaNvC5TeiZjBAJ9D6GqNsC7I0YKqvX3rYhYrbupJCsQcD1rnkdURqy7ZEX+IdQK2XTy4XeRWyeEPoaoW0AEzb2CnHBPf2q9cXMklsg2l3Un5uwH0qblPUbGwTOFPP3jmrSxSSgBI8YAAxx0qvsJsUYEbsk471diimS2bdlJCoZeeSKlXYMbboj748AKV7tzn1qpd26hUJwQh2kAdu1aul2gmMsbR7peE54KEnrTJoBBlQAMOVPOeVqlfqK+tjKCHCgqSQMdOoNUr6EPLuSMEZGV6YFb88kcd20kPKAhlB7Go7mzF3HPMhJRjyuOKdh81jJsumHJKhjjPFaKsinaylgejHjFQqCUjZwDtGOPQVPfyhx5o2qxA+TNQF2DFSpAGMc5FIjOY2UEeuabGw+zk7QGBBLZ/SmLPHuZWyG9B0qOpRciuYQyiQktwGB6E0+7MYljkQAY5GKoShCgcBccAilV8wMoXgdRmtU9LC8zYiu03EMu6QYIc9RVq+1aG+iw8IidFwSDjdisJb4m2EGTs3BunXiozJyAXyvbFXzEuCvc6Ww1jybRbdWCxdQO4NWDrGo2dosYnBhlJO1eo9q4+WU5woAJ46U9TIAFeQhT2PSnz2JdFPU24rp7kljkxxnJGc81t6bfQwDc7KpP3ieWUegrjYglujyRyZI/I1RvLx5PmDbSByBVqpbUl0efQ6Xxj4mW4u7ey0zfuzkle5rk9X1+ZLgxSLItyTgs9Zc9+9vcpcKApjHBHc1l3l9eaneLMyEYPJNEqiepcaPK0khZbWWfUUiuLoBGOeTwCat2cLRyyRpJvVSRkd6ia0lKEAZcnkmtC0UQRAMMMRjp3rLc32LJAKARZCnnFPBRQoPU8dKgD7SWDBgOPrSMTIQd2FHP/wBakQyOaVA3zZxnHFZF9L83ybgh4ya0pm56Dg8Cs65ZXQnJJBqkBlXMg8kovOecVBFE2wHYzO/yqijJJ9hWtp9idSv7e2h2iWZwgZuAPUn6Vmwmzn8VS2dtrEkEaOEtb0RHBlyAuR1Ubs8/SqUepEpXdjn5SyzlIw4cHYysMEN3GKKbdidL+6juw322OV1lBbJLgncc/WitYLQ55zsz0mzkLW8TLkOp3c1ez5x3hjgnOT3PpWLps7xwhZYtyn1FacEzxKcDKEEYI6fSuA7C5bSNvLtkFT94VJJ5ToQAWLt19PrVdUG0uGBUEHYKsqvmW075Cc5IHegGV5oTDPHIjNt6ccYNRxKI0k87LI45I5rQ3CRGEYJUdqfp+20mdzhx0+bkc0LcL6HJoqfaQVXYpzjBzjmtzRNZnsLgCLG7dwG70+G1ie6dm27ZGwcfwj2q3q+lyRpDNHGNhAXfjqfatFs2hScb8rOxv9Rmv47SViFlRNgUnnHv7U7SJHaMvcQh3Q4GR8oHrmsvT4mkjhUsquBls9WA9Kvw5Qy+RM+wjDE8BeeD9K05m9TmaUVyomOpwpMftAZowhwBxgn+lNu7hpZVyPKYsGAB+VwPaql4scq/uk5yAQOQ2OuKJJ1uHiTBUjoB6CkpPYfIt0X5tWkt3kaSRGVRuIK5HNP0W+twrSswfzXKeXyWXPcf4VkRF7h5TKNwYHjbtzRa2hZV+zOkdyXKgq+Dj/PehNpicE0dRJd2ktwbZEMfXc3UVTu7aDbJLHuEG3bGJBtyR1IqhpsMcUgSNnaWQcfMMe+akhllnEqOZJRGduSeP/1U27iUbPci0ye5hSXBcRnlQMZB9eaBfLO8a3MbfK2TIeCR6H60x5IoWVGw2AQJFGQxP1pzRbx58rB36hV5BNTraxppe5EJFF0nlJJHE5J3J1C+1WbkxCPMcrQqBu24yzHsKrNPhFdGBd+MdNvNNnjzukVy+zkEDHPeoK63Ibhoti4Dhy2Sx6/TFU5mCTERg7SQV3d6m3tcshYSMo+UFRjPtUckxSYMoyQuwFux9qllrQSUhpDIX3tnkjiql3JukDA8D8TUwOVb9R6GoHBA3FfvHFIZGnTPBHb1onYMwbACdOPWlZAdxUbVUfnUTHJIY8dqaExY5WRixwyqOAayb1hNbyl2wy4OPXmtGdfJYIMM5qvPbARQySL+7OefUCt6ZjJHPauJFjEO/CEhgWqmryOxR3GePpWhqrQXUa7QoVNxLZ6+grNswpCNhtxGWzW09jKOjNe2PC7Tlc54rVtTlgMEAetZNnPHGjpg+YpBX2rQspmebJPDZOfSuZo6VsbNsEeVC/3c9xmrNyvlIojO5SOSMetQRgWpjYESKyfMueQasKkcgAizxg4xUsa3BUUwOAGyHUfMPuitq+s54IS6sJOFbkfyqK1jSS4Z+VSZMqMdGHapxeXAVidpI6g9hVq1tTOTu9CXS2MVw97Mvzq6yuhPJTH+NUp4FuNXn3HyEZ/MHJOM8imgyx3KmQcDjbng55/EVrRSQxNI8qM5ckfKQNuORihO+hN+V3KIaOKQRzWqSRTIVLdwW7/gelVZFl0xmVA7IxIKt6e49affMfNXe+UPJHYZ9PxoivNodJSJNwwWPJHpQVYoII5IirDEpHGO1V5oxFErMynI4yc//qq7Njy9yL+7B4OKqOFbfn5lAyCaloq+pHC0axHJIYdAe9Vpl2neCACcDFTTcAIvfnjtVR5D5eMnKnrU2KRcRcxlV+/97PpUeVBBbdubjA71n29yBKyg4J6satLeRSEBhmQd16VorCdxJXIcBWyp647U85YBtwVRxx3pskkaAkJwxzwelIk0ZJRR17mi1hpsekuwFApB67jUomL4LDIHb1qjLMowQSWBwRTllwAQeT3oKLkkqtAFwxkBz6DFU5mDkhIzhepp4kOCSyEkduoqH7RtDAct3o0COhC9qk/TGPQ1DFFsVj8uM9Kmcq3Q7cD86Ug7VACkEc0tGVexG295AwJXPanSqwwxzxxg1Kx2HLjPbjtUckjspZzkA8HFMm4oiEcSsCAT2FVzJ+8baMBfXvT/ADmzswP61DIxXHAB75oEV5nJYgqfqKpXLmNGCjn61alY4Kjn6VnXLRoNrA5xnOeapITYlrfS2V3BNZnN3GwaJQNwdvTHv0q2uj3UWofbrfwDdJqRk8xEkvQbdH6htnXg84JrE0jU0sfEumSu8UcaTgs8pwqj1OOlFzoWnyX8znxpprIXJVpZJAxyc/NxWq1MJuxg6rJJbC6mvHb7YZXM27r5mTn9c0Vl61IZrvZPKrWkblfNXkSgHqPY9aKuxyyqK568qBhEynAU4yavyQ7pU2HcqjcccCqGXwjJjlsY7mrTExt5hI24ya4GekOKBELbcIW4PpViIkop25Ve/tVUTCdRHklM9MYqVQx3hiCgAzj26Uhl7IXdtUcnt1pgO13Q4G45x6Co7SUiNWBDcdTU8yNIrXCYZB8pbpQK9hixqWwo2gjjHerqSM0ajJKLwgPQGqiEeWN2RjJ/wqdndI9/DKo4FNaFPsattNgecu3cowQT936VoS3XnxlLeSNXlHQgVhQTvPGh+ZQc8cYBpy4VvMcYOOCvrV8xjyXdzU8q5s/3b4LYw4J6Z9KiaaCKQZRm6Ko6VGLmTgtKGUgck8mmyzLIVVWGUbggUm+w0u5o3D/2hcMUcQtsJ5PUegFVUhkDJH5iqdh2M3f2pZFjJVo3IcA7wT941mTuz3AKkHC4HPNFwSuW7NJbGQ+cfvdR1b/61a0uqR3McccFt5flghcHJbPqaw4xJK4LtgSfL34q4V8qARsg3KDj6U7voEopu7L0TReYu8hpUU428oCe1MQz3E23cFA+/wCg/wDrVlWweVXCIRxkc4qz9rMSiKBMyP8AeJ5/zilcHHsTx6a9zeyPE4McJA69Se49qzpmkZ5dzbo923IPGau3V1OlkLVQdrneVHGcetUfOZI4cIAAe4yM0NroOKfUsXN1MYIouBEi7RtHf1qhy7sp6Dlt3UmrDlim4OGfvUY+SNDtJYnqallrQjdyqkYBB5wPWnSgLbq5Iww4X3pmc7tu0noDmo2kIyHIwPUUgEQIrqs7EKRltvNQM/BaNeQeKlG0fM4yrHBHtUQBP3cc81aZLQyIb5HMiFiOSfSop3eSVAx/djgLmphkl1B2g8nHem2pYyMzIGAGNzH7p9a1gRYzNQs4VgeRf3ZBA24+97iufISKQYlJP8Q9K667Zr37R5rxqVXC5GAcelcjdvGFjIZ/OYYkDLjGK30sYNO5PAVaQ46jsetaunJlzgjPbPasS2bJUg/N6VowTFZc4PzDIrnkmbxdzoYWLDazYY+3WrkEgSYFWCt1I9az4pFkAIPb8qsp87IGPzKCMn+VZPctG3DPnaWU4U5IDcnPepkdgzyLl0J2k+3pWNbXG1lU/dwflParcMhRmAbIPJOaLi5Ualwz3kgddoIVVAzgYFNN0MpFIqkDOeMEH3qpDPh3y4A6D61DIQWL7sk8mi4uVdSeS4jkXy8AuG6kdfxqqAVLbwTjoQaXqQCuD6UyQ8AE546UXuVsKH8sHByo+8P8KgeQDIQioXkAB2t34qtPcqgKsKol6lqSXd94dB0qtK645PGOgqn9qDnC9qaZWfO445x0oQrkMqKzlkyM9M1CjOrHqPpU8kqmRFc4A4wKUOgGFI3+h7VViucYkp2nuM81IJGZ+PlWpIY02k4wW61K8cYUEMvfOByKEhc5VYsJFYLnPBNTr5YKnJ25qvLKQoxnb64qDzsDO7K+1OxaZdmlVYzjCgniqTSttfbnHTJqNp1YAbu/Q0nBLLuK47Ck1cadidJNwww+lWkbbGCeWzg1St1wylQck4ye9WEYNy+MmhITkTxEnJPU889qSTcSMtnNIZAF5cAY61E8m4YBGRRYz5hrEDczHOOaqTSGQs2QcdT6VM8qbSZQTkYX61mS3CoMActwaaQcw+VgpbbkEDNYt/MxJOckt0J+9RqF6VjxGc88k9vasO5meWaOJMmRh/CenuK1SvoZynbVl+x8Sx6XDJG+kaZeKrlhNdRbmH+zn0FVj43E8hb/AIRjw75KnIDWxJY/nWPfrbpbrDLMszt85VeMNWRp1skl7ClxceVAzBXlI3bFz1x3xWiVjklPmLFzcG/unlliiiLuzCOIYVQTnA9h0oq5cw2MN00djdveR84doTERg+mTwetFWokJnrdnJvH73lBgZHUGr8jeW6rKU2McEAZGPX61kw8oAgbeCc4rQZDJCgwMrg4rgZ6j3HMpjC7WU4Jx2pyE+YSDu+XP1pjhSpY/Pg8j1FRmXyyCBgkYwazLLMEm/kqRnjCipo3aGPyUZirHcwPSq5umXayBY3HynA6+4p6I8iZz0JH50D33LSyReUSAcn1p8Tu8BjbaRiqiQSElYQCV5IzVKW6vbaUo0GOe4p9Lit0N+3ZgirGpLL2PStBbSSezSdnjUBtuM4/GsiGV/s6MxOG9PWpreZ/IaPcSuckk8U15id+hphlkZUdVVQAM+n0qAWywytsJKO2eeSaignMSkOMegIq1HtDecz5PcZ6fSgVmtSV0/fJvUg5ACgYINKNPW3D7stgnOR0PpTHujHOij96cbt2OambMavLNvZT8xGe9AtRVSR0LzEKoXKDPT0qtBKbjCx7mcnBYjPFPinW5yGO4EjPoorS1GayURrbRFCgx5mMbzTWwm7Mo3TIBiOQLGp27Rnr61FDLsjd1UHIwGHaox5W8RqeCe5pZIndRhguTtBB4FLcvYgkvCpXaG80tkccVJFC8rqhyGZxkds5pFgcM8qlDGo8s+9Mt38t2IYnHHP8AOls9R77FzUIHs5HhZVRcjpzmq08pDhcFsDAPQEfSogTK7M+5gO7Hg0SPnZsBIHNAlpuQlH2uy/KfSkaPeFYncT/P0qWacsAvG3HI9aj42kRA+/1oAZ95BgkL/CPeljTORjEhHJIxihZWyVOFcdB6GplMgklJYZYDccZxTWpEmVgzHKqeenSm2rhIZIiAVLZLN1xVlYUw8sEhUgY21WaNuDPt4xkjt/8AXraOhN7oY1qGy6AlR1PcAe9ZWuxw3MsLNGF8vAZlHUV04KLMsSozLxtHQH61BcabvmlR1XeeRtOVrWNzN+ZwFxF5cxCk7Oq+9PgZgwLEgit/WdNTCxxxtlQQWz0rn54ZIUHDbR1z0aiUbkxk4mvY3PVJDkVq28uDuLVyqSqhQgMoPc9a1Ir4NgFsHFYSiaqZurIsjKQMMRjNWUdXO3GW7YrBiuMsNz8eq9atfaW8wEFdp6gVFi0zSLEsy5JyOuO9TCdduwBhx+FZwvEdmDkgj+6etMFwgbdu46daOUXMajXBICnGVGRntVWWYq3BOe9Zkl4iSZLkDPPtVWXUsysM/N/DjvVchLmkaU04VcoOPeqMt2xBUgMOmMVnHUVZXDuQ3TaOtSRSSKQTGwjzy3UVagS6iQAuCDggfxY7CrAuMgDjd2qGSO7W1WcwkRucBs8Hmoc3AkUGJv8AeA61apsz9smWSuHHzbg36Go/KRn+VjuHNV55WiRzgghsE0w3ahA0ef8AaJ60uRlKpc1Udogu5gTjvSiVsnjOfTvWNNO4AkeVSDyAKcty2FO4E9OvWlysfOjSa6+XGNuflas+R/3hHO0dBTHZwQBh1Jz70sZTYC7/AHepBz/k01EFUQxhuwXIweOnSpkk2wgH9D1qBpFmGyNiIye/rTTNgrjGMnrRyj9oaCSqEGSPl9KQXWThD1HWst5mZSSQBnkimmVidzEjtSsDkajy71HmHCgYAzUMl3tRsMOuPeqZmwxBBKg45FUJ3VJWTOWHpVcpPMakl8SwTPB6H3rNuboAsH4OdrHPeqxLGEuGVecgH+lZdzdIQECGR17t0PvVJLqZyn0Q+/lILkkIgBbOc/5NYM17K0o8gMiDkN/ET70S288zofM2gtyueDV6K0wGG07hVX6Iyd3uQeFNPh1PxVpdlqBYW804WTDY3/7Oe2en416BpOnNp4slHh21/tPW9QcSWM0Jb7NZodpxnlR1O6uN0HRptT1q0sQwi8+QL5nXYOpP1GK7C6ttHuJdEuYptaWG/lmsJLp7jdMcEKrey5IJX0polqxyF7Z21tq97FDKHtY7h0iOeqBiB+lFMvIP7O1C5srkb5LaRoSQOCVJGRRVpiPTFUIpkjL+hI9atRM7qCSfLXjHvVO3cHzArgBuQTmrKH5slduFx7Z9a849V2JWVxIpiyUYdcdD3FR3MwRWRkJjblHI5BqWC6MabT9zPJ9ai3iRPKmG9ASRzjGaLIeoqDIQOcEc1bicAkMTk9RVaJBIkiMApx8vNWraBnibcMKgxuP9KSiHMkWrWcROGYLj0PerWpyLeFJMrhUA2gY5rLVAitt+bPHzHgVJEGCscDC9RQpNaDcU3cuFUMa7edo6UkEIUlhuI6jNMRUKIzHk/pUiyMRgYYA9qL3Cws8cgi3nk5yfb2qzalPKLOmSDnrTQ6OvlscEdPxqEIFyocgA+vJpWswvdGmXgEamNGZ2HzdiBUEitNbKSxCbvXtUZmCuqE/MeeeOKnjm4LbdxI6Zp3JtYctukWYrTJHQHHJpiwTbR5u5lY/IO5pYZHjjUw7jMT6YwPXNV7m5cSbG5cHjBz+VNjRpxwRqvmYJk24Ue9VXWRcowQMx+8f4aYhZETcAFPUjrQZvNusk7FByXxkCkJK242OPBZN+cHg9jTxFGwEe0bhySp5NLdK+dykEP9w5BOPeo5UWByjS7m4BZRQFxJCpUjIRAcDHf3pmEVJZHZcAYGe9Nu2Ck7MlR3NRHAQKFOeuDQMYzJ57b+Gxxig7Utj+7Ykvy/tT9qlWcn5xkYphDeQuckf3KA0SJoI4JbhA2UUtkkntSpKWnYKxFruKrn0qrGgnU8lUHBGOlXhErhIo42CopyT3H0q46GTtcWESOHbcoCjI4/Ko/JR0iGCzs2W9KtwWyG2L5IUk5z+lPt7J0KnG4Jy2R0rRIhtD5LWa3aNGkAx8wxzn2qy0crpGzgQgHk4wSK00jWWOKfyzIx4EYPLGoZFF3O+4YAGxx12//XrdGTfM9TCuoYvlEZIVsnLdTVMaTDcWMhkcJMpwse3Pmepz2rS1O2ljkiMSfL2PfHuKtpb+bYt5svbPA/SmnqKS0PPdS0JoZSIWGzB2qxzz7Gsh4J1XMsO3nG4ntXp62sU0QO7DjKqcZAqK70lCiqIS6qCG3DAz9aLX3J5rHmquYsbiyN/dx1qRbqSTyxCrMckHjgV076dcyXixbFMa5AYr7VHeaZc2cBEaI+TtMQ6gdzS5EO8jIm8+AkzKuW5Azzisq51dbabbGrMAOoGRXUz+HyxiuJZmAI5jJ6emKrto0cMTzBTIP4cLz703FAn3Zyh1GeWLEcQyx+b3FKsU0wRjJkjqB1rpbHQTcRSTRrjZzj61Yh0hISOQxB5OOfpUMq6WxzlnYvu3Fdx3Z+bvXS6ZaeYZLVzIUOGCIvQ960Rpm2YOi5jQjgDp9avyXMFrMsqnBI2sw4GO4qYqxM5XMxrWJo0tbMSMy5D7jkH0wOxqzoYmW6e12LI2NjI3BX3rWslsYJWvDKQsj5AVc4OOBV94DPqMVwLcI0sWN6nAOOmTWq7nPKV9LHL6zpMcVpLd3NvtjiJIixlmx2Fc2umGU+fPGU8xQ0UfTH1r0TUJbmfUVt5Y1aJQDlWyBWXdqst/5QUNInV2PGPSh6hB20Z5/qsGZoo4QMudhIHAI7Cob61FtFDCuDKGGOud3eu8OmAW6JhXnLF9/oc9qoapZiC92DawVPmlb9aBqRxc6kTNLKHRSMBhxzWeszwybY2ZkJ3c88111/aLdwQfZgBbs+Nx5yKpyaQBNHgDyweT04pMuLM4mMIi7yI1ODnueuaq+YWdVJ/dA/dHUVvS6YJZN9vCREq53MfvGp20U2yKzp80gDY7ik2OJhGNkXd5gDuNwXHTHalaF4wmAzDq2e1b0OjOZ2PDBxjk/d96vJpqrlI0DnG0896dxN26nLFX2s8hDJ129Kr7CIWZkZSowHA5wfWuz1DS4/KEONxVcnjGKp6bZRvHLhg64wFNFxJ6HHCxbAfhlxxjp+FVm0WR5TIEGcZzn9K7uxs4ZEk8yEqqdGI4BqmwQtKrfe9B2rOxondHGx2qKpDRHejfNx29qkjsi0vzkjByrDoa27xGeCRoiu4d+2Kpx/v1K7sqR1HeqvYTjoZ2ki6i1q1h0tib9Zg0OSBhu3J4/OvRBba4kEQh8I6dFf2rvNCTdqyxSNyziPdwc84PAriNLurOw8QWN1dIWWCZXdQMnA/i98da17Ox07Ttaj1afxbaTW0c3n/IWNxLznbt9T0PaqTuZtHK6zpuo2N+v9swvHLcFpPN3Blk55IYZB560Vs6zdWNx4bs7e0ljeae9mvvJTpaI3Ajz6n0FFMlxuWLe9IIYjaQ2GGe1b6XbEiN13RYyCK5SyDzO4I+XpirkVxcxOEKEoOK43HS56t7m5cSiLBA+VuAPSlRcqxGce9VkYMg2gnPJqYy91yB3qLFlhUkdFwSVXqRVp5pAkcchwAc8eprPtJ2B+V9ocEHjrVuGUFFXdv2+oqnoLW5KpdMjrH609XZZjsXcvTPeo/MTzQQSSDyKtqQWYhcA8jmoGx/zlOD7AYp1irRoBIfnOelMQMjkyHAC9D3NJDITgkjI60bAWipYkhcEYx7GpFA3pvA4PWoA3yklstu6e1SRSodwYDIOcg80xFqOVHl3GNZOwqN7kR3W0KVPUY5pkThNwjBxw30qPcZFyCOD972pDLEF2kyFc5n6qPWpVuZPNZ5UQORgEDpWZIhh2mNV3EfeB61ZhU7U807jnkelVfoLl6l63mVXyqkvg7T15plxdLKiqsQjK8yYP3qhlA2blwoI+WmGA24JklDg9SOaVw0HRux/eFdiHgHHWn9XBb5Vxz3NRZkk8sFsIOBnsKR352hiy5wM0hjHyxJDfKex70MSZAG5AHXpQ2za25jvH3RjimqCykO2MDJzTEOJaQqgxgckZ71MmZ0UyD90AQPw9KgHygqCue/0qVPNZiQikD8MfSmiZFmCF2VFQLgHzHGMcD1qdZGa7cgKpdQMZ7etQG9dITbkgFyOdvJHvT4X8kA4UNnqewq7ojlZdt5IzIsfltLHFyRnAya0raHyrSdHUSSyjO5jjFZlqpWRYwMsxDNnpj3rUiVHmd7ifLD7oPRRWkWYzRctFJW3PnAlVwdowE9qkcrHbiGNV3s2/3B9TTDeJZ2UjbSeeqrk1Us0kuIzK+8SzAkDHRa2TMrX1Y9vMWT97i4ZeVCDjn3pZrMKolnY4H8J4xV+wjit7FEaPzJTkIxbgVK9tHHFPJcAuuMsD0X6VRk5nPXwNvbwyonyTNyF7Y6Go7t5FceYd2WBbB4xWnM9rLDEbMb4x94r3qtdxRq0keGAYbk3HAU/wBaLWLUk9yGRFMQIbaSDg4zgU+xskW12SYaZMu7EdVqOC2lCwmSQeWjZIU/eqxeXETeaYg4DDqernpj6Uk+pMuyMS4gXUFVLYAiLLls9RUZkS1geFApeXGGxyPUVpaRarFDI0hC4J3ZOPpgVSEUTJPOUBZOQx7fhSsUhLSBYzshwFK7pCcfLVfT9LlluZmaTMSEtubjPtWpLDYHSXCTFrl8FgOGB9qqyvPa2ywpG0x6lye+PanYjm6ocNO2343yFbOQZDDr+NLqVtAYEtDCM5ykv9c1NOim2gkurjBAyq9vpTZnlmmLNGFjj6ejD2oJu2VLYtpb3SXio8aDBPX6EVqQTXc0SrBGRDIPvEdPpRDGzTyyGJJVZcLuPytRJDdQXEMiS7IM5aIeuO1JCk0SW1ukVl5Urh7gseccmsnyRbzXUrJmRF6kcCrsF4kt7fz28MvnovlKHHyg+oqoJZFsYBNFI25isp3dST1p2JTMmWR44rK7lkXiUuFHcelUWtJ57hbqV2EUgI2kdOau3tut7fwpysVuC2B0A6D8aZdyTC2SSVgzYwEU8hc4pbGkUU5T5KLBujNuQSeMFT2rNnLrFJMBwo2qN39Kt30UJgkkUfKQATn09KqRW4cFyxweinripuXGJfsjhR5mDGASRVwsJJo/MG5WwB7VWtnh8o7hkdPrVhisUQYqRkfLUtloWONXkVB9/B5qeyTZEI2JmmVv3bjjn3qO3UxgIrDzH5+g71pwLFwIGOU6M3rVJkSVihqEV3MGRCqyl8FjyKq21jJPE7GXyJlYqNuCD71rXCC+mEcNw0TIMuy1AuktN5PlXpSJ2IOByaszsUXtWjtYUMm+TrLx1rLu7KA3BkjiyxH3q6dbOGGeW13NIzDiQmsWaEOrKp5U469KxmzpppGFNbxwSGIKAr9azJ49m7YNijIGBXQ3EQb5WI3joxrLuIzsZZRgnpU3NHEoeHrKK68S6bHer5ls04Vg/R/RT7E11llqN3JFYSPotk0w1JrK6hWzAaJTjYenBGT164rndJsf7R1O0sDIYGmkCmTHQeo9+OKvNq+i6fd3UsF/4iSS4JWaRJEDSgcZOf8A9dXFmUonEazA1lr9/FvWXbPIC6jAc7jyMdM+goqaVIGllMJYxbmKFzlsZ4z70VomZ2LULtBtYZwW5Nalrd+YgWVRuHcdxWNtfd8xLYOcVfhuBsCqoBBzzXItD0HqaFpKFLAE47ChBtdy74ycgGqhnYR70Gcn9aikeTzFLhiFPT0qGi0bAl2BAhBB71ZRk2DqHxyP61kRsXdXjGVzkj0rUikjkXnOOnFAMtAosQOAS3fNSpJiHk8jvVVV2qDgMuMZ70LcGJwzwh4iMYxRYZqQuXPzvlWH502LyrUSeYzYxkn096iim3tujQgY4FSW+/y/3gJbJIpWFctRMJE353BhlSO9ORURPL29Dkt3NRhXMgKH5cc8cA1PErl2IAYY5JoGCglSpHXj61LKoULGgw3YjpioonMig8kZq4sDxqwmADNgA+gosJuxAsaGNWzkDtnoaJozuARhyeWNO8sxjzN27nAAFKH2/MMlm45FMdx5gHlL+8BH8WOtRFwrrhc+2KA5RhGQDxTXmIzsUfLwSO1FxCSy4yWxtGe3WovMYjcFIHWp/s3yRyyq2113AZ60kxWQsAPlJGPaiwXXQrvkuozgZqeLLSFFQOScZ9PeljUAO6gbweh9KdbbljZQdu/qfUU0hNkkQURn7igZO5hndSxys0+6AZUDjIxSyM7EAxgYGFUd/c06ESBRIwCrnaBnmm0SmJCrRAzum9m4RcZ59a0USJLRGuQCQc7QKz45mVtxBJJwoHar0iPKER/ml4Y84CiqiQ902T2k3nlI4rUgsSSf71ag0wSQsZygk3AFVPA9jUmkQedBt25AG0MOMGpFWTZJEQjOnTHetYKyOec7tpFswxsiKzruDD5RjaAPenaiZ44lNt69VXmmLbL5Ko5AJGVbvWiGzZqjO26IfdH8VbWVjFyaMOA/Z5HlmdnDcbD2P0p9xLI6ODMWjIz0yPcU9CJw0ko8sA8s1Z1z5sNwyRyh7Zzvye2e1LYLpmlocdra6bOuR5JGcj07isjVrRtQuLSWGVVVG25LcEGrdtGYtOu7YlWgZMgp29jVC1tYY7HyJHbeSGVi3T2q73I21LwSGGGNpAGeP5QQeCM1iavemG4jCphJHI+Xsf8ACtOeMvDHtK+ZEc5DfzFVZ/LtrXzZlVojxluoJ7ik+wKQ+V4RYlnfCDA346mobB4owfM3jf8AM/GQw9MVX1Kz/tbR2tbNjBn5kYdMipLGO5hmS5ndXZEAaPH3iOuaOW5DlbckiFhI0rqdrZCpgDoOoNVtRSVIGi04qJ+M5b86ZE2m6pLM8J2KeSF4wQeaBLbQzhkUtKxwSvzcetA7k/lRy28cUzBmT5lY+vfNJ5dzqFvgnDRvgEN+XtSWNzHcQylLVyrkqQ4xx3q1A8NqiQFWQPwoycqe2aVu4c1thzPeRJAltbjBO1nLYCH1qO1u5xe3IumUBCUQsfve4qSzNzb6PJDdypNKMsRnG7/69FrGjWZ3xlM/MFPUEDpVpIh36mZpt5NcW13a3TPDcRlg524X2Oe+RT5BNOkUg+SyiT7w6u1W4UbVFKT20iI3Dbhg56Yq3fQLbrHBaqqxMNhB7fh2pNhFanOyNDbWUkoWQsybXUA888Vn3gd7uINtEYHzD19BW3qd0uyWKLDSD5VUfw/WsOVmu8MoMUrAAhx93HWs5OxvBXIJ2zcKkW1Yx/CfWqsr4V5MgBiVA6VPd7XaQKNygYz71mX0YWZGlZtpABXsKi5s7rUsfalh+SSM/Lxgd81tCNmZGLh1ReB1rnPtAkkR3UiNzg8cjFblpBM6qYJBsIIKn+lG+gn3LluSXeZEBfOxd3AAq7tWG8jQN5gIDbU7t6VScl4lSNgJIsAgDr7mtrT0t/sqSEBZWb5S3UY6012FP+YY8MskpiiAWTG5we/tWhb2U32dnkhFu8f3B2p9vcbknnjVZc/KpXqDVwTyCEieOQhQMZ65rRamUrlK5iTdAskY85lIZsYGa5XUNJ8qXzkOFLnDKfvfWu3vIJpLiOadgYmQkKv8PrVC4trOOxbAfYEymeQWrOSNYOxwV6oIbcuCelZEx3kq6NuTpnvXV6lawskDAncBkj0NYd2jBS6AMN3IrDZnXujO0aFJdf0/7SkhhaZQyoTn26c9fStjUJvEH29zP4VspG3nOLAvn05zz9ar2drpzp5l1q72U6v8qpEzFfQgjpU0sVixKnxhep7iOTj9a0izKSODvIQLi4LRCJy7b4wMBTnkY7Y6Yoqe+QGaYeY0qbjtlxgvz94/XrRVIjlKULMsYLHc+MHB7VYhmWQAY2r0zjnNVLdhuwAevOakUmNsoCV96xOovo/kNhm+U96vlopyHGAEHb+KsVJzK/zDj0q9bYA4OAP4aL9BtdSzboBIRHnYeea04H3hwiYOORj9aqRksoZQu3uO9OJYMhRnTjkA9R6VNguXEba7Ki4C8kmrEcu5PmUFuuCarw+Wx7Edx3p0YkD8D5B0z1qS7lu3JC8qQPUVNmUMBCeMZJNUYbtld1bll5xU6XDO6hQAetAIvLI8fUgjvjtUkU+5wyZBHHTrVaJyNxzmkWdWG0kg55oA1jMmRGRs78dQaYzEMS0pcdfmPSslr+OK42E5zgZ64q4pDKGbgf0oFYsmYvIUTJXue1BRhJgnJz07VCjO6HYR8vUCnL+7OZDlj79KBkomcK6IMj1x0piMSeeg5I9aXznZcRqQrHpSkgrtwOf1ppCbG3E7v90HHQH09qiAlaQBRlT+lOVBkhDhR1JqdG2xuVU4JxuoE/IiP7xsLhFHcnrVuIrNIzu2FXAUYxn8KTyY1ikkkc+irUfLryQu3gE1Wwr3LkM7hiQoLY49Kjhi37fNCh2O7JOBj2qaFYYtkssm8Lz5Z43Gl8wSAjYDuOcDsPSmSTBkhaNY0WRhyMDNWLS3WSNpZ3O8tgqOtQxOvnpk7WVsYHUiriDbDJJ96TduXmmiZaF+JpPMCbmiVDuAAxn3qxBcG2kBk2sJCSpHUH1rNn83yY5CxLtgKD2qa4URhGwQcdPetEYOxoedHJal3dgpOM/jV2zuPLhbDqwI5JOWP0rDt2t2XbKGXggBTkE0JKY2EUIwD0J6r61qmYyXRD9Q1EW0SeY3E7YAbpUbzyJBG4jJUH5lC9BVLXYk1MrbyuweJxIhHGMVKlyI7jMzkx4ywXoPen1uT0Ker3jpqVtFZudlwPmA4IxUxthK9xbXTebG6feU4K/Q1TvcXN+JrUNJ5ZyrDqB3qGz1Oa71R7SZcPGMcnAApg1dFu0RkiCQOrvGuxieo+tTW8sj6e0V95TDkE4wDVbTYbMahcSrKQ8vDruygx6U8JCLmZXlM1nMpXB4waZmyaSFLe3jeGRlhI4xyM1Vt9VmhgEcyolxICoXsw9aS4iEFmILWYmMAlEfjJ7Cs7zkVob25TbLjy9rHIUnjNAJIsO8VhdxRxxMrzPhio+XkcmnRWf2JBDbzowVtznOSMmqd3MIb5ICSJGG9DjINFwkrHbHgzyAFmHBwO9C1G9DY+2BXSKMxh+Oo680+ysZvt1xJJKjIx3qp6rUAhjIVS6M2OOzZ9TVrTIjEkih2d/7/U/Sp2HbqTGx2zn7cdzr8wcHgVFcWsdyY5objypUBCksdrVZEN+kUfmqkkLtzx2qPVmtVjSEnBQ544xSbaHZPQtWBaN1S+uIlgC5B759KWSydJZpfPMreXiOMngf/XqlLKllG7gCSFwCFbkr3zShWuvLnSVgn3mKdxVXIcNblYQ/aLZJlgBfnzEYYYn+tYs27zWO3YSuwZ7GupiWJZf3UjlpRtDN2FZFzGPN8k/PJv8AnZRwR6/Ws5G0G9jmrhXt38nG5i25j/dqhPCtwHJ3Haa272JVYpGAGz8x7kZrKvSVt28g7RnnHWsr6nSo6WKbQC2JMfIPUZ6GtO3ef7ATavtkU/KGHbvVW+ZBLGYOVZQckd/Q1a06ZXYO0gCt8hApp6g46GyyMunxvHFslZQzOO9aun3dsnkw3EYDMmCG559RVC3RpIzCJfuJge4onRftEE8ZLwrhGPf3q09bmW+jNvSpLiGWP7LBE1sXO4Z79q20lvG0+R3hUO0mMseB9awkktlBXTndljbdjHOa1Fl85R5EExR1xKrN3q0ZuN+hJrMKWzWssrnZKCjbPurWU9wEtZbWBlkgjIJDnnHtU91BNCIY4j5qycIrHOPas+6cwTTQXVsgfbg896iT6m0Y30M2/EZkEi4CuOAvOKw72NFmdARtx1FbE8zRKWjQABdvTtWM0oliJZSJQ/4YrnbudMERWehX99E09lArwZKkl1Bz+JqCXwnrRlGbRcdMecn+NWLCBL7VrezYlY5ZNrFTyB1OK0hZ+GnitJWs7sQXVy1uC1wflcYxnHY5FXBEzbuef3FvIk8kUq4KEqQDnBBwaKvX0JgvbuGVRCYnZCgOduCeM96KvmIscvG4ifO3g9KvIkJhyHGSeaz9yhCCD061IjoQWDEEY4rM0J0A83BjJUd+lW4onzvVeQeR7VTfcSpDMB3NW4ZmAb5iV+nWkhitPOFzFnA6gVcS6Z1Qldp74FV2lWTaqKC2PpRC7mUqPu4xSKWxpLwFO5R3I7mpi7MygkjIyM1ShkQqdwIYHirMkjeWNvztjik0OLvuW8jamAN3UnFSxvhxgDPqe1UoColwWO3HT0qxG53ErjA6e4qSi5GjtKFLAL2zTsDLKyjIPJ9ah3Ngszg9x7UpZnwS4Bxk4oAtCKGFCUjDZ67hmmyykFWRW2gfdAqMPsh3k/jUwdmwTuGR0AobuCVh45RQoPIzToclXzzjrnvVZScEI5YdA2OMVKknlKMHI7n0oGy3b3RcFFwdo5qQSxxRPviJY9D6fSoFkDRjykxnq3rSLITIQTuIx1poza1JFJUAcjIyc96WcOMJkAdcVIMk72ABHTNMJAUsQSWPWnYVxyR7nUBjuA4Gc7jSzxgBY2UvIT0B4FRoTuBVsY6mppflkTy8qMZz3PvQF22Tw2pcF2IEScEE1dAimkDRjBBCrj071ltulJZmIVRya0YhLFbLNvX5uAB2FVEmb01Y9yqzRPCMNyoz6etTJO6BUKBt4wvHU1nRj94XZyCvQCtE3KGOBVhdZs8O3pVpGc3Ymeeb7UqMyMowcKOh9K05CJrZ1lcGVlJXaM9ulYs0krKq2cRC7t7HuaLqd7WRZnLRbvug981cVYwk7k2hPPFbEyRgtjBL9VNV7yOWDWEbeSssW5COmQasndGsc2W2bcsPaobyCOdEmglb1APTHpVohsoDUHlu7pHZleMA59R61o6UTPYSrqEiheRE464IrMuCkkjTIn79YyuOxHvWYYbufRvtCP5LiRSQTwBmqREtdzQihurS0zZsJJl6nPBFWUkjNyrmEG4kQZ2nrSFvKWFdxBdcg9KxNNuri6vpEjUecJWX2wO9PVbC6G7YSQxm6ZIAS0hO1h0/+tS6Nb5jmS6bcplLqV/hX0qHT4HhvJDczblkzjaPumr9ralbmVI50LHIKkcAHvQk2TJopW9qlnNcvNIbiLdvjI5IHpUUtr9scS7vkYY2EcCm3d1PYJcJelGEXzAoONvaoLUT3CSTSkJG4BQLwce9JsuOyJrqNprNDcgKIXyuxuT9asQtbuqtFIrTMPkOP61GY5WKBAJIyoBX+9UDCOKGNvL8vaduPT2pcxTiXlgO4XTRhZWG045GKtASvaM1oQAvBLVnwyXMUCR20uYt+XST0PfNacu1oDHDJsbjJUUmCuizHdbdOkFzMU8s5L54I+lRJtls0uVzc7yQpUcBf61EbCWTyxMqm1KkbhySfp70+2me0ixZAJHG+1om6AU/Un0J50T7Ak7N5QQBmJGaIJ5XsGihkEYkbO4DqKYyTSvCVCiBj86d/pWvBbwX7mIWslusI3RhxySOv4UA7lWRDb24Mybty8EjHzdqz7mPy4o5NjxyFSckZBPpXbLpks0DO7I6hMeWBkg1kXggvLRo5Va3mt/kUEfePpUyRcJXPPrhgx83B8zknPaqEgB5KZHUV0OsW7RXjRkdRggjH0rHlt3VCDlGTsR96udndG1jGlyJPmBCntUtt8kuBtA6gVYmhU8sck8/SoI1Ak2AgljwTQh2Oh024h2M1wjkkfKy1ZgEhhAtlUYYkZ6NWPbylGbPHGBirVtIUT5ivH3QTz9a05kYuGpsQLOsUsrhI4zySnrVwz+ReR/ZbxnVkwSB1rDhmV0w0jBCeRng1a+1edEItixonRu5p8ysCiXLkyQ3JRiRHx82ehqleBsF3kZmU5z7fWprYvL+7dsxng5qO6gRZGiMmFHGCOtRfqVZJ2GPHthY3RIhZSUA6k1zeGm4UHh8ZNbU1wDEIQ5aP09Kx7ySOMNtJUg5FTuy43RFZx3R1SJbFMXolHlkdmz1rRt57lNcu7TOkyvJL58QdT5PnjAHl+h+vGRVTTdQltJobqO2eWXzfl+UnzOOVHvirH/EstnN5Hp+uSyI4eO0Nvgbgcgb/TNaRiRNnC6zcTfaZvtO77QZG8zd13Z5z+NFUr+6uL3VLma7+SaWVmdP7rE8iiq5Acl1Mg5HBwQefpSIy7zzt461FI2YyNxzVdg5VSjAH0qbDuaUdyzOAucdxWnEQUOGO7+77VztvcEkhx8wrStnIQMM7sYyahqxRbWQq33cNnANWA7yFWjGAvJrPVncBeozzmrVtgow5GOtIpovBsnkZXqeaninVJNu7g8VmoSobBBHbJqePItlBwD1J71Nh3NMgxOSr5zyPSp4pdiLk5DenasgO/Q8h+/pVlJo4VCB/u+vekM1DtyoPCn361Knl+WcEDnv2rKafcQTuAPSlSUDKs+89vY0WGaSb2JBDbB09DU5kKjLNnA/GsxbiXdhVzjrVwMUBxkNjJBoC5LHMzqSDtYnG2lU+YQjjjuRVN7htuXyCT1qzGDEoVyeen+NIdy9GRGME/KPfpU3mZZmjjz6gfzqhbK87AJ8wz19K1bWMxF08wE1cUZzdh2yUQ7pNoUgE0EbUUgkDORn+IUrTJsHmJgqeQaTCSOCRgA54PFBKfcs+QirGsr7Yz8zYpmVYNsB25wuT2qJx5jMiglm6dhRLhYwoPzDr7UMZObcl0ZmKqG4/wD1VbNwW3COMsFGMn/Cs8TyYjVtxHb3qV5jFN5bPgsN2R39qtIzlLuP82QMMryzYzjgUQE/bbk3MhdkUFCTwKrzSfZTmc5P3sZ9aqyec0sbQ7Sh5YnuKtGUmbX2lYilv5oZjyCvXntVXWfNuLALKCViYOufrWaLgT6uk+3mFCCV4Gewq3NeJqqvEspXDDfgYxV2Mrvqa0txCYVAcoXXaFPSm2z21nEltLcEqvyqx7k1l3n7yM+SQskONuTmq1us17bRT3YCHfuCHjGD3q0QzZNhHa3Fwqy+bvGf/wBVZ1zbx3tskLySbA2fl4xjsaLe4ub0TSQRYRW2q+PvU5S10kkbMIZFOMtxn15pBe/Une8gMkFp5YZlHBB7VFpsT2mo3JX5hN8yKeMH0qu7m11AMgYM67AwXIFMtmutkiXGw3By0ak4pq4jSQSzrIs4aKRgWOOcY96pxxypdrLaSBGPyyFudwqcNcW2lySuDLcqv3QKoXP2pnt5bXZh0+eP0agE76GjJi4AimVS+NrAnqKW9u5LcxwiAOjEIT/dFVrad8o17GrOowdvGKt2+2TcJmEiEkgDqKm6LsXWgjjkBhkO4AbTniopis/mLLAcqOHHc1X+zRtiGJXEfUHOOavQCZXRJGAGepqWylETS7WSa2lS4xkHPyd6pao8iw+QI5WjkIG5Oqe5rWiEnnl7f7wBDD1FQ3M8sNqCIjJz1A4pJjaLgacW0MUQYg4Ac/qatX9nBb28d1IHEsgxwOvuajW6sx9nuzvA4UheefStqBzPZyvOQYpD8gPVRV2M76mVY2iXEMQdmDA7g2cVt6Mf7Uu7hJQ8KQgqWHBxVSx0yS3dZ7YmSMsCys3X/CtrSbp7i4u7e4t0hOBtPt/WlHzKns7Es1osRW1sblvm+ZmZsfSqd7aloczyL5ok3EDnNXDBbxztdl2MYTCgHqR6+9VLGRrq7YizeHK7ixbI/wD11TJjocjrUJuL+WRi7DPB68YqtqAN3ZK77Q8SYPHJHate9229pNaLLkyyMyn0FLp9vbPp6wOm3ILIM5y317Vjy3bR08+iZw+xS3PJ9cVVa3CSghAT3zXU3NkTNKVQDywflqgtoxRdyEBu59KzaaN1JMxoFCyASAgVKUdWBI4xWqtn5hxgBgMjjg0qWMomEUg+YYP0FFmPmRQiVnBVTj6+tW7BPMXywGMnbNa89jAYGJYeZkEOB1FZ8r/YiHRgznr3quWxHtOYsK0jQbJEARThmX+E1l312/nuAysDwe+aLi/ESSfPgSHJ9M1iXd4q5ZGBY8g56UPyCKd9R2o36ptJIGOCBWJqOpxhTvYZxkAVmazq8LOy7t0hHJ9DWC88s5BdvYfSqhBthKVjsNI1KW7vtPsIbu4iZ5wVaLkxsRgsB64rWjvba51RbCHxvqvnNJ5aN5RCM3oG3eveuC0y5uNL1W0urUBriKQMikbtx6Yx3znFdq2jizm/tS38J3A1CE+ctq1+jpG3Xd5Q+cgdcV0KFjmnPscv4o077JHHfWl895bSzvFI8keyWKZeWVx79c0Vm6troutIt7KOAo/nvdXUzNkzzN1IH8IA7UVqooz9oZ0UivwcDio2jCsWU4qMAAgdvWpEKsNpPArjeh0piIPnyKvw3BAGPxPWs6aIsQA5Qe3erECrEgXcMipZaZfMig7h1Pc1LkrGWkIx6g1niXLDIx65q3Dc5DfJuHpms7GlyeF0ZVDE4znjvVgmNjuBZQOnvVPz8lQq7amP7zO48H0oFcsRzl2ZY2x+FSqyyS7Sudo/OqsLbQojzu6DNWHJGMf6zufWhoafcsxsTIARuGccdqmMWZThhj0AqtHIIrcSZx/PNHnuWAXHPJzRYV7lwyNbjYr5ZwOlTqvnOJJFZmUcZNMR4lZHUpvA6+1MuLoISYcsx98UWHc0LVA8wypYD9KtTFFdfm3D+VZIeYiPa21h1INWY95JcAZ9aVhs0VKQFhFnPTir0RYoAsZEgH3+tYkM6hxs3Ng/Nu9a2FlKqGblm7CnEmQrscJuGQT+tWiFIQOpwDnAqGEo8i70G3tmiSQDzFiP3Ofxq0jJysSTL1ZeCvSmq+2N9+C5GMdapSXMmNzEjsfeo0lEo3Lk9sCixV7IuJcjf87bigwOelTJMhUuQQT0z2qp5C2tq1y7ZeQZ2Cmm582Jpdm0lePSteSxh7RPUfqoe6tGCH5+m41atwYo1Vjlto6Cs7UrkHTk8s4yyhqltr9XaaMuAwXAHc01Gxm5XKwkS31SaHyziYgp37cn86NGZUuLkLg73+U56+tEZiUG6KsZ9mFP9Kk0ZoprdLh1VCcnaOxq0RIfayouoXkZc5DLtqe0uheXU0N0Nscb7dw4BrLiSZ7y78krtU5DNwc1duZZ5Ypo41G6NNxOMfNimZtmktytpeGzjc+Sq+YCvvWdqeoI5FqgzPI3G09s8mqdswaAzp+8meEK+D0qfTooGhjuVXL7flPoKRpZF65Ba32WknIxjI6Cs+R5G1WGRwdiqQWJ6H1qSK8haVzAhBI2svp706Z/MbJwIAMNmpbsxxjzFm01SeechAJLID7/AKnuKsRQpHNMYTsMnzKM5qnblUgRbaIBCeoNNIguHV4XfdETuC9iO1JyZSgtieC4kZmjuotrk4J7cVIZQl0qyRlV2/K2ep9KfbyJIrM6ktjFO8+VpUSRSYgpzkVNy7FiymnvJCHZEkU4BB4xWh5cz3QXduO4FWHes6MxH95AgQdOOtXdJlXckMxlaQElGI7e5oSuNpolhknhupJNgG3171rwbZVyhAaTOYiOB9Kz0uYlExzlVbhcZzVmPyZIFm8wxKp4NLYbVy5bw4uvsrRrEEG4ZOQa0LZrZtPFvd4Dhv3cg7j0qrbNbzRvJLKWwvGO9Rwz2tm8DwswdiS24bgPaqTsQ43L0crw3MqXVuSoGUCN09M1civ/AD2M9vgOg2lXGMCsy41R55fMmU4YHbIi8k9qhm1BZGR0haOc4xlsKSO9Fw5bm45jvE+0eYxRQcpjABx6ViXmqlQYJXfyCMxrj5s/WqT6ut5LN9uuvImRSAFHDVzmoar9olDeaCoXA9QKUp22KhTu9TpDfW8UMjXjESqpMaEcc+9Z0OqMbdlgAVuisewJ6VzxvFkViW3t6mq0uoRoPM3bVHvWbm3sb+zSOtg1EtMyBVBOSSe4xzTU1O3aHayEhEKquOpzXCz+I4cbUXa5P3vanLq0flGRHxt5GTyTTTY/Zo606lGi7UwrDGc9fpV231FXJmuBlVB29seleYJq0sl2ZP4i3y1eutQugD+9yH4IHrTuwdLQ7BtRU3DNEx2t1XHArPv7zZAVz8zc1zz3v2QBwxc4zz2NVLvVQdrSMuD6dqEmw5bEepahI85iDZNZd5PIIwBJz0+lVL26SS4LQE89zWdc3hIKr361ShcblYrSbnncFs4qxGQqjH3h3NVImzk85NSE/KATyOtdEVY5JyNXw9qkWmeI7C8ugTDDMrSEDJA9R9OtasOlCz1yHV5/EumizhnFw12lzmV1BzgJ97cemDXJJZaheq8tnY3dxFnbvihZxn0yB1qXw/o2qjxFpkk2j3wiF1FvL2rYxuGc5HSqvYybM3XtSjutUvLmBfLinmeSNP7gLEgUVU8TFT4j1chQFW8mCqowAPMPGKKLoi1yS2umZAJBgjocVYtsFmctz6VShcCPLLmrCupwynFczOpMuIBIxyxxT3Vd/Gc+tVhOCrBeopRL6c4qGaJ3J5GxFnPzHtSR3ix4WIl2PbHAqIupxv4GOtWLV02gKFA9QKNLDuyzECjZf7561NHKyq20YGcE1BcJ5ibvMxg9KeuUhxu5Y8mpZUexpQsCq9dw5BqRHK7mkKjnIHrWdHJI0e3IBHQ1Ye4/doMYcdcDrUFlmRTPFn7pB4NODOYeuccZ71AkwkyJTjHQetWrdk8vKtnn5QaEguJEXMbZGEx1PWrVkoMewgt6560xyQoAA2P2H86cnloEEZJOfmPrRYHqWwpBVACq/wAXrVpA64GCPU1EGZlITkDvVqFtnyMQdw4JqrBew4lUjyCS+ecDr9Kt20wcDggHuaqxAQR7bl5JCOdzdT/9aljImjZgw9qaRDl3NXeERQvzAck1Vnl3AsOEB3E561XecLEsalW9TmqWoXWyycxEE4xtHWr5Ohh7RJFyMyXcJaM/uyecmiCSK1ChDlue/WseK4ubmGK3tT+9bqOmB3qTTx5F9PNOCyooCD3q+RIh1GzekuYG0ecTO5vMbFjXkjPeq3mJDBDb/MoKYJ7k1DKYS/nbju28kVh6pdSW15bSj5kdvLBPQe9aJ3MbWWhsNeW1raMXYyOzY2EcVUt5WMszRKDM/IB7CqOoXIhMbOoZN2M4qa4uIkuopkcRkjaQO5puIlI17cOZFS4YBChy2ehqijf2d5pd2a3jGcnvk1WtNVVt6kCRpG2fN1/CnXzrPdJZxklWQkg9qaSE79TR01/OiuiSUWRi0ffimwyTx2k0kkpFw4JCH24q6jwpapAAFKDCkD86yrO8aS+nyoZosBc/3al7jSL2mukFhGWY7iNzirMVzDbWDtCNgGWrHNvc3N8JGYRxch1PAxUcixCzaJ2YQB9p57elIaLGmXKL5ewktKd7t7V0AmQjb5e5W5z6VhM0UKi306MDeuAfQVoRmWSyaNDg4wMVEjWOhNvWyd9rM/mtgL6VZsIoQrGBtm/lvc1mW8cyXMYILALhmPatSKHyo/8ARlG4HPPpUtmkVrcZDAI9SkZnZRtAKk8Vrowd+gYHhecZ+tQPlyweLa2MliOtN2MQpjfbj7wx1qGy1EtxBZZEUna33cVdtgsF4HYjjAxjis3AAXk8HNWN0bDzfMJK8VNzRo0rd8yTBBt3njPFOguZLSGW3YDef4WXIPvWV5ykgklj1BHap5L6OSLEjtu6EmncEjUiNuLCNJCQ+cMqdcVMlxYQKqxedIWUqd4xtPY1hx3i26sU+bdg8jpVC81gGTlByeeetFyeVtm5f6yI4ESV2KKm1doHX3rCvNeaaJEmlJRBhR0rntV1WLLbBu5yBmsGe+eUsBnB7Cmk5PQpRjFampqWqkykxsQehNUFvJMMWZiO9UhDOwLbSFPensjZEYYH1GetbKl3E6nYtjVm8soByR1rOubqRsjdx9akaNiR8oA9+KglTLY+U49KpU0L2hAxPAYn605VPl8sTinpFkdeRzirMcSAKyYBx3o5R8zZUhJHJO30rTikcmPJbjnJ6VWfHQqBUbTbMDLe1HJfcfMaOoynyCXYHmucubgOxCdPSrN3KWxknHpms+THORj+tVGJLkMlZVhVedx6n0quSRwaezgZ44zUcj7skjpwKq1jNzuCHjA/OkupBFGSaiaTy161m6jM1wwRW47mnexlZydkWLfxHqllH9n0zU7y2hzuKQylVz3NSHxR4kdhjXtSAHYXBq/4V8M6fq+n3s82sfZJ7VTLJALYysYh/GuCM+4HSrUWh+Gdwz4rO09/7Of/AOKpJN7m8cPb4jlWV5ZWklYvI5LM7dWJOSSfrRW9DaQM0ojcSIGIVyNu5QeGx2z6UVpyWNLRWljCWTYAe1SwTIWIPTNZ8O7dhzn2NW0AHCjHqfWuM5ky0oGG2n5jVhPukdM1mxxuJN5c8e9XlfeeKTQ4seIfMjy5zU8YQLiMnAqvEWViueBUyShSBsGM9aCky2CVQbweemacGO4FgCDUMk+7qeB0FDSAR55NQ0Wn1LRkABwx3VJGRgluWPrVJHzGCVwakjdjwWOKnlNVIuRs6gcdevtWlEIiu1m+fHasuOQgYJz05p+/GChOc5qdhvU1x5armM4A7ZpYZGhdU4KnqxHNVYiUi+ZM981OkoITeM+1PqJFyBiJ2CHCnrV6N1GGIJwetZ5woEicYPI9qsGQEAZ+X0qkiJSL7yC+fahIQcc02RktoHjCA+X1IPJrNsG2zyBWK85H0q1YzTSPNviBbJ259K3jFHNOT6CJJGsIkwPOfll9Kp3FzGjuWUjI4OKrAStfNG67N75J7ADtU+rKDGrHawA+XBrS3UychsTJbWzXcjmKXHyge9R2F5Jd9f8AVJkNnjJpNQfzbFImcZ4OarrKuzEZ2o2cgdzRdvQnrc0Y9RSS1Z5PkiGcDoTVbU2jlsY22BQv3fUn1rLUCeY20vyon3AKvT3CKqxFN7r68ihA2OlRZoRBKT8oByao+VJLIUVvljkDZzzinmZpGLM6rngbjS2d8kV9+7RZdhBb39qpJPclto1mtIUaKaM9eB659abdRbGRYp9sn98DnHpUeo6jHGJJ5MKW5AX+Gq0Ehktkd3wzcjPWpbSZUdUbDzuqlWJCkY3dzVW2by7xyOFKjkmop7kRW5UfvGxjcexqtaxvAXkuC8hkwRjtUp3NHE1oLvz4ZlZyXBIpTLCttFHOhYuegX+dNt18uFyigFuSTVuzUSwg7gpHGT1qZOxcYsmZHN1A8SARkc+v0rUjUAjA2heoqkC7xmMsA3QN6VYtQUO3eztjOT61m2axiKqSGdpPNAU/dWr1pI8YOSH3dqhRGKk/KG64qeEfuwdwHPIqGy0i1JNkEBs4657VGC8jMd4EfWqszb8jlcnlgKeZ9jAYzSZSL8YRdrdeP1oEhjTPkrg/rVFrnagyMEngUwXOw5diwxwKRRbuJlXd5QAJ4IFVTexw8FV9TuNZd5q0ERIVcvjOQa5zUdTedsLwM8VSg2K66nQ6hrSBWVXOfasC41KSU7cn1zmqEaO4y4IGetWbaIRncwB9jW8aNtzOVVdBbdPtLsXk2nHpyatrFDFtaNhj+Ivzj8KSPyojuz1/unmmtcwAuPJLj+EE9K3SUdjBybJj9nfIdnfB4K9/rULPaowKxu7DsTxUEj5DYwikdBTA6iPt1pN3HZFie5aRSzIoU8AYqpvUqAQBzwaV3JGWIwO3YVAGBBPBApNj0Jc4PzHj2oEgycHjFU3lJPWlB2/NnFId7EplJJHVvftULyEElz09KikuAobaAT0zUDMzAKep61dg5ySSUOQRn1xVa4Zi2GXgdqnkxHjjmoJZEXJJHPWmkQ53IHO1QpHPWq9zMioMnGeuKguLo7iE5NVWR2bL0b7FU4SnogkkaYgcgA09Yc5AxToYSe3FX4YAPvDFOMbnp0aCgWtD0fWpQLzR7O/baWQTW6McEjDDI9jzV1fCeuDj+xNR6cAW7Vf8NX93ZPcWtrFcXMF3GUltoWYEn+F1I5Ug85/CqeoL4jsIme6GrwoBy7+YAPfNV8Jo079DFd2s52ikUo6EqysMFSOCCPWis6V3klLOSzMclic5PrRUOpqS6avqZ67Scg8j1qSPhjk9aiRlKgAZPrUqlGUFu3c1ynkkwBB9qlQiLlSTnmoVKuoAzj1qWPaqjuKQ0WIyQCyr19akU7lIP1po+UDJ+Wo1DeYAo+XrSKVicDact+FLvIGcE0y5HmfLnAFOUELhaLDTsWUZSgJJOKeqM5LDgdQKgAYLnA5p0bMpBLYWk0UmWVk/eBSBg9asrKFfII24wKzsAHzA27n1qdF5yCTnmpcS0zWtpNxxuJPoelWHUptDcsOfpWTCxhYnk5HSrUF0Cx6k9waBOVti6t0+4YBLehptlLNiR5/XjHaq13cIySeVkuBjA9amsIpLeyE0h3Y5PPStIpmMpalmymLfvLobAThQOtW55ZI1LwtnccDnmsHUr0yohhXncFGO9XUkEMCrLJ8+Mn0q0Yt2I9Tu5GmS1iy0jDczelKIJJYkMpCuSCB6Csm6uDbq91CS7MdufartlP50bST7t3RV9qom4sjG482EOAytgHtUMkqqoUEFgdoA6+9SRbFkcxfU/Ws23tHa4Nzn5cn8KuJk2Tm5WXVJGj+Qqm3n19ai+0k3BMm75fvN2qvdgwXixbP37d/606YPFbukoBwcn3qmmtwWuxcSNJLZXOWw+7caRZ445yFGC3JxTbGV5LC4dUxGp61DcSILZXQ5mY42j0oaS1Ba6EsVzHdrLG4yC3U962FMaonPFc/agQsCeo5q3DJ8p8w8ZzWT8jeK1NOV485GSD2q3ExWAKpGO1ZcUyEYFTq4JyWGKy1NTWQApyRk+9WLd9oCqgHrzWRFMhYbWJ9eatJIoIYEgUmik7G3HdKq4k4NTtLuQbW2571z5lAcPyQexqyt7HuALjpxS5S7nQRTDaACSB6jrU4kXG8dfSucOohEwXODzSSasuNykAjsKXKylI6M3AHL/dNQzSx54bk9B6Vyv9tFXOcEDnrVO51RppCQ2N3oapU2wckjpbrUkjZlZhhfTmsWfWJASIXyvvWQzksTv684pi4wMHGeea0jRXUh1Cy0pkJZiSx6U5AA3AP0qGN9nIGfrUyzRseWG6t0kjFybJwxCDGVx3p5HGTu9jmqouEYbQQDSif5QNwPtmlrcdibzNqkZ4qGaXy13HNR+YcE8e2arvdAc5B9eKbQkm9i55xYbsfKRTPNAbJ69qpG6XbkBiB7VXkuyzfu42J6Zx0pFqEn0NGWceWAT35qubhT8qnFUJYp5CN7474xTltsA7WJNKzZssPK2pZdmYAA8UjOzDqfTFMijm2FRzVq3sbyZj5aDPY01fsRKi1voQQou0Mxy3f61MAI1LudpPTdWpbeF7yTG+UqDzgCpbvw1bxRAzyyOR6mrVzF8idmzmpLkMxC5kf0UVWS2nnfBQqPU12tla2kVv8Au40GO+Oax9RmVXKpxV+ztq2FNqb5YoxGtYbYZHzP6movKMj54z1q2IC7ZI+961ct7VTx70b7Hq0aaiilDAeDjGBzmrihT7Y7etTTR7AAOPrVORiqnnj09KeyOuKudh4fkup/C81n4fu47bVTcl7hfNEUk0W35QrHHAPUZpmk2Pi3TtThuNQv3s9PRw1w95dq0bR5+YFSTuyM8AVlWEWl2fh8arrFnNfm4uWtoYEmMSptUFmLDnPPApD4esrvUtI1DTWlutCuruOCaKZsyWzk8xvjsezd6xkzKUUr/wCRyeqyW0mrXklihSzed2hXptQsdv6UVY1i2jg1jUbeIbYormSNFz0UOQB+lFZGbdjl1ypyD+dPVsx4JxTWbPfg+1IExhiM1Fjx7kokMSrgk55q3G5baD1IqoCJGHHA6ZqwySOMpx70WC5YUuzfMcL6VbjIKDnOO1UYuFIJyfWlhY88Y7UmUmaCSRsSM8ikZwTuJ6VVAIzgYOKgjWZmZy34Uhl8zEdOfrUi5eLDECqcW8D58HNTRgkjBxjtSKTJxsXALGrJ3nBjO0CqSOrucdRVlZNy57ikVctecV54J9hViCRSEOB7+9Z+9QN4PP8AKkabkBSQ/U00ricjXjlj8xokHIGc1A3mLG6s7Bc9KytKu2e4mbdkk4FaqsWB3nnOarYz3JWRVljc9hwvoap3U0wnZmUmMcYp0Mjz37fN8ijjNXJJQM4xjoTVozkZLXe5xbJF8vUmrFpKY5efvE96gN3Gtwyou5iecU5ZVnnKKvtn0qrmfUmuBMtwfKYASjB9qIXeELECML19zSzyLlUBwy9ahuiqqoQ/N3OaOYOXQdcbZLhpZRukXoR2rOv7gyPtU8k1aWcwQuDgs/8AFWbLIN/3SfenJ31HFGhFcSwWjWwYBZDk4qMSkNgdRVW2inv5ljXjmvSvD/h+1SEC+iBwM7sVSi5bhdROR0/TLnUZQIlJz0Aq+uiTxFkmUhxwQR0r1wWumWGm20mmxATg4OR1qjqiCS8jmeELgglscH2q+WMTanUv0PNG0NygGSv4Yqs2lzqCQTgV6r4muoL77P5FusbqPmwKwpLX90SBkdxitOWLWx0wSe6OBFrcxkhM03fdI2COldo9qqjIxmoZLNDklRmo9lFm3sl2OU+13CnGzio5pJiu8A59K6drOPGAoyaQWMeD8vWl7KJXsEcm09ycFhkCnJJI454zXTnTYmbAAB+lMm0pQQMflR7NESomAI5+2MVLbWktw4UDrxWlJphjzsY/jU2mE2848wDjoa0UYnPOnNK6LsnhG8gt42mGN4yDioW8LXG0nf26YrsP7cN9FHFM4+UcCtLTIPtkyxowye5rVwhbQ4Pa1I/Ejz6Twrei337ifbFZcmjTJJ84bjrxXtV1btbkwybeB1FVTZwyHLqpP0rN010Lp4xrdHkP9m7Co8puR1NNFiqOSynJNevTaXbyJjy1z9K5u/0VVugqHknpUSg0ddPGRlo0cQ1nnOB+FPjtEAxsGPpXpll4YhMQMnzMR1qX/hFYM8Din7N2uN46ktDy57UYAC8dcYpBYOx+VO1esReGLRc5VTVqHQrWMjCAmk6bZLzCC2R5KmhXEmHKHaBj61q6X4ZN3Lyu0DsRXpk1tDDCQFGAKr6OI9z8Z5pcijuYyx05L3TCt/BtvGoLDJrSttFt7YDagBFdE+0YPSqdy4WNmGCKrS5yOtUnuzFuY1XIVe1cl4jVhCV6V0OqaikSMF5Jrj9RuJZ8l2/Oquup0UaEpO5hwSS5KDP1zVe4j+Y/xN61akYxkkfeFVnl3NkjB65qG2z2aNC2pHEwB+ZfpirAYY+UEVXDYZiOW9aQzKEw3BIyfammdnsxtxcDJyMkelU5JskgDH1ptw69VPFVPNGTzkms5TsbclkbenapdW+mX1gogls7jlo5kDBGxjen91veq+ga7faBqDXGmSJlsLJE43xyAHI3D+R6itTwraqtmL2WO2knmaTyvtQJhgjjAMkzgfexkKF9TU+kXceu2kzaulhLFHIiOYbcQT26uQqzKVADKGIyp7Vi5XOeUlqrepyt7cPdXdxcyoFeaRpWA6ZYknH50VY1C3a2nmtZdvm28jRvg9SDjiinYyZxpZsDYOvSpI2bhWFR2nQ/Spl+9Unh3LQ2BMKR7VIkxXAPSqKf638asr0agL2LeBncvemvkMCBj1qOLtU1z/qlqWVFjmlAAA4NCJtyd2SaYOq/QVYH+sX6VJdiujyM7Ky7V7Gp4m8tQSRn1pH7VE/3qAJ4ZEMhVeKmcuq4T7xqpEORVi1PD0APjUlcyc1Zk2iHK45GOKrXB/cn/dp1l/qB9atEydhdKtRDEW2kZPJq3vLEmPkDrT0/1BqKH/UPRuxdBmnZmuJXII5wKltN73FwxOI09e9TaaB5I+tQy/dm+tUZvchgg8uSSXbkseKmR1iGWUBz14qOT/Vp9KQcyJmkyrCOMO0pzk1WMpkjJ7itPUuLaPHrWYP9SfpQPcrRTFlYOCCKftMjKu3r6VEn3WqzZf8AHwtWtNSFqbGjqLSdGOM9ea7ux1F5lVSvyk4rhk/4+Y67XTf9RB9aqMm2W4o6kMkyKPuFQMVV1PUnWJUKhlQ8571Yuf8AVR/SsS75Az60SLopN3Z02jW8mot9pMaLkBQprQ1jSGsbdpCE2MMY96bo3ywJt46dKh8VyOYcF2Iz0zVp6Gik3UsczDZGaYxqw6Zz1xVO6i8pzCeWHFb/AIdA/tPGBjZWHrny6pKBwMngVSelzuptudiP7OBCZGHaqj5OCoGK0pP+PFarxAZk4H3aGzojsVEZc4A571IDhuQMHiqsf3vxNS3PRKm5o4oc67shelVpEGR8v41LF96j/lofrQmS4Ir4ZDuU81dstVuLWUOjHcO9V5fufjUI7/hV3MKlCElqjo38STSODISzepq1B4hUgAgg1yTdRSdCcUmccsHT6Hfw63Cxzu5A9ayJ9TB1BpMkr7GubQndTcnzOpqubSxh9UjF3PSrHWoPJXc4B9CelaC6jEw5Yc9Oa8xticdTWlCxOMk9fWp52c88LFanfJdpyNwP40rXKg8EVxEMj+evzt+dbCsxRskn8aiVSRlKgkybXdWSGE4OT6VR0PWIc8uFLGue19j52MnH1rFiJW6iwSOe1RzN6s1jTXLY9f1i5gtLJZUlDt9a5C71eWXcFYhaqFmax+Yk89zVGXqa1erua4ehHqNupmbJJHFZM8rH3yatXh/cmqMXQUpHs0acbFaXb82QMk1m3LBCOmfart79x/rWRL98/SpbsehSgmOSYjOap3c7EnHJ9RTj0P0qnJ1rGU2bcqHbyRjp3pwTBBzmoz0qXtUJmcjovDepwrarZXE0EMsLSNA1yCYJkkAEkEhH3QcAhuxFaKmw0mBzPDp9jbMyySQ2179rnu9h3LECOETcASTzxXDHvUeAC2BjpTSOSdNNtli8upLy7uLqYr5s0jSPjpljmiq5+8aKq5gz/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory papules are present on the nose.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37653=[""].join("\n");
var outline_f36_49_37653=null;
var title_f36_49_37654="Montelukast: Drug information";
var content_f36_49_37654=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Montelukast: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/18/13605?source=see_link\">",
"    see \"Montelukast: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"    see \"Montelukast: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F197951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Singulair&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Montelukast;",
"     </li>",
"     <li>",
"      Dom-Montelukast;",
"     </li>",
"     <li>",
"      Dom-Montelukast FC;",
"     </li>",
"     <li>",
"      Jamp-Montelukast;",
"     </li>",
"     <li>",
"      Montelukast Sodium Tablets;",
"     </li>",
"     <li>",
"      Mylan-Montelukast;",
"     </li>",
"     <li>",
"      PMS-Montelukast;",
"     </li>",
"     <li>",
"      PMS-Montelukast FC;",
"     </li>",
"     <li>",
"      Sandoz-Montelukast;",
"     </li>",
"     <li>",
"      Sandoz-Montelukast Granules;",
"     </li>",
"     <li>",
"      Singulair&reg;;",
"     </li>",
"     <li>",
"      Teva-Montelukast",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F197987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Leukotriene Receptor Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F197955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients with",
"     <b>",
"      both",
"     </b>",
"     asthma and allergic rhinitis should take only one dose in the evening.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Allergic rhinitis (perennial or seasonal):",
"     </b>",
"     Oral: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Oral: 10 mg once daily (in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bronchoconstriction, exercise-induced (prevention):",
"     </b>",
"     Oral: 10 mg at least 2 hours prior to exercise.",
"     <b>",
"      Note:",
"     </b>",
"     Additional  doses should not be administered within 24 hours. Daily administration to prevent exercise-induced bronchoconstriction has not been evaluated. Patients receiving montelukast for another indication should not take an additional dose to prevent exercise-induced bronchoconstriction.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F197972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"      see \"Montelukast: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients with",
"     <b>",
"      both",
"     </b>",
"     asthma and allergic rhinitis should take only one dose in the evening.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;1 to &lt;2 years:",
"     </i>",
"     4 mg (oral granules) once daily (in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;2 to &lt;6 years:",
"     </i>",
"     4 mg (chewable tablet or oral granules) once daily (in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;6 years and Adolescents &lt;15 years:",
"     </i>",
"     5 mg (chewable tablet) once daily (in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adolescents &ge;15 years:",
"     </i>",
"     10 mg once daily (in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bronchoconstriction, exercise-induced (prevention): Note:",
"     </b>",
"     Additional doses should not be administered within 24 hours. Daily administration to prevent exercise-induced bronchoconstriction has not been evaluated. Patients receiving montelukast for another indication should not take an additional dose to prevent exercise-induced bronchoconstriction. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;6 years and Adolescents &lt;15 years:",
"     </i>",
"     5 mg (chewable tablet) at least 2 hours prior to exercise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adolescents &ge;15 years:",
"     </i>",
"     10 mg once daily at least 2 hours prior to exercise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Perennial allergic rhinitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children 6 months to &lt;2 years:",
"     </i>",
"     4 mg (oral granules) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;2 to &lt;6 years:",
"     </i>",
"     4 mg (chewable tablet or oral granules) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;6 years and Adolescents &lt;15 years:",
"     </i>",
"     5 mg (chewable tablet) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adolescents &ge;15 years:",
"     </i>",
"     10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Seasonal allergic rhinitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;2 to &lt;6 years:",
"     </i>",
"     4 mg (chewable tablet or oral granules) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;6 years and Adolescents &lt;15 years:",
"     </i>",
"     5 mg (chewable tablet) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adolescents &ge;15 years:",
"     </i>",
"     10 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F197956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F197957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F197958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling; has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F197926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules, oral: 4 mg/packet (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Singulair&reg;: 4 mg/packet (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Singulair&reg;: 10 mg [contains lactose 89.3 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 4 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Singulair&reg;: 4 mg [contains phenylalanine 0.67 mg/tablet; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Singulair&reg;: 5 mg [contains phenylalanine 0.84 mg/tablet; cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F197912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F197928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When treating asthma, administer dose in the evening. Patients with allergic rhinitis may individualize administration time (morning or evening). Patients with",
"     <b>",
"      both",
"     </b>",
"     asthma and allergic rhinitis should take a single dose in the evening. May administer without regard to food or meals.",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Granules: May be administered directly in the mouth, dissolved in 5 mL of baby formula or breast milk, or mixed with a spoonful of applesauce, carrots, rice, or ice cream; do not add to any other liquids or foods. Administer within 15 minutes of opening packet.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F197927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and chronic treatment of asthma; relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis; prevention of exercise-induced bronchoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F197994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Singulair&reg; may be confused with Oralair&trade;, SINEquan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F197985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Children &ge;15 years and Adults:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Central nervous system: Dizziness (2%), fatigue (2%), fever (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dermatologic: Rash (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (2%), dental pain (2%), gastroenteritis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hepatic: AST increased (2%), ALT increased (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Respiratory: Nasal congestion (2%), cough (&ge;1%), epistaxis (&ge;1%), sinusitis (&ge;1%), upper respiratory infection (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Children 2 to &le;14 years:",
"     </b>",
"     &ge;2%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Dermatitis, eczema, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, gastroenteritis, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Ear pain, otitis, otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Laryngitis, pharyngitis, pneumonia, rhinorrhea, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza, varicella, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Children 6-23 months:",
"     </b>",
"     &ge;2%: Respiratory: Cough, otitis media, pharyngitis, rhinitis, tonsillitis, upper respiratory infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Postmarketing and/or case reports (Limited to important or life-threatening):",
"     </b>",
"     Anaphylaxis, angioedema, Churg-Strauss syndrome, depression, disorientation, eosinophilia (systemic), erythema multiforme, erythema nodosum, hallucinations, hepatic eosinophilic infiltration, hepatitis (mixed pattern, hepatocellular, and cholestatic), hypersensitivity, insomnia, pancreatitis, paresthesia, seizures, somnambulism, Stevens-Johnson syndrome, suicidal thinking/behavior (suicidality), suicide, thrombocytopenia, toxic epidermal necrolysis, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F197931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to montelukast or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F197916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Eosinophilia and vasculitis: In rare cases, patients may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. Healthcare providers should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between montelukast and these underlying conditions has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric events: Postmarketing reports of behavioral changes (eg, abnormal dreams, agitation, aggression, anxiety, attention deficit, depression, disorientation, hallucinations, hostility, insomnia, irritability, memory disturbances, restlessness, sleep disturbance, suicide ideation/behavior, and tremor) have been noted in pediatric, adolescent, and adult patients. In a retrospective analysis performed by Merck, serious behavior-related events were rare (Philip, 2009a); assess patients for behavioral changes. Patients should be instructed to notify the prescriber if behavioral changes occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute asthma/bronchospasm: Not FDA approved for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus. Some studies, however, support its use as adjunctive therapy (Cylly, 2003; Ferreira, 2001; Harmancik 2006). Appropriate rescue medication should be available. Montelukast treatment should continue during acute asthma exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin-sensitive asthmatics: Montelukast will not interrupt bronchoconstrictor response to aspirin or other NSAIDs. Patients with known aspirin sensitivity should continue to avoid these agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Corticosteroids: When inhaled or systemic corticosteroid reduction is considered in patients initiating or receiving montelukast, appropriate clinical monitoring and a gradual dose reduction of the steroid are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chewable tablet: Contains phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F197980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F197921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F197948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease montelukast levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F197923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F197934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Montelukast was not teratogenic in animal studies, however, there are no adequate and well-controlled studies in pregnant women. Based on limited data, structural defects have been reported in neonates exposed to montelukast",
"     <i>",
"      in utero",
"     </i>",
"     ; however, a specific pattern and relationship to montelukast has not been established. Healthcare providers should report any prenatal exposures to the montelukast pregnancy registry at (800) 986-8999.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F197961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F197936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F197933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Montelukast Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $169.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $169.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Singulair Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (90): $565.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (90): $565.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Montelukast Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $169.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Singulair Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $188.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Montelukast Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $169.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Singulair Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (90): $565.67",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5952224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mood or behavior changes, including suicidal thinking/behavior",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F197937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Airlukast (PE);",
"     </li>",
"     <li>",
"      Anxokast (TW);",
"     </li>",
"     <li>",
"      Blow (CO);",
"     </li>",
"     <li>",
"      Brecare (PH);",
"     </li>",
"     <li>",
"      Immunobron (PY);",
"     </li>",
"     <li>",
"      Kastair (PH);",
"     </li>",
"     <li>",
"      Kastair EZ (PH);",
"     </li>",
"     <li>",
"      Kipres (JP);",
"     </li>",
"     <li>",
"      Leukast (PH);",
"     </li>",
"     <li>",
"      Lukair (KP);",
"     </li>",
"     <li>",
"      Lukast (CO);",
"     </li>",
"     <li>",
"      Mediruka (KP);",
"     </li>",
"     <li>",
"      Mokast (TW);",
"     </li>",
"     <li>",
"      Monolair (KP);",
"     </li>",
"     <li>",
"      Montair (IN, PH);",
"     </li>",
"     <li>",
"      Montecad (PH);",
"     </li>",
"     <li>",
"      Montek-10 (TH);",
"     </li>",
"     <li>",
"      Monteka (TW);",
"     </li>",
"     <li>",
"      Montekast (PH);",
"     </li>",
"     <li>",
"      Montelair (MY);",
"     </li>",
"     <li>",
"      Montelukan (KP);",
"     </li>",
"     <li>",
"      Montelukan QDT (KP);",
"     </li>",
"     <li>",
"      Montemax (PH);",
"     </li>",
"     <li>",
"      Montena (KP);",
"     </li>",
"     <li>",
"      Montexin (TW);",
"     </li>",
"     <li>",
"      Montiget (PH);",
"     </li>",
"     <li>",
"      Oxair (MY);",
"     </li>",
"     <li>",
"      Singulair (AR, AT, AU, BB, BE, BG, BM, BO, BR, BS, BZ, CH, CL, CN, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, GY, HK, HN, HU, IE, IL, IT, JM, KP, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, RU, SE, SG, SR, SV, TH, TR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Singular Chew (KP);",
"     </li>",
"     <li>",
"      Sinkast (TW);",
"     </li>",
"     <li>",
"      Ventilar (EC);",
"     </li>",
"     <li>",
"      Xalar (DO, GT, PA, SV)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F197915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor. Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. Cysteinyl leukotrienes are also released from the nasal mucosa following allergen exposure leading to symptoms associated with allergic rhinitis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F197930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &gt;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 8-11 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP3A4, 2C8, and 2C9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Tablet: 10 mg, Mean: 64%; Chewable tablet: 5 mg: 73% (63% when administered with a standard meal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.7-5.5 hours; Mild-to-moderate hepatic impairment: 7.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Tablet: 10 mg: 3-4 hours; Chewable tablet: 2-2.5 hours; granules: 1-3 hours (fasting) and 3.5 to ~9 hours (with high-fat meal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (86%); urine (&lt;0.2%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bakhireva LN, Jones KL, Schatz M, et al, &ldquo;Organization of Teratology Information Specialists Collaborative Research Group. Safety of Leukotriene Receptor Antagonists in Pregnancy,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2007, 119(3):618-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37654/abstract-text/16708374/pubmed\" id=\"16708374\" target=\"_blank\">",
"        16708374",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Camargo CA Jr, Smithline HA, Malice MP, et al, &ldquo;A Randomized Controlled Trial of Intravenous Montelukast in Acute Asthma,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2003, 167(4):528-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37654/abstract-text/12456380/pubmed\" id=\"12456380\" target=\"_blank\">",
"        12456380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cylly A, Kara A, Ozdemir T, et al, &ldquo;Effects of Oral Montelukast on Airway Function in Acute Asthma,&rdquo;",
"      <i>",
"       Respir Med",
"      </i>",
"      , 2003, 97(5):533-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37654/abstract-text/12735671/pubmed\" id=\"12735671\" target=\"_blank\">",
"        12735671",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferreira MB, Santos AS, Pregal AL, et al, &ldquo;Leukotriene Receptor Antagonists (Montelukast) in the Treatment of Asthma Crisis: Preliminary Results of a Double-Blind Placebo Controlled Randomized Study,&rdquo;",
"      <i>",
"       Allerg Immunol (Paris)",
"      </i>",
"      , 2001, 33(8):315-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Global Strategy for Asthma Management and Prevention",
"      </i>",
"      , Global Initiative for Asthma (GINA) 2011. Available at file://www.ginasthma.org",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harmanci K, Bakirtas A, Turktas I, et al, &ldquo;Oral Montelukast Treatment of Preschool-Aged Children With Acute Asthma,&rdquo;",
"      <i>",
"       Ann Allergy Asthma Immunol",
"      </i>",
"      ,  2006, 96(5):731-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37654/abstract-text/16729788/pubmed\" id=\"16729788\" target=\"_blank\">",
"        16729788",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lougheed MD, Lemi&egrave;re C, Dell SD, et al, &ldquo;Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,&rdquo;",
"      <i>",
"       Can Respir J",
"      </i>",
"      , 2010, 17(1):15-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37654/abstract-text/20186367/pubmed\" id=\"20186367\" target=\"_blank\">",
"        20186367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Philip G, Hustad CM, Malice MP, et al, &ldquo;Analysis of Behavior-Related Adverse Experiences in Clinical Trials of Montelukast,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2009a, 124(4):699-706.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37654/abstract-text/19815116/pubmed\" id=\"19815116\" target=\"_blank\">",
"        19815116",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Philip G, Hustad C, Noonan G, et al, &ldquo;Reports of Suicidality In Clinical Trials Of Montelukast,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2009b, 124(4):691-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37654/abstract-text/19815114/pubmed\" id=\"19815114\" target=\"_blank\">",
"        19815114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sarkar M, Koren G, Kalra S, et al, &ldquo;Montelukast Use During Pregnancy: A Multicentre, Prospective, Comparative Study of Infant Outcomes,&rdquo;",
"      <i>",
"       Eur  J Clin Pharmacol",
"      </i>",
"      2009, 65(12);1259-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37654/abstract-text/19707749/pubmed\" id=\"19707749\" target=\"_blank\">",
"        19707749",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9539 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37654=[""].join("\n");
var outline_f36_49_37654=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197951\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197952\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197987\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197955\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197972\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197956\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197957\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197958\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197926\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197912\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197928\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197927\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197994\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197985\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197931\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197916\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197980\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197921\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197948\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197923\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197934\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197961\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197936\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197933\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5952224\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197937\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197915\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197930\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9539\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9539|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/18/13605?source=related_link\">",
"      Montelukast: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=related_link\">",
"      Montelukast: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_49_37655="Cytarabine: Pediatric drug information";
var content_f36_49_37655=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cytarabine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"    see \"Cytarabine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/27/13749?source=see_link\">",
"    see \"Cytarabine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F155998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cytarabine Injection;",
"     </li>",
"     <li>",
"      Cytosar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antimetabolite",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"      see \"Cytarabine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Children and Adults (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      AML remission induction:",
"     </b>",
"     Manufacturer&rsquo;s recommendation: Standard dose: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 7 days",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose continuous infusion (over 12 hours) every 12 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Remission maintenance:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 70-200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2-5 days at monthly intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     SubQ: 1-1.5 mg/kg single dose for maintenance at 1- to 4-week intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     High-dose therapy for refractory or secondary leukemias or refractory non-Hodgkin's lymphoma: I.V. infusion: 1-3 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours for up to 12 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intrathecal: Infants, Children, and Adults (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Meningeal leukemia:",
"     </b>",
"     Manufacturer&rsquo;s recommendation: Usual dose: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     intrathecally every 4 days; range: 5-75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 4 days or once every 4 days until CNS findings normalize, followed by one additional treatment.",
"     <b>",
"      Note:",
"     </b>",
"     Optimal intrathecal chemotherapy dosing should be based on age (see following information) rather than on body surface area (BSA); CSF volume correlates with age and not to BSA (Bleyer, 1983; Kerr, 2001). Age based dosing: Age in years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      CNS prophylaxis:",
"     </b>",
"     I.T.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &lt;1 years: 20 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     1 to &lt;2 years: 30 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     2 to &lt;3 years: 50 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &ge;3 years: 70 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      CNS prophylaxis (ALL):",
"     </b>",
"     Other age-specific regimens reported from literature:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Gaynon, 1993: Administer on day 0 of induction therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &lt;2 years: 30 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     2-3 years: 50 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &ge;3 years: 70 mg per dose",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:10em;\">",
"     Matloub, 2006: Administer on day 0 of induction therapy, then as part of ITT on days 7, 14, and 21 during consolidation therapy; as part of ITT on days 0, 28, and 35 for 2 cycles of delayed intensification therapy, and then maintenance treatment as part of ITT on day 0 every 12 weeks for 38 months (boys) or 26 months (girls) from initial induction treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &lt;2 years: 16 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     2 to &lt;3 years: 20 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     3-8 years: 24 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &gt;8 years: 30 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Pieters, 2007: Administer on day 15 of induction therapy, days 1 and 15 of reinduction phase; and day 1 of cycle 2 of maintenance 1A phase:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &lt;1 year: 15 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &ge;1 years: 20 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Lin, 2007: Administer as part of intrathecal triple therapy (ITT) on days 1 and 15 of induction therapy; days 1, 15, 50, and 64 (standard risk patients) or days 1, 15, 29, and 43 (high-risk patients) during consolidation therapy; day 1 of reinduction therapy, and during maintenance therapy (very high risk patients receive on days 1, 22, 45, and 59 of induction, days 8, 22, 36, and 50 of consolidation therapy, days 8 and 38 of reinduction therapy, and during maintenance):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &lt;1 year: 18 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     1 to &lt;2 years: 24 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     2 to &lt;3 years: 30 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &gt;3 years: 36 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Treatment, CNS leukemia (ALL):",
"     </b>",
"     Administer as part of ITT weekly until CSF remission, then every 4 weeks throughout continuation treatment (Lin, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &lt;1 year: 18 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     1 to &lt;2 years: 24 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     2 to &lt;3 years: 30 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &ge;3 years: 36 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     I.V.: The following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Aronoff, 2007 (cytarabine 100-200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ): Children and Adults: No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Smith, 1997 (high-dose cytarabine &ge;2 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose):  For serum creatinine 1.5-1.9 mg/dL or increase (from baseline) of 0.5-1.2 mg/dL: Reduce dose to 1 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment for hepatic impairment:",
"     </b>",
"     I.V.: Dose may need to be adjusted in patients with liver failure since cytarabine is partially detoxified in the liver. The following guideline has been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Floyd, 2006: Transaminases (any elevation): Administer 50% of dose; may increase subsequent doses in the absence of toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Koren, 1992 (dose not specified): Bilirubin &gt;2 mg/dL: Administer 50% of dose; may increase subsequent doses in the absence of toxicity",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 100 mg [contains benzyl alcohol (in diluent)], 500 mg [contains benzyl alcohol (in diluent)], 1 g [contains benzyl alcohol (in diluent)], 2 g [contains benzyl alcohol (in diluent)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 20 mg/mL (25 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 20 mg/mL (5 mL, 50 mL); 100 mg/mL (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: May administer SubQ, IVP, I.V. infusion, or I.T.; pH: 5-7.4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. infusion:  After reconstitution, further dilute in 250-1000 mL NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W. Infuse as a continuous infusion (standard dose) or infuse over 1-3 hours (infusion rate based on protocol). GI adverse effects may be more pronounced with divided I.V. bolus doses than with continuous infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     High-dose regimens or for use in neonates: Diluents containing benzyl alcohol should not be used to reconstitute the drug for high-dose regimens; high-dose regimens (dose &gt;1 g/m",
"     <sup>",
"      2",
"     </sup>",
"     ) are usually administered by I.V. infusion over ~2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     IVP: May administer over 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.T. administration: Reconstitute with preservative-free NS; may be further diluted to preferred final volume with Elliott's B solution, or preservative-free NS or LR solution, do",
"     <b>",
"      not",
"     </b>",
"     use diluents containing benzyl alcohol; the final volume generally based on institution or practitioner preferences; volume range is 3-10 mL and may be up to 12 mL and should correspond to an equivalent volume of CSF removed; filter through a 0.22 micron filter; antiemetic therapy should be administered prior to intrathecal doses of cytarabine. Administer as soon as possible after preparation. Intrathecal medications should not be prepared during the preparation of any other agents. After preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ administration: Rotate injection sites to thigh, abdomen, and flank regions; avoid repeated administration to a single site",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F156056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, amsacrine, anidulafungin, aztreonam, cefepime, chlorpromazine, cimetidine, cladribine, dexamethasone sodium phosphate, diphenhydramine, doxorubicin liposomal, droperidol, etoposide phosphate, famotidine, filgrastim, fludarabine, furosemide, gemcitabine, gentamicin, granisetron, heparin, hydrocortisone sodium succinate, hydromorphone, idarubicin, linezolid, lorazepam, melphalan, methotrexate, metoclopramide, morphine, ondansetron, paclitaxel, pemetrexed, piperacillin/tazobactam, prochlorperazine edisylate, promethazine, propofol, ranitidine, sargramostim, sodium bicarbonate, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible",
"     </b>",
"     Allopurinol, caspofungin, gallium nitrate, ganciclovir.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, methylprednisolone sodium succinate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Metoclopramide, triple intrathecal therapy (TIT) (cytarabine 30-50 mg with hydrocortisone sodium succinate 15-25 mg and methotrexate 12 mg).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use appropriate precautions for handling and disposal. Store intact vials of powder for injection at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); store intact vials of solution at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Powder for reconstitution: Reconstitute with bacteriostatic water for injection [for standard dose (100-200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )]; do not use a diluent containing benzyl alcohol to prepare high-dose I.V. therapies. After reconstitution, store at room temperature and use within 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     For I.V. infusion: Further dilutions in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W are stable for 7 days at room temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intrathecal: Powder for reconstitution: Reconstitute with preservative-free NS; administer as soon as possible after preparation. Do",
"     <b>",
"      not",
"     </b>",
"     use a diluent containing benzyl alcohol to prepare.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Intrathecal triple therapy (ITT): Cytarabine 30-50 mg with hydrocortisone sodium succinate 15-25 mg and methotrexate 12 mg; compatible together for up to 24 hours in a syringe; however, should be administered as soon as possible after preparation because intrathecal preparations are preservative free",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remission induction in acute myeloid leukemia (AML), treatment of acute lymphocytic leukemia (ALL) and chronic myelocytic leukemia (CML; blast phase) (FDA approved in children and adults); prophylaxis and treatment of meningeal leukemia (FDA approved in children and adults); has also been used in postinduction, postremission consolidation, and salvage treatment of AML, treatment of primary central nervous system lymphoma, treatment of relapsed or refractory Hodgkin&rsquo;s lymphoma, treatment of non-Hodgkin&rsquo;s lymphomas (NHL)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F156059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cytarabine may be confused with clofarabine, Cytosar&reg;, Cytoxan, vidarabine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cytarabine (conventional) may be confused with cytarabine liposomal",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cytosar-U may be confused with cytarabine, Cytovene&reg;, Cytoxan, Neosar",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       <i>",
"        Intrathecal medication safety:",
"       </i>",
"       The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (Jacobson, 2009) encourage the following safety measures for intrathecal chemotherapy:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Intrathecal medication should not be prepared during the preparation of any other agents",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; After preparation, store in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Delivery to the patient should only be with other medications also intended for administration into the central nervous system",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F156055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, pericarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, neural toxicity, neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, pruritus, rash, skin freckling, skin ulceration, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anal inflammation, anal ulceration, anorexia, bowel necrosis, diarrhea, esophageal ulceration, esophagitis, mucositis, nausea, pancreatitis, sore throat, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Myelosuppression, neutropenia (onset: 1-7 days; nadir [biphasic]: 7-9 days and at 15-24 days; recovery [biphasic]: 9-12 and at 24-34 days), thrombocytopenia (onset: 5 days; nadir: 12-15 days; recovery 15-25 days), anemia, bleeding, leukopenia, megaloblastosis, reticulocytes decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic dysfunction, jaundice, transaminases increased (acute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site cellulitis, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic edema, anaphylaxis, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rare but important or life-threatening:",
"     </b>",
"     Acute respiratory distress syndrome, amylase increased, angina, aseptic meningitis, cardiopulmonary arrest (acute), cerebral dysfunction, cytarabine syndrome (bone pain, chest pain, conjunctivitis, fever, maculopapular rash, malaise, myalgia); exanthematous pustulosis, hepatic sinusoidal obstruction syndrome (SOS; veno-occlussive disease), hyperuricemia, injection site inflammation (SubQ injection), injection site pain (SubQ injection), interstitial pneumonitis, lipase increased, paralysis (intrathecal and I.V. combination therapy), reversible posterior leukoencephalopathy syndrome (RPLS), rhabdomyolysis, toxic megacolon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adverse events associated with high-dose cytarabine",
"     </b>",
"     (CNS, gastrointestinal, ocular, and pulmonary toxicities are more common with high-dose regimens):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Cardiomegaly, cardiomyopathy (in combination with cyclophosphamide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Cerebellar toxicity, coma, neurotoxicity, personality change, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Alopecia (complete), desquamation, rash (severe)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Gastrointestinal ulcer, pancreatitis, peritonitis, pneumatosis cystoides intestinalis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia, liver abscess, liver damage, necrotizing colitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (motor and sensory)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ocular: Corneal toxicity, hemorrhagic conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Pulmonary edema, syndrome of sudden respiratory distress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adverse events associated with intrathecal cytarabine administration:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Accessory nerve paralysis, fever, necrotizing leukoencephalopathy (with concurrent cranial irradiation, I.T. methotrexate, and I.T. hydrocortisone), neurotoxicity, paraplegia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Dysphagia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ocular: Blindness (with concurrent systemic chemotherapy and cranial irradiation), diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough, hoarseness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Aphonia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cytarabine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Marked bone marrow suppression necessitates dosage reduction or a reduction in the number of days of administration; use with caution in patients with severe hepatic dysfunction; dosage reduction may be necessary. Use high-dose cytarabine with caution in patients with impaired renal function; patients are at higher risk (up to 55%) for cerebellar toxicity and other CNS toxicities; dosage adjustment may be required. With high-dose therapy, tumor lysis syndrome and subsequent hyperuricemia may occur; consider allopurinol and hydrate accordingly. Should be administered under the supervision of an experienced cancer chemotherapy physician. Adequate facilities must be available",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal. Causes significant bone marrow depression (leukopenia, thrombocytopenia, and anemia)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use with caution in patients with prior bone marrow suppression; monitor for signs of febrile neutropenia. Must monitor for drug toxicity; high dose regimens have been associated with GI, CNS, pulmonary, ocular (prophylaxis with ophthalmic corticosteroids is recommended) toxicities, and cardiomyopathy. Neurotoxicity associated with high-dose treatment may present as acute cerebellar toxicity or may be severe with seizure and/or coma; may be delayed, occurring up to 3-8 days after treatment has begun; possibly irreversible. Risk factors for neurotoxicity include cumulative cytarabine dose, prior CNS disease, and renal impairment (incidence may be up to 55% in patients with renal impairment). Cytarabine syndrome which is characterized by fever, myalgia, bone pain, chest pain, maculopapular rash, conjunctivitis, and malaise may occur 6-12 hours following administration; may be managed with corticosteroids. May cause nausea, vomiting, diarrhea, abdominal pain, oral ulceration, and hepatic dysfunction; irreversible cerebellar toxicity may occur. There have been reports of acute pancreatitis in patients receiving continuous infusion and in patients previously treated with L-asparaginase.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used for intrathecal administration, should not be prepared during the preparation of any other agents; after preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only; delivery of intrathecal medications to the patient should only be with other medications intended for administration into the central nervous system (Jacobson, 2009). Some parenteral products contain benzyl alcohol; do not use products containing benzyl alcohol or products reconstituted with bacteriostatic diluent intrathecally or for high-dose cytarabine regimens. Benzyl alcohol may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flucytosine: Cytarabine (Conventional) may diminish the therapeutic effect of Flucytosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F155972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F155985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were demonstrated in animal studies; limb and ear defects have been noted in case reports of cytarabine exposure during the first trimester of pregnancy. The following have also been noted in the neonate: Pancytopenia, WBC depression, electrolyte abnormalities, prematurity, low birth weight, decreased hematocrit or platelets. Risk to the fetus is decreased if treatment can be avoided during the first trimester; however, women of childbearing potential should be advised of the potential risks.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, CBC with differential and platelet count, serum creatinine, BUN, serum uric acid; signs of neurotoxicity",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Converted intracellularly to the active metabolite cytarabine triphosphate; inhibits DNA polymerase by competing with deoxycytidine triphosphate resulting in inhibition of DNA synthesis; incorporated into DNA chain resulting in termination of chain elongation; cell cycle-specific for the S-phase of cell division",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: : V",
"     <sub>",
"      d",
"     </sub>",
"     : Total body water; widely and rapidly since it enters the cells readily; crosses blood-brain barrier achieving CSF concentrations 40% to 50% of plasma concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 13%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic; metabolized by deoxycytidine kinase and other nucleotide kinases to aracytidine triphosphate (active); about 86% to 96% of dose is metabolized to inactive uracil arabinoside (ARA-U); intrathecal administration results in little conversion to ARA-U due to the low amount of deaminase in the CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal: 1-3 hours; intrathecal: 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: SubQ: 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (~80%; 90% as metabolite ARA-U) within 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/27/13749?source=see_link\">",
"      see \"Cytarabine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by prescriber. Notify physician immediately if any redness, swelling, burning, or pain at injection/infusion site; sudden difficulty breathing or swallowing, chest pain, or chills. Susceptibility to infection increased (avoid crowds and exposure to infection and do not have any vaccinations without consulting physician). Maintain adequate hydration, unless instructed to restrict fluid intake. May cause nausea, vomiting, or loss of appetite (small, frequent meals, frequent mouth care, sucking lozenges, or chewing gum may help; if ineffective, consult prescriber for antiemetic medication); diarrhea (if persistent, consult with prescriber); mouth sores (use soft toothbrush or cotton swabs for oral care); or dizziness, headache, or confusion (use caution when driving or engaging in potentially hazardous tasks until response to drug is known). Report immediately any signs of CNS changes, change in gait, respiratory distress or respiratory difficulty, easy bruising or bleeding, persistent GI upset, yellowing of eyes or skin, change in color of urine or blackened stool, or any other persistent adverse effects. Inform prescriber if you are pregnant. Consult prescriber for instruction on appropriate contraceptive measures. This drug may cause severe fetal defects. Breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1046775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Consider corticosteroid eye drops for prophylaxis of conjunctivitis prior to, during, and for 2-7 days after high-dose cytarabine; pyridoxine has been administered on days of high-dose cytarabine therapy for prophylaxis of CNS toxicity.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 98, 170.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker WJ, Royer GL, and Weiss RB, &ldquo;Cytarabine and Neurologic Toxicity,&rdquo;",
"      <i>",
"       J Clinical Oncology",
"      </i>",
"      , 1991, 9(4):679-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/1648599/pubmed\" id=\"1648599\" target=\"_blank\">",
"        1648599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bleyer WA, Coccia PF, Sather HN, et al, &ldquo;Reduction in Central Nervous System Leukemia With a Pharmacokinetically Derived Intrathecal Methotrexate Dosage Regimen,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1983, 1(5):317-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/6366138/pubmed\" id=\"6366138\" target=\"_blank\">",
"        6366138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capizzi RL, White JC, Powell BL, et al, &ldquo;Effect of Dose on the Pharmacokinetic and Pharmacodynamic Effects of Cytarabine,&rdquo;",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 1991, 28(3 Suppl 4):54-69.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Lemos ML, Monfared S, Denyssevych T, et al, &ldquo;Evaluation of Osmolality and pH of Various Concentrations of Methotrexate, Cytarabine, and Thiotepa Prepared in Normal Saline, Sterile Water for Injection, and Lactated Ringers&rsquo;s Solution for Intrathecal Administration,&rdquo;",
"      <i>",
"       J Oncol Pharm Pract",
"      </i>",
"      , 2009, 15(1):45-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/18772215/pubmed\" id=\"18772215\" target=\"_blank\">",
"        18772215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaynon PS, Steinherz PG, Bleyer WA, et al, &ldquo;Improved Therapy for Children With Acute Lymphoblastic Leukemia and Unfavorable Presenting Features: A Follow-Up Report of the Childrens Cancer Group Study CCG-106,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1993, 11(11):2234-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/8229139/pubmed\" id=\"8229139\" target=\"_blank\">",
"        8229139",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grossman L, Baker MA, Sutton DM, et al, &ldquo;Central Nervous System Toxicity of High-Dose Cytosine Arabinoside,&rdquo;",
"      <i>",
"       Med Pediatr Oncol",
"      </i>",
"      , 1983, 11(4):246-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/6888324/pubmed\" id=\"6888324\" target=\"_blank\">",
"        6888324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson JO, Polovich M, McNiff KK, et al, \"American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/19786650/pubmed\" id=\"19786650\" target=\"_blank\">",
"        19786650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kerr JZ, Berg S, and Blaney SM, &ldquo;Intrathecal Chemotherapy,&rdquo;",
"      <i>",
"       Crit Rev Oncol Hematol",
"      </i>",
"      , 2001, 37(3):227-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/11248578/pubmed\" id=\"11248578\" target=\"_blank\">",
"        11248578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G, Beatty K, Seto A, et al, &ldquo;The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1992, 26(3):363-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/1554959/pubmed\" id=\"1554959\" target=\"_blank\">",
"        1554959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lin WY, Liu HC, Yeh TC, et al, &ldquo;Triple Intrathecal Therapy Without Cranial Irradiation for Central Nervous System Preventive Therapy in Childhood Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2008, 50(3):523-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/17455314/pubmed\" id=\"17455314\" target=\"_blank\">",
"        17455314",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matloub Y, Lindemulder S, Gaynon PS, et al, &ldquo;Intrathecal Triple Therapy Decreases Central Nervous System Relapse but Fails to Improve Event-Free Survival When Compared With Intrathecal Methotrexate: Results of the Children's Cancer Group (CCG) 1952 Study for Standard-Risk Acute Lymphoblastic Leukemia, Reported by the Children's Oncology Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 108(4):1165-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/16609069/pubmed\" id=\"16609069\" target=\"_blank\">",
"        16609069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pease CL, Horton TM, McClain KL, et al, &ldquo;Aseptic Meningitis in a Child After Systemic Treatment With High Dose Cytarabine,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2001, 20(1):87-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/11176579/pubmed\" id=\"11176579\" target=\"_blank\">",
"        11176579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pieters R, Schrappe M, De Lorenzo P, et al, &ldquo;A Treatment Protocol for Infants Younger Than 1 Year With Acute Lymphoblastic Leukaemia (Interfant-99): An Observational Study and a Multicentre Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370(9583):240-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/17658395/pubmed\" id=\"17658395\" target=\"_blank\">",
"        17658395",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith G, Damon LE, Rugo HS, et al. &ldquo;High-Dose Cytarabine Dose Modification Reduces the Incidence of Neurotoxicity in Patients With Renal Insufficiency,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(2): 833-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/49/37655/abstract-text/9053511/pubmed\" id=\"9053511\" target=\"_blank\">",
"        9053511",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13197 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-DB96A30595-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37655=[""].join("\n");
var outline_f36_49_37655=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708668\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046767\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046759\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155976\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155961\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046771\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156056\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046762\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046770\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156059\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156055\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046774\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046758\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046757\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299114\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155970\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155972\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155985\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046766\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046756\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046773\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046764\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046775\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13197\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13197|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=related_link\">",
"      Cytarabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/27/13749?source=related_link\">",
"      Cytarabine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_49_37656="Skeletal tuberculosis";
var content_f36_49_37656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Skeletal tuberculosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/49/37656/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/49/37656/contributors\">",
"     Malcolm McDonald, PhD, FRACP, FRCPA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/49/37656/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/49/37656/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/49/37656/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/49/37656/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/49/37656/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/49/37656/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal tuberculosis (TB) refers to TB involvement of the bones",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    joints. It is an ancient disease; features of spinal TB have been identified in Egyptian mummies dating back to 9000 BC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], and analysis of 483 pre-Columbian skeletons in Chile showed lesions consistent with bony tuberculosis in 2 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/3\">",
"     3",
"    </a>",
"    ]. Subsequently, molecular studies have established the presence of Mycobacterium tuberculosis complex DNA in ancient bony specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical issues related to skeletal TB will be reviewed here. Other aspects of TB are discussed separately (see related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal TB accounts for 10 to 35 percent of cases of extrapulmonary tuberculosis and, overall, for almost 2 percent of all TB cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Reported rates of extrapulmonary TB are higher among immigrants from endemic areas to developed countries; this may be due in part to immigration screening procedures for pulmonary TB. One retrospective review of skeletal TB between 1980 and 1994 in France noted 103 cases of spinal TB; 68 percent of patients were foreign-born, the majority from Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/10\">",
"     10",
"    </a>",
"    ]. The proportion of skeletal TB among HIV-infected individuals is comparable to the proportion of skeletal TB among HIV&ndash;uninfected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common form of skeletal TB is Pott disease, a disease of the spine; this entity comprises approximately half of musculoskeletal TB cases. The next most common form of musculoskeletal TB is tuberculous arthritis, followed in frequency by extraspinal tuberculous osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During primary M. tuberculosis infection, bacillemia may lead to seeding of organisms in bone",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    synovial tissue. In most cases, small foci of infection are confined by local immune processes and infection is subclinical. Following primary infection, reactivating foci may be contained by the cellular immune response. CD4 and CD8 lymphocytes play important roles, as does interferon gamma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/14\">",
"     14",
"    </a>",
"    ]. Reactivation of infection with progression to clinically apparent disease may occur when local immune defenses fail, as in the setting of malnutrition, advancing age, HIV infection, or renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Active TB disease can develop immediately or after decades of latent infection. In highly endemic regions, musculoskeletal TB usually manifests clinically in the year following primary lung infection and therefore occurs most frequently in relatively young patients. Outside endemic areas, musculoskeletal TB is more commonly associated with late reactivation of infection and occurs mainly in adults.",
"   </p>",
"   <p>",
"    Rarely, bones and joints are involved in contiguous spread of TB from another site. Contiguous spread from an apical pulmonary focus of active TB, for example, can lead to atlantoaxial TB, involving the joint between the first and second cervical vertebrae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forms of skeletal tuberculosis include spondylitis (Pott disease), arthritis, and osteomyelitis. From published series of spinal tuberculosis (TB), there is wide variation in reported rates of active concomitant pulmonary TB at the time of diagnosis of the spinal TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/10,17,18\">",
"     10,17,18",
"    </a>",
"    ]. The largest report series including nearly 700 cases had the lowest reported rate (2.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/18\">",
"     18",
"    </a>",
"    ]. The proportion is likely to be similarly variable for other TB bone and joint infections, but series are too small to provide reliable data. &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Spondylitis (Pott disease)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculous spondylitis (Pott disease) most commonly affects the lower thoracic and upper lumbar region; disease involving the cervical and upper thoracic region is less common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Infection generally begins with inflammation of the anterior aspect of the intervertebral joints; typically it spreads behind the anterior ligament to involve the adjacent vertebral body. Once two adjacent vertebrae are involved, infection enters the adjoining intervertebral disc space. This tends to occur later in Pott disease than in bacterial vertebral osteomyelitis and may have the radiographic appearance of relative disc sparing. Eventually the avascular disc tissue dies; there is vertebral narrowing and subsequent vertebral collapse. Gibbus deformity, a form of structural kyphosis, distorts spinal canal anatomy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60628 \" href=\"mobipreview.htm?0/1/22\">",
"     image 1",
"    </a>",
"    ). The spinal cord is then at risk of compression, resulting in paraplegia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/21\">",
"     21",
"    </a>",
"    ]. Occasionally, late-onset paraplegia occurs due to osteophytes and other chronic degenerative changes at a site of prior infection. Formation of a &lsquo;cold abscess&rsquo; (soft tissue mass) at the site is common. Noncontiguous spinal disease (eg, disease at more than one level) is uncommon, although in one South African series it was described in 16 of 98 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common symptom is local pain, which increases in severity over weeks to months, sometimes in association with muscle spasm and rigidity. The muscle spasm can extend beyond the diseased area. In some cases a characteristic erect posture and 'aldermanic' gait may be observed, in which the patient walks with short deliberate steps to avoid jarring of the spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/23\">",
"     23",
"    </a>",
"    ]. Constitutional symptoms such as fever and weight loss are present in less than 40 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/11,17,24-26\">",
"     11,17,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of Pott disease is frequently delayed as a result of its subacute course, especially in regions where the incidence of tuberculosis is relatively low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]. In endemic areas the clinical presentation also tends to be relatively late due to limited access to medical care; in these settings patients have symptoms and signs of cord compression at the time of diagnosis in 40 to 70 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/17,27\">",
"     17,27",
"    </a>",
"    ]. Thus, late diagnosis is a major factor in determining the outcome of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/28\">",
"     28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Arthritis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6350100\">",
"    <span class=\"h3\">",
"     Infectious",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculous arthritis can occur in virtually any joint, but it tends to occur in the hip or the knee; usually it is monoarticular. However, multifocal lesions are reported in 10 to 15 percent of cases in developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/29\">",
"     29",
"    </a>",
"    ]. Hip involvement is the most common presentation, the most difficult to diagnose, and the most debilitating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/6\">",
"     6",
"    </a>",
"    ]. Clinical manifestations include swelling, pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    loss of joint function that progresses over weeks to months. The joint is generally \"cold\" (eg, erythema, warmth, and other signs of acute infection are usually absent). Constitutional symptoms, fever, and weight loss occur in only about 30 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who present late in the course of infection often have evidence of joint destruction including local deformity and restricted range of motion. Some patients with advanced disease have draining sinuses. Granulomatous changes typically accompany synovial proliferation in tuberculous arthritis, with joint effusion and erosion of cartilage. The consequences are slowly progressive destruction, disorganization of joint architecture, and potential deformity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Inflammatory (Poncet disease)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poncet disease is an acute symmetrical polyarthritis involving large and small joints associated with active extrapulmonary, pulmonary, or miliary TB. In general there is inflammation of the involved joints but no objective evidence of active TB infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Poncet disease is relatively rare and the pathogenesis is unclear; it is probably immune-mediated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/32\">",
"     32",
"    </a>",
"    ]. HIV coinfection is also a risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The arthritis generally resolves within a few weeks of initiation of antituberculosis therapy, with no residual joint destruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/31,35\">",
"     31,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6350127\">",
"    <span class=\"h3\">",
"     Prosthetic joint infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely M. tuberculosis can cause infection at the site of a prosthetic joint. Diagnosis has been described at the time of initial arthroplasty as well as subsequent to hardware placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For cases in which TB is identified at the time of initial arthroplasty, the diagnosis is typically a surprise to the surgeon who sends abnormal appearing bone for histopathologic examination or culture at the time of joint replacement. These patients generally have a favorable outcome after standard antituberculous chemotherapy, even if the joint prosthesis is not removed.",
"   </p>",
"   <p>",
"    For cases in which infection is identified following hardware placement, a dormant nidus of infection reactivates and present with clinical findings of an infected prosthesis. These patients usually have painful, malfunctioning prostheses, and hardware removal is required for cure. Some patients with late-onset tuberculous prosthetic joint infections have coexisting bacterial infection that may mask or obscure the underlying coinfection with M. tuberculosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6349732\">",
"    <span class=\"h2\">",
"     Osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to tuberculous vertebral osteomyelitis (Pott Disease), tuberculous osteomyelitis can occur in virtually any bone, including the ribs, skull, phalanx, pelvis, and long bones. The onset is often insidious, but in rare cases the onset may be acute or subacute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/37\">",
"     37",
"    </a>",
"    ]. Typically, osteomyelitis occurs at a single site; the location and presentation can be variable as illustrated by the following case reports:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sternal osteomyelitis due to M. tuberculosis may follow coronary artery bypass surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/38\">",
"       38",
"      </a>",
"      ], as a presentation of underlying mediastinal tuberculosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/39\">",
"       39",
"      </a>",
"      ] or as primary sternal osteomyelitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bony tuberculosis of the rib may present as a breast mass or chest wall mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tuberculosis of the small bones of the hand can occur spontaneously in patients with no clinical signs of pulmonary tuberculosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tuberculous mastoiditis can extend into the skull and produce facial nerve palsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lytic bony tubercular lesions in areas as unusual as the symphysis pubis, sacroiliac joint, and elbow can be misdiagnosed as metastatic malignancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Involvement of multiple bones is rare and may result in an erroneous diagnosis of widespread metastatic malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An antecedent history of trauma may lead to diagnostic confusion; tuberculous infection can develop in a bone or joint injured by previous trauma or surgery. Tuberculous osteomyelitis frequently presents as a \"cold abscess\" with swelling, modest erythema or pain, and little or no local warmth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/13\">",
"     13",
"    </a>",
"    ]. Spontaneous drainage may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6350413\">",
"    <span class=\"h2\">",
"     Other clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal tuberculous can occur as an abscess in the epidural space (creating pressure on the spinal cord), as an extraspinal soft tissue mass (eroding ribs and adjacent structures), or as a psoas abscess (which can track down to the groin). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22839?source=see_link\">",
"     \"Psoas abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12709474\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic imaging can be useful to identify and establish the anatomy of musculoskeletal TB, although there are no pathognomonic radiographic findings.",
"   </p>",
"   <p>",
"    In the setting of tuberculous spondylitis (Pott disease), radiographic abnormalities are usually first observed in the anterior aspect of a vertebral body, with demineralization of the end plate and loss of definition of the bony margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/49\">",
"     49",
"    </a>",
"    ]. Subsequently, the opposing vertebra becomes involved, and in some cases a paravertebral abscess may be seen. Involvement of contiguous vertebrae is common, although it is uncommon to see noncontiguous spinal TB at multiple levels. As infection progresses, the disc space becomes obliterated with anterior wedging and angulation. Reactive sclerotic changes remain localized and the remainder of the vertebral structures is often spared (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72424 \" href=\"mobipreview.htm?25/15/25854\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In some patients spinal tuberculosis presents with osteolytic lesions in the absence of disk space involvement; these lesions may occur at multiple sites. In one study of 103 French patients with spinal tuberculosis, spinal tuberculosis without disk involvement was observed in about half of cases; plain radiographs demonstrated osteolytic lesions and multiple involved sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of tuberculous arthritis, local soft tissue swelling, osteopenia, and bone destruction (with relative preservation of cartilage space) are observed. Subsequent findings include structural collapse, sclerotic changes, and soft tissue calcification (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77123 \" href=\"mobipreview.htm?9/14/9455\">",
"     image 3",
"    </a>",
"    ). In some cases Phemister triad may be observed: juxta-articular osteopenia, peripherally located osseous erosions, and gradual narrowing of the disc space (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65352 \" href=\"mobipreview.htm?5/56/6031\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of tuberculous osteomyelitis in children, cystic changes may be seen in the metaphyses of long bones and in flat bones, such as the skull. In tuberculous osteomyelitis involving a hand or foot, phalangeal bone(s) may have a ballooned appearance.",
"   </p>",
"   <p>",
"    Computerized tomography (CT), myelography, and magnetic resonance imaging (MRI) are all useful tools in the diagnosis of musculoskeletal TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/19,52-56\">",
"     19,52-56",
"    </a>",
"    ]. MRI is particularly valuable in demonstrating soft tissue extension and encroachment on nearby vital structures, such as the spinal cord (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86251 \" href=\"mobipreview.htm?0/34/546\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86252 \" href=\"mobipreview.htm?27/29/28112\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86253 \" href=\"mobipreview.htm?15/18/15648\">",
"     image 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86254 \" href=\"mobipreview.htm?34/17/35103\">",
"     image 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest radiography is not a sensitive test for the diagnosis of skeletal TB since there is no evidence of active chest disease in more than half of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/5,13,17,58\">",
"     5,13,17,58",
"    </a>",
"    ]. However, chest radiography should always be obtained since it may inform decisions regarding isolation. The diagnosis of skeletal tuberculosis should be considered in patients with focal bony or joint abnormalities and a chest radiograph compatible with old or active tuberculosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\", section on 'Chest radiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6350875\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest challenge in diagnosis of skeletal tuberculosis is to consider the diagnosis, especially since there is no evidence of active chest disease in more than half of cases. In addition, delays in diagnosis are common given the indolent nature of tuberculous bone and joint disease. Clinical clues usually come from the history, which should include questions about the country of origin and history of prior known or possible tuberculosis (TB) contact. In addition, the diagnosis of skeletal tuberculosis may be overlooked in patients with HIV infection and relatively high CD4 counts and no other signs or symptoms of tuberculosis.",
"   </p>",
"   <p>",
"    The diagnosis of musculoskeletal TB is established by microscopy and culture of infected material. Tissue may be obtained by needle aspiration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy; CT guidance is useful in regions where available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Biopsy and culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of musculoskeletal TB is established by microscopy and culture of infected material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Drug susceptibility testing of isolates is essential. Tissue may be obtained by needle aspiration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy. CT guidance is useful in regions where available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. However, the high cost and technical demands of rapid automated growth systems and nucleic acid detection methods limits their use in the poorest countries with the highest incidence of tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of tuberculous arthritis can be established by synovial biopsy, although examination of synovial joint fluid is usually not helpful. The cell white count can be high or low, with preponderance of either neutrophils or lymphocyte, and no other specific diagnostic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of one or more draining sinuses, culture of this material may be useful, although in some cases cultures may demonstrate colonizing bacteria or fungi that are erroneously assumed to be the causative pathogen.",
"   </p>",
"   <p>",
"    Additional issues related to diagnostic microbiology are discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\", section on 'Diagnostic microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12709251\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of skeletal TB includes subacute or chronic infections due to pathogens such as Staphylococcus aureus, brucellosis, melioidosis, actinomycosis, candidiasis, and histoplasmosis, depending upon epidemiologic factors. Multifocal bone involvement may be confused for metastatic malignancy.",
"   </p>",
"   <p>",
"    The differential diagnosis of Pott disease includes degenerative disc and facet joint disease, spondyloarthropathy, vertebral body collapse due to osteopenia (due to a variety of causes such as osteoporosis and chronic corticosteroid therapy), pyogenic spinal infection, and malignancy. Each of these can present with similar clinical features; the main challenge for diagnosis of tuberculosis is consideration of the diagnosis. Most of these conditions can be distinguished with imaging studies where available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6689718\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of musculoskeletal tuberculosis consists of antimicrobial therapy. In some cases surgical intervention is also warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to selection of antituberculous therapy for treatment of musculoskeletal tuberculosis is generally the same as that for pulmonary tuberculosis. The drug regimen varies with whether or not the patient has HIV infection or drug-resistant tuberculosis. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal duration of therapy for treatment of musculoskeletal tuberculosis is uncertain. For most patients receiving first-line agents, six months of therapy is sufficient. A longer duration of therapy (9 to 12 months) is warranted for patients on regimens that do not include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    for patients with extensive or advanced disease, particularly if it is difficult to assess the response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, longer therapeutic courses (12 to 18 months) have been favored for musculoskeletal TB because of concerns about poor drug penetration into osseous and fibrous tissues. However, several studies have shown that six to nine month regimens containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    are at least as effective as longer courses without rifampin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/68-73\">",
"     68-73",
"    </a>",
"    ]. The efficacy of shorter course therapy is illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large prospective cohort study in Hong Kong demonstrated that 6 months of antituberculous therapy combined with surgery (radical resection of the lesion and insertion of autologous bone grafts), was comparable in efficacy to 9 to 18 months of antituberculous therapy alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In three randomized trials of short course chemotherapy for spinal tuberculosis in Hong Kong, India, and Korea reported after five years of follow-up, six- and nine-month regimens with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      produced comparable results to 18 months of isoniazid with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15141?source=see_link\">",
"       paraaminosalicylic acid",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial of 203 Korean patients comparing four different treatment regimens [(1)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      for six months, (2) isoniazid plus rifampin for nine months, (3) isoniazid plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15141?source=see_link\">",
"       paraaminosalicylic acid",
"      </a>",
"      for nine months or (4) isoniazid plus ethambutol or paraaminosalicylic acid for 18 months], a favorable outcome was achieved in 77 percent of cases after three years from the start of therapy; those who received the nine-month regimen with isoniazid plus ethambutol or paraaminosalicylic acid required additional treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One small retrospective study from the United Kingdom did report a high rate of relapse with a six-month course of therapy (62 percent); no relapse was observed among patients who received nine months of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical intervention is warranted for patients in the following circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/21,42,74,75\">",
"     21,42,74,75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with spinal disease and advanced neurological deficits",
"     </li>",
"     <li>",
"      Patients with spinal disease and worsening neurological deficits progressing while on appropriate therapy",
"     </li>",
"     <li>",
"      Patients with spinal disease and kyphosis &gt;40 degrees at the time of presentation",
"     </li>",
"     <li>",
"      Patients with chest wall cold abscess",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Forms of surgical intervention may include decompression and use of hardware for stabilization of spine, abscess drainage,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    debridement of infected material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/20,75\">",
"     20,75",
"    </a>",
"    ]. In some circumstances, reconstructive surgery may be important once antimicrobial therapy has been completed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/5\">",
"     5",
"    </a>",
"    ]. Hardware is rarely needed for stabilization of debrided bony lesions, but its use is not contraindicated in the rare situations in which it is needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/76\">",
"     76",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The role of surgery in treatment of other presentations of musculoskeletal tuberculosis is not always clear. In one retrospective review of 70 adults with thoracic spinal tuberculosis in India, medical therapy alone was successful in 69 of 70 patients (mean follow-up of 40 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/74\">",
"     74",
"    </a>",
"    ]. Criteria for exclusion included advanced neurologic deficits, worsening neurologic deficits while on antituberculous therapy, and kyphosis greater than 40 degrees on presentation. Abscess was observed on presentation in 44 patients (21 of which were epidural), and 7 patients had signs of cord compression at the time of presentation.",
"   </p>",
"   <p>",
"    Similar results were noted in a retrospective analysis of 52 children with TB of the knee [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/77\">",
"     77",
"    </a>",
"    ]. The outcome of medical therapy without synovectomy was excellent in children who presented with signs and symptoms of synovitis as long as the joint space was normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Monitoring clinical response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to therapy may be monitored by clinical indicators such as pain, constitutional symptoms, mobility, and neurologic findings. The role of inflammatory markers in monitoring the response to TB therapy is limited. It is not useful to perform serial radiographs since radiographic findings may appear to progress during appropriate treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of 43 patients with Pott paraplegia, the most important prognostic factor that predicted six-month outcome included muscle power, paraplegia score, sensory evoked potentials (SEPs), and motor evoked potentials (MEPs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37656/abstract/79\">",
"     79",
"    </a>",
"    ]. Patients with mild weakness and lower paraplegia scores were more likely to recover completely by six months than patients with more severe prognostic indicators.",
"   </p>",
"   <p>",
"    For patients on antituberculous therapy for skeletal TB in the setting of antiretroviral treatment (ART) for HIV infection, it is important to monitor for immune reconstruction inflammatory syndrome (IRIS). IRIS typically presents with paradoxical progression of TB clinical manifestations and constitutional symptoms in the first few weeks following initiation of ART. In the setting of skeletal TB, new clinical manifestations may appear",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resolved manifestations may reappear. IRIS is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6689951\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skeletal tuberculosis (TB) refers to TB involvement of the bones",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      joints. Musculoskeletal TB accounts for 10 to 35 percent of cases of extrapulmonary tuberculosis and for almost 2 percent of TB cases overall. The proportion of skeletal TB among HIV-infected individuals is comparable to the proportion of skeletal TB among HIV&ndash;uninfected individuals. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tuberculous spondylitis (Pott disease) is the most common form of skeletal TB; it usually affects the lower thoracic and upper lumbar region. Infection begins with inflammation of the intervertebral joints and can spread to involve the adjacent vertebral body. Once two adjacent vertebrae are involved, infection can involve the adjoining intervertebral disc space, leading to vertebral collapse. Subsequent kyphosis can lead to cord compression and paraplegia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Spondylitis (Pott disease)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common symptom of tuberculous spondylitis (Pott disease) is local pain, which increases in severity over weeks to months, sometimes in association with muscle spasm and rigidity. A characteristic erect posture and 'aldermanic' gait may be observed, in which the patient walks with short deliberate steps to avoid jarring of the spine. Constitutional symptoms such as fever and weight loss are relatively uncommon. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Spondylitis (Pott disease)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tuberculous arthritis tends to occur in the hip or the knee and is usually monoarticular. Clinical manifestations include swelling, pain,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      loss of joint function that progresses over weeks to months. The joint is generally \"cold\" (eg, erythema, warmth, and other signs of acute infection are usually absent). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tuberculous osteomyelitis can occur in virtually any bone, including the ribs, skull, phalanx, pelvis, and long bones. Typically osteomyelitis occurs at a single site. The onset is often insidious but in rare cases the onset may be acute or subacute. Tuberculous osteomyelitis frequently presents as a \"cold abscess\" with swelling, modest erythema or pain, and little or no local warmth. (See",
"      <a class=\"local\" href=\"#H6349732\">",
"       'Osteomyelitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of musculoskeletal TB is established by microscopy and culture of infected material. Tissue may be obtained by needle aspiration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biopsy; guidance with computed tomography or ultrasound to obtain tissue is useful in regions where available. Radiographic imaging can be useful to identify and establish the anatomy of musculoskeletal TB, although there are no pathognomonic radiographic findings. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of musculoskeletal tuberculosis consists of antituberculous therapy. The approach to selection of therapy for treatment of musculoskeletal tuberculosis is generally the same as that for pulmonary tuberculosis and is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"       \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19002?source=see_link\">",
"       \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/52/32586?source=see_link\">",
"       \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The optimal duration of therapy for treatment of musculoskeletal tuberculosis is uncertain. For patients receiving treatment with first-line agents in the absence of extensive or advanced disease, we suggest 6 months of therapy (rather than 9 or 12 months) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A longer duration of therapy (9 to 12 months) is warranted for patients on regimens that do not include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      for patients with extensive or advanced disease. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical intervention is warranted for patients with spinal disease and advanced neurological deficits or worsening neurological deficits progressing while on appropriate therapy, as well as for patients with spinal disease and kyphosis &gt;40 degrees at the time of presentation. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Daniel TM, Bates JH, Downes KA. History of tuberculosis. In: Tuberculosis: Pathogenesis, Protection, and Control, Bloom BR (Ed), American Society for Microbiology, Washington 1994. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/2\">",
"      Hershkovitz I, Donoghue HD, Minnikin DE, et al. Detection and molecular characterization of 9,000-year-old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean. PLoS One 2008; 3:e3426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/3\">",
"      Arriaza BT, Salo W, Aufderheide AC, Holcomb TA. Pre-Columbian tuberculosis in northern Chile: molecular and skeletal evidence. Am J Phys Anthropol 1995; 98:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/4\">",
"      Donoghue HD, Lee OY, Minnikin DE, et al. Tuberculosis in Dr Granville's mummy: a molecular re-examination of the earliest known Egyptian mummy to be scientifically examined and given a medical diagnosis. Proc Biol Sci 2010; 277:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/5\">",
"      Watts HG, Lifeso RM. Tuberculosis of bones and joints. J Bone Joint Surg Am 1996; 78:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/6\">",
"      Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res 2004; 120:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/7\">",
"      Teo HE, Peh WC. Skeletal tuberculosis in children. Pediatr Radiol 2004; 34:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/8\">",
"      Fanning A. Tuberculosis: 6. Extrapulmonary disease. CMAJ 1999; 160:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/9\">",
"      Peto HM, Pratt RH, Harrington TA, et al. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin Infect Dis 2009; 49:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/10\">",
"      Pertuiset E, Beaudreuil J, Liot&eacute; F, et al. Spinal tuberculosis in adults. A study of 103 cases in a developed country, 1980-1994. Medicine (Baltimore) 1999; 78:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/11\">",
"      Fuentes Ferrer M, Guti&eacute;rrez Torres L, Ayala Ram&iacute;rez O, et al. Tuberculosis of the spine. A systematic review of case series. Int Orthop 2012; 36:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/12\">",
"      Trecarichi EM, Di Meco E, Mazzotta V, Fantoni M. Tuberculous spondylodiscitis: epidemiology, clinical features, treatment, and outcome. Eur Rev Med Pharmacol Sci 2012; 16 Suppl 2:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/13\">",
"      Vohra R, Kang HS, Dogra S, et al. Tuberculous osteomyelitis. J Bone Joint Surg Br 1997; 79:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/14\">",
"      Kaufmann SH, Cole ST, Mizrahi V, et al. Mycobacterium tuberculosis and the host response. J Exp Med 2005; 201:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/15\">",
"      Ellner JJ. Review: the immune response in human tuberculosis--implications for tuberculosis control. J Infect Dis 1997; 176:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/16\">",
"      Lifeso R. Atlanto-axial tuberculosis in adults. J Bone Joint Surg Br 1987; 69:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/17\">",
"      Nussbaum ES, Rockswold GL, Bergman TA, et al. Spinal tuberculosis: a diagnostic and management challenge. J Neurosurg 1995; 83:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/18\">",
"      Turgut M. Spinal tuberculosis (Pott's disease): its clinical presentation, surgical management, and outcome. A survey study on 694 patients. Neurosurg Rev 2001; 24:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/19\">",
"      Weaver P, Lifeso RM. The radiological diagnosis of tuberculosis of the adult spine. Skeletal Radiol 1984; 12:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/20\">",
"      Lifeso RM, Weaver P, Harder EH. Tuberculous spondylitis in adults. J Bone Joint Surg Am 1985; 67:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/21\">",
"      Khoo LT, Mikawa K, Fessler RG. A surgical revisitation of Pott distemper of the spine. Spine J 2003; 3:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/22\">",
"      Polley P, Dunn R. Noncontiguous spinal tuberculosis: incidence and management. Eur Spine J 2009; 18:1096.",
"     </a>",
"    </li>",
"    <li>",
"     Girdlestone GR, Somerville EW. Tuberculosis of Bone and Joint, 2nd ed, Oxford University Press, London 1952.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/24\">",
"      Hodgson SP, Ormerod LP. Ten-year experience of bone and joint tuberculosis in Blackburn 1978-1987. J R Coll Surg Edinb 1990; 35:259.",
"     </a>",
"    </li>",
"    <li>",
"     Hopewell PC. Overview of clinical tuberculosis. In: Tuberculosis: Pathogenesis, Protection and Control, Bloom BR (Ed), American Society for Microbiology Press, Washington, DC 1994. p.25.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/26\">",
"      Pigrau-Serrallach C, Rodr&iacute;guez-Pardo D. Bone and joint tuberculosis. Eur Spine J 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/27\">",
"      Hsu LC, Leong JC. Tuberculosis of the lower cervical spine (C2 to C7). A report on 40 cases. J Bone Joint Surg Br 1984; 66:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/28\">",
"      Kamara E, Mehta S, Brust JC, Jain AK. Effect of delayed diagnosis on severity of Pott's disease. Int Orthop 2012; 36:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/29\">",
"      Kumar K, Saxena MB. Multifocal osteoarticular tuberculosis. Int Orthop 1988; 12:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/30\">",
"      Isaacs AJ, Sturrock RD. Poncet's disease--fact or fiction? A re-appraisal of tuberculous rheumatism. Tubercle 1974; 55:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/31\">",
"      Sood R, Wali JP, Handa R. Poncet's disease in a north Indian hospital. Trop Doct 1999; 29:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/32\">",
"      Dall L, Long L, Stanford J. Poncet's disease: tuberculous rheumatism. Rev Infect Dis 1989; 11:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/33\">",
"      Kawsar M, D'Cruz D, Nathan M, Murphy M. Poncet's disease in a patient with AIDS. Rheumatology (Oxford) 2001; 40:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/34\">",
"      Cuende E, Almeida V, Portu J, et al. Poncet's disease and papulonecrotic tuberculid in a patient infected with the human immunodeficiency virus. Arthritis Rheum 1998; 41:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/35\">",
"      Kroot EJ, Hazes JM, Colin EM, Dolhain RJ. Poncet's disease: reactive arthritis accompanying tuberculosis. Two case reports and a review of the literature. Rheumatology (Oxford) 2007; 46:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/36\">",
"      Spinner RJ, Sexton DJ, Goldner RD, Levin LS. Periprosthetic infections due to Mycobacterium tuberculosis in patients with no prior history of tuberculosis. J Arthroplasty 1996; 11:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/37\">",
"      Zahraa J, Johnson D, Lim-Dunham JE, Herold BC. Unusual features of osteoarticular tuberculosis in children. J Pediatr 1996; 129:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/38\">",
"      Rubinstien EM, Lehmann T. Sternal osteomyelitis due to Mycobacterium tuberculosis following coronary artery bypass surgery. Clin Infect Dis 1996; 23:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/39\">",
"      Gondal GM, Mushtaq S, Masood R, et al. Mediastinal tuberculosis presenting with sternal osteomyelitis and discharging sinus. J Postgrad Med Inst 2011; 25:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/40\">",
"      Platt MA, Ziegler K. Primary sternal osteomyelitis with bacteremia and distal seeding. J Emerg Med 2012; 43:e93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/41\">",
"      Frouge C, Miquel A, Cochan-Priollet B, et al. Breast mass due to rib tuberculosis. Eur J Radiol 1995; 19:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/42\">",
"      Kim YT, Han KN, Kang CH, et al. Complete resection is mandatory for tubercular cold abscess of the chest wall. Ann Thorac Surg 2008; 85:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/43\">",
"      Karanas YL, Yim KK. Mycobacterium tuberculosis infection of the hand: a case report and review of the literature. Ann Plast Surg 1998; 40:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/44\">",
"      Hadfield PJ, Shah BK, Glover GW. Facial palsy due to tuberculosis: the value of CT. J Laryngol Otol 1995; 109:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/45\">",
"      Tsay MH, Chen MC, Jaung GY, et al. Atypical skeletal tuberculosis mimicking tumor metastases: report of a case. J Formos Med Assoc 1995; 94:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/46\">",
"      Ormerod LP, Grundy M, Rahman MA. Multiple tuberculous bone lesions simulating metastatic disease. Tubercle 1989; 70:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/47\">",
"      Muradali D, Gold WL, Vellend H, Becker E. Multifocal osteoarticular tuberculosis: report of four cases and review of management. Clin Infect Dis 1993; 17:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/48\">",
"      Lynn MM, Kukanesen JR, Khan AW. Troublesome Tuberculosis: A Case Report on Multi-focal Tuberculous Osteomyelitis in An Immunocompetent Patient. J Clin Med Res 2012; 4:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/49\">",
"      Yao DC, Sartoris DJ. Musculoskeletal tuberculosis. Radiol Clin North Am 1995; 33:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/50\">",
"      Phemister, DB, Hatcher, CH. Correlation of pathological and roentgenological findings in the diagnosis of tuberculous arthritis. Am J Roentgenol 1933; 29:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/51\">",
"      Choi JA, Koh SH, Hong SH, et al. Rheumatoid arthritis and tuberculous arthritis: differentiating MRI features. AJR Am J Roentgenol 2009; 193:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/52\">",
"      Shanley DJ. Tuberculosis of the spine: imaging features. AJR Am J Roentgenol 1995; 164:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/53\">",
"      Jain R, Sawhney S, Berry M. Computed tomography of vertebral tuberculosis: patterns of bone destruction. Clin Radiol 1993; 47:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/54\">",
"      Kim NH, Lee HM, Suh JS. Magnetic resonance imaging for the diagnosis of tuberculous spondylitis. Spine (Phila Pa 1976) 1994; 19:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/55\">",
"      Desai SS. Early diagnosis of spinal tuberculosis by MRI. J Bone Joint Surg Br 1994; 76:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/56\">",
"      Pui MH, Mitha A, Rae WI, Corr P. Diffusion-weighted magnetic resonance imaging of spinal infection and malignancy. J Neuroimaging 2005; 15:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/57\">",
"      Jung NY, Jee WH, Ha KY, et al. Discrimination of tuberculous spondylitis from pyogenic spondylitis on MRI. AJR Am J Roentgenol 2004; 182:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/58\">",
"      Davidson PT, Horowitz I. Skeletal tuberculosis. A review with patient presentations and discussion. Am J Med 1970; 48:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/59\">",
"      Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/60\">",
"      Colmenero JD, Ruiz-Mesa JD, Sanjuan-Jimenez R, et al. Establishing the diagnosis of tuberculous vertebral osteomyelitis. Eur Spine J 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/61\">",
"      Merino P, Candel FJ, Gestoso I, et al. Microbiological diagnosis of spinal tuberculosis. Int Orthop 2012; 36:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/62\">",
"      Mondal A. Cytological diagnosis of vertebral tuberculosis with fine-needle aspiration biopsy. J Bone Joint Surg Am 1994; 76:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/63\">",
"      Versfeld GA, Solomon A. A diagnostic approach to tuberculosis of bones and joints. J Bone Joint Surg Br 1982; 64:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/64\">",
"      Patwardhan SA, Joshi S. Laboratory diagnosis of spinal tuberculosis: Past and present. ArgoSpine News &amp; Journal 2011; 23:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/65\">",
"      Allali F, Mahfoud-Filali S, Hajjaj-Hassouni N. Lymphocytic joint fluid in tuberculous arthritis. A review of 30 cases. Joint Bone Spine 2005; 72:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/66\">",
"      Blumberg HM, Leonard MK Jr, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005; 293:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/67\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/68\">",
"      A controlled trial of six-month and nine-month regimens of chemotherapy in patients undergoing radical surgery for tuberculosis of the spine in Hong Kong. Tenth report of the Medical Research Council Working Party on Tuberculosis of the Spine. Tubercle 1986; 67:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/69\">",
"      Upadhyay SS, Saji MJ, Yau AC. Duration of antituberculosis chemotherapy in conjunction with radical surgery in the management of spinal tuberculosis. Spine (Phila Pa 1976) 1996; 21:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/70\">",
"      A controlled trial of anterior spinal fusion and d&eacute;bridement in the surgical management of tuberculosis of the spine in patients on standard chemotherapy: a study in two centres in South Africa. Seventh Report of the Medical Research Council Working Party on tuberculosis of the spine. Tubercle 1978; 59:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/71\">",
"      Five-year assessment of controlled trials of short-course chemotherapy regimens of 6, 9 or 18 months' duration for spinal tuberculosis in patients ambulatory from the start or undergoing radical surgery. Fourteenth report of the Medical Research Council Working Party on Tuberculosis of the Spine. Int Orthop 1999; 23:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/72\">",
"      Controlled trial of short-course regimens of chemotherapy in the ambulatory treatment of spinal tuberculosis. Results at three years of a study in Korea. Twelfth report of the Medical Research Council Working Party on Tuberculosis of the Spine. J Bone Joint Surg Br 1993; 75:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/73\">",
"      Ramachandran S, Clifton IJ, Collyns TA, et al. The treatment of spinal tuberculosis: a retrospective study. Int J Tuberc Lung Dis 2005; 9:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/74\">",
"      Nene A, Bhojraj S. Results of nonsurgical treatment of thoracic spinal tuberculosis in adults. Spine J 2005; 5:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/75\">",
"      Upadhyay SS, Sell P, Saji MJ, et al. Surgical management of spinal tuberculosis in adults. Hong Kong operation compared with debridement surgery for short and long term outcome of deformity. Clin Orthop Relat Res 1994; :173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/76\">",
"      Oguz E, Sehirlioglu A, Altinmakas M, et al. A new classification and guide for surgical treatment of spinal tuberculosis. Int Orthop 2008; 32:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/77\">",
"      Hoffman EB, Allin J, Campbell JA, Leisegang FM. Tuberculosis of the knee. Clin Orthop Relat Res 2002; :100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/78\">",
"      Boxer DI, Pratt C, Hine AL, McNicol M. Radiological features during and following treatment of spinal tuberculosis. Br J Radiol 1992; 65:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37656/abstract/79\">",
"      Kalita J, Misra UK, Mandal SK, Srivastava M. Prognosis of conservatively treated patients with Pott's paraplegia: logistic regression analysis. J Neurol Neurosurg Psychiatry 2005; 76:866.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7658 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-16712FB15A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37656=[""].join("\n");
var outline_f36_49_37656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6689951\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Spondylitis (Pott disease)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6350100\">",
"      - Infectious",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Inflammatory (Poncet disease)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6350127\">",
"      - Prosthetic joint infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6349732\">",
"      Osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6350413\">",
"      Other clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12709474\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6350875\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Biopsy and culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12709251\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6689718\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Monitoring clinical response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6689951\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7658\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7658|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/1/22\" title=\"diagnostic image 1\">",
"      Potts disease in child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/15/25854\" title=\"diagnostic image 2\">",
"      Pott disease in an adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/14/9455\" title=\"diagnostic image 3\">",
"      TB arthritis of the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/56/6031\" title=\"diagnostic image 4\">",
"      TB arthritis of the hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/34/546\" title=\"diagnostic image 5\">",
"      TB of the spine Pott disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/29/28112\" title=\"diagnostic image 6\">",
"      TB of the spine Pott disease 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/18/15648\" title=\"diagnostic image 7\">",
"      TB of the spine Pott disease 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/17/35103\" title=\"diagnostic image 8\">",
"      Post fixation spinal TB",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22839?source=related_link\">",
"      Psoas abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_49_37657="Measuring quality in hospitals in the United States: Core process measures";
var content_f36_49_37657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Measuring quality in hospitals in the United States: Core process measures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/49/37657/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/49/37657/contributors\">",
"     Mark W Friedberg, MD, MPP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/49/37657/contributors\">",
"     Bruce Landon, MD, MBA, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/49/37657/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/49/37657/contributors\">",
"     Tejal K Gandhi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/49/37657/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/49/37657/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/49/37657/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/49/37657/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12467887\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the early 1990s, health plans in the United States have been measuring and publicly reporting their performance on measures of quality of care. In part, this was a response to healthcare purchasers who sought better information about the quality of care they were purchasing. Performance measurement and reporting has now become commonplace in most healthcare settings.",
"   </p>",
"   <p>",
"    Predated by regional efforts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/1\">",
"     1",
"    </a>",
"    ], national efforts to measure and report hospital performance on quality measures began with a pilot program of the Joint Commission on Accreditation of Healthcare Organizations (JCAHO, subsequently renamed &ldquo;The Joint Commission&rdquo;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/2\">",
"     2",
"    </a>",
"    ]. Beginning in 2001, the Joint Commission, the Centers for Medicare and Medicaid Services (CMS), the American Hospital Association, and other organizations formed the Hospital Quality Alliance (HQA) as a mechanism through which hospitals could submit performance data to CMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Hospital participation in the HQA has been voluntary. However, the Medicare Modernization Act of 2003 made receipt of a hospital&rsquo;s full Medicare payment updates contingent upon reporting the initial 10-measure &ldquo;starter set&rdquo; to CMS. Consequently, the vast majority of acute care hospitals in the United States participate in this reporting.",
"   </p>",
"   <p>",
"    Hospital-level performance data, which can be searched by geographic location, category of health condition (eg, general, medical, surgical), and by quality measure are available to the public at the",
"    <a class=\"external\" href=\"file://www.hospitalcompare.hhs.gov/\">",
"     Hospital Compare website",
"    </a>",
"    . The original &ldquo;starter set&rdquo; reported in 2004 reflected processes of care for only three health conditions (acute myocardial infarction, heart failure, and pneumonia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The range of measures reported on Hospital Compare has been expanding and now includes measures of process quality, mortality, patient experience, and utilization of healthcare. While all of these measure types are important, this review focuses on process measures of hospital performance, as defined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5177478\">",
"    <span class=\"h1\">",
"     QUALITY MEASUREMENT AND QUALITY IMPROVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite having higher healthcare spending per capita than the healthcare systems of other industrialized countries, compelling evidence accumulated over the last two decades suggests that the quality of care delivered by the US healthcare system is suboptimal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/5\">",
"     5",
"    </a>",
"    ]. A core principle of quality improvement is that what is not measured cannot be improved. Consequently, performance measurement and reporting has become ingrained in our healthcare system.",
"   </p>",
"   <p>",
"    The ultimate goal of quality measurement and reporting systems is to improve care and outcomes. Efforts to improve documentation without changing the content of clinical care are unlikely to achieve this goal. For quality measurement and reporting efforts to be successful, hospitals and physicians must engage in efforts to understand the root causes of poor performance and develop fundamentally better systems of patient care that will lead to improved performance across a broad range of potential measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12467894\">",
"    <span class=\"h1\">",
"     MEASURING THE QUALITY OF HEALTHCARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality measurement in healthcare rests on a conceptual framework presented by Avedis Donabedian in a seminal 1966 paper [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/6\">",
"     6",
"    </a>",
"    ]. Donabedian&rsquo;s framework conceptualizes three categories of quality, and quality measures have been developed in each of these areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Outcomes",
"      </strong>",
"      represent the ultimate goal of healthcare and include measures of patients&rsquo; quantity and quality of life. The 30-day mortality rate following hospital discharge is an example of an outcome measure of quality. Health outcomes are affected by healthcare, but they are also strongly influenced by patient factors such as prior health status and health behaviors. Consequently, in order to make fair comparisons among healthcare providers, outcome measures of quality require robust adjustments for other risk factors that might influence health outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Healthcare processes",
"      </strong>",
"      represent the delivery of specific clinical services to patients. Targeted healthcare processes have been shown to be associated with better health outcomes in controlled clinical trials or are recommended by panels of experts. The percentage of patients hospitalized for myocardial infarction who are treated with a beta blocker at the time of discharge is one example. Process measures are often based upon clinical guidelines. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/35/20024?source=see_link\">",
"       \"Clinical practice guidelines\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Structure represents",
"      </strong>",
"      the characteristics of individual healthcare providers, organizations, and facilities. A hospital&rsquo;s possession of an electronic health record, an intensive care unit, or its percentage of board certified physicians are examples of structural measures of quality. Structural characteristics can enhance quality by enabling better performance on processes of care for patients that in turn lead to better health outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these three categories, an additional component of outcomes, referred to as &ldquo;intermediate outcomes,&rdquo; is also often measured. Intermediate outcomes are measures of clinical conditions that do not directly reflect patients&rsquo; quality or quantity of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/9\">",
"     9",
"    </a>",
"    ]. Achievement of recommended blood pressure, lipid, or hemoglobin A1c (A1C) targets in diabetic patients are all examples of intermediate",
"    <strong>",
"    </strong>",
"    outcomes. Better performance on intermediate outcomes should lead to better health outcomes (eg, lower rates of morbidity and mortality). Intermediate outcomes are also called surrogate outcomes and are studied in many clinical trials. For instance, determining whether an intervention can achieve lower blood pressure or A1C is often more readily measured (requiring fewer study patients or shorter trial time) than longer-term outcomes such as mortality or incidence of new myocardial infarctions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12467901\">",
"    <span class=\"h2\">",
"     Validity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In measurement theory, &ldquo;validity&rdquo; represents the extent to which a given measure actually captures what it is supposed to measure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/10\">",
"     10",
"    </a>",
"    ]. For quality measurement in healthcare, this seemingly obvious statement has at least two important implications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Process and structural measures of quality are valid only if better performance on these measures actually results in better health outcomes. For example, consider a hypothetical quality measure that counts the percentage of patients with condition X who receive treatment Y. This is a process measure, and it is valid only if treatment Y actually leads to better health outcomes for patients with condition X (on average).",
"      <br/>",
"      <br/>",
"      In general, the validity of process and structural measures of quality rests on published studies that demonstrate causal links between the measured processes or structures and health outcomes. If such studies are absent or flawed, process and structural measures will have low validity. A good example of a quality measure with questionable validity is the intermediate outcome of achieving A1C &lt;7 in patients with non-insulin dependent diabetes. For this measure to be valid, lowering A1C below seven must lead to better health outcomes; however, the ACCORD trial showed worse health outcomes, including mortality, for these patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H11243121#H11243121\">",
"       \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'ACCORD trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A valid measure of the quality of care delivered by a provider should also, at least in part, represent something under the provider&rsquo;s control [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. This criterion is especially important for measures of health outcomes, which are strongly influenced by the patient&rsquo;s prior health status and behaviors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measures of process and structure are generally felt to be more directly under providers&rsquo; control, and these measures rarely are adjusted for patient case mix. In general, process measures have restrictive criteria for patient inclusion. These criteria create clinical uniformity among the included patients. All patients who qualify for a process measure should be receiving the measured service, according to the guidelines underlying the measure (eg, measures of rates of beta blocker use after myocardial infarction [MI] only include patients who have had an MI and exclude those with a contraindication to beta blocker use).",
"   </p>",
"   <p>",
"    Despite wide acknowledgment that patient factors such as adherence and socioeconomic status also can influence performance on process measures, these measures rarely are adjusted for such patient factors. This lack of adjustment may be due, in part, to concerns about perpetuating sociodemographic disparities in care and &ldquo;letting providers off the hook&rdquo; for patient adherence, which providers can influence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/7\">",
"     7",
"    </a>",
"    ]. None of the process measures presented on Hospital Compare are adjusted for patient case mix. A 2007 analysis showed that safety net hospitals had both lower performance and lower rates of improvement on HQA measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12467908\">",
"    <span class=\"h2\">",
"     Reliability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reliability reflects the degree of precision in quality measurement (ie, the degree to which differences in measured performance between providers represent true differences in performance, rather than measurement error). Reliability is a key determinant of the likelihood that a particular hospital will be misclassified as high or low performing strictly due to chance.",
"   </p>",
"   <p>",
"    As a general rule, the reliability of a hospital&rsquo;s performance on a given quality measures increases as the number of observations increases. Hospital Compare recognizes the lack of reliability associated with a small sample size and designates a warning with some performance data: &ldquo;The number of cases is too small to be sure how well a hospital is performing.&rdquo; When this warning is present, a hospital&rsquo;s true performance (ie, how well one could expect the hospital to perform, given additional patients qualifying for the measure) could diverge widely from the performance displayed.",
"   </p>",
"   <p>",
"    Further information about reliability related to quality measurement can be found in a web-based primer (",
"    <a class=\"external\" href=\"file://www.ahrq.gov/qual/value/perfscoresmethods/perfscapp2.htm\">",
"     file://www.ahrq.gov/qual/value/perfscoresmethods/perfscapp2.htm#C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/7\">",
"     7",
"    </a>",
"    ]. More rigorous technical treatments of reliability are also available (",
"    <a class=\"external\" href=\"file://www.rand.org/pubs/technical_reports/TR863.html\">",
"     file://www.rand.org/pubs/technical_reports/TR863.html",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12467915\">",
"    <span class=\"h1\">",
"     RATIONALE FOR REPORTING PERFORMANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two primary reasons to publicly report hospitals&rsquo; performance on quality measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To inform patients&rsquo; choice of hospitals for their own healthcare [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/14\">",
"       14",
"      </a>",
"      ]. Hospital Compare has been designed to be understandable to patients. However, research indicates that patients rarely use publicly reported quality measure performance data to choose their healthcare providers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/15-17\">",
"       15-17",
"      </a>",
"      ]. Instead, patients tend to rely on recommendations from close acquaintances or their physicians. Patients&rsquo; use of publicly reported performance data may increase if reporting entities can find ways to deliver personally relevant performance data to patients in a timely fashion (ie, at the moment when patients are choosing a provider).",
"     </li>",
"     <li>",
"      To motivate hospitals to improve their performance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/18\">",
"       18",
"      </a>",
"      ]. If patients make choices based on performance data, then performance improvement may attract more patients. Additionally, making performance data publicly available may motivate improvement by appealing to hospital leaders&rsquo; and physicians&rsquo; sense of professional pride and responsibility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are numerous other uses for these types of performance data. For instance, many health plans incorporate measures of hospital or physician performance in their &ldquo;pay for performance&rdquo; contracts, which provide increased payments for delivering higher quality care. In addition, some health plans are choosing hospitals or physicians for tiered copayment or limited network products on the basis of costs and quality performance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26601821\">",
"    <span class=\"h1\">",
"     ORGANIZATIONS GENERATING MEASURES OF HEALTHCARE QUALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several stakeholder organizations in the US involved in defining clinical quality measures. A challenge for hospital systems is to develop processes for improving and reporting performance, both of which can be further complicated when quality measures differ across organizations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    insurers. As a result, many organizations involved in defining quality measures have agreed upon a few sets of measures that can be reported uniformly across hospital systems, permitting a standardized benchmark for comparing hospital performance.",
"   </p>",
"   <p>",
"    The Joint Commission (",
"    <a class=\"external\" href=\"file://www.jointcommission.org/\">",
"     file://www.jointcommission.org",
"    </a>",
"    ) and the National Committee for Quality Assurance (NCQA) (",
"    <a class=\"external\" href=\"file://www.ncqa.org/\">",
"     file://www.ncqa.org/",
"    </a>",
"    ) are among the two most prominent organizations developing measures of hospital performance. The National Quality Forum (NQF) (",
"    <a class=\"external\" href=\"file://www.qualityforum.org/Home.aspx\">",
"     file://www.qualityforum.org/Home.aspx",
"    </a>",
"    ) and the AHRQ National Quality Measures Clearinghouse (",
"    <a class=\"external\" href=\"file://www.qualityindicators.ahrq.gov/\">",
"     file://www.qualityindicators.ahrq.gov/",
"    </a>",
"    ) are the best sources for validated quality measures relevant to hospital care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12467922\">",
"    <span class=\"h1\">",
"     CURRENTLY REPORTED PROCESS MEASURES OF HOSPITAL QUALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospital Compare, a quality tool provided by Medicare, currently provides performance data on 31 process measures in 5 clinical areas. These measures were adapted from those developed by the then Joint Commission for Accreditation of Healthcare Organizations for use in its hospital accreditation program and were identified as a &ldquo;core measure set&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/21\">",
"     21",
"    </a>",
"    ]. The &ldquo;core measures&rdquo; represent the 10-measure starter set selected by CMS when the HQA program was first rolled out. These were selected from measures already in use by the Joint Commission related to treatment of pneumonia, acute myocardial infarction, and congestive heart failure, which are among the most common and clinically-important reasons for hospitalization among Medicare beneficiaries. These measures are now categorized as &ldquo;timely and effective care&rdquo; measures on Hospital Compare. In addition, some but not all of these measures are reported separately for inpatient and outpatient hospital departments.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute myocardial infarction (AMI)",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Pneumonia",
"     </li>",
"     <li>",
"      Surgical care",
"     </li>",
"     <li>",
"      Children&rsquo;s asthma care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additionally, two new &ldquo;timely and effective care&rdquo; areas of focus were added in 2012:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Emergency department",
"     </li>",
"     <li>",
"      Preventive care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Details of measure specification (eg, which patients are eligible for measurement, how performance scores are calculated) are available from the National Quality Measures Clearinghouse (NQMC;",
"    <a class=\"external\" href=\"file://www.qualitymeasures.ahrq.gov\">",
"     www.qualitymeasures.ahrq.gov",
"    </a>",
"    ). The measures are also described on the Hospital Compare website (",
"    <a class=\"external\" href=\"file://www.medicare.gov/hospitalcompare/\">",
"     file://www.medicare.gov/hospitalcompare/",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Process measures are valid measures of quality only if better performance on these measures leads to better health outcomes for patients. The NQMC measure summaries list key studies underlying each measure (ie, studies linking processes to outcomes) and identify the clinical practice guideline on which each process measure is based. Guideline details are available from the National Guideline Clearinghouse (",
"    <a class=\"external\" href=\"file://www.guideline.gov\">",
"     www.guideline.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The process measures reported on Hospital Compare reflect hospital-based care that is delivered to all eligible patients (not just Medicare beneficiaries). Hospitals&rsquo; report quarterly performance on these measures by abstracting patient medical records; performance data are audited by CMS contractors (",
"    <a class=\"external\" href=\"file://hospitalcompare.hhs.gov/data/aboutdata/about.aspx\">",
"     file://hospitalcompare.hhs.gov/Data/AboutData/About.aspx",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Details about the specific process measures publically reported by the HQA are provided in a table (",
"    <a class=\"graphic graphic_table graphicRef70921 \" href=\"mobipreview.htm?4/16/4352\">",
"     table 1",
"    </a>",
"    ). A synopsis of the targeted measures is provided below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64981567\">",
"    <span class=\"h2\">",
"     Acute myocardial infarction (AMI) care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures related to timely and effective heart attack care are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Outpatients with chest pain or possible heart attack who got drugs to break up blood clots within 30 minutes of arrival (technical measure title &ldquo;Fibrinolytic therapy received within 30 minutes of ED arrival&rdquo;)",
"      </strong>",
"      &mdash; The percentage of AMI patients with ST-segment elevation or left bundle branch block on the ECG closest to arrival time who receive fibrinolytic therapy and who have a time from hospital arrival to fibrinolysis of 30 minutes or less.",
"     </li>",
"     <li>",
"      <strong>",
"       Average number of minutes before outpatients with chest pain or possible heart attack who needed specialized care were transferred to another hospital (technical measure title &ldquo;Median time to transfer to another facility for acute coronary intervention&rdquo;)",
"      </strong>",
"      &mdash; The median time from emergency department (ED) arrival to transfer to another facility for acute coronary intervention among patients with ST-segment elevation or left bundle branch block on the ECG performed closest to ED arrival and who were transferred for acute coronary intervention. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\", section on 'Reperfusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Heart attack patients given",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      <strong>",
"       at arrival (technical measure title &ldquo;Aspirin at arrival&rdquo;) &mdash;",
"      </strong>",
"      The percentage of patients with AMI or probable cardiac chest pain who received aspirin within 24 hours before emergency department (ED) arrival or prior to transfer.",
"     </li>",
"     <li>",
"      <strong>",
"       Average number of minutes before outpatients with chest pain or possible heart attack got an electrocardiogram (ECG) (technical measure title &ldquo;Median time to ECG",
"      </strong>",
"      &rdquo;) &mdash; The median time from ED arrival to ECG for patients with AMI or probable cardiac chest pain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\", section on 'Initial assessment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Heart attack patients given",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      <strong>",
"       at discharge (technical measure title &ldquo;Aspirin prescribed at discharge&rdquo;)",
"      </strong>",
"      &mdash; The percentage of AMI patients without aspirin contraindications who were prescribed aspirin at hospital discharge. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H12#H12\">",
"       \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Secondary prevention of CVD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Heart attack patients given fibrinolytic medication within 30 minutes of arrival (technical measure title &ldquo;Fibrinolytic therapy within 30 minutes of hospital arrival&rdquo;)",
"      </strong>",
"      &mdash; The percentage of AMI patients with ST-segment elevation or left bundle branch block on the ECG closest to arrival time who receive fibrinolytic therapy and who have a time from hospital arrival to fibrinolysis of 30 minutes or less. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"       \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Heart attack patients given PCI within 90 minutes of arrival (technical measure title &ldquo;Timing of receipt of primary percutaneous coronary intervention [PCI]&rdquo;)",
"      </strong>",
"      &mdash; The percentage of AMI patients, among those with ST-segment elevation or left bundle branch block on the ECG closest to arrival time who receive PCI and who have a time from hospital arrival to PCI of 90 minutes or less. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H4#H4\">",
"       \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Time from hospital arrival (door-to-balloon time) on outcomes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Heart attack patients given a prescription for a statin at discharge (technical measure title &ldquo;Statin prescribed at discharge&rdquo;)",
"      </strong>",
"      &mdash;",
"      <strong>",
"      </strong>",
"      The percentage of acute myocardial infarction (AMI) patients without statin contraindications who receive a prescription for a statin medication at discharge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441581\">",
"    <span class=\"h2\">",
"     Emergency department care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures related to timely and effective care in the emergency department (ED) are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Time spent in the ED before inpatient admission to the hospital (technical measure title &ldquo;Median time from ED arrival to ED departure for admitted patients&rdquo;)",
"      </strong>",
"      &mdash; The average (median) time patients spent in the ED, before they were admitted to the hospital as an inpatient.",
"     </li>",
"     <li>",
"      <strong>",
"       Time spent in the ED from decision to admit to ED departure (technical measure title &ldquo;Admit decision time to ED departure time for admitted patients&rdquo;) &mdash;",
"      </strong>",
"      The average (median) time patients spent in the ED after the doctor decided to admit them as an inpatient before leaving the ED for their inpatient room.",
"      <strong>",
"       &nbsp;",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Time spent in the ED before discharge home (technical measure title &ldquo;Median time from ED arrival to ED departure for discharged ED patients&rdquo;) &mdash;",
"      </strong>",
"      Average time patients spent in the emergency department before being sent home.",
"     </li>",
"     <li>",
"      <strong>",
"       Time spent in the ED before evaluation by a clinician (technical measure title &ldquo;Door to diagnostic evaluation by a qualified medical professional&rdquo;) &mdash;",
"      </strong>",
"      The average time patients spent in the emergency department before they were seen by a healthcare professional.",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Time before receiving pain medication for long bone fractures (technical measure title &ldquo;Median time to pain medication for long bone fractures&rdquo;) &mdash;",
"      </strong>",
"      The average time patients who came to the emergency department with broken bones had to wait before receiving pain medication.",
"      <strong>",
"       &nbsp;",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Patients not seen after presenting to the ED (technical measure title &ldquo;Patient left without being seen&rdquo;) &mdash;",
"      </strong>",
"      Percentage of patients who left the emergency department before being seen.",
"     </li>",
"     <li>",
"      <strong>",
"       Stroke patients presenting to the ED who received timely head CT scan (technical measure title &ldquo;Head CT scan results for acute ischemic stroke or hemorrhagic stroke who received head CT scan interpretation within 45 minutes of arrival&rdquo;) &mdash;",
"      </strong>",
"      Percentage of patients who came to the emergency department with stroke symptoms who received brain scan results within 45 minutes of arrival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64981557\">",
"    <span class=\"h2\">",
"     Heart failure care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures related to effective heart failure are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Heart failure patients given discharge instructions (technical measure title &ldquo;Discharge instructions&rdquo;)",
"      </strong>",
"      &mdash; The percentage of heart failure patients discharged home with written instructions or educational material given to patient or caregiver addressing all of the following: activity level, diet, discharge medications, follow-up appointment, weight monitoring, and what to do if symptoms worsen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37929?source=see_link&amp;anchor=H14824336#H14824336\">",
"       \"Strategies to reduce hospitalizations in patients with heart failure\", section on 'Discharge support'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12330?source=see_link&amp;anchor=H11#H11\">",
"       \"Hospital discharge\", section on 'Discharge summary'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Heart failure patients given an evaluation of left ventricular systolic (LVS) function (technical measure title &ldquo;Evaluation of LVS function&rdquo;)",
"      </strong>",
"      &mdash; The percentage of heart failure patients with documentation that an evaluation of the left ventricular systolic (LVS) function was performed before arrival, during hospitalization, or is planned for after discharge. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39369?source=see_link&amp;anchor=H17#H17\">",
"       \"Evaluation of the patient with heart failure or cardiomyopathy\", section on 'Echocardiography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Heart failure patients given ACE inhibitor or ARB for LVSD (technical measure title &ldquo;ACE inhibitor or ARB for LVSD&rdquo;)",
"      </strong>",
"      &mdash; The percentage of heart failure patients with left ventricular systolic dysfunction and without contraindications who are prescribed an ACE inhibitor or an ARB at hospital discharge. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link&amp;anchor=H16#H16\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'ACE inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64981580\">",
"    <span class=\"h2\">",
"     Pneumonia care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures related to timely and effective pneumonia care are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pneumonia patients whose initial emergency department blood culture was performed prior to the administration of the first hospital dose of antibiotics (technical measure title &ldquo;Blood culture prior to initial antibiotic received in hospital&rdquo;)",
"      </strong>",
"      &mdash; The percentage of pneumonia patients whose initial emergency room blood culture specimen was collected prior to first hospital dose of antibiotics. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link&amp;anchor=H8#H8\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Blood cultures'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Pneumonia patients given the most appropriate initial antibiotic(s) (technical measure title &ldquo;Initial antibiotic for community-acquired pneumonia [CAP] in immunocompetent patient&rdquo;)",
"      </strong>",
"      &mdash; The percentage of immunocompetent patients with pneumonia who receive an initial antibiotic regimen within the first 24 hours that is consistent with current guidelines. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of community-acquired pneumonia in adults who require hospitalization\", section on 'Treatment regimens'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441590\">",
"    <span class=\"h2\">",
"     Preventive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures related to timely and effective preventive care are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Immunization for pneumonia",
"      </strong>",
"      &mdash; Patients assessed for and given appropriate pneumonia vaccination. Recommendations for vaccination are shown in a table (",
"      <a class=\"graphic graphic_table graphicRef86782 \" href=\"mobipreview.htm?11/48/12046\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"       \"Pneumococcal vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Immunization for influenza",
"      </strong>",
"      &mdash; Patients assessed and given influenza vaccination. Recommendations for vaccination are shown in a table (",
"      <a class=\"graphic graphic_table graphicRef81840 \" href=\"mobipreview.htm?38/2/38955\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"       \"Seasonal influenza vaccination in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link\">",
"       \"Seasonal influenza vaccination in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64981602\">",
"    <span class=\"h2\">",
"     Surgical care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures related to timely and effective surgical care are based on the Surgical Care Improvement Project (SCIP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. The SCIP program was implemented by the Center for Medicare and Medicaid Services in collaboration with the Centers for Disease Control and Prevention. The measures of timely surgical care are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Outpatients having surgery who got an antibiotic at the right time &mdash; Within one hour before surgery (technical measure title &ldquo;Timing of antibiotic prophylaxis&rdquo;)",
"      </strong>",
"      &mdash; The percentage of surgical patients who received prophylactic antibiotics within one hour prior to surgical incision. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of control measures to prevent surgical site infection\", section on 'Timing of prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Outpatients having surgery who got the right kind of antibiotic (technical measure title &ldquo;Prophylactic antibiotic selection for surgical patients&rdquo;)",
"      </strong>",
"      &mdash; The percentage of surgical patients who received prophylactic antibiotics consistent with current guidelines for their particular type of surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of control measures to prevent surgical site infection\", section on 'Antibiotic selection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Surgery patients who were given an antibiotic at the right time (within one hour before surgery) to help prevent infection (technical measure title &ldquo;Prophylactic antibiotic received within one hour prior to surgical incision&rdquo;)",
"      </strong>",
"      &mdash; The percentage of surgical patients who received prophylactic antibiotics within one hour prior to surgical incision. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of control measures to prevent surgical site infection\", section on 'Timing of prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Surgery patients who were given the right kind of antibiotic to help prevent infection (technical measure title &ldquo;Prophylactic antibiotic selection for surgical patients&rdquo;)",
"      </strong>",
"      &mdash; The percentage of surgical patients who received prophylactic antibiotics consistent with current guidelines for their particular type of surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of control measures to prevent surgical site infection\", section on 'Antibiotic selection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Surgery patients whose preventive antibiotics were stopped at the right time (within 24 hours after surgery) (technical measure title &ldquo;Prophylactic antibiotics discontinued within 24 hours after surgery end time&rdquo;)",
"      </strong>",
"      &mdash; The percentage of surgical patients whose prophylactic antibiotics were discontinued within 24 hours after surgery end time. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of control measures to prevent surgical site infection\", section on 'Timing of prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Heart surgery patients whose blood sugar (blood glucose) is kept under good control in the days right after surgery (technical measure title &ldquo;Cardiac surgery patients with controlled 6 AM postoperative blood glucose&rdquo;) &mdash;",
"      </strong>",
"      The percentage of cardiac surgery patients with controlled 6 AM blood glucose (&le;200",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      on postoperative day one and postoperative day two.",
"     </li>",
"     <li>",
"      <strong>",
"       Surgery patients whose urinary catheters were removed on the first or second day after surgery (technical measure title &ldquo;Urinary catheter removed on postoperative day one [POD 1] or postoperative day two [POD 2] with day of surgery being day zero&rdquo;)",
"      </strong>",
"      &mdash; The percentage of surgical patients whose urinary catheters were removed on postoperative day one or postoperative day two, to reduce the risk of infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H29#H29\">",
"       \"Placement and management of urinary bladder catheters\", section on 'Catheter removal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Patients having surgery who were actively warmed in the operating room or whose body temperature was near normal by the end of surgery (technical measure title &ldquo;Surgery patients with perioperative temperature management&rdquo;)",
"      </strong>",
"      &mdash; The percentage of surgical patients who were actively warmed in the operating room or whose body temperature was near normal at the end of surgery.",
"     </li>",
"     <li>",
"      <strong>",
"       Surgery patients who were taking heart drugs called beta blockers before coming to the hospital who were kept on the beta blockers during the period just before and after their surgery (technical measure title &ldquo;Surgery patients on beta-blocker therapy prior to arrival who received a beta-blocker during the perioperative period&rdquo;)",
"      </strong>",
"      &mdash; The percentage of surgical patients who were taking a beta blocker prior to hospital arrival who received a beta blocker during the perioperative period (24 hours prior to surgical incision through discharge from post-anesthesia",
"      <span class=\"nowrap\">",
"       care/recovery",
"      </span>",
"      area). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link&amp;anchor=H4#H4\">",
"       \"Perioperative medication management\", section on 'Beta blockers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Surgery patients whose doctors ordered treatments to prevent blood clots after certain types of surgeries (technical measure title &ldquo;Surgery patients with recommended venous thromboembolism prophylaxis ordered&rdquo;) &mdash;",
"      </strong>",
"      The percentage of surgical patients with recommended venous thromboembolism (VTE) prophylaxis ordered anytime from hospital arrival to 24 hours after anesthesia end time. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H12#H12\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Timing of commencement of prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Patients who got treatment at the right time (within 24 hours before or after their surgery) to help prevent blood clots after certain types of surgery (technical measure title &ldquo;Surgery patients who received appropriate venous thromboembolism prophylaxis within 24 hours prior to surgery to 24 hours after surgery&rdquo;)",
"      </strong>",
"      &mdash; The percentage of surgical patients who received appropriate VTE prophylaxis within 24 hours prior to anesthesia start time to 24 hours after anesthesia end time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64981618\">",
"    <span class=\"h2\">",
"     Children's asthma care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures related to pediatric asthma care are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Children who received reliever medication while hospitalized for asthma (technical measure title &ldquo;Relievers for inpatient asthma&rdquo;)",
"      </strong>",
"      &mdash; The percentage of pediatric patients admitted for inpatient treatment of asthma who received relievers (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      ) during hospitalization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11642?source=see_link&amp;anchor=H6#H6\">",
"       \"Acute asthma exacerbations in children: Inpatient management\", section on 'Short-acting beta 2-agonists'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Children who received systemic corticosteroid medication (oral and IV medication that reduces inflammation and controls symptoms) while hospitalized for asthma (technical measure title &ldquo;Systemic corticosteroids for inpatient asthma&rdquo;)",
"      </strong>",
"      &mdash; The percentage of pediatric patients admitted for inpatient treatment of asthma who received systemic glucocorticoids during hospitalization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11642?source=see_link&amp;anchor=H11#H11\">",
"       \"Acute asthma exacerbations in children: Inpatient management\", section on 'Glucocorticoids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Children and their caregivers who received a home management plan of care document while hospitalized for asthma (technical measure title &ldquo;Home management plan of care (HMPC) document given to",
"       <span class=\"nowrap\">",
"        patient/caregiver&rdquo;)",
"       </span>",
"      </strong>",
"      &mdash; The percentage of pediatric patients admitted for inpatient treatment of asthma for whom there is documentation that a Home Management Plan of Care (HMPC), also known as an Asthma Action Plan, was given to the patient",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      caregiver. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11642?source=see_link&amp;anchor=H39#H39\">",
"       \"Acute asthma exacerbations in children: Inpatient management\", section on 'Asthma action plan'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12467929\">",
"    <span class=\"h1\">",
"     CONTROVERSIES IN QUALITY MEASURE REPORTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important controversies in reporting hospital quality process measures center on questions about the validity and reliability of certain quality measures and the potential for adverse unintended consequences of reporting such measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5177221\">",
"    <span class=\"h2\">",
"     Validity of measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Validity is a pervasive concern for process measures. For example, better hospital performance on processes of care for acute myocardial infarction (AMI) has been only weakly related to lower 30-day AMI mortality rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/25\">",
"     25",
"    </a>",
"    ], and having a home asthma management plan was not associated with fewer subsequent emergency department visits or hospitalizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the process measures reported on Hospital Compare, the measure of initial antibiotic timing in pneumonia has been the most controversial. This measure was one of the initial 10 &ldquo;starter set&rdquo; measures and originally reflected the percentage of patients with pneumonia who received their first antibiotic dose within four hours of hospital arrival. The measure was criticized for having questionable validity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]; the studies underlying this measure were observational [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] and were felt by some to provide only weak evidence of a causal link between antibiotic timing and health outcomes for patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also important that the measures clearly identify appropriate patients for inclusion, so that interventions are not promoted that would be inappropriate or unlikely to improve outcomes for certain patient groups, such as those with limited life expectancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5177228\">",
"    <span class=\"h2\">",
"     Unintended consequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a possible approach to improving measured performance seems antithetical to good patient care, then such an approach is obviously inadvisable. Responding to performance measurement does not absolve healthcare providers of their duty to uphold the principle of beneficence in patient care.",
"   </p>",
"   <p>",
"    Nevertheless, it is possible that clinicians, aiming to achieve targets for a specific process component, might adopt behaviors that could negatively impact patient care, even if unintentional. As an example, some commentators were concerned that in an effort to improve performance on the antibiotic timing measure (which is no longer reported), hospital emergency departments might prematurely diagnose pneumonia and give antibiotics to patients with respiratory symptoms who might not require them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. It is also possible that patients with respiratory symptoms would be given inappropriately high triage priority (ahead of patients with non-respiratory conditions of greater true urgency). Two early single-institution studies suggested that these adverse unintended consequences were occurring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]; however, two subsequent studies (one multi-institutional and the other nationally representative) found no evidence that these unintended consequences actually materialized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In 2007, the HQA increased the timeliness threshold in the antibiotic timing measure from four hours to six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/42\">",
"     42",
"    </a>",
"    ], and the Infectious Diseases Society of America completely eliminated the timing threshold from its guidelines for treating pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/43\">",
"     43",
"    </a>",
"    ]. This measure was removed from public reporting in 2012.",
"   </p>",
"   <p>",
"    In another example, quality measures for hospitalized pneumonia patients include vaccinations for influenza and pneumococcal pneumonia. It is likely that many hospitalized patients are receiving unnecessary repeated vaccinations because prior vaccination has been given in an ambulatory or hospital setting but prior documentation is either not recorded, not available, or not looked into due to expediency. Whether duplicative vaccinations result in patient harm is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5177236\">",
"    <span class=\"h2\">",
"     Little opportunity for improvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be little rationale for reporting hospital performance on measures for which performance is uniformly high (ie, average performance near 100 percent such as two of the process measures for childhood asthma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients cannot use measures with uniformly high performance to distinguish among hospitals (ie, which means that these measures have low reliability), and the vast majority of hospitals have no room for meaningful improvement.",
"   </p>",
"   <p>",
"    Some have advocated &ldquo;retiring&rdquo; such quality measures from public reports, as has been done with oxygen saturation assessment for patients with pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/44\">",
"     44",
"    </a>",
"    ]. However, if there are some outlier hospitals with persistently low performance on such measures, then there may be a good case for continuing to report them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12467936\">",
"    <span class=\"h1\">",
"     IMPROVING PERFORMANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Public reporting of hospital-level performance measures has been associated with significant improvements over time across US hospitals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition, there is some evidence that public reporting of hospital performance on hospital quality measures has led to better patients outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/46\">",
"     46",
"    </a>",
"    ]. However, there have been few systematic evaluations to identify which particular efforts to improve hospital performance are most effective.",
"   </p>",
"   <p>",
"    Cross-sectional analyses of differences between higher- and lower-performing hospitals have found that higher-performing hospitals are likelier to have made greater investments in advanced technology (including electronic health records) and higher nurse-to-patient ratios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/3,47\">",
"     3,47",
"    </a>",
"    ]. These studies suggest that by making such investments, lower-performing hospitals may achieve performance improvement. Examples of successful initiatives include the Michigan Surgical Quality Collaborative, which focuses on improving surgical care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/48\">",
"     48",
"    </a>",
"    ] and Project RED, an initiative at an inner city hospital that developed low-literacy appropriate patient education materials and utilized a dedicated &ldquo;discharge advocate&rdquo; to coordinate discharge support for adult medical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/49\">",
"     49",
"    </a>",
"    ]. A prominent study of door-to-balloon found that better-performing hospitals were more likely than worse performers to employ one of a number of strategies to facilitate early catheterization laboratory activation by emergency department staff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/50\">",
"     50",
"    </a>",
"    ]. The strategies included direct activation of the catheterization lab by the emergency physician, use of a single page number for activating the catheterization lab, en route transmission of the ECG and potential early activation of the catheterization lab, presence of a cardiologist around the clock at the hospital, and provision of real time feedback to emergency department and catheterization laboratory staff. (See",
"    <a class=\"local\" href=\"#H64981567\">",
"     'Acute myocardial infarction (AMI) care'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, results of observational studies should be treated judiciously, since associations between hospital investments and process performance may not be causal. Multiple confounders might account for the differences, such as the quality of hospital leadership, the culture among hospital staff, or unadjusted differences in patient populations. Future studies that seek to identify the strategies employed by hospitals with unusually impressive improvements in quality measures (ie, studies of &ldquo;positive deviance&rdquo;) may supply valuable guidance on quality improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/49/37657/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5177272\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A consortium of organizations, including the federal government, has been collecting and publicly reporting data on the quality of care delivered by US hospitals in a number of domains since 2004. The Hospital Quality Alliance (HQA) reports hospital performance data to the Centers for Medicare and Medicaid Services (CMS), including measures of process quality, mortality, patient experience, and utilization of healthcare. (See",
"      <a class=\"local\" href=\"#H12467887\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A major goal of quality measurement is to be used as the basis for quality improvement programs and ultimately to improve care and outcomes. (See",
"      <a class=\"local\" href=\"#H5177478\">",
"       'Quality measurement and quality improvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Healthcare quality measures can be categorized as measuring outcomes, processes, and structure. The core measures outlined in this topic are measures of process. Validity and reliability are two important attributes of a measure. Validity represents the extent to which a measure captures what is meant to be measured; reliability reflects the degree to which measured differences are true differences in performance or are due to chance. (See",
"      <a class=\"local\" href=\"#H12467894\">",
"       'Measuring the quality of healthcare'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two reasons to publicly report quality measures are to inform patients&rsquo; choice of healthcare providers and to motivate improved performance. Measures may be used as the basis for pay-for-performance programs. (See",
"      <a class=\"local\" href=\"#H12467915\">",
"       'Rationale for reporting performance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hospital Compare currently provides performance data on 31 process measures in 5 clinical areas: acute myocardial infarction, heart failure, pneumonia, surgical care, and children&rsquo;s asthma care (",
"      <a class=\"graphic graphic_table graphicRef70921 \" href=\"mobipreview.htm?4/16/4352\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12467922\">",
"       'Currently reported process measures of hospital quality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Quality measures have limitations. Some process measures may not be robustly associated with the intended outcome; efforts to improve could conceivably produce unintended consequences; and some measures may already be widely maximally achieved, with little opportunity for improvement. (See",
"      <a class=\"local\" href=\"#H12467929\">",
"       'Controversies in quality measure reporting'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/1\">",
"      Rosenthal GE, Hammar PJ, Way LE, et al. Using hospital performance data in quality improvement: the Cleveland Health Quality Choice experience. Jt Comm J Qual Improv 1998; 24:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/2\">",
"      Williams SC, Schmaltz SP, Morton DJ, et al. Quality of care in U.S. hospitals as reflected by standardized measures, 2002-2004. N Engl J Med 2005; 353:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/3\">",
"      Landon BE, Normand SL, Lessler A, et al. Quality of care for the treatment of acute medical conditions in US hospitals. Arch Intern Med 2006; 166:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/4\">",
"      Jha AK, Li Z, Orav EJ, Epstein AM. Care in U.S. hospitals--the Hospital Quality Alliance program. N Engl J Med 2005; 353:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/5\">",
"      McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003; 348:2635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/6\">",
"      Donabedian A. Evaluating the quality of medical care. Milbank Q 1966; 44:166.",
"     </a>",
"    </li>",
"    <li>",
"     Friedberg MW, Damberg CL. Methodological Considerations in Generating Provider Performance Scores for Use in Public Reporting: A Guide for Community Quality Collaboratives. Agency for Healthcare Research and Quality, US Department of Health and Human Services. Rockville, MD: 2011. Available at: file://www.ahrq.gov/qual/value/perfscoresmethods/index.html (Accessed on October 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/8\">",
"      Landon BE, Normand SL, Blumenthal D, Daley J. Physician clinical performance assessment: prospects and barriers. JAMA 2003; 290:1183.",
"     </a>",
"    </li>",
"    <li>",
"     Physician Consortium for Performance Improvement. Measures Development, Methodology, and Oversight Advisory Committee: Recommendations to PCPI Work Groups on Outcomes Measures. American Medical Association. Chicago: 2011.",
"    </li>",
"    <li>",
"     Hays RD, Fayers P. Reliability and validity (including unresponsiveness). In: Assessing quality of life in clinical trials: methods and practice, 2nd ed., Fayers P, Hayes RD.  (Eds), Oxford University Press, New York 2005. p.25.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/11\">",
"      Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/12\">",
"      Werner RM, Goldman LE, Dudley RA. Comparison of change in quality of care between safety-net and non-safety-net hospitals. JAMA 2008; 299:2180.",
"     </a>",
"    </li>",
"    <li>",
"     Adams JL, Mehrotra A, McGlynn EA. Estimating reliability and misclassification in physician profiling. RAND Corporation. Santa Monica: 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/14\">",
"      Hibbard JH. Engaging health care consumers to improve the quality of care. Med Care 2003; 41:I61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/15\">",
"      Schneider EC, Epstein AM. Use of public performance reports: a survey of patients undergoing cardiac surgery. JAMA 1998; 279:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/16\">",
"      Fung CH, Lim YW, Mattke S, et al. Systematic review: the evidence that publishing patient care performance data improves quality of care. Ann Intern Med 2008; 148:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/17\">",
"      Faber M, Bosch M, Wollersheim H, et al. Public reporting in health care: how do consumers use quality-of-care information? A systematic review. Med Care 2009; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/18\">",
"      Berwick DM, James B, Coye MJ. Connections between quality measurement and improvement. Med Care 2003; 41:I30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/19\">",
"      Marshall MN, Shekelle PG, Leatherman S, Brook RH. The public release of performance data: what do we expect to gain? A review of the evidence. JAMA 2000; 283:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/20\">",
"      Hibbard JH. What can we say about the impact of public reporting? Inconsistent execution yields variable results. Ann Intern Med 2008; 148:160.",
"     </a>",
"    </li>",
"    <li>",
"     The Joint Commission. Core Measure Sets. Available at: file://www.jointcommission.org/core_measure_sets.aspx (Accessed on October 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/22\">",
"      Bratzler DW, Hunt DR. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis 2006; 43:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/23\">",
"      Dellinger EP, Hausmann SM, Bratzler DW, et al. Hospitals collaborate to decrease surgical site infections. Am J Surg 2005; 190:9.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Medicare &amp; Medicaid Services (CMS) QualityNet website file://qualitynet.org/ (Accessed on November 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/25\">",
"      Bradley EH, Herrin J, Elbel B, et al. Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. JAMA 2006; 296:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/26\">",
"      Morse RB, Hall M, Fieldston ES, et al. Hospital-level compliance with asthma care quality measures at children's hospitals and subsequent asthma-related outcomes. JAMA 2011; 306:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/27\">",
"      Wachter RM, Flanders SA, Fee C, Pronovost PJ. Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure. Ann Intern Med 2008; 149:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/28\">",
"      Yu KT, Wyer PC. Evidence-based emergency medicine/critically appraised topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in community-acquired pneumonia. Ann Emerg Med 2008; 51:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/29\">",
"      Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/30\">",
"      Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/31\">",
"      Dedier J, Singer DE, Chang Y, et al. Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. Arch Intern Med 2001; 161:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/32\">",
"      Silber SH, Garrett C, Singh R, et al. Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe community-acquired pneumonia. Chest 2003; 124:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/33\">",
"      Lee SJ, Walter LC. Quality indicators for older adults: preventing unintended harms. JAMA 2011; 306:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/34\">",
"      Thompson D. The pneumonia controversy: hospitals grapple with 4 hour benchmark. Ann Emerg Med 2006; 47:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/35\">",
"      Pines JM. Profiles in patient safety: Antibiotic timing in pneumonia and pay-for-performance. Acad Emerg Med 2006; 13:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/36\">",
"      Pronovost PJ, Miller M, Wachter RM. The GAAP in quality measurement and reporting. JAMA 2007; 298:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/37\">",
"      Metersky ML. Measuring the performance of performance measurement. Arch Intern Med 2008; 168:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/38\">",
"      Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007; 131:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/39\">",
"      Welker JA, Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med 2008; 168:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/40\">",
"      Fee C, Metlay JP, Camargo CA Jr, et al. ED antibiotic use for acute respiratory illnesses since pneumonia performance measure inception. Am J Emerg Med 2010; 28:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/41\">",
"      Friedberg MW, Mehrotra A, Linder JA. Reporting hospitals' antibiotic timing in pneumonia: adverse consequences for patients? Am J Manag Care 2009; 15:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/42\">",
"      Mitka M. JCAHO tweaks emergency departments' pneumonia treatment standards. JAMA 2007; 297:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/43\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/44\">",
"      Lee TH. Eulogy for a quality measure. N Engl J Med 2007; 357:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/45\">",
"      Chassin MR, Loeb JM, Schmaltz SP, Wachter RM. Accountability measures--using measurement to promote quality improvement. N Engl J Med 2010; 363:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/46\">",
"      Werner RM, Bradlow ET. Public reporting on hospital process improvements is linked to better patient outcomes. Health Aff (Millwood) 2010; 29:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/47\">",
"      Elnahal SM, Joynt KE, Bristol SJ, Jha AK. Electronic health record functions differ between best and worst hospitals. Am J Manag Care 2011; 17:e121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/48\">",
"      Campbell DA Jr, Englesbe MJ, Kubus JJ, et al. Accelerating the pace of surgical quality improvement: the power of hospital collaboration. Arch Surg 2010; 145:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/49\">",
"      Jack BW, Chetty VK, Anthony D, et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med 2009; 150:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/50\">",
"      Bradley EH, Herrin J, Wang Y, et al. Strategies for reducing the door-to-balloon time in acute myocardial infarction. N Engl J Med 2006; 355:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/49/37657/abstract/51\">",
"      Bradley EH, Curry LA, Ramanadhan S, et al. Research in action: using positive deviance to improve quality of health care. Implement Sci 2009; 4:25.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14592 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37657=[""].join("\n");
var outline_f36_49_37657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5177272\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12467887\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5177478\">",
"      QUALITY MEASUREMENT AND QUALITY IMPROVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12467894\">",
"      MEASURING THE QUALITY OF HEALTHCARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12467901\">",
"      Validity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12467908\">",
"      Reliability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12467915\">",
"      RATIONALE FOR REPORTING PERFORMANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26601821\">",
"      ORGANIZATIONS GENERATING MEASURES OF HEALTHCARE QUALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12467922\">",
"      CURRENTLY REPORTED PROCESS MEASURES OF HOSPITAL QUALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64981567\">",
"      Acute myocardial infarction (AMI) care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H441581\">",
"      Emergency department care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64981557\">",
"      Heart failure care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64981580\">",
"      Pneumonia care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H441590\">",
"      Preventive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64981602\">",
"      Surgical care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64981618\">",
"      Children's asthma care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12467929\">",
"      CONTROVERSIES IN QUALITY MEASURE REPORTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5177221\">",
"      Validity of measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5177228\">",
"      Unintended consequences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5177236\">",
"      Little opportunity for improvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12467936\">",
"      IMPROVING PERFORMANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5177272\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/14592\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14592|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/16/4352\" title=\"table 1\">",
"      Process measures of hospital quality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/48/12046\" title=\"table 2\">",
"      Pneumococcal vaccination indications for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/2/38955\" title=\"table 3\">",
"      Indications flu vax adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11642?source=related_link\">",
"      Acute asthma exacerbations in children: Inpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/35/20024?source=related_link\">",
"      Clinical practice guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12330?source=related_link\">",
"      Hospital discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37929?source=related_link\">",
"      Strategies to reduce hospitalizations in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_49_37658="Anaplastic large cell lymphoma skin 3";
var content_f36_49_37658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83092%7EDERM%2F83091%7EDERM%2F83089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83092%7EDERM%2F83091%7EDERM%2F83089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous anaplastic large cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4AUoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwUDgU4UgrQ0HTZNY1e00+JgjTyBS5UtsXqzYHJwATgcnFZnGyGztLm9l8qzt5Z5cZ2xIWOPXAroLXwPrFwWRW05Z1GTC19EXA9wGO38cV2zz2PhXRbZYjKtvFIbiGN3Aa7lCjaSoHzffzk8IETGckNa0fSp7SQ31xa2+jX9w+xkeG5eWPKqRvdSka5VgeMsc8gtnDsPlPKNT0fUNMZhe2rogIHmqQ8Zz6OuVP4Gs5jXsk0z2mvT6HqkMSajbqUULGskNxB1GDtG5BhjtKnALYJwFHnPjLRV0u5juLVQtlc8rHkkwPgExHJJ4BUgnOQw5JBpWFydjnHaq0rU+VueDVSR+tNG0UIzgZLEYHr3qtNcEgAEjaMDFLO/yYPeo7FRJdopUsT91fVuw/PFUkXsrktk9vDvN3vJKkqFXJJ7DnoPfn6VC8zTuqRKI16AKf61G7lp2efc5Jy2DgmrUV2sdzCyWsUUattOFLn0PU9aYeZWjdmn3lueSTUltAZmZFKodp6nJOP8//AK6sNFFtnhjjKmJid7A7yM9x25wPxrS0O3trqWa4ug62sCgrFGdvntu4DHPTqT7AgEdadhSlZXILTTIoDHLeCWVzgrboMk/72DkKfwP04q5OLu8vyqpCkmCRa2CbYYwOgbH3j27n1NRfarm4vT50kMdrwzCPbEh/2iP4jyeuSe1XNPeZNp+zym1GCXEHmIp65YKB39+1UrGMnIq2mjvaFJ9QuFjK8+WpDdfQ5xn2GaoxSxr50tvbF5CpIluWyV9cdBnH1rZt/NeC6uJoYlQEKywjiYEY79O3HFYupQW9xdM1mDCNvMTEkgjtk/T8KT0HF8zfMOFvdXEUbSCCSMv/AMs3jVsnHJ7457013WfUDBAW2g+WrqxAx0yPrWf5TCKV9ykAAHDZ7j0p9s5ZPKLKkYJd2P5fp6e9I0sOukLXkqLiRU+UsMY/McfjWhpQtrAmae8RZ2QgKqF9ufXsDVKNPl+YbIwpeMPgb88AnP1PP5VHeWy2xTe7SGQb1KjCspzyCfcenY0baia5ly3L3lWk93Zw/aXEbSIrttDFUzyRz2yTg46VPPeW+pXkksjPHGD5cMUagYU56+5zWDnH3evQfSrFkjbyyqCv3Gc/wkg4/wA+1FxuHmXvs8FvbMzTIGIPHLOvOOnAH4nP86iZbWDT45EcyTyM3GANqjA5AJ9zzUcKx+QkJAYSy/6wcYwB7Z/ioaWNm8m2toh8/wB7LEsB9T070AkyKGOSWRFd2HmMuNxODnjd9BzzUkX7tzDhSm4kyrjcQM5wT2pbg/PHEXwu4ISQPlAOB/Umm28Dm5ljTzcRg5MfLbeh4+maQ+hEskeGRlIVmzkHJX/H6UjQsqqQQyN0ZTkfj6fjVm7slEaywSI6lc4GQw+q/j1HFQMktu0csYkjBUEMR14GfqOf1oGnfYg5UkEY5wRTa17cWt+8Ud4v2WZ8BZkHyEcjLD8AOMDrxS3Xh+7t59pKmLIDTD7i56ZPYH1NOwudXsyhFIJEWAxKeTtO4gg+3OP0q1PYeRGso3FGGSP4k9yO4qG8sZbS58uULnAbCtnI9RWv9pQ6fLbXUwmiiC7XT7wUkcc88HigUnaziYjtGw5BVwTkdv8A61V8kE4JGannkXzJAD5in+MjBPvVekWhQakjI/iBqKpEYj5QOe9AyRW9qsxEqdr/AHsZzVJjyQDkZqbOERt2T39qQGjDKCR0r0jS3H9mWnP/ACxT/wBBFeYWwZoZJeip+pPSvSNLcf2Zacj/AFKdv9kUiNGzjgOldn8NoYPN1i6uZI4/ItAFkkAYRl5o0LYJAI2lgRkcMa40VveDbuO31kW90Yfsl7GbWYTEhCCQy7iCMLvVCTkcA8jrUnOnqbPirU7qTxvp91bBryaNYDAqEuZMncqrgZJ+bAIGemOa7u2g0uxghma51Gb7MIZINKuZt8azyJmNvM27W2oQiKoBOFIIBBqpZadY2Piy31aWyuFtrKOWB7NN3mxABgjL8oJxllPH8OV3YNXoPEfg19GtlTVpI7m2SSWMcjBQrsj3GMcYXCsAGAY4UkABlJdxPjLb200Vx4w0y/s5buG5hiWdpn81JI8AxogATcp5I6Y56k1wXxB0+HT9KMtpBPFFeXom2ybgqkrJlU+QDA4HDN93+Hoeu1K70vxBB9j0exvx4ee7+2O925CzOq8RxxcgNnKsycYOAMlVPFfEy8UL9ka4Se5ln+0OqEEKApCsSoAJbcx4/hCdRgllpX1Mn4eeH7HxJrl1barPdQWltY3F7I1qFMhESbiBu45xW/J8OdFSzn8RzavfnwdHp8V+GW3UXhaSZoVg252ht6Nl87cYrhNF17UPD97LdaVMsM0kL27lokkDRuMMpVwQQRx0qdvHniFWf/TkML2q2bWxtYvs5hViyp5O3y8BiSPl6knrTRqjrvEfw1tbXwzNqukXtxf29z/Z76arxCN5EuWlXbIvOHVoscHB61zHxM8J23gzxGlvpd7NeWMkW6G6kjKF5EdkkwMdA6Nj1BU85zTE+IfiVnDS6odkbWzpGLeIJH5BYwhFC4QIXYgKAMnOKzdf8W61r9vaQazqd3qMNrK8kLXZ86RN2AwEjfNjCj5c44zigZg3SGKdkJDbf4h0I7Gr1jFG9i6upaYsJFXdj5R1NZzDhTuySPyqWMyLIRCW3FMfL1xjJpiaui35sb/a51LFpFK4PYkjH16GtnVootMihsRIWleNWljXO4kj5Uz2AHJx1Le9O0DTFN4EuQjTRIJzBnjCDgE9MliBVbW5Zp9SZbdVe7kYRlI1yQAoUDPv3qtjG6lKyIbhYLPTbILJm6u988zcgIMlVXg89GP49+Kt6ZresCx8i2uW8ln2JEAC8jHoFGCTzjP1rFuh58zNJKMxxqqqozwoAHPTn2z1qc3kIe0S1tWTbzv3kyOT79B7YA/OhMpxTWquX2hvtSuhaSbcLu81o04Ug5wxHpwTj6deKln0S9jSZLa3eK3ztfcVDv6ck5APHH061PaLHpqQwDzmnlcFokGQR1+b1PBwB0Oc/dxV3XLh0ijycRIQWk8rIBIBxGp+9wQdzD0PGRh2VjLmd7LY5y90mWCE5mD5+ZVB3ccZYnpgDv8Ayqe5gtbPT4DaPG9ywDyTSMCF9EUEdupJ68Yq3dajCCqrA6GQ5kkwrOy5zggjavTOAM5x6VlanL9vkzF5k80km4sxJIGDhfyyePaloti1zO1zMlLlnMnzOSCWJJJ/GrsURmuLSxd1OHA3A8KHwSD9P55p2l2c1xd7NgYxMpZCcE4zx19sVbt5IYJikcYku5mZWaMH5Uwd2CepPIPGMD3NJFuXRGIG2ZKd89u1a1qv2XSLgSKfNuAAqgnIUMMk+mMfjn2IMojtppVmuSpih2r5MWQZH4yoGMHqMnj2zVsRSXc969wiG4WMuyrwEJ2hEHHYdfw570JClNdTnMH7MpQH7zZI9MA/0NOjgkHnMNyNFhTjrk8f41qZtoIJEkDCeRPOwuAARyPXj5jx/s/SrWo20YtoL23i8uOcylhtxteNRkev3iDj3osPn6ENzprtqa2sKSuJ4kmG4fMdy7gQT161Bc3NzDHMq/uyGEhdVALNxk569SOO2a2JbwQ3UWo3DsHWCOKFc/dVYlB/Mgj8frihLdE6hcXIiR4ZtskgGQTuA+UH8eOM5HtTsZptkdjBc3/lvaLJLJEcyLsz5ZyM89cdSPTkfW/HY2kdzNvkK+cpEakA9sBsDPbI9jUcl5d6bYPPFO6faZGjdDw20DGT/wACUH61Vh1XYXilSFjv3KdvOQx446cE/wCTQL3nsRXGl3NusbblCrzGGBy3fjj27461qzXgj0+K6ijcnGNrkOuCMEZxypOev5+s+salZ3digsSuUYNuZNrKR3x64A6Zzg+lYs2qJdWaRtEkdxz8yLgHr/DjHJ9KNthq80roz7i4jldiY9jgbQvYe3X6/wAuKcxRUk3NlimMP/EMqR+OM/lUF1LK5DSSGQONwLHcep/rmpNy3DICiouwgADA3Dnt/nmpNuhUJzjjpSVJKjRsN4IyM/0/pRIhRmU/w8cUFCRoXV9oJKjd+FNzj/GgU6JdzgdR1P0HWgCTDMA8pYEgbRt5Yev6UhU8Y6mhp3eTc/IyPl6DA6Crj3Mcsce+LGBt3nnBz60haiDetqiDoTvP8q9E0osdMs+v+pTuf7orz+VwkCRKo8x+CR0AB7V6Zpa26abaKRkiFAT/AMBFIm9jiqcPSmium1nwtJp11HbpO87yLIUxEP3hWMPhMMSeoXPHPTNSczVzS8MeMUtoWttYSRydu28iwZBtGFDg/fC5O09VyfvD5aXWNVsNQ1uK8+36T5J2mcXFjJK7HPzHJiY/Qb+3aqZ8Gzfare3N5DFJJHbSP5ylBF50TPhuuNpRlP5+oBJ4IvYhF59xDG7zR27oFZ2SVn2FCqgnKvkEe3y7qY1zM1ta8ZWUCXf9kNJNJKSkMbR4ihjxgAkkM+B0UjbzzkfKfN7+5mu7mS4uZDJM5yzYx+nYdsdhXX3ngi5t7AXMl1EuEeZ1K5CooYk7lJBOFJAGQexNUYPCX2qxhuU1BQHhSaRDbS/IHkjjUBiNrHdIvQ8DOcHig2SfU4qY8dutVHbOa9Am+Heo/abeA3drFJPxH5pIHDMCWIyFA2H37EDnEL/DjUY4FnkvbaNW6BlfeM56rj5Tkcg46jrzijQ4WRfJQ7/vMOBnp9ahySMenNLIrq2JFZWwDhhg8jI/Q0ymMnfDRq6MowNrgZyfer9nAyWn2/IUArEhPUMc8j6BTWaIyyFk5C/eHdff6Vfvp3/suytEIMSBpiB/eLYOfwApoiV9EjV06OV7fU7iFmLC1RecEgkpnr/nmqaTzq19JC2ybcUaQrgjLHv2yOK2PC19avHOtwGQNbCJiFB+bIAPP0AqpAY01UMXAguotkzOpwsikK+eOefm/wCBCqsYt2vdHNxyOiMEJ+b5W+np+n6VoWZeC8i81AW3BYzjgfNgn6cNj8adPpklnewpNjymdec8MpPX8qtRRkQyXjhF/eiVVxyFw2AB7f0qbWNXJNaBbyyyebfFi7FdgGOjMR8qntgHk9efcmruoS7ZmgDgiFfKOMuZn6fkGw2D3wO3DorM2GsWFptMZju0Mxcg/MGIPTsOn4Zq3ptmZdQS1iitzP5KyDd0DFwoyfUlhnjgA4609WZOy1Ijbx29rI97FvWNMyRRtu7gBcjucgZ7c4qKysoI7+71HU0YWVs3luoPytKcgIpx0wOmOn51rPOLexe1jYbXuXR2YchVzukP/AdzH3FY7XCalq0UzRmO0twJVjPOFZyMY7sQQfwp2JTdmTWdlPIkphg8hZJCgZTgkAB5CT2AG3pjr9az7jzNKAjVU+0sqAvg5iQoCwz1BwRnHQE960dW1n7LPEEB8sR5wG4Y5LdPQnZn1C1mS6gkdnuiMr3SoIZpsjIy27IPPOcgn0UY60OxUb7jNMeCC+tFuceY1xHtUn5YU3cs2P4uvHbnPOKfb6oTHq8tupQOqYGMYAdCB/46eP8ACsAgcvv5zjHf61ZaKT7OlyThXYqvGN57gewGPzqbmrgtxttKGuI5LsM8Ma4ZV43AA/Lntnpn3q6+s3cqSQxv5NpI7MY0A7n35J59aoNAyQO+7lXVCOc8gn9MfrTDFIWYMpDgbiCOgxmi5TSZc+3LcSbL23SVcBVYYjZMD1Axj6g/hVi4v4I7VIrJWVlO8zFsnP5Ajk8Hk4/GqxiAhG7cZZV3qXGAygZPOeuc/l9afpYiW6ikkSMEI0ioCTuKqSM88ZIx+NF2S0h/2mC4t3W4xE4Y4HJznnPX6/mKpyeYkXmS+WwmGBwMkZ6+oppnd4wrnKL8pHU4znv396s3ywieKJnJAyrS44znsO2OB+FA0rOxR3uCCGPHI5qYZkhQoCJVLfw8EYyfb8OP1q/FpqwD/S3Xa4YLtGcsOmD79j0PQ4rR0yHT74fZ7af7Ndt90/MATj/63oSCeOKEglNLUxklia2aNiY1bBUGMMobgHnqBx2z274NWDpc6lYo5YyzNwMkYbA/Ug/lWlJZSQ6ZPYvbBp1k86GePljxzj16dsHpVnRZYJsSXFu4u4nO9rfB3Lt/u9AQBuHY5Ip2M3PqjmGtXd5Fz8yA/K3Bz1/lzVjVbR4j8w+aNFDlTkHsD+g/Ou7EVlcCW5TbLLEPKkHXPHXPUg4znr9OpwrO2GtXDxJwvyknAzhQcj/xwUcthKrd37HHqhO/j7oyfzx/WlB2wYHVzgnvgY4/X9K0o7NpctEu5Ziqc9c7sH+R/A1DqMHktDGBnbEpyORlju/TcBUm3Mm7FADP5ZNSRF2ljEY2sSAoHrTnGIcR/dkkOM9cDp/P9Kmtgf3lwFwqISMcY/hB/M/oaB3Ll2d+oqYwGVcJjr90DJPp3rv9Mcf2baZCZ8pM4z6CvLYZjG6ZyUByVzgV6zpdur6ZaMshAMKEZQf3R70ifh0ON7V2t3ouitLOseoQw+UjNbLFdRymVRt2sTu+Vsk5T73cLwc8VzXTB/CRlG6PVViCbzhlLFjtOwdgBucbuc+WpwN5CwcyLt/4c0m0s9Ulm1aEz2vm+XAl5E7SsrgKvHdlO7IBxyDyOW3Wg6AhLjWUETT7I1F1E7eWTw5x0OACQQOoGQQcZUx8OutqYTdxOU3XCy/MgfAwqlfm27mOT1wgxy3Eup3XhSbUZp47e8WGWS5fy1wiqDLmEADp8uQRyBx3pmsUiVdI0SS0s5G1t4zeNCsq+fGQgdvnLgHd+7yD8ygNgkEVQ0TTtFub0DUdUNvZpNbKVM6glHdA+CR2DOScfLs55Ipt5N4WewkESXkU5glcKFBCzdEAY8lOBkE8ZPeqKv4XFhOk63b3aq6pIhIWQ7FKtjnB8zcMHA2f7WKZqkaOmWOh3djpM15qMdnLMjs7pdoZFnEkoWIoWBjUokWJGwAXyTjpX1XT9FuLybzdckmcIrCVrhDuYyQqR35CyMx5P+qP1HI6pJbvqV09kmy2aZzEuOiZO0fliqoywkcjJGDmmUd/rPhnQkaFY/EFvcSrAS+L2Equ2UIFU55/dhpOxOAuASKhvvCmguNVl0vVxOtut5NFGsqNmOJgEJPbIJAB5bGRwRXCSI0bsjjDDgimnBAwOaYGv4l0yDSNYa1tLkzoEWVXxggON6qR2YKyhh2bcO1RWq+Z5UqNDEQrK5kA2E9R19c9vQ1mjGDnr2q5ZRPcblUkZHzfKW/HGO3+NBMtjb0G9hN6beS3t4o3V0LxE8EjjqSMZA5GMVPreyZibgCFp+CxB4Ycg49xt5/DtziGCcLAkSqsiD7mSfM5zkdiPp6fWuljuINStgixukrKyXabCyxc8MR125OcjoQParT0MJq0lJGFKs6whZ5ZQ4csETDBB/eHtweOnTHWtvT7W3v5FvACsTA74hkhCWJKg/qM8jNUrZ3VPsxMV2SzEK0nlsMjGUfPzZHBUg/Q0lgn2hlk+1vbvDgYY9z059eOOKSHLVE2tE7zAHJnjjJDc58z5mbPXnitoERavq9wzQszWaeWSwG0lAw6dcZ6+1c5qDgy6fJDvlbYAzbt+JFyMZHUEFTxzzU9nBc32CkbMfJaCVxgYZw6jd6fOwGfbmjqLl0Mu/lmaK5lWT5CxiIOd3zOWP8ALB+oqtLcszmEOwUAsSvchML+AA/U1f8A3t5pEiQlXeJlO3HzFdpUnn0wPzrLiR0u0L5VSdhOOgPB/rSNUrk11L5qRhmDAScN1IBAH4fc/Wlt7v7O0hkt4Zg67Sp6Yznqpz26nNRWKxtvjkbClSWyhIDDpnHIBzjI6ZqSytLa4uUS6vEsbQDJkkBkPTsqjOT26Dpk96VyrLYvQafJcRtc20QkgXHypEMg56MSe3cgkDjOM0+71CV4fLhkUsSMyomCzAcRxgAYTJ/H8ssTU2t7f7KpfypB0kZgoAzg7Vxk9+pHPfJzUW5XzYGtrfc8XJbuznvgYGeOPcZ5qrkWb3LEcNzNaXAKBvIkUzbDjruypI9wBj1pIiPs8rCFnKuonG3aGzubZxyBlR+mMV08LXiAYEdnYoR502Cij7uOMEjB6ADJPr3zb6zs4dO8vSkkuPtMvlRSnG+V84wByAB7EklsZxmmSpXMC8ka7uUMaC3ijQbVBJESjJOM84ySfqaQzGPU4JlXaylG2ngcD5gR78/rWp9lMDx28blpoJFZpkOFVmx8u4dQfX2JHHWCawle6uJJGQFQQ7JgBQeAvOMcZ44wKkq6IdMtvI1HDx7jvWJQwPy7wcP74HP5fjClk0yjlY+dvzMSGIHJH5j2rb8VStYWllYhla48sPKwA+RsEYB74UgZ+v4Zl3BJHa2ZSQCWTc7RrwwLMQBj325x6U7Am3r3G2l60dktvKpntnI3Ak/IeR/9cf8A66uxj7TbxQrCyXMbbYJkGCT/AHD7+nb061WjlDzh4YikUyiB0A4DYGTyT3+b27dBV+G4SOKS0lfyY2iyxiXqOD0PcH5hjHUmlYJMjmu57mIzuGS6TIkCZVk4wGwOxOOfU+9YPmywziSNmRgeNpIx7V015cCS3klFwPtseQp2giRSDjb3xwR/3z7gc4LlWQCZN/zlyM9c4zz+H86GOG2xp3t20lumoxxLAZGKMIvu9cjHoR6Htt9aveGJEGqTu8wUyozHBx2PA/A5/wAmsB2EcdzBGT9nk2yxhj3B4P1wWFLpFx9mv4pGPyDIOTgcjH+FF9bg4e60dqywLZWZGInc+VGccZAGG/E5NGsWbTS2emQBR5oCvKOSFX+L2OD+WK45tRnlktQCzGMgIAec/wCcD8K6qLU5oLwscJLIsoQNywXO1R+JB/Kr5rmDg42OduTDc+fJHGRFCPKjJ9Mdcds/MfqQKzrlDFFErApIRuZCMcYG0/zrqdOhtpL9EDBre2JnlIHyu4GTgei9B75rHvUku7/zrz91cSyF5IiPuJ1/x4+lS11NYT1sZLgIw9QBx74r1XR7JjpFiWlRT5CZBPI+UV5fK4BExO6dyWI/unPf1r0HSif7Ls+T/qU/9BFQa6swCaQtSMcdqYW6dKg51EGbg+lV3b6ipHPX2qtIcgnrTNIoikfrzUIieUnaoJ9BSTcMWHBHUVAZCDkcVRoOmhaHIlBVvSlsw5lEagETfKcjtnr+FQO7OxLMT9avW8DQvBLcEQ7XU4Y4Yqec464/xpg9ipMjJIY3BWRDtbPbHb8KfZrKzlbeIyu/yBAu4n6CrereTDeh4F80P8+92Jyc+3Q+vJqF9Sumt2txMYrd/vRRAIjfUDGfxoEm2i3DpQmaVGkihZRnEsgVkOOhXrjPtUEll9kVJHa4bd9xooiEf6MSP5VWggkkG6IgnpjOOfTnrWtDFqMdssIVolkYbR5gKlu3y84NMl3XUZDqkrxeSg+Uc/vZRn0+U4GM/WkSGZ5HnsI2Dpgsxc5H45wRnHf8KjubWUEyTTW6zocMFJypHrgYzVeV2hLGKeTLfe5wC38X69KLgoroa9m0cabdWtMRONqyxoTz6EdCffI+tW2nCAGzmj8tW2mJgZG29iGHT1AJ69ax9Jmui7JbmcJ/G8DFT17nB/oK6rSLNWWSS604h1XeMqGdvckJwOnOTQmTKNjlbqCaeSS2kQvKr/uRGrbWJxkAHkZ4OMdajtb6aCVFkLYYkPztJDY4J44BAP8Ahmuka7hntroRR+SHXDxh90bgEEEAuMY9h9KyL9be6uDPaxO+5QXUncSe/wBT7nnP5lXLSb3Q/ZHIxuHIhEwHnYP3H3dSOoUsASR03YHpWa6nd5U0O3D4JQ7yPpz3/wAKv6O7215tlSPYU2tHNwGXjgg/Trg461d1jSrW7CPasIpcHCqwKOBwMZIIIGPX/GblWszI020W719IY4wquWaKNj1baSqnPqcCsxnKylozg54K1vaVoN2t2Dl43+7GyKSQ56emDTv7KhkkJSKSRmbgeeqHk9NpXindDs7mLNdTXGIwXw3G0dz+AGa07ILZWiX0sazXQ+aBSMIign5sfxHOcduDnJ4Ba6VctI6QRlCsZMsjHqO4X6j+vbJqzLod9c3MclwhES7UwpA2LwAPb8Af1zS5kh8jZQ1PUrq5Ma3chKn96Y2ORk9CfX5cfqKtabPPIYUjUB4AWiVzgRLjO85IwTkck8kjpgVGbLUL7VJZIoMS534wAEHb6YH+NaDaTeRWki2cbSidcTztgE856t0HT0J7+lPmF7J2tYparrRW5aLTjGlvEu1WVcl2yCzknqSR+XYdK0tMuY5dNRZUeUQM1xIZD8pYqNuTj7pO5j7DPesqHS4UVjIWllVgvyqWjye2RyW9AP5Va1m9EET2IZVlDssuUxyRg5AGM9sAkLjgntSZEoaWRlajePqWozzFFkeRiFyMYH/6vWo0vDJqMM0uPkKBeBjC4AB9eBiniMnzora3mMmCJGxnA64A7D3z0+uKoshXurY9DmlcrlRsxakkd9O5TKmct06jIBGPpmqcrk2UeX3Mp2Rkddo7fX5v0p2mFJVuIpkLBoyyHPRlG7H4gMPy9KgWZ5ZUigRQTiNAcErk+v1PWm3clRSZPbSQpEBMpEmQgySAsZzuJ+hPHHc+gqtdrtAjdNs0RMb49jTr9Yop3SMHCnaOoOBxk+56kdqdJJKrfa5FO58AMejHAyf5GkUV4nKumegOM47d/wCdR9gO+etSxncqRLgDcWyx6cf/AFqjA3ZYnjNAyxp0RlvYFAb74JIOMAGtnX5ljvlnGPMWNdi9CAQTn9aqabBPbSSTj5fLjV0ZyAMtgjr1xnP1ApIfKuBLc3m9tmDhT976/pTRnLe5p2UjWWnBUWNr67H3Mf6tBjbx7nn8PeqMo/s+KS43brmXKJ6qO7fX+WaYuqtHcPJYRnzyOZpBuYADqB0Xj8vWs+6mSUnAfI4BY5+uabZKg73ZZitLeaOMxznzD94FMgV6DpVo40uzGY/9Snr/AHR7V5pZT+TKckqhGDgZr1rTL+0/s20wshHlJj8hUlNuL7nByGom6d6fKcHv06VExPGagSQ1mwuDUMpAUMRx61K7YB4qrO7BlTPBplIhuGGCODVYkbMMTweBT5iVJXBzmo93GAMGmWOQtGokXGd2AeuMf/rFTwTjz5GmwwlQhi43EkjqPfPeoTJm3jj2jCszZ9cgD+lMHIAzzzTFYnuvuKqqAD+8wvbIH+FMtozLKFVGkPdV64qW1Czr5JdY5Ryjk4HQ/L+Pao413n/Xqjf7ROaANCztypyyR7EJDCQsjKfU8itEXFpcFBtuS65JCOGAHrg5x/8AXrHNncEMskqjaejybQOPU8d6uWyLGhZHaRRx5rLmNfXG7gn6AnuKLkONzRgtbeX/AFzBBJnyxDhpDg9WPRenfn2Nb9hpOiRRq1yqPLkblYeax+mT169hXBzzFWUwxyQR84YyFi/vnp+VdLpdmzQRMoE80g3lJn2jGOrY6L/s9T+WDmsDg2tzoGv7O3WKz0q3Sd2b5FB2KpzweMZPoarvaGScrdNJddWcQsCoPb5h8oxz3NQaYk2WhSVm3Hhvu8DuM5wv5ZrqdP0ma6m2RGQr1LtycDjrgcVDmONO2xz9tp8klyIoLaBADtPzGQ5/xrRbw8skEkk/mKoJADfMrH6Bl7+xro4NAuIpvItpFMshyR1CjjJJ/wAK3LbQmXy4y294/wCIZ2g/Qn/OahN9jfk7M8yfwnJ9nd7uGMRhuJEycexIH0rPm06W2AS14jUcDI5H5cV7taWT744Gw6gkk9Oa1RpdoBn7PFv6k7aLX2KTtueEWOjzzwqbpYboSDAjuVYAEf7QANEukKJUSOKedt2NsePkY9gQQPxIzXrF5ZRyzyN9nQxodoO0DJ79Ovb8qhKwwKohtCpUBgdg5/H8KTehpGF9kcVo/hsAI5jjRS21Ru4X/E/4Vu3/AIdVbVYoXZFUc7QBx3Az0rop382NSYGHP3jjv9KiliJj2jPOQMGpNYwZxkmm21gpVUSOPqTnLEn19fX/APVU40mG6jMwtlYKuPMkPA/Lj27101vaIFSJ4kk2A8kdz35+lStbYjJlEfyjdhRwaQ3BHl95ozTrLPC+2YN5cRHBX5j0PUfh/WsJtBUPNazKrsxJRjjIPTBPTPB69a9RNis27cQg3N8wHfOf8fyrn9VsXPnqyhpN2Q68k9s8/wCNLmaFyJ6HmtwHtUWEpv2kbllZvlODwMY2n86ptDC8gZVZSMZU4AA7kMCAT07D6V3q2T3EDpuMbDIGG5xnp+tZeoadcQTIPMYbjjAY4P1x/StI1EzKVKxz8FpG9z573JMYR97iMMc7e/Tucc1nXEcsOCD5a8sgwN3Pckc12AimtS0EtxHNkgkgsvP1GM9/aoxErknyVdz0B5x7k8f/AF8VXPYy9mcOkZYZ4O76k/WmsN0mF+Yk4FdTf6bJISAEiOOcLyR1z2xUa2sVtbhnAlySQMDLfXPaqUiXE51UKyKh4znJU9u/9ae6rwGbZnBBYdvwHvW3BY29vOk05ZnIJ8or6jvz+n51KVgiDXAVJJ5AfLSUjGexK4wAOw7+w60nczehTvI/MlYQzI4WNI3eV1HAxngnsQB+FZ00ZVsvcRKvICo27C9/u8fnT72yuEnJlgfLfOWj/eAg9/8AJqqyIOVkG45BDKQRTEvUnvnt1AhtFcKB8zsfmk9z2H0qlV2OC3SUeZOrRHnO1hu9ccUXEyqD5bRckny1iyBz6kUDXYpV6XpW3+y7Pk/6lO3+yK84LoVOYxv7EHA/KvSdJmYaVZ8J/qU/gH90e1AzlZT15FRMSMYxUkjYPQVA8g2/KoJ9O9QZojlY4PYexqtGQJiZMgBSRnnmp3kaORWMZDgZ56Cqk2ZZDIZERz2yaaKQySU3BUSEBh/Gf61GY3AGFyD0I5zVu2ghmmCTzCP+84IIx/jUvkQwzSNb3gRQ2EO/LEe+BVDv0M9kYIjY4PAPvTkRihZBuA4Zc8/XHpWjqaW7QRvbXBl2nkYAwT1J/EfrVKCV7WdJoyVIP3h1GaQJ3RC2WOcnk9zzU0M0yIzj5lBCtuAb6cH6VpX84ufKkhjEjKuCCQy/UjtWYsTSArHC7MOuznFAC+a7cBV55+VFH8gKl+ySLCJ3SXYRwyqcE+m7GP51as7JxwIlMjgjfKCqx+4z1P1FTWsDXV7uuJnuWUkkscqcf0pXKSbGafFJPM0UKL7ysN4+mcV0WkaU7ylQwMac4zgk9Mk1Z0qzaby4xAsYC7mcnHHpn/DrXY6HbwozrHG4AXAYruLHjgAdP8Ki9wemiKuiaTJFKgVY3Y4bhSOfQGuttrS4VH8+Y24/uqPvfjVnRtKmCCUtl35Zu4XsPp7V0FvpivKktyzZXlRU+hol3KGnaTLEftEjnkY8sDaAPf1rSihOd2SIx7fe/wDrVdEKKQqZI7L2H/1qt/wYK80LsU7sowNiTAAzjgVZkBEZC8EjqaljCowbHPQ06dgwxn8qbYW1OduUMcRjZxjHJPrVW2AUHzOCeeRW1cWpYnzFOOoBFFrpomYKgGPfpWerZ2R5UjKGWIQHCDoSMZ9qnWPauVVcelaNxZBAVbr7VV5j4bkdjinsPRrQpyRgSnBw2Bg+tRyjcjK68YrQdFZQ+QMenpUFxH8ppCZz9umBLHuO9DjHqev9aZNaI8a/Km9GzhhwT71cSLOpzuudmByPWnXFu28umTx09amw0jnZ7GCaQsscW4n5g4PX8Py/Kq9xoySxnYNgH8KjBH410txZiZNynD4xnHX2qpGWbKO4V14wwyD+NAuU5p9GhQgNFj36496q3GiiE7i/HfbXVNvK/MpOPTtVSdSjhHVnQ9KZLRzM+lb23RzMy55QrnH41CdGhZC5RY8/LkDkH15rqmVSBhCAeoqpdW4kBVAxLcYHFO5lKJyN/pZit/NgCswzyRkisa6tQqNkbxId+SMkDHSuzlby0MDrsaNh+I6Z/Wsq8ttsxXcFD/dz0z0NNSMWu5xU1qZ7RzBMxmiJIXnJB6gGsmGW4MuWZmCjkPzgfjXWXUMdmzMrFS5wwrFnaCy3lpBNdygkc5WMHpn37+1bxdzFqxX1i4j84R2yIojG0sFAyevFUA6YPmJuJz8wbmmliFKEDrnOetM7daoSVlYnZbcquyWUNj5gyDA/EH+leiaUB/Zdn8w/1Kdj/dFeb+W3leYRhCcA+pr0fSiP7Ls+B/qU/wDQRQNHJzt70yBYidzkkgFunSmXTcnntTLfmCaQ52qMYHepItoQNczRs7AsoPTPSq5ZXTBQBwc7hxkfSrWy41Ar5aLhcKqg4qxdWI0+zUkB7o8kg5CimO6WhkjKntWhZJG8EhkhXcFL7i+3gcY/Oq1rbS3Um2Jc4GWPpW4/h2QWMLvIA7ds8badrilJLRsq2WniZi0Ctjqylhtx6Z79qhkjg2R5kZUOFZGySME5xW/p1us9qsdoAibjuZevHH9aZqVnbxEW10mD9+JU5ZRjkk/55ot1I9p71jnIYpSkiRTRrCzYJZwoPpmtNbmK2tZbO2eeRD0baApbv/8AWqeDTzBaRMbdLoSk7ZACAF7k+9S/YJgUSwjdQeGYufXpgHiobNkrkM8E13OrQBxCRgAkLgfic1u6DZtDGI/IAI43hd2f93Peruk6LPJZZlEhiJwzBdiH2L9+ldBYQ2dpFGrbSQOVQd/TPWspSNoxuNsNPQBZbkuS7fLH1yPU+pz+H1rtNMtT5qRNuWJewHX2H9fWsbT4HubsSqgSNfujpXXWYPnfL/cAJ/z9aL3RXJyu5pRsVQFsKo+6op8chkPWmC2EhG5sVbENugzycDn60rsqMV1FiOMc/NU24AEliWpIwhySR6ClwpOOeaZXKSRlcdTT1YFQQDjtQItqhe5469KaB8oUkfKMUXZFkJKcpzjHvTJJTKny7QAOQB1pCwYkZBUcdKC8cfWlc0RFNxH1znoMVQ5fqKu3FwCuOMGqwUgE8ep6Um7m0dFqVFik3sUDBfUH+lMkSQDYGOD+lXiGcZRcdiTxj8KY8J2eoPU+tFhtmYq+TKqAhVxwTn9f0qUgg8KWHtVmZMqAyAkceuRUJYx7gyvgd9pOfajYVyIBVP7s4YjuKp3dur/Mw2svIYVdfEwIC7mB4zUUsTSOu8dOwpD2M0R+ZESVYOOvGOPenfZYxGdvPvVxlIO4ghsdjwaSJAVxHnjsetK4mZLwlGJUcVWf5mBI/H3rVmjZZNvQYrPu49u9MdsjFK5DMbVbVZSd/I6E96zJrYyRskqhwMHd3zXRXAEkfPXvWe8XlylhnJ4PNBk0cTqllJl9ysYiOG67a4bUYvKnfJO4HBBFezXlsksTDYNwOTg4rz7xLaRxvIzQN5m0/wAZwfTgVtTl0MJo44gjGQeenvUuxYlcTBhIBgJjH4mn/amwqqkcYHdV5H4nmq5z361uZigM74GSx4AAr0zSreX+y7PMb/6lO3+yK85svMFwjQECRTkZr2nSrm5bS7MmEZMKE/8AfIpqxEpNHkN0fm74oRjNEYYhgE5J9BTLxCpDNwD0qzoZzO29VMYHzA9/aoG3ZXOi0i2T7AiW8I3AfNIevPeqmoaaZJBEsgBfjOc5rSvrr7NpMcSr5bT/AHsdlrP0kqjK7HPJ2Ke3vWjtojmhzWczTi02LSIoiypkoCQDksfUiqc7X1wX8rfsI+QqRxUk7s94sAALyA4f0AGTTrC7QKYY8tIT8p/Snvp0J1S5t2OeEizSNXa1fjJRs78dao21tdM8+PKMZBy69QPTnmtnVrG3ujZCCd/NhLCdNuAPQ575p9nsRmkaJXK8jI+9z0I9KmehdJ3ILWZxH+5LLGqhVUZG0f5yafDJLHKrbmIHX1JprzIU5GV3YwBzxUkQLyqkfC7hk4rklKx3whc37K4lZSzM7u42rnn+dalrEwBM2N2SAOwqlaRhAoHUdDitWJWMaggYJ4Oayu2dkIpI1dMiMUKs7EZ7DvWtbSeVGCcl2rHglCoozls4x2FW7ItLLyDnNVzWWg+S7uzqrb5wM5+Uc5pzBWTCc+tVo2YKwwc1PbRkHAz+dWmSlYlgVm9h71K6MORkGrqQgLnv/KmyDMZwM4NU9Cee5BuZEwWPqaqSyMzEw8n3plzcsWZRkYHPt7VXMmMjnPcVlKV2XyW1Y77SVY78g98HIpRMrtkoSPfFMt8NPubB4yAcY4qywHIK9RwQeBRysE0U1jctk4H6mpdikheC3XnrViGH5dwPXnFBjUncTzTSsXzXGBMg5yG96iY84U9ferhXy1GH6EA8VHJDk7gOR196uxNyoIptxfbgdODwaXqDzk9cVM5IB2bcEZwRnmom34ByuT220g1YhiVeoIB5B96YoXJP4U7OflZc8g9elACeYF6ZzjPGKQ0itLEPriqkkZD5Gea051IYDv0qq6b9yn07mk0BSuM8Ej86zpUVy/Xd3zWtPHlSwwPaqMsYD7skFhipZBmSAFQMYA+UmqFwrK+QMjuPWtNxkFCMFuc1VeJg7KevWlclooMoCKx6EkfWuQ8VW3mOhVeSpB+tdjdIQny+udtc9rEZeRfzHvTi7MxkjySXAkbYMdiPSlT96yqxAY8Bj/Wr2vWwtr99vAck49KrW0DMvmbC8Q+9jqK7U7o53obFppDhEbaBKAd65zuB6EV6PpVrerpdmNy8QoOh/uiuL02SMQosTiTcCADnOO/Neh6dcRjT7UCO4x5S+voPerVrHO5SvY8Xuz8578Va0csQMcLvAY46Cqs6NJLtAOTVvT8MiQRn5PNDSP2AA/8ArVBrLY2tTmE0vm4PlIuAPX2FNis18uJ8gAYLE+hqJZUvS6qMpnanv71b12JvsIigPzgDI9BVLW7Zgm42iZ11f+RqF/NDgRpF5MS56bsc/pVzRVUSW0q/6xYVbJ9elYH2ctZLKFfzMdxwa67wTZ/apVimkRWUE5Y9cdqE7suaUY6GnD+7E7SNudsLRHHgSccIvNUXuDK0TEgZcrjv1rTuAI7V1zln5x6CprS1Fh4tLXqUUhJljwuQPmYVbtk3SI+3Cg5wfrToUQfadp3YAH6VOR5flKO6jNcUmejA2dOXdEny5BJNbkC52ABeOSP0rI06MMqgdOBW3E3lxE8biAAPShI3ix0MfzFz0Vcke5q9ar5S5zjPTFMwsURXgnHI/GplAKQgv1XnA6U7FpmpHcHaDjIAxV+O6VQAw571lop4BPHr/SpVYoPV2PSnqg5UzXe/UAIDwR09KbJflwVQgt6elZEbDnI5z36mrEeEIx8o707sfs4ok2gyYkTA746mlW3DybRhf9o9aBIMscjcerZzxSqwT94GGfTHakkKV2RrGYgckODxwM4qZQ4B+UDjof6U9Jd6LnPUnFSx5KMQMAc8j71MlCxSARYMSt6sDyaPNi2jI24GDxTdrO6xqdpOcdeaaQyOctwetArIWQx7g0MgGcAjPWntG5AJdAW7ZFVpAu0j17imi2TaRuweoB71SGkTpbmQEr69SQPrROoxn5eDghagjJXIxlTzViSYswYM20nkH9KLoNbkdxAu7cM7iM4AqDYD/EBnj1qd2wwJY8e9UZZigJ2cA4/+vSZUUKw+YgHkj8M1E5IUhxg8YNSu5fJA498VGpLREMvOMdKVgsVpm+X0zx7Cqk43Y9F/nVxgrqQSNxGQMfpVNRsQluT9alisULmLdgg88kVCCQ/zjORitEgDaWBDA4OB2qldJtlJ5xxzS8yHqZN78sQxwQTj6VhaiuGDLyB6VuXuS2zGQuax58NE4JwVJU0luZzR554ujBkSUKGABU+3vXPW8k8DCaEsvOMj1rutehEu9NvJAwa52ztPNmjl+6knyun909AQa66b0OadkbPh+6tZ5IWliEd0RgtkYf2I9a9RsooxZwDZIMRrwMY6V5nHoq7GnlTbcW5+V0OA47Aj6V3un+SbC2JuHBMS8ZHoK6FdLU4Wk3oeMtvO6OFSWbqRUbfuh9liY7XwXf6elSy3QiDrEu3d1Pc1DDLtglkOAxGwGsTq1N3Q2jV/OTlY48L7mtO0tTNcTNM7EyYLAduMAViaQwt7K2clQxfJB9M11duVj1NNjoA21m79OauJz1NGLd6VnyraHAeJTye/FUtLk8tzuC/I4Unpkmtea4T7Q8yybtwYKR9cUy90qM2qGJWB2LIDn+LArTl6oxUujMm8ENpOvBLq25c+/eteOM/ZdzZ3tgmsy4tpZpVjulxu+aOQencGtrfuhBbjjFctV3Z3UVaKKsTFXkJx83WrYOdmOu3r+FUJMKcetaMYARORuwMKK5nudkDdsW8qIAnkDNbVviRgScAD9KwLBGaQB8/7tdBb9BjHPFNGqLjAy5BwpJ5qeNFLKTjjLYI6elRwLna2cbhkmpf75J49DVpDvroWMkrhsDp09KmVRw2P0qMriJCep5wafEDnpye1OxcWSRBQRg81YATA6/XtSKMK2F5PU9cUgjf72TQVe4MVHKgn29qYjxqfmbaxPH86R94POai8kPIrnkjofSpLSui9HKMkj04PTvUysZCMfhjqaojAXaWAWnRksofccdB7UGUlY0EfyyuMF/TpQZi3O0fU81QMxzx0pWnPyjuB3pORPLcmJBfBG4VGSEBRcrgevaoSrMxkLdDxjvT87l56Ec0Iu1hRKQfY859aTz8Hn7pB4xTFQDAAIA60pTAJxnmnYBwlRiCznd2OMZpJJASTuI7EYoZfkCsM9xULnIwTz6VQxSoCnaRmmNIVGcY9AaIwAqkduKbKQYwT98HAxSsT11I3+aRW7EZ9OahmXMZx271KeUUMOV9Ka5G0MByO1KwmV1PHPI71UvAQDjJx3xVteYx6g4GfTGaqXzbQ2O1SSYepJwXHUAE+1Y8nAlGcdK2tRbhhnIJ/MVhvkxdcHvkUrGMjJu0WYunB3ArWRbWEbW5MgIEbbWA/un/69bDllBcjoMjHfms+BpNtzsXehJjb/d7Zrem9DmmneyJ7O4t4rKS2ZmaVGO0M3zEdfxrqbGSzaytzk8xqeh9K84ud8LoVYmSNvMQkc+49+K7/AE1LSXTrWTkbokbGR3ArpUro5nBRkzx+5Hz5PWmSo2yNM4UdT71anYxyglQcdmHWqskitKrlSFBzgHNQbodfMGuvKgLCNQFAz6VpaZPcRSOZZeIxsOeozWPuJuFeMneW+X60SSS+ZIjOSzNhvc0BbSx1mnawkUMKM5Mvz/MfTJrt4LtJdJsZeGV06V5bdxJBax4yZD8ijHPvXTRXy29tY2YLfKoVsHIAq4ytuc9Smt4nT3io+1gAIv4fY1AeYwKo214HAUkbAxHJ71eGDu56c1hWd3ob4dWWpWlQc9jWhaEdc8qufxqkcuxapRMIonOMnBHHfmuZbnYnZG7pbjyDMc53YH+f1ro7WPMSk8EDjnqa5zRYD5EXmZ45xXVWeSils7B29a1RpG5OnAVWOSKsW6CQtkZUdarxZcsfU8Vft1KR7QQTTTNOWxJ5e7bu5xx+lThCBkjDHvTymUU4wAep702EFic564/AVRGu5PboHX/GpXjEa9SPx61Ak3l42Lls8VYjYmN5JV3AcknoMUaFWZCYwxx1JPNPS1wnKqpPOM1jQarG+sfMHSLaQQ2CM5AyP8/yrpVRZQGRsge5rOElO9jWpCVO1yi9mPMw3AqJo1hTAyc81pzqyIXYkk9/Wqjxgn5epOPwpyM+ZspEYGR+Ix/Kk4Y+9TTJtHA6VVLEMp9OKzLSuWFRjgg4NBjcnjhalhdCPmNSiMOQM4HtVJEtkSbS+wrk05kUZBAHpVv7PmPjqO4/nTfKVsBjwTzjtV2JUkVlRT9OvNRSxjb0BxVtYmWUAHI2ncCKbJAFRdxwGOQaAbM1VIVhj1zURUqpYj7pq6EGzBX171GUPlkEc5FFgvqVJdok45HWoHR0lZVbKt0/wq5cR7Gzj5h0qqMh0JOD70mguQfeYbcZ2ngiqOpMBEjbcZ4ya0H5lG0ck8fWsm9cMhU/eVsZ/GpsRcyLs/MUPCg5FZD8RHtjNX5W3yNtJzzkHoKzJMtEW/AfSoehk9Si3zphhkL/ACqrp8ggUyOpMUpKuvqexqxKhe2ldMj6VU0xRLDmXOzsCenvWkHYynG5n6rBi5WVF3RiVQOfUV2Vg1stjbhoE3CNQfk9q5eaRxdMm0PESCecFSK7KxXzLG3fcPmjVunqK7I2scc3aWp5XLGk6MJF5UcMO1Y0sbAY6/pWtcbgGCHBI5rLdygZXGcjjNZo0gUzkY7VLEV3qSTv3D8OajABzzinRRFnUAryepOBVGhbUyPcM8BwiElS3QVctLrzRdzSZ/dQhVx+VVr5lj22lrggDLsO5qqW/dCOPIDEbv8AaNIW50Nk8yMTH9zejYb0IrsF5DsOO1cTayyLcqgUtEGHz/TiuwilDKwNY1DWmPVwsTMfpS6arXd6o42oQx7j2FVrh8AglVAQ8n1rf8H25NssrLjexb8O1ZpW1NVqzpLKEIgBHPcVr20LGMEnHYD0qraxfMN35VtwbQoAA6cGnY6k1FEcUGxQOpIPOOlW+IVLdh2FJEzZOcD05p8m5lyw5JyOc4qrBzXZMxGFPJXg8fSnHKBSerdTj7tV0dRuD8bumO3vSedjOW3cY60CsWnlAlAHqMsB0pt6rC0CrJghxuU87u/A/wA/pVQS+YSeCelSTRR3EDB8kgkgHPt/h+tKV2mawSTVzBleKQySuyZ2gqgAGST1+g4rsdCJNqN4y+Mc+gFYFppO45uGGPRevHue1dJa+XFg7RjGMGs6EGtWbYupFx5Y6k19yqJkfe5xUEgYjCc4Haoru7U3Xlggsq5NKZAIxggk4rV6s4EmiheuRu9utYTXDujHa2VweuBWtqjJtbcSMZPXvVPSYZW8yaWCQwL8xJGcAc856U4xTOuDUY8zC1kdowzcqCOR2rorNlCgMRjOPWuQudTi/ti4jTCx4VdoOAe9alneHzBswVJx17f5xRp0JqQclc6xR0YYA6c1VlKNkAfN169KjiuD5RLcA/8A1qbLJuO7I60znSaHeZiZWwcjgj9DTLn/AFTgnHTb+vH+fSsq9lY7hGxVe5B5rHm1OaKUhHWTgYIJOPrnpUXFezNwS/vApIB6GppkcEyBvfpzWNHqUDP+/b5zyCMHP5VsW8qyncJAwI9c5potyTd0QO3mQkA/OvRieorNkyoG8Ec9a1LqMIX8sEKCeBWfODgJng96TLST2KczE4ODjrWXqOQ5kBzuGT71uSQZQYHPJrKvI9yFWB9aXqZSj2OVMwMk4HXPFQFSITjH3dtOuVaC8G4Haxx/SknDDbHjqxFKSOZPUoIc2zp6nFZ9mfLCwbNzpwTWigGwhQOG9aiCiBHcjLMcD3NKO43sY9xKpun4+fGBjv8AWut0y1n/ALNtMPx5Sd/YVzMNvvvCzKcu2Ca76xtnWxtxnpGo6e1d0IXiefUqcs2keRvHuB296y7u1lUZKE4H4VqspIJXO4VVnunUAE5HvWSKg30MOVCD0x7UxVJ6VoBw8rZiznjgVKNLlmZViibJ/SqubrXQrzx7IVmVtxkGGA/hPpU2jW6TXK8E7FLNnoD2rWttFe3R1uGwkgwyn+dUr+2fTkmggRv3mMuORt+tJNPYbi1oTaLE1wZpckRREBPQ10mlsZN7YyKy7KNbDRWGSS5zWtoWFtQTnLc81lMuA27ia4lMSjGRkmvQ9Hi8m0jAGeMVx2mQmW9YkDjFd7aIRbbgOKmxrFl6HDgEdR2xWhBNhVBBz6Vi+b5c4wevOc1cWfGMMD+PSmbLsbdvJz8g+YetTb5GVtwQdMZP8jWOtxtwd2GPbNX7LLngl2xnrwPzpcw+V7i3cKSIoGcj+dNhRlQhiCO2B0FaKqu5oyFBHp60MijAznNNsWpiMTFJlSMGp0uASMkY9qnurNZRnOM/pWNPDPbOTF86UrmqknubqSY6fzqcTZwOmPWuXTUpFO2RSoq2l9uX5Dk0JjZoTyruQA4ZmyTWhEVPA5GP1zXO28580+Zgkk1s2ksjfKoHTmi5LQmpRKxLzBgobIAGf89KwNQ1lppIbOFlhgYHcBwW+nv6V1t5H5kbDBUMMYwea5i806CO4imkSUPGOADwPzptu1kXSs9yoLaOa8S1trUokbKSshJ3dclyvfntWhLcQ+cBBCkQHG1WLDI9CfWqU9x5cLxQMTG53sWPJPbP0pluREDJOwXHRe9QvdVjbl5VdnTQylI13Dt3pJ7nam4An1ArnItTJUbj07D0qb7WZG3IrE1Skc/LrqaUkm8YJwPcVV1GFTBtWNHXqRkg/wCFLCzs37wEZ9qvGIyAYJA68U0zKpBPY4S6F5AWe2tWlA+Ux7TjGeoI9q19GucPGLom3MmCo3KQx9twBrof7ItJMyMHEo5B4OPc+pqvJp1uBIj28TqR/ESMj6YNNIzirOxdiwqsBJvpkigLjHPX6VTs7YW0myMIiAdFJNWJH+TJ7cUjYaWxF06d6pXMSjDHBB9amEod9gPUZqCRiwbvg8VIHK69ZeZCWXIZeQR6isiWTcRJ2BBPse9dbegOu3tiuLddslzE2QQ2VGOtBzVVZ3K9s37xweOtJcNlYwTwGNRWZ+Z8nPPze1JfthC3RVFK1mQ3dIqJ50l6oU4BOR+Fel2EzixtgVGfLXP5CvONLfe8LHdjcT0rtrO4P2ODJ58te/tXowVoo8uT5ps8kkYqeKq3EqEDzEyfap7jjpWZdk4GRyK5kdMEiWS+WMbYkVcetdh4OC3tmXx+8GQa89Y56/zrW8MatJpmpRtvYQscOvaiUbo3g1B3PVbbT4bptsvJ6HNaEvhuznt1iZMjHWqdlcBr2NkPySLmutiG1EI6Y5rJKx26Sjc8m8Wab/ZrJbLnYTx34qxpcW23IXA2qKt+PJVuNXhiQ8r1qHSIjIsmO5xilNmMUb3h22V3mbb0IANb9/cPp+i3k8IUtFA7qGGQSASM/jVHw5GI4mBAyTzVjxE6nw7qY5z9ll/9ANNMtRsjymT4m6m7BvsdkCPQN/jTh8UNUH/LlZH6h/8A4quAorblRh7SS6noa/FXVlbP2KxP1D//ABVW7f4y65bj93Y6d/3y/wD8VXmNFHJHsN1Zvqeqf8Lt1/du+w6bnGOFcf8As1K/xt15jn+z9MB9lk/+LryqijlXYXtJdz1I/GnXf+fDTf8Avl//AIqmSfGXW5Pv6fph/wCAv/8AFV5hRRyR7B7SXc9HuPizqlwuH03TQfUK4P8A6FXoXhXUbzUtB06/mjQG7JGEyADvKgcn2FfO1e/eBU8z4d6UA+AA2Qf+ujVnVSiro2oSblZs6kTFJmXAO04yDmt/TJGYejdq43Twxm8oMcL3FdlptuVjGDkjrzWKbbOp7G9LKwg3AAAdMCsi+2uG3qDkenSr7I6RjzN+OvU1j30qepx2GacpE0/IwLwBEYquVVgSemDUdrA15Nl8+WOvPWmX+xnkCM2ByMHgGo5NZsdE06G51WYwW7EJnaTljk84HsahXbsa1JN7s6CJbW3G0RxnHXpxS/abcsdqAEe2OK5STx/4Sc5XU4x6/u5Of/HaoyeOPDbzhTrMYiB4IhcHHP8As/StHCRz3h3O5S9iO4E8VoWsiOmBwa89t/HHhRfv6yo5/wCeTnj/AL5rQt/iH4PiyX1WJsdNsUoPX3X0oUJA6kUd3G20e3fFVbrC5+Yn2rlB8S/CIU/8TVMgYGIpMZ/75qrL8R/C7ZA1aPB7+VJ/8TVWa6ApRve50ckx3ZzyKjkuC42kHb6iuTn8e+GHzt1WP/v0+f8A0Gqv/CdeHgTjVE5/6Zv/AIVNpdjXmh3R2IIU7+cfd+lVJbpQx9cgda5tfHfh5l2nU1JPYRvz+lWkmM2qtGvKJ/Oh6bkNprRmw6b+T39a5DUomTUZD/eBP5V6AYvLt9zLzjArjtcjC3DsRjKNihHNN8xzlvEYbidM5B5qC9IETKThWq7ndK0kYPCqD+OaydXmCRhTxhqtbowlezGaVdblSMsM+YVH516BZWsX2ODdIc+WufyrzbSZYlimYqpkDZT613Vjcu1lbts6xqf0rsUlbU4OV8zseXXIO3ism7yMGtmcAqayrtTxXOjppvQoN1oUcZApWFaenQCS3ZHA+foao0bsejeB1kutKglfqF4J9q7mNy9kRnHHJrA8I2f2bSbeIdAnU1oX05sLeYsQEKkjNZLU7ZRcIpnnVzMZtYuZD820kAnmt7QIttqD1ZjmuXjBdJJVzmR8ZHua7jTI9sMQ24CgCsZhHXc2dNQhCO4NM8QKf7B1Mt/z7S9P9w1ZsYgWzjGDT9StnvNMvraLaHmheNS3QFlIGfbmhbpmttGfMtFejf8ACptX6i+08j13P/8AE0z/AIVXquMm+sAPq/8A8TXVzI4/ZT7HnlFekR/CLW5F3LdWW31y/P8A47Th8INa732nj6l//iaOePcXJLsea0V6cvwd1lhkajpn/fb/APxND/BzWkQsb/TiPYyH/wBlo549xckux5jRXpr/AAd1pWx9v04/Rn/+JqM/CLWR1vdPHqdz8f8AjtHPHuHJLsebV7z8PYXl8E6eMkKUbkf77Vwknwx1JJGUahYPt7qzkH/x2vT/AAbplzYaFZ6ZOyEwhgXTJB+YnjP1rOo4yVjejCSd2jQ00LHKSQPQHtmupspVVASe3esC5gSBRtyCD3PWr9lMNuBuOBj61z9Tr5bo3t6umT2/SqF6ocZzmmCZgMqo4pouPMDDbj6jrVXTIUWtTm79QtyVUABxzjiuU+NJ/wCKRtx2+0R9P91q6/VseYrY6c81xfxdYSeCIDn5lu0U/wDfLU6fxImrflbPE6KKK6zgCiiigAooooAKKKKAJLf/AI+Iv94fzr6H8PAi4eWTaN3OOvevni3/AOPiL/eH86+lNIhPmbWxt6KfX3Nc2I6G9Hqb0rLJCQvGf0rjNeJaNtwyRwDXXTABMA8+nSub1uMYXCDZnk96iMhy0RgPCscDsucPx+Vcf4nlEKM2CScD6V6HfKv9mLInGDXEami3V0U2hlx0raK1OeTsrlbQLdJdHBIyztwe/WvWdN09f7Otcrz5SfyFcRoGmx29skYB65+lep2MSiytx6Rr/KtZXRFFKSb8z57lGRWfdrlR0rQc8Gqc4LDnn8KlGVMoeX+4ckVv+FbT7Xd20GMgHJrOtkMbmKdfkcEg5rufhbp/m6rJI3IUYFEtjop+9JI9G0qwEMMakcAVjfEGMQaM7Zr0C3sSYhtHavNPilcMbV7dfuqcMfSoUbI7alRPQ4/R1jkgtoxjCDcT712ViCSgAwODzXIaBCEWLjIxuNdtZKCgKnJXgVi9wgals+3IyM554qwGAiJBz+NQQqduAB6E1ahjEmAo47e9UjaKGqzSYBIVc9qnhhUknBI65xTliKgK3PzdvSrMKZDEDq20DqcUWLtoSGWQRqoP0VTilRo9jEoQRyeM5pNpCkDjHAAzk81IJFjILAknsBx+dJoVkiWNW2AlduemRipXjjQZcsV7+tU2vssAAdy1DIZZmwDwR6daVjOUSe7v4I1CxE5OCQPX0NYN5cS3LFMgR9CR3q/cW6pGOOnFUCuTj+EevegUYdiO2gUlePbp0rZs41Qg5PAP0qrawKVLNkepz0qe6mSJBhwSeBz1po2a0sUtUnDlEUDg8mrthkxDAyMdcVk/6yQ8Z5rbtG2IFwCfpSt1GtiYrjA2nHrUEznGB0HcGrxw65PJqpdRqpzGTnvTaJ3MnVPnXcew5FeffFMMfCUSICym5QggZ/havQrneFw+SOORUFphU2gYxwB6c0RdnciUeZOJ8y+RL/zyf/vk0eRL/wA8n/75NfVMBUgxvgqfX1rRsRFINh3b1Pc8Yrb2vkcroW3Z8i+RL/zyf/vk0eRL/wA8n/75NfY4iUHICsPenm2Vh/q1Bx9Kn23kHsF3PjXyJf8Ank//AHyaPIl/55P/AN8mvsV7SBFz5Yz+JqIxR7coFU+woda3QXsfM+P/ACJf+eT/APfJo8iX/nk//fJr6zuJZIgQ6fIeuOoqhK8YJaI5B5x0Ipe38ilhmz5fghlE8ZMbgBhyVPrX04lmyMMO4qzbNvIDZIJyc1cVAc7uPSplJVLaGsKfs76mVKnlnKuS3eq1+FmjYjg4wa0ryNAj7RnNZQkBkbceDjj0pctjOptczJ4S+ky56pXDxkf2k2FJ/pXeXmUtZ1Q5VuDmuBdyt8+3uMk1rB6o5ai9xnT2TGJDx0ru7GVzZW59Y1/lXmmh3gnBiYkttyK9KsJf9Btv+ua/yFbTZlh1o0zwR+RVOWVSGReNw4NT3LlEI9ayXbdIMcgVCJhHQS5lmDJvfpzkV6t8I3H2KSUMS24ivI5JA52kDA6GvSfhTIY4Jod3JYsMemBSnsddC3Pqezf2m8NuSG6CvP8AxYouNMup5uWYk1t3d2iQMjtzWB4olV/DDsh4oXY0qpLVGDoYxFHgZ3KAK7KxUYAGQMdfeuW0QApDjHCj+VddbcxqemeKwRtBaF5QfLwg6ngVq20OxFDn5uuRVGHPmA4yV4rUiJ/i+ZsZxVGyegNGQ4yMjnJqRFCyBs4IB59PxqVnwyNIgGOtQySq0jKgyFOfrSsO9yTdszhck9Dnk1FJvU7VJBOMcVKoAiDkZlPXPb/Cq+6NpGbGB9cUPQErgkY3HZk9iePyqZYiqHHA6mpBE2xdoxuOcetPmOFxwRjG0Ugtcz54iUJY8jqAaowJvk2gg89K1p0YrtKjcx59BT7W1WBNwVS4GSaBq0VdkCRhEy4yT2rC1uAXZjDs0fkyCRCvB47Vr6jOFITnH3jXP6ncGX93Cfmbpj0p2IuyWzkViWJwtattcKxXnIrEsbaWQgEnYvocZrftY9iAbcjFLRGiVkX0mJBATA6VDL0ORgD9KkhV8fMMelMuUkZW44HJochJamPd9Hx0J6H1qmDtlQjqevrWncp5kOdoDe5rOtkH2gKzAtuxgjmlHUio7O5oY4Drw3pU8ZOcxnY4Gajj+X5H+5U8cfyKzDvjp2qrBujXtpMj5wN7cg5+9VlASuUxuPYn9KyIA3KNhsDjnFWYJSkjISOg464peplyNbFv7ykE4briqrnnjb+eMGpzIN4Q9h27VUkjZiSCpb/ZGAPqKRpGNyC8USqSRwD696z5IF2hsVpeUXHB+gP8qheMx8Nx7D0otfU12ViqpCj6jtUwbdkMCAOhoYJsyobPpRG3ysByR2qkZ2KU5YybCcZ7VlXg8piR0PStS9U7N6khhz+NZ2pneAV6VSM6i0Mx5hJbvjIJHI968+1J1i1EdSckAV3cxCq+OgII9xXC6tB5+pAxdMkimnZ3ORx5vdI9Fu/IcupyyZBFenafqZewtm55iU/oK8rgtHiv0ZU5Y/Mue9enafbn7BbfJ/yyX+Qq27kRjyM8fvm+QYBOKyX5IFbEg3A57CsuRAJFLnAOM1SMoaKxXNu4QucBa6XwHqMttqYRQdrKRXO3gzMEjO5RwMV0/g6zIvYl48w5yO9D1RXNbU9ShjjS38+5+Yt0FY2vTrJpN1EiYTGR7V1BtS+nxew6VgaySLSS2EWBgktiuVzcalnseo6UZUbx3KeixAWUROOQK6mBMCPtj+dcroLGSC2APQc12VuN0O70cAfhV2MaepPZu+4K4Iyck1pxHEwzjk8k+lUUA2N65GatufkQkZA9KEbbk1/KPKQKTktzjjimR7VBc4OfzqKUgkggZPI56U+HBIGDuxycUNlR0ViwRlVDZ2jqRUkEBMpfACbcYFImCFQYOOvNW4lK5BIANS2UmOiiZmG3gY4NPaD5guSOetSwL1O7rzgCpRsUNyenHfHTrSEyssG4YZRzznOP896yNb1RLKMBQC+MKB3q5qF0IoXdTjAJ69K4pwbq4MrEsM4XceaeyFa+5DPNdXjlmYgnqfT2rQsNOwQf4yOSepqeztwFCkDIbP1rSgYRyduaH5j22JbKyULk4GR2rWhs/lyBTbMKQu4/lWzbLEXAJwfc00rkynYoC0BAOQOOhqCaEAYOfQV2sMFiVG6Vdm3j5u9c7qCxB3KNx0/+vRKNiIVeZnLXkIBIAwvp71g3Lm2nWULkA5rrJ0EgbB7dT3rntShBDKfTGKmJc9dCH7SssPmoQQf4f7prcsWWayhEg3upIJXucdf1Fca8Dx42na47joa6nwhd7jJG4DPtPB9eM1fUWyLrxMqgA8g0sYDSZxhgMEjvWhcRAxA8HcMD1qjsIJK54Pekylqrl3aHiI4J69OKhVWTBUAqR16bfepbZww59OlO7bcA/hUkrTQpkjPJ5ByD6/jRJGCxLYOeP/r1NJHmTcSThc4X19qaoEkZKgnbyQTzTTG5GZtIuGABwDSsNmMcVNKwO7I+Xrx3ph2yc55AzyapClIy7/G7aMj/ABrImYgshGQPetm8B3YX+VY12RvfgZxiqJnLQw9RyI3bp8tYmjwreX65Awikn8a19dfyoCxI5BrI8IbzdsQThuDS06nK3aSZ0VpoKXWoIVIAxzxXotn4aC2kA8wcIo6e1clpcwhuyCRkV6BaXoNrCc/wL/KrjZIpxbd0fKE+QxI7Cqc2ZISuBmr1wMHFU9jmVQp6VaOOOxJpUaCMzOcMpIAP0rf+HAM/iiR2PRTxXPzRoGQdHHbNbHgST7L4mRwf3bpjPvQHme8bB5CYqtqVtFJZyu4+YjFWbF1kjTDZ4pmpklFjHTOTWe7OyLajY898NkxuwPRWKj867ixG63x6HNcVpOEv7xOyTNx+tdpaMfLIHG4c0jSlsXI8nIyBk4NTb2ETEDlTgA1SUsskeCAM/Nn0qeZyjlRj5mzikaMl4cEkfMeBU6gAfJ9D61XUYbcG+UcZ96uWuCDvGcnioZoixbD75xkn144q8oO4EEbjVaEAtyD0qZZCTtA471I7FlW56/L3zSXLgKdx4HGc5oC/KD6e3Sq1yxZTt6dyBxVAYmrypDZXG4qdylQCeueM1lWyDyACORWxeQLJGY3XcG4INVrCJIJxBcbtuflJ7ihFStbQqC5WPLElfbBqeO5jmUAEZ7YNb0tvZm22xnJPHP8AM1zV1pSNck2jMidQy8E+9OxEU3qjasbnaME4Pv3rSW5zggiufhtbiFM7t49SKEuXVwrZGfUUaie51i3ZVPl5z71UvLsEHOOnNZ0dySgxjj0qne3sKMFyXc8bV7fU1NhK1y2LpipUAD6VTm2nAC5PrWTcX0ovkTZGgIJbnPHT29amW7LHc23YeMqen4U1oW3rawXMSsC0ZJGfSl8Nqf7RK5+UKWNWQymE5GSe1V9HH/EylHfYfw5FMcl7p3IBkt0divTiq7x/ODk4PGKsWUo+yoHPzgen5UqozqS4IHUccGnuZQdijGh39eOuKncbgoU4yT+NRbQrjAwT+tTMVA27sEAc+lQVLuRbyNucFSfxFV34lJ3EqQM49KnUZXccg44qtPJkLtIZc88daEZsr8F2OQBjIPaqw/1hBONo4I9KSVSQ/A4PaoI5cyHL9uRWiIbZHOMvuY4ArGvxmdiMBe2O9aErmSQp71lX7sucdv54oQSOX8UykLEoPGM80nhSMpEz4PXj3qp4hk8yeMdQqAmui8FxrPGHfHB6U3bYxinKWhbWzk3GRiQTXYWRxZwDd/yzX+VVri3jaAsuM47VbtVH2WHj+AfyqlqXJtbHzlOM1XOxZUc4A71ck+lVZ9q4z071SPPiyPUlQMJYySp9KbbXBt1W5gcB0I4x9anMYMJCjd6A1l3SGFwMYz1FM0W1j3DwN4hg1Kyj/eL5wHzL6GusmUSruHWvmKwv7nTrnzrKZopB6d67iw+Jl7b2oSeHzJQMbgcA1Dg+h0KqrWZ0NmQur6iOhEhzXW2Mv7jB64ry/wAL6tJqOo3U9wAHlGcDoOa9M03Drj0IBNS9Dai7mqmWYAdVHNFxw5PrxQ2Y5Tu54zkd6JiHIx0J4NSbE0B+RSep6A1chOFUZ5zgiqpOF2LweDVqPhvmqWWmXEYheKnCg9Bx61WhyXAAOOxqw8gjHykZpIdx7THy9nGf4qrPLukAJ4xUFzc+XGdrfMSckVWEhKgqCDjrVMaRZYp5gBP40yWNJRh1JPb2qONWbB3A560+QlUKZyx4HPNFhTVimfM3ELI23gY74q1aoSPQnpgVCCxYhcj09607SMEDPHTFNRH7TQuWCoIGGCSBwO9Zd/ZxDcI+ck5U9M1oxu1srh+pOeKY7MQxIHP3cjpVvQycU3cxEtpsERREvjAweM1LZaUNj7o2D9Du6k1pQXAiV8jJOeaZHfortxlBx17/AOf5UrCScXoYt7oyGeOV+dp5BPatG1022iA8zaFxnr/n2puoXK4+U53dKzkW5nHy4Ck5GTk4qEkmdF21q7EmptHCjmNvoKZoELmV53x+8GFGO1PhsgxD3J389D0q/NKlpEsuPl7UN9SW+b3Ymtayc7cgEevatFJB5eCCoHGMZ/8A1VztpOXcMjAEjIrYRi0e9cFe4z0oizOUbOzGTL825chh2PWociSZQGz688VM4LZPXHXFV1wrAY6+lSylsPdhhRxz+dUJ9wzgfN0P9P6VbkfBx1bPP0qvOwC7s5JPHPTtSI2KErEqQeNx69Mms9WASUkjcGx0rUuMeUFX74OQaw3bYZAOuelaIxm7sQHMxck4J4FZmrHZG5571oRk+b8xODkge1ZniB/KsJCc5PNUkQ5aHE3B86VyT1baK77w/p6WdsGQ8ketcEYs3EKdM8sa9E0dWjtUQsWA6VD1diqKaTkaKM4gkx0rStf+PWHn+AfyrNmJS2bJx61YtrmP7PFz/AP5VtGJlVq8rPAWqvOm5frU7dO1RS5xximcMClOZkVWibp1pEv0aQC7hVh0JHapi2Y5QRzjvWOwy/PemjZamre6dD5HnWj5U84zWMetWVYwowB69qiLKQeOaY0rHR+CW2zSHnrivYtJcbef4un5V414OOTOMcgg165pThrWP1xkVlLc66Jts2+Fzz/d5PSpVT5VYjnmorZPkUHkkZq1c/LbseCTgVnsdDYQtzuOPzq0rZKFc5HXmqNr8ylSP/r1f4jUHr2pDTsWWkEajoWPSmGTHXO71NUrQmeUy5yueMelSsxZirgAt0oQ0MZTPIQRlRUu0JhCMnHWpHQIyk8A/L+tQXIPnKEJAIGeOQKuxUZX0JoCI48nAI6DPX8aZBC80gdmbB4HQA06Ab3IBynr/n6VdtoD5chIG0dR3wT2FNGcm3cyiSkwZcbd3IUE8nnr3q/b3DoU3DORjavXrSzQEQAvEpYk43Dpk9M/TFNNuWKLEUGTxwTjBNaJXOdycS4s6shLMC6t83HT86JWMuPT3OKpGIKwKFvnJUqecMMnk/hUaTMD8hJ553c49MVMkXB3RZkeNLfdMAoJGM4z+VZk2GlBtwvXGDxg9On49f8AGp54jMyG4JVN4H3s5/Ht1/SrMcOGjRpQd+4gkYx16d88j8qaWhM5tMyruGT5Bn5z8oOflH+c1ftk8q3UvtLsMgryOelNuBHLcr5AB3KQWHTt/j/OmxXEcZZtrBR90MMbQO1DSEqje5YIBjxjk9eKcw3qAScAdKY7OuGReCe4yP8APtUV1MVVmjVjnsOfes2jojPsSQkQSDA2ngZrVtW3RnZwD2PrWBJMGjAxg55571f0y5MkZBO3B24z3qbBOV9y9I2EyMjIpkcgKnqT6Ckck8gHb70xOASc9ahsq+gwsTIy8cjBzUcoAXdgjtTpTjIXHNRO37rHUdaSYmU7qQ87fYDmstfmuiGAAU5Na7HKqTj5TnmsVyst2fLJz5mDWsTGewqEm4BPGBgVzHiy482eGBSRvOTz2FdBPKEck/3iPwriL+7M1xcTnooKLVPRHM3fQ0PDdimo3c8jqCkeFXNd8lqtvEnHAFcr4Fkgg05i7rvZsnmr/iHxPaWcDBpMnHQGixpGaS30F8TaklpYTPnopwKw7C/uJLG3fn5o1PX2rgde1+bU7k7WIgHAGc5rsNLlb+zLTn/lin/oIrRKxy1HzM4d84qGTIFWGFQyL0pGEGUJXKsSeB71RnAzxzWjcJwazZAQTVI6EQNSYpzZ702qGdN4I5lueeflP869TsGxbAg8jBryrwS4F1cof4lXH5//AF69RtGxFGOxGKxnudNLY6mzcOq89qdfPiBV6Et2qhpsuVx7gVZvsNPAueRkmoN7WLUGFUDIz6VJdswgEY+83eooJF2PnGew9alPztHnHB3H8qmw73JLQbYQBgsAMjPappQGaMtxgYzVi1QS58oDNMuYyqgyBlYe3WrQc1mSxShtmQNwFVLlgkhK8jPr2/8A1VRkuPJblhg07zwzEhgR1FF7grJ3L9sQZFUjCjGOPwrTt9uVUkqu7p+f/wCusKG9jDqzOoxwauf2taLyZUyOxPSi/c0ab2RqSQKZnJ6buDnOB/k1FPAzKzYTOc7iMFRjk/WqB1603kZDA+9RDxHHHcySRBmJAHzkkce3br1/wp8yRPsZvoa8sZ2o5BICgHH9BTYUiKunA24wOMfUVXt/EcEoInVck5wO1aEJtZkVxcIOOaXNfYHTcVZorNbFtkiucjPAJAyTx09OlQvGZVZfnHmAYIGD1z+FaSG0UKyTAscZIp8k0AiKKw47n0qlIycPIwTbeUuxFAUuW68L0NULyExhpk+bZnheCc9//r+1blyvnZ3uApPQVRmt1JKIxHTc3t/k0c2oOCsVIJ5JITEY9ygj5v7w9e3v09KtfcSPGAB3A61XMHzbk+Vmzu47Zz/U1ZRWLg5O1RyfSk32HCFtzPuMK+BkBuvHFGPLGP3oYHPynHP+FTyhWmz2XmmBi7EleD09/WkipK5rRzERLyDwMH1pofzQemc1UibbEFOSFAVT6gUzzQkyKD8x7VEkTHQndsk+nSoy+ATxwKfMMyDjjHaqF3JIsZEKgyNx81Z2KTuOmlUHg5JGMdhWTMyxSF8ckk8euasNKxKgjBU8n8KzL+byw5JBIGMfWtYmE2tjG1vUXhRlUjexx16Z61zN05ijQDJUglq1rrElw0sg3bck57elY2pzGKCR8gI67QT06VW7sczfU5GO6m8+YxzyKC3ADHFNeSSYbnLN9TmmpEVIkXBXuKlXLHC8LWxA63UnGRXpOlj/AIltpz/yxT/0EV5/AmMV6Lpi/wDEttOT/qU/9BFIhy1OGxUbrxUtI1I5kylcJ8rfSsu5TBOwGtqUfKc8iqLKoDM3bp7U0dUHoYx680lS3O3zSVGAe1RVZoa3hmXytVjGeHG0165akNaqVP3QK8RgkMM0cq9UYGvYNFufOtUY90z9eKxqLW50UXpY6az4lwM84P41PcSf6ZubOEUA/wBarae5Yqx7DFF/KqXjg8l9oAqFqbzdrF+wbzZQrcAnAB7+1a0URBKtwe+az9Lt1LRylRvGSOOlamxTy65Ocg5NJmsUi1agRlmAI2nsMiklRrgZUlU5PP8AF9AKgFxJhldmUDOAO1Sm7YwrCGfcnUA/lj86pNA4N6ozTp0MsxdlchRjJPU019JgU4XevHZiBWqFKlQeQB29anaMNCzFeCOD6e1J6kc3KcXLpe+Q+XJKQDg5binxaYyg/KT75rVxh2IGAwzirdsU3LkDOOmKk6IszrbTl/jV/Yg8GrX9nwrz5Lf0zW1G0SoS4XGcY6c801541G0qNwPPp/nrRsUpp9DDns7MH5gUIHO08D044piWJUti4ITqCDn8+Otak12i4dbdMZBJ45wat/bbM4UWpC8EH3plX5dUYosLgD91dHd15XrVeX+0IXA8xHx2JrpLeSxbhlOT14ps9vbFTs+U9SOmaLAqivqc6up3qgefA20cHbg5/WpP7aiLKJW8o/7QIqee0WN/kb3YZqg9iJdwYDg4qVdBOEWrl8XtuyDbKp75zSyXa7BhuKx49Kj835F2nPbjFXG01DtYSP8ANj+I8VSOeVkW7YiZmHPqfer6RbVPOF9KzbG3nSV/KlDIOit1x9a1YgJU+6SQOc1RhJu5XP8AExqHywzCQj7oyDirLISRuGAe9PWMpDk9G5/Co3G9CEkCNDuPJ/KqUgYXSc/Kc/WrshSK3EjA8H+tZl1MBcEfMx56dvSko6mEp2RVuni8zHJXHQ+lc7eF5FZVbaE69efatO6kd5ZWx8qfcbvWTebhCAHOWYsciqvYyd2ZEkxiYgffbqfWuZ8Sz7bAQFs72yoxW7cq6lgWzzxXK+Kp1l1aNFHyRqBgdM1dNa3IZRhBAw3p0qxGmB70sajb0FSqPatDJyFRPSvQtMA/s61/65J/IVwCjivQtNH/ABLrX/rkn8hQZc2pwQpDQKDSMUQyDg1TnA24xyavPVWReaaOmDMiWLnGO9V2XBxWt5W98D19aqSwFLsKwyM1SZtcqKrMflBNd/4MvXezRJCQ0fyHPp2qjDpsdrD5qoMMM5qBJH0/UkdOYZT8wHb3qakbodGqubQ9V0lyOOoPIo1Xi5iJ5OQazNEud3yk9G4Naupgs6P2/lWEdjtnsjp9IKGHP+RViYkIcEAdqy9JYtErA8Y5FXHIKE5xzSLhuOgyJfmbC0+IGMNvQHcMg+1V1OD1608Ekkc4PFBvzGjE3mElQQoH51bkx5O0bs8j61WCkRI/O3Hp1qJrrapTy3Yjof61d9DFxuZ8qlHxjgVPbRgsMOM+podhsZGYMWyR7U2zlMl35aFVKjJJ6YAqC4ttFmZJBnC5K9cHj86qyJPIvDgcdTwK2AE+xRy+aDk4bnke3rWTeqJbhCiMYwDg5x+NFjSEm9CXT4hdRgSqHWIc4HStH7OH3zh8fLyM9fb8sVnxyB41MSC3xnnP3u+Ov4VK0c0m9vMjEYOenfHT1/8A11cU7Dkh/k7QjoQOM4NMkZlQ7lIb1IqZGKqfnO3jC8ZzUdwUIIbAPvzinYlN3KzktGwYcnv3qoqOSCQMHqBV4sqR4OCW6ZHSqjbSx2nAzjHqamwOfQQKFjLYwSeDUkShwO4qREHTGcDirFsoRUUgFup44oMHIbbxtHLlRgY571M6HnyT83tUxHO0Y5qND8xYYGTnAoBSHQwtuAmGRimXrBEAX5VHvU4kyxyoP4Vj6rcEKSvr0z1pENkc97GFCHoTjFZoOTLcHPPyr/8AWqq0heTacYPJGakuHIiRCRtGSCOxpnM1qU7h98a7E3ZbjPGMVhapK4YbeO341pSTsvBDHB9egNY2oIGulLtuVcEgdqlq7C5TuQkLqrybcrubvXD3siXN0zAEsDWx4kuGVGCvuklJAx/CK5q2Dlznr/Ot4KyMnvc04s4GTmp8VFCpA561MBTMJPUcteg6b/yDrX/rkn8hXAKK9A03P9nWv/XJP5ChGF9Tz+g0Cg0gI2FQOuasmoZAeaEbQZWJ2sCPyqGZXbDqAanccfj3NVpWI6HAqjZHSaVqUbWvk3BXOOMmsbUjJFdQIvMbsBkfWsaRiT1q9Y3zPJDDKAw3jB64ptsIwUXdHeaPIba5VG5GOprsHbzYlJPGOtcpHF5pBBww6VuaZPvttjD5uhHoa5vM7IyurG7pEpTaucA9q1nGS2DwRWDZsqyHn5hg1sOxEKbeB60GkWJJ/q8kmlSXeoXdgjvVWWYbSAR04ogA2q38Pc0mdENWbcEzyFVLnbjAHrVghVfaBnJ5OenHtWJLcn5EtwcFgCy/X+VbFsI5NyqFxGRtJH3j601qOcWtSC5tnhl2xnzkboTxt9qomF0uMQ5575+7+VatxeGKPDJ85PHJNQaepa4R3yMt0P0ocSYyfQitYD9pTzDgE54HH/166M20ckfysBg4OMH0/wAarywqFDpyMYCkUZCMGwcyDHrx/P0qoqw5Pns0QS6cWdtrhQR/CDx1qVLWOMqC5AXn5wc/h7datxLKSM4ULn5hnIqPG9lHDFxtyeBnp+NWHM9rlC7cRnaNrlu6nOMfyqFCHAwy4PPXgVelghniPyrGyLgdcsfSsq7BgKbCGU9VAA21EnbUpWashkiFpsZ5xnpilgi3zqWHGCACOlLAxVC+Q2farUS74gxPc/8A66i5lIf8gCqCBt4phkVcFeu7HNRyqAjPkHFQpJmIPjjsPxouKxbEihlz93nNOVw+MEKAeTVeRjtUY6cmn+YGXaMZpiJTKQpznnP/AOusHUDmQKCWzzWtNMdpBUZxWIz/ALwkE7j3Halcl6IZFGgbO0lVBO484NU55cuy9PQ1p3DtFC4ZizONzZ9awL2bcCxOMHAHtTkzEo6hK0MR2lXGQM+lZGq3UaWu0qAynJbPP0pbmQTykvyhOeD0xWP4iObMyepwPeqiu5g3rdHOSyNcXDO5JGflHpUkaDOcYqGHoMc1bQVqZSZIBxT1HFIvWpVFI5pSsCiu/wBN/wCQda/9ck/kK4Ku+03/AJB1r/1yT+QpowUtTzwcUtIOlL0pGrBulROKlNNYZoKi7FSXpVKfv61oypxVGdccZpo6YszpD60WxxcxHPRh/OiUYJ602EkTxkf3h/OqND1jTXUxjI61dkR4Z1mQfuiBuqlpa7rZGzgVuxBXgVcZBrmWujOlLXQfbyhlUgjG7DEHt61qQ3isnlqQVXjI9a59RLZXGdhMOa1FmiVMouVbk+x9qYPQkkO6bC9R0qSB2dih+4PSqvnIjmReeas2zDZu/iPWk0b0ps1Yk3AEYAHAxWlYvHGAWX5F7Huay7ZiuVJ+XHBq8h3xhmODkcY/z7UHQ1pYuzRib5gFRQT0P8qY52yxiMbm459qvWiRC2cuMyLgqQe2ORiolVY5lLg7er4qzFNIkgdiC7EtgkbcCpoAmFcSICyA8n8xUIKS8xbQT2PtUtpHBLIY0Vhlu/A5607EOZbVVCAjup3468n1qK3tYUEhRmC5zubofU+3/wBahSUMkbAHaMAg9aebq38iJJFZjndhTnj/ACDTsHMxlxEfJlBXe4JZGA7VzvD3Tsw6etat3ek7wm8dcZA59aqRwEREucSM2cgdqllwnZO45Hwso4wxzxiqjSCESrITxgqPTmkumCO2H+ZgAB+FRwIsiMZiScgEg84qXqLRakZc4w/O/nH4VJHKE2ruHAyKguDtmCjjAwtNfEaK4HzdDU2Y73Lkj7hszxjJx3p8RURZORmqy7+WJCk+9MnlKlUUZpsmTHX0pOB0yOtVFUg7gy7U+Y57n0pt+RuVH6N0HfNQzyARFN2MHkD19KEjGcr6EeoT7t0jt75rmdVut6/uztAGCSOtXr28jJSEMfvHJ7Vj+VNOWabGzOVCjrVpWV2Yzld2RGIdyqrEspHAFY3i0YtoY8YGeldPaxYlywOQO9cz4uYG4RMdCTST94h6Ruc7Em0D3qdRjpTVXipF7Vqc8mSJzUqio161KKRyVGLXe6b/AMg616/6pP5CuCrvdN/5B1r/ANck/kKaMIas88FLTaUUjrYtB5oo7UCGMOORVG6Xg8VfNU7ojHPT3oRtTZjzDB5qOH/Xx5/vD+dSTnJPFRRHEqfUVZ0nr+l7RZhePatvTz/o4BHzCsPScNaqCOcVtWi4YDGOa5UzqiXMbx5bD73TNUL22mt/mT5kHJXPStNkJIdfvLzipP8AWrhh1FVuW46XOfNzDLGSnyuRkjpzV2yugYuDlgcEVUvrQLOygd8gioREyhTHxJwSc9fah3IhLlZ18Lgphc/T2rShbceMYrlNOv8AdiNvlZeOa6SzlVQckj+lLc61K6NW0Y7ZBn5G4YYzmpJTGId6jkZB5z+nes5Z3A4J9gOpqF5mJCICpbgYP3T05/OqRnUNFJMIArHDZK5x83T/AA7DvTre+a3mJmwSQSST+Q/nVFASxSRlZFBA28cVVuHd3kcBhGnI/X/61Wc+i3NmS9JlULwobnn8xUV9OEUPtAjyCQBknJFZ8M/cHcCMjJ4HPQVVWV0+aVgUViVIbqR0FNDk7bGmzlZ+BlVwxbIO4HI/rVt8xogAZcLgL6/54qlp85ZBvUZIGU67fSp5Z8ggY3EYGe1TJmlNaFN0EhbgVFkMxwW5OeOg4ofG1lDEZPGTTQVSJwuAB3qC5kd4x3hcndjAwM1LsEcIEgyw6DqM1FA65MmQXIwAe1RSXBdiCQB2oJTLcikQAs+WPNUDdfOUZslTwT7Uy6usIPm5Pc1CiGI+bKdxPRPT3NCRE3ctyStGpmlwSy4UEdBWBq17FFbMVbLDCgDvTtVuxIw37uTwFqpHZm6uEkKsNox83rTSMZPoRadbtcKjypn5iee+e1aGoMIyBHEEAGNvpUzQmHadnK9AO9VbtzJIQRyeeaTkJQGRoViEh/EmuH8Ry+bqL/7Nd7Of9CCdABk15xqbb9QmOf4qIbk19I2IAOaBQKBjNbHESpUgqNKkFI5agprvNNH/ABLrX/rkn8hXB13mm/8AIOteP+WSfyFMzgjzsGlyM1XaTFIZeR/jSO7kLBNMLioGl9OKgeb2FOxSplqSUAdqpXE3HHNNeUkHufSqsznnmmkaxjYgkbJNMH3hSsaaM5GKos9h8Oc2SMRk8VulWjdCO3NYfhhd1hHuGDtHFdMqDajMR9K5EdcdNS1A/mfMoHzCrAi2ncuCCOmOlU7IfvDg4UHpWxalCdpOKou+hg38QdiVOG9KobSCSB2rf1GDZ+9j5GcGswQn5iCAPSgykijJCW2yRna47DvV+w1FUPlTfK3Y9jTY49hC+vIp0sC3HLFVftSsNTaNUzLKqshGRTPtGRg43AMASen/ANftXPBZ7cndIdqkDcBjIPt7Vct3lcRSrJHIpJyhyOB69qqzG6yaszUiumZwiI2Adqn1OB2qFJWlwgZCGHyqeTx7flUCvcJlY0gkUNu47kf0HFSiDCrOWVrgqU8sNgp79O+cj8c1aSMJTb2Fa7Nvsjz5jYJ/DnJ/z603z1LREjA5bDYwQVOP5iqbJPbf8ewDEqF3nIKjHIx3HUfiDSJF8+0tzwqsVyAvGePX/wCtQHO+ptQXSj1HPGDTpLxSwAbp2BrHkAt9wkkyxJ246bc4/pURu2UbljYnoePWoaOiNVWNlplbtsGOvU/hVK6uU3KoJ29hnk1mtdzSxHCqF65zzUMpdFVlkVlJxkde/wDWiwSqo1Gu/LXCqWY/MO+KhedfL3yNheu0dfxqmJPK3b0aSMgDb2Bx601VMkY3fLznaOlGhn7R9CW5uYSS2/OD8oB5A96b50t2vy/KMdSaEs9zBgM7jggdqftKNHboAQTycUddRXdtCpZ2jSzqSwYqeTW0IjCMMBx3zU0NnGsjbFOMZJ96klQBODkVMmOENLspygK/nMd3HFZ2fMnLkYFXLuTbGyoASaqBSEAk4Y9allpFXVJfLs5COhrziWQNPIR3Y13HieYW+myHtXnUU25iT1Jz1rSkt2c1bV2L4PtSrUCtnmpkOa1ORqxOtSVGpqSkcdTcSu903/kHWv8A1yT+Qrgq73Tf+Qda/wDXJP5CmKB5I8p7c0nm9PT0qrkd+9OB4GaZ6tiw7nGeRURbr0/Kp4baedRtQkmtWx8PXE5BdWA+lDaQGDk9APyp8dnPOf3UbN+Fd5Y+FI8qXUmulsdBhiUYj5qHUXQrlZ5nY+FrucgyKVFb6eE4IbcsyMWHOc16FDYqo+7Ud9bhbZzjtWbqNlKBk+HVKxAfzroTGA/P3TWPowAT3z0rbJ3RnK4K1nE6ESQYRh9auRjDqRyc/pVJEJjRixPOOO9WFYjIz06Vdy0tC1OCyOnesqWEqgO0jNXxLwxPUdKddRNjPBQjIpmcjPQBuQPY0zZzgjHPWrMS4Xjr3FSeWGXkc0AU7q3V8CZzswVA9c1Ukg8qR1hYJZxKGJGF+vXk1qhGmVkK5PO2oobeOJfKm3OZMk7iOBVJmNSOt0UVkhxuhuEOWCjHQe+aSOZFuPkaRnKcu3p3qWSCJED26KCp+VGXhfQmnJCZYJpGKvMmEGVxk/h2pEp21ASttBEgx645qK4vSCFcsSBx8tQxRzq+Wfkfd4GM96hktpvtC+c+4EZXH15pXNOYu2couFdmjO0Dkk9DUElq3Es7tCu9k29RjHX65NNSGc7BDvRX3Fh6k/8A1quC283Dy72Y46nvT5tNDPWTK9hCi+UxjHmxgjORyuOBiidQZQ7Igb+6OlWxZvI5G3Zxk/Wh7ZQdioSexFLmNFBFKOI5GTx1Iq2tqrNhTtYc88/hUps1EHzdf1p/kNFCkgHbBpJjaK8sjLvKpg9OlT6bbIswkcbwR82D0pqbkl67kPXIrUijijiIVvvdaLhZvQhCqmTGcqetV9QJ2AoApx0NWZSEAUfKo/WqN2d8gPJHapbNUrFHyy3zSduaryP5jE9h3qzMW2FAOvXNVrj90mBgVLdintY5nxLC15E0APBPSuBvbSSynKsrbfWvUba3a4kdyM+lUtW0eO4X5k59qulUtoclRO90ecxTfT0q5DJk81JqmizWrbkQkVnRyFDh8giui6exi1c2UbjrUuaoRTZ71ZSQEdaRx1KXUmNd5puP7Otf+uSfyFcCGrvtN/5B1r/1yT+QpozjGx5za+GriU5fj2ro9N8KxqB5ig/Wu0i09Fx8oq/HaAAcCsXNs9hQRz1pokMQGI1zWnDZIgG1RWssA44p/lD2qGzRRRWtrccfKKupb8dKfEgA4q0q8ZoTBqxUMQA4FZurgLavn0NbbgAVga8wEDc0iTM0g4TpyTW5GcLkisPS2Plg8VtRyZABHBpI1RNCy5wRge3apUI6bTVcIEkJOcYq0DuXK9KstDUIyV2jJNT4LIQeSBxTIlDqeQGFCsRycg+9UKSIcFGzjGamHTd19KilYMoGfmU0+1f5GB5I96CLDnh3OpRyKjljXeu5SrdM9eKsRt84U9T1qWJgXKsPmHY0XFYzLqB5QBGd2WqFlmVBEGIIGSRW00eHLKcgnjjFQNbxs7DaCwHX0pMnluZiupVFkOUByTjkmmpbMZQynIzxn0rTFqMklMjrU0MJ+UMQF/nSuPkW5RSBljU7tijoM1NHF5ALuwbdwParslsoZcoG/pQUUnYACo6k+tMOVEEe1txJ5PKimKjlxtRRwcZqaNQRwPxFSoyhttJhYrmBAcyAkAcD1NRurSxkL8ozU8wbCqp+XPOaidSm0BiBjikHKQshVlDAHmnSIFGO55qRVy4JPFJOcKc4yOlBso2KNxukcc4VRzmoosPlt3A4qScEg9uO1RqoyAOAOp9afQbIWRRuIOfes7UPuHOelas2AnA4FZt6cxnIGO1ZSIZJpEGLUHuas3FtkZwOataRCDaJgdquywgjFIm1zlrrT1kTDKDXJaz4aDZaBQp9q9Oe2BHSqVxZg8ECtIyaMJUzw+5gns5MSAgdKWK5BABNeoavoMNyp3IucdcVwGseHpbR2aPlBziuiM09zJx7kMc4NeiaY4/s206/6pP5CvJTI8LbSCDXpOlTqdLs8gZ8lO/+yKuxn7NHoKCMfxp+dWB5Sr99M/UUUVzncNDx9A6fmKTKH/lon50UVDRZYRoxj50/76qQzRgffT8xRRQkQyjc3UYB/eL+dcprl6smEVxz70UUWEO050VMFlzkd62IJk8xV3Lg89aKKEjQulkYAl0x060RzKAIw69cZyKKKqxaZYQxJ0dMjvmoJ5R8r70CDrgjNFFCHLYc64+dZIyMdCetRo8bEEsEPsRRRVGVx7TRI+TKiqP4s1bS5gcDZIhYd880UUwempNHOjKMOn5ilaSInHmLuPfIoopWGmMLRkfNMqqpz94U5rhWwI5IwRySSKKKEhsbvBAVpk45yWpxniGAskQA96KKVhEAvIySFYAdzngU5pkJzvXB4zkUUVLAjhlTcys68epFOmaMoPnTA96KKLDi9SsbiMkfMvHvSNIpP+tXHTG6iinY1k7EKkAsC6fXNJIyIc7k596KKRmVZpFbOXXH1rMvpEPAZfzoorOQmdHorxi2j+dOnrV52jJOHT/voUUUhREHl9C6fmKY6R4++n5iiirRDKc8UZz86fmKyb20ikVgxQ596KKohq5xeveHYZw5jMatjg1r6bocq6dar5g4iUfoKKK1hJmbVj//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multicentric primary cutaneous anaplastic large cell lymphoma of skin on the face of a 47-year-old man.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous anaplastic large cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multicentric primary cutaneous anaplastic large cell lymphoma on the chest of a 36-year-old man.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous anaplastic large cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4AZEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC9Gc20oC5PUHPT/GrGnebBLFJEjZMbZdRuKgdWPYfWokxM8xICHGcjq2AAFH41btppYrWSOM8z4hkGcHGeg9vWvMW5q9rElwUMz4wE4GO2eMmpo5Dbzi4Kb4iMDHG4Dv8Ay5qBYQX2u2GbqW7Adc0JI8Vpcwqdu4DfxksByF9hTemrCK7EgLTMkkzO78lz1wKvK/kRyhPnaRBGe2CewPeqttCBB50u4JIdrbD3xnA96dn5MSDcqqQBnoexNTqty92TLtcRRqAAfvEjkf8A1qkvGiR0iWJcDoy8lx7fyzUQcxuYljBeTAUqpzgjoKLbe0hhC7ZN4VmOMg5wMVV9LBtqAXe6IfvNgqM4CjPUenvStuinJR13Iu0knaMei/X1NPMfl38y5AkikKkJ8w64IFWLxka6JIZC0R5HJcd+v8vapSLTK2oXam3coSyMQiDd9wDrx2z29qjsC4Du2zJG0qf4hj9KY0USWEborbS5C5xg/wCRU0SCF2mJcKy8NkDj1Hr6UtW7l2VrInsrlIrW4iKuZDkkgAbRjgc/5HaoryTzLZCw+4MI3fB6896ISqCTd84kX7vqQfWrL2qmPa27eQGQBuFJ6ih3krE6JkUjuEWRYhGVQ71znrwP8+9LbnMsSA/IxySw6ev4U23VhHLBEQXwXJPUf7tRWbbp2AZ1ROd4BPGeuKY7aFsI0oKdm3OPUjGc/pTLlY0tJWwVDAAA9cfWnvL5kgVcbt+SegP0HbpRcsgiCbR05I9OeP1HNVcizuQ6VFc3F1cIsfEZUoQeJMDJ/wAPwq/cOJHnEn3WkV3Cn5tuckA/pUVrPGmnMJXeN2Yb8cKYyCc+xzim2quZMSDaXjDYP15FaJE7CzxpM7FCI1jkHlQsCWcMemf6+1Vb6WPy7dIYfk/49lkxxIVOS2OxIq/cWz/a7MoI1tXUq8gY7lYdD+fejVLaOO9njVvNRcbR9072A+YAdOaUo21GmpaIksLS3QzM25w9u4CbM+Uw6fQHrnt+NZVwY4mhiuJo083KrucLluMZz+Vbdq1w95Ikgf8AeRNGWH3mcjAOPfpUGoafbahbyrqEED7ZAQHAbBXA2qPrzmh2sS009BI4fIvI0miEcKSGByxIMfs3p1PPtTLiMxSMYlJJZwV4U8cAj69RWhC4Rrhr2Q7JrWN3GfmOOAoP06ntSuEfUkiDKUCFQzHqAMg57kZwaYSuZun3g1PQoQmSzOR8wxtdGwAe4HXPuKtSW8Go6R9glUlJSQAWwQG7p/wIcn6VZvreLyiLZSrgh0MjDJDY4PHXNRCZDPbPbxtGEbegAyFXGGUjsdx6/SnZqRm1pqRTxFrVixYSIxAbbj5l4K4/mPeqstteWmoG9twkmn3KMlxA+QUcrkMv6gj6GiDUWbW5dHusrLAEkKkdd5OGHqeDk962bjfe3myMfumAXzFOeAOCfXn8RWhmrMpXXlyWzwucqXGGYckFcCqWifadOt7y2uIWuFQfuz1yh7H3XP8AKrtujGwEdxg3cMjIGBGMAjnHr0q5Y38MGoIl/sUO+2YYIG3PDD+f4Uk9S72RmT3P2R44XbEQlAyPmXBXIB+meladla28V1GozEiRyTQTI2GYngL9OpqC9sRI1xYXseIpIy0ZUYYDJIOfXnNUQ84sFjuijyQbU3oT94cFh9RyR0p82o9yTSLxojNZ3smRG4UPjqucgA/5xUWqz+VavI6sVV96yk5OCf8A61XfIaUy3MRWR5gd5I+6OwPo3B6UNYw3mmyWy/vIhlHI4BUjdSV7EtJCpKG8sH5C8gZiF5QkDBHrVS8SUsjP8sxRkycMsjK/Y9jgCksop7TT7VnuPOECqVn2gOuMhCf5Z9qoa5LdSax9pWQ/ZJ41eWP+FJum8Y6bgMY9aq8XHUztJSVjWkhFxYC9t5RIGiaeZOmxwQM7fY/pzWXbqsmjX0b5Bba5P9wg4xj36/nV25E0mqRzQxFRMio6INqvxwPY8D61nX1/Bp0kEt0xEd0RbgLyS7DcAR6cN9KWjY29C1p800FsLGWQecs2Q56MADgg1gm+kF1NplyECxoUBPOF3Zzj/Ct2CSNltkQKZ4n3Rqy9VIxtb8uKwrm0M2uDWd2xUR1kt8cOWIyAe2MVV7LQVtQvoLm80a7061MfmKuY2bIAI5yf61NJOX+ztKucMCHx8rMMbj9O1T65cDRLSSSWMm0Xbvf7u0Px164/wqfVrePVNGkaS8WKS1twbMbOrnkA46j/ABolF2sZp63MyWNxFbsJQwcecqr0jw3Q1rTqmoXjpcypEk2CbmTLbCedue+egrI8x5DbfIu6JVUqvAYdx/M1dmuori1uLYu6wpK00LNw2QMKMevv2xXK4rc6U3Yh1aP7BqkNlHNDLLcLhHA2gA8jPof5EUy98wyX0TPulyhfB5f1Hv61FqDS6pqbSbvMndQwc8HCrz+IA603TZf3yyNtSJMsD0xkdSe+OuKyUk5cq2KUWldlu2fzJ0ePyzbKnlO204XcPTru46+tVLdiHaRhgxbowV657A/rUHh3U47G9MgY7JJdkihNxC9uDwRnqtTWd0LN7l5YvOt3Bjlz2yckr3BFauytcEm1dD/tlx/zyf8A75NFO8/TfW4/7+UU7r+b8RcvkZMTkLGrt9xTu4yAe2D9Oavyq1s8UEqkOVVl5B6jg/8A1qyTtiPmBvkz90HuKsw3LX0zSAs3y5OFyFUd+Ow9awjPobuHU1LSQiURzkBWcby3pnv7UYO+RgSXZup7qecmm2zx+QZWYh3/AHXK5z9T2qW6SXT5thTaGjDgk5O09GI7Z9DV30uT1HXdxj5bdm8kS5QN0JxzntVjyVGlrNHIfPfKlG/jBzyPpVGCPCqzk7s7tuDn6mr7yRpC0LcAMwyeqn2+vrVLuyn5E2mTIk4ndfMlRCY4z/G+P5Dqfaqd359yftUhjTzAAqou1TnoqgdAOuKtWlhLJp9zeGRI0hAUBj1B7KPzp5I8wbG226kZxglAO49Dx1pSV1Zk3SehCf3EFsIGIeUYkHdcN3P1Galu0lS4iaRQEbIU7s8Z5APue9RahILfUiPKEchKlsNuIbr17E8ZFT+Sslq0ssyee7COOEct67iPToBQn0NNhssGVCSKREqlgB/Dn/8AVUUE3+hOJEJUgIp67OScfj+lWSR5SYxhF2sq9XbqW/8Ar/WmQW/lhUkYLHkuST3wcc++KT30GnpYbGV/dyso+YHp6d8U55cIiDPHJA688jFVo7iWSTCoQiDIQDOB6fSrabVeaUAKgOGJXJz3Ptk8Yp3LasIilvNmJMc6HzECnjaBzx/SpdNEca7p1XzEVuH6devv1GO1UI3aMK6Fw0YwGPbOf6UskrhQ45kAVNuMjb3J9O1JSS3G4FlA3m26OoUbGKkn73J/xp00W52R87VJG33A5XNTBY5NMt1lkZbgy4UH7oQZIIPfJqnDcym1VOd5ZtoI53D39Rz9ap6Oxna+pbmfNqimBTvVY1fsSDuwPyrNvZ5jqtqIkkliln8hmX/lkCuQxH93IwT2rSnkje1s413/ACfMw6bCzZOPbA/CqondZHEagTANJtRemeo/Dp+NaXM3HQ07UTTztax7WaLcSGbK43DgUy95lj3BioXa5IwV57+mDUFgXtzNcoP3G10D7cjacZ+hB5qSG6yJXuDjzg28NwMHofwNK90aJdS2t4fsXmInzrjcevO7gn3OODU0ZjaCRpW27G3uQRkZ4/ziqun4OkOIlV54g0x2nJkj4zn/AHcVct4I2Em+Muk6tKZOP3ODww/DtSs3sLQisIiLs4HyRqUZ36KHGOfrRZOG0qWKZ4hcJNmByfmBVehHoRxmpDkExygRu0SgL3ORjOO4bGagksIrS6hnbHkSZgkTfuZW/v8AspPA+hp6xQNXWo+OdhEN7ZVyJSQO69QfpntWNr142lJFezGWO0mwZ5VHKoxG1z6D1NbNuosI762Zg6vEQkj8tGzHOM+xpVsI7yGSSUJKEAElvj7wGAQB6dSfarvoYuN1qQX0lrd3j3JhRbjAAuP7ydgD1PPNWbSX7LFJHMjfaFQSJjoccioktbcSkwF2hXcsKp1X5eB/T8Ke0k0lwkcaYnjwYyRjBxn8cmld3uHJpZE+ryxoY5vKYPu3ylOjKeVP+8KZqFs2tR2scsSsXfckw4XacY/L19KguDhbe3uEG+QAwvG+QWLYP49iKTSUutAc2vmHyJZ5Gty/JjEgGYz9DnH1q09+xDg9i4s1zMu+SWRbmPIDd8dAw9sD9ap+eY7SW4G1mK4Ax3HXntx/Or0to85mMBKPbuqgMegOMD3FZwltr2HUbdo2jmiCiUDJBZTjP4jkfSi1hK1xI5oEYWpkKwuRJEDwVPGQ1So0sV8IoS7KJGjcLx5i4zn644xWB4kguBOl5YkylHGN3BkXup98Vri4ljmj8xiCJQzF+ANwxz/ntSvd2Bq2pdhVHs5VBKQ+W4ZVXrz8rc/lntVSeJIYHtyAZQFkVjwG6FRj8etSXNuYruRluVZRIYiy8iRSPvenqc96ZrsE1zYxxq+2ZYN8ZwflPYfh/WqsQ79CLUZBGiLJCUeQgkZIABOMk+oBrM1swG+tzGElkXG0DhScbc4P8WO/er1hK99pVpJfo0U3lDfH1ZHPX69OBWS2nk6l50mTIUHz9TsU5AFKTsOKYWO4s6JKS4wW9T2H5ZrRtkRFuPP2qVPl7evfk/THesq+0y8i8SWN3ZyR/Zt7rcqxPTqrD6HqO4rXuVP9ox+VhVvHG4k7lVwcHPse3sacJL7hNORRuHhv4WspYxPbyByQ3ImXHyfXHT8KSzLLpSwIq7MrtbHKhT0z+VVrXTZrHVtQvYJZGslkWYROvyxOwwyof7jYJx2rSghQidMMFLCSILyMex+lROV5Ow4RtHXcx9QRm1OxuJ2jaATETMoz8gB+YD3PFTXKRBGjjZWZ+jAk9P4QfXmr17b7Y5TNDucKCAMFW/2j/s1hYYWyxBsSCTcoySVHQ8f56VzybWhrGK3LqypDZyW0hKo/7xiPvMwBAHsP51PaSL5cUkcCp5dsfOJ5DDtIcdM8jIqvcy/a7OApAuy0Bj3L3BOefXn8qhjleS38tSuCCpizjzAT0BHbvgntWMJNPc05U9ChY6N/ZloLe5mXbPI8wZCS8RLbgG68Lkc981ZM95qazswiJKiNiqYLDtnHU8VERLZpLDEQVnUBpfLKGQY5TPXHPToeKjgkijlkaJmVRt9RkemPXoaHJ3KtZaE39kXn96P/AL+iiotyf3ov+/Roo5Yf00TzSKEb7WjSRcnkgDocjNaenuLa3uYLdikk4EbkcYTqR+eKr3UUcbjbyBwcjHPfHtVkKGywXarE7VBzwOx9KqO5pJpo07UrLLtggZjEmyJRySc8saihlf7U8zMZJwpwWAbaQPQ8ECq8XmwzviYMHXHycAA9qsFRbO3fcMJg8HnqfaqvzGdrBp92hBWUSFpfkZh1A9v0q7Zrvu/nB2kZOOeR7n86oLA0cqynbuc5C9m7Hir2mS7bgbWwVUgg98clfocY96INqykXJaXRoypIsNzCy4jWRWwOzYwB7dzVO82ksYj8+wZGMZPv60lxcPK8zRRiKGWTd5SdOeQB7Cn2yu5Vo8SSv8o56ZHJ/SqfvaEKNtRkeya4EisW+bcGJGSR3P5UkQmjlVYzulbcFAHIA5Lfr+lGl2rW87wnasm75T0Ge4Pt61PLs+0LMi4VNoIHPTknPfntUct9S/IfsEcUTLuRHI3FzwM8Zz6VA7jZMQrBeRkdCw6N7fT3qXUTlWjyXmL5DgZGSo4A9icUyPaLYtIfLjceSVA3OuD1HuTVvew4lrTkYR+aoPYKFxkk8c/7Pqaht0Yqy+Y2JTuKdnA6H356UsRZHMEe5OWC7hk524C+/X8MmrZEhEU7KsaW48sKW3EkZ3Hnr834CrSTHexTvFAghJX5WYeYI+wx0x696iEAaNvJOOMBhliwz0P4VKk8d3ez2oUxLBH5rYGcZ4xk/ebPbsKdE2LcBEHmKSSSSMH0+n86TSY1K60K0ck14La0Dsyw/d4woyf0FSSW7RXflXC7V+8oUde2V+vrRcww28qCIidHjUyY5UE84H0q5dtDLaJcQR/6Q7fdLE7QuDkH0Pb0qFf5je5DMlwITeIct0dB0IPy/ifUUzRLS5069uFFybj7SrAO6gGIHBCr/ifWhWe4s3l3sByzf7Lev8hihZF2LiTylYeWSxyTjB49BnP4VqpW1M+S4kIb7Mtrhhk5jUn5cH26En+lS20y3kBnj/eRSgZcnj5SQ4PvU18gnu3jgjZWhiZ9mc+WqtkAepwcipVsYorRntFXfd3ImwnAkyMEgf3uOcdf1q0tLDW46wgKvDbgGEbhEpU4BQnJB9QByPWtKaJbezS0RHCNIHilUZZkJxgj6j9ayYJ4FR5kmRJUYYJ4Kqc5wO+KtWdxNNd25Ql5AvyJv53AgkZ9GAOBS0WhXKV5UuNRhW4ccxFYxg4OF4xnsa1tQX+0hG1vEoleAsyIMAyA8Ag9GwD+OaoavKs1jDNHthif5WjJ2lXXJ5Hpg4z6iluXaLUWfzGO+Jcu5x5rAcHjoTwAaXSwmr6liWWG6e0t1UNbyjcxGQxUc8+4yT74qtbM1nKVZzvdyyMo4mQ5AYH/AD6U6K0iW78rzXilKLLG6njJOdpHfHanXVpKLWNlJLxOVkGBkPnP4ZGfzpWfxEuyViOVswTXcDAI4xIi5AOe4qTzBcaXbyq22WGTacH7yAZ5PtV83EDPc7FHkbI/kHJAx/Qnp7VlsksDXBCKbZpCMZChiOeB/LselW9DPdlmXbNCg2gRPIwWJuSDj5vp2PvVCWK4ilW1vcyafcPvjuVOWiOeVb39DS6g88scyLhZWUHzDhgQMYzSWKzNaRtqUaRTxnbJCJC+wjgHnoG6+1HN0MmmmX4p2lk2Wsu2S23MwH/LQdEIHUnB5FVZxKZZ7yJBAFhRXQAFZVzkN9Rk4PcZFVLhmi1iaK0DR3lqwdO5QcFRnuMc59quWWpTXYnkk2o8u2GQIoUBBkgL6ck007S5ZFwSkrkVxmO7E0/zpgO6b8hh3YEe3OPSq48mbRU2gzxXOY8A7djL0IP6irSEFTCqLbptLhSM7n6Yz6H9KxtOhvbWTULMIp0hZTc2zN/rEzw0ZA7A5Oapy0uhON2aOnyk7vMZpNqCM5AG9gM4+pFX28xb8W043yL+7DMeB0OM/Q1lPdrYaxDa3e1YJCBDPt43nlc+pPIx3rRkDrcQxqp3BmAQDPPXAPuOaE7C0ews0cC2jqkgS4tyZAxHqfun6etV4IFnmgV5MBiImZFyU3Z7e9TlIxLcXCyl02Aoy+jcbiPT+VU5YCipdQO4liVEaOM8ODnt1yPWh6it2JIi11crZFkjK5WQk8PsBxj9ap8wNIlu3mbwwiXPPy8fmO1XbaEm4lEixmTarLvOFPXIJ9xxj3rMmlSO7D28W5ZJPMjXPKL/AHDUNtK7HboRtfrNsVmCkxiOVBnr2I9x1H1IqYlvs7mHICEqr9s4yayvEFncnWYLqw2iOSQeah4YxuDjHvurTjhluEhtotqOzCNkd8bXUc5B6dP0rFyfNZglpdivexq7xLmNxjYmOin7yc9s8isU2FzcawsqTIYIYmRizYJB+YEep6g1ckh+0XSzyMGymFI7Ae1TQp5VwJVIEiLt25yrKRkilP39EJabmdG5UCPjHIGRwPertxaLbxCOZMQSx7oiOrNj7/PY9KrfYyL6dYVJNwildw4BPoT0+tW2g/0VJZXlmURqkfP+qYn7nJ5wOePWuOUpRdnuaxfUybyNm02YOjedAck5JJBPOB27fWmwybvLzH5jYyFYdT6mta7kljhlljmKys4ZvUgdwR09Ky7eEnDyFY7cymPzBz82Mj8OlW09LFPW7E8wf88x/wB90Vb8q6/59rf8xRWnLIz5iGRreREBXaASTtbJPp16Yp1ooa3kjjjIlOMMDwFA5yO+ao+UVfAOGByQeuO1XY2RLURlfnLZ3Z5A9Mf1olPvoaNW2HWCCRwWX5c7cD+daF9GTI+QiEqG46YPIX61HYlreZ1BVti5IBGCeo//AFUss7SRK7bTulLkDAJPf8K0ilyk63uOtcPGYuhOX4GTkDjn09aXTCLW9E01uJVh+9EDjd2HNJqEqpKHt32PJ/rNi7UA7Bf6mm2EkcSM82F2ZACjPB7n6dqd9V5Gi2NG7KgH51kVQqK0XCID82PqOc0AfZJw6EwQ4DcnHUHp3wR/Osu3nKlShxGj7yrc5OOv4VZv5TLdSzLFIsCkKokfeST1/M5OO1Lm0uh8tmTaajXUl1NvWMJGZfm9fQVJbmT7NboAT5wO0Y5x/F/KoHdIY8RyD5xsyD05zjFWXkWLUIZ4WDKTkIG+6fc/rTTSQ7X1IrSF7i+8uPLsFLjacFsdwfpz+FRybmSaZcMS6hdnQgdx3I4p84f5pIgVIcoRnjJPXjr61PbRFI5HR8iNggP8QXHDH/CnHXQrzKlzfwC8gsnkVLkozIhbJZ+pZfXp0rTyxsi2xVmChcc7l3Hr+Q49s1kNHaXMOLmATDfvCEZ2sOhB65zg8VszQNII0WUSySR+ZkHPmc4xjsRyB2q99UTy20ZW06PzFkZio2sfvH7x2k8+2Rj8as2ZSSG0WVj+9JDgkDpyCe4PUe9F9cWaRrHApC7AkzMRmbGMNjtjofpU10+UmkCKFmVYmCc88FSPf39xQrLS4MyY5PIuYyyFo8HMZPODnr+OPypUR/swh7tgwjPDLySAfz4q5KJLZZ9yKJ9r7mzlivTJ9PXPFVLphDBDHbgMhPyOeCA3BOO3OSDWfw7lp31HF/senbY5leG4QsyDjax7/SnQR/6T5kufljIdSoJAI5zn25/CiS0jgSNVmjlRTyw5JRhgnB43A1mR6hANSurC4b/TrXE0SuvE0TZAbI4O0jn0NXyq1ieazsX7K7a21CMWzI7OSiBs4K9FOfXGant2ZIZIJ8rLFGViUHhSeeDVS0twZkXzVGCMPIMEDsPY5/pWpeJH50N6u7F35yMqchQBt3Z7nPNOMWkVKzehh62ZoZNOvraP7RHIqLcKB80I6DHqOOe+K3NHS2W6lZVdpWRZI9uMoD9emD39KV4tymY28i6fMVjZIwCVk6BcngE8/TNSWVnBEhieKNrgoJC5YkYz909+mBj1ppPnuhaWJ2ubcwT200apGXZinPHfaD23cDNUZ4pTp00NtjzUXfC8q/eQ8Mp9cE4HfvVy8hijhvpraSGeGJoiWGTjdwM+/qOtOSGAsIpJkKRKsaODlMHnB7596qwtLaCW1w09ojSqwVPm3jgq+B8p9DxgUtldGW5kjn/dtMcfP/eHGf6Uy1GI5TG6hZ8xIzjO4jqMevofequoXf2HSt0qrj7QDMAMjI5BB9xwRVW7mMrLcuXCKLqYROjS+VvjyPkbB+ZT6Y6/pXPx+ILNNbj03WZ3UToqK7JtBx91A54BHp1roYr2zns1aML5W4hVPLJkhgc+nJFVNSsbY+dA0C3ETMsmxxvHmL1OO1TK6V0Tdtli28hog748uDCS7ycMucZx78HP4Uy8eWO68/YSI9schJyWAIwfrwB+FZRvl+2zeeGDCMeWOi8divfg1s2YldY1tI5J52TzGh3EBwBk4H1Gc+oqIS59OpcklqyG1imudWF3NHtaceXCc8AZI2E9upANSG3ijuppXlSRIZgrn7qso/u985qsFuHsR5OGguXIeFvlYHrwT268Y604XqTeZGV3JFiORn6uBkgt7jOPwrSMFfzM3JR2LWppAYbRVDYXLHYCTGc5/Pvii0jImP21nLb1LhPvbfXHckdvSksib6KQmZ1cMJ0MfBJAxuz6DH50yye4u4oJLmJDdk8hAdu0Ek5+mCauSJjK5N4iitdWjCRQrNgrGqYxlgcrz+oPaqsol8yB42dpo5G8tmwNxUjII7Y5zQjbladGxvbeUVuFXPysPTgkn61DdAQXbDHBAO0E43HqfeobT1LUbaDLTU7VdUubNm8uNiy5OCUUnLD0wSPwqpcXbWtxHcLGUjKCJhu4BHUg/r7VheOIpNJvEvYw00MbhGkAwGX+PaB1C5yK6PS3a80CVYozIY2WaTaoygHQ4PYjqajnbfI9w5eo+6iWeC/LuxBkUq6/dBxnn0OefzrDluVRMPI23hJinXd13c+47VctpEmhlSV/neZN209uhP8A9b8azobO3vZNQs5xtaZfJibO0AZ+8T7YyPX8aiacrNDS0Zcup55rKG0nBDRRCaPB6oeTyPzx7VGskl8WcIGkiTMxXjeB0PHc9z+NR28c8lmse0+ai72ZVO1scM4HYdc9uan0y5VbVJLaNWeJmhkjK9V6nPfpWSjzMG1FWEtJUZk2t1kJY54VccY78f0pssiLDDCW2zSBiDj5W4JBz746Vn6Cnm6zrCMUdbZIZ/Lz8xjfOdvuCBkdauXFsLiIxOGDcldvVCDuGD64ransZNN7Fue6ka+tMfPhVjC/7JH3alviLbzDbxg2xXy4HIywYnofQ8H6VUuItohYAMchsqCeMZAHtTNUl/cC4DgODlwvUv13AemBis2ua7YJpBGJkZ4mB805XAP3fUe9ZzxTNP5CKwXLFUH+fU1qtcNHpUWBCfPYTLIG/eI2MEZ6jPWq1oxN4ruActuLE4yx4wx9MZrJRXwF82lzO+x3Hr/4+aKsfY4P+eK/9/KKPqq7C9qVYJRJcPKWHJLYf0q7BuU7sAxK2FbHLEd/wrMiy9ydu0FjwO2avKxyLeDJlY7PmYYJPUf/AF6FqbNGgse61eXChASOuDn6d6USLiIsuZF4bPp2H1qC5jaOeW3bJ8t8FSO/0q4c5Y3WV8uIt0yW54HtWlm9ASJhdAzuYwTlfJgVhuCqf/19arXEccVx5EchMIbBdsY3fXuBSW9wWTzGX95klc+h4/OoYZA0ZJVzCrHcRwqk9B9abd1Y0jEvTRx/YixHzr8rHOF64/HjnIp1zqDSXDNJH9yNE4UckdT7Z4qnLnMbn5ivI4429M/Spo1RWdwC6sSrPJ9wHsfr9fWk79ClGy1I3iRhuSTdKedoGfwq4qqbZHkAUBchF5JPctnoaLAi0bzPLcvKP3LH7ytkAN7dfxqygWS1kgnUBwxB49Tg/wAv1qlAUr9BljNbSRukjfupWyrbvu4B6e3QfhRKifZB5UjqZd4YAZbYvTP8vemNELe1hhgRUmjJWNl42qeqkdO/4Uy3l+zKojcgod6E4IyVIz9etJN3sxxT3HQITBNcHHmfdVO/1HqVxWhJMYrsy20u7Y6KJ1IBDFeSB6f1qppDyx3becwe3ZBuSTjYccMCOQRmrNvCY3mTduUZlYqPlZFbIOPTPerTshrd3Kk2nS3NxEEYjz5MxrnALZx19PrW99miOnyfZVkVoVIkjDAqCvcnuSQT9Kr2pTyHjnxsddy7cYDE5wx+n+FIkx8yTf8ALHdISVYligXgZ9wPWhJR1XUl3M2TUjILkoAFd84Az17fhipdVgNtcwxNNFO8v7x3V8iPPUA+nr9KpuqRTO0atjAG7HIGRhiPer0pe0SeOVEeF4zGCyAgL/s+lTC9veKtZ6FPUJZEijS6i2BNzRnABwf6Hg5pYJLaTSYmaEvcrI3nSgAkxnHyj0P86q6pva2L4kNwy/umZsoMdBnqQBxVHwnPeX1ncCeFreeGQHYrZWQjjAPoevPpVQupcqCVla50wtI7DWpXZWklSMNG2Q2QwyCc8bgMfjRcXCQXUKvJuRIuY48AYbDFD+tUllezthckBj0HOdrnIKNnrgdPSpNJthIY3lYYztxIBtI749v61Tm+bkQlG2prX06ppj2jrHLHE32iPk4QP95f9phkfQGq8ZuEhs5FhZ7iH5m2nLzJjnA9uBj61Vlinv8AS7143jdjLvWRyVRAM4AxwA3oB2qTT7ucQ2d/cqbeWFAkiBgSjEkE578gVad2JK2hca0ijgMlpIRBKfNXrtLjqx7YyeB65pslu9pYRrMirO+HRiMFlx938CT+QqY3bLO9tDJFHI0vnWyFSygMMYA6Z5J59TioLhmubVT5eIVBxuORFjohPZhgnPuKtrsSrpDb2wuvsk7jy1TaHXy2/izjHqD3PpUWqRCbRJmSKMKyqxTklmAw36ZrUtrlL2zZiHMm0rLLjGxP4RjtuIANVoLhLWW4P2feI18qSPHygOMA/rzRZfeRLV6nKeAbW+tVl0yeaGW2R2NpcSH94E6iN88cdAfTrXT6fsS5ifcYXL5y2duT1XPb8appA1ozvGfMG0Iqnksnf8jW0sllPZh/OEjPuxgZy2eCPQnv6YqacXbUzlaOxRliWWfMqRBjmP5h94qcr1qOC4NjeWzAkjbsQs23bu6KSOhB/nVOLUWeU6TqKPHI5LxT+XuCMpyVLds8/j9avssWb6Ddi3lLOjAcHKjKn09qFa5Sae4iMiJPI+HQSgzKOqfT27EfjWFrkNxa+IbK70ffNZy74bpAOikfK/PXBOD7Grc8sunW7XMrokCN5UyPwYzjIJz1Ujv+FaAljjtpgbV5Ld/3ZXODGzKMFWznrg/Sr6ESSbsR6BavbFYd7TWplbIGd0a5yFYdcen61e1CTzWdXZEkLqGIG0biMcAdiB+NV7O5U25meR/txO+RlwCy92H0GMD61UkkktrqG5gO/Of3hOd2Rz19jQ5e6OMUnoaV+sdrID5iFZFWKQbdpQ9PywP1HrUGsSxtLDbxhkiQnGeoz/Cfrx+FNtAb1JYyhmZmZnAPLADIXPeqk4Bnura4kJ8ttvmLyp4zuz7DAqXqiuXUm1Braf7Il6ks1qFKBIuTDjncAeDkdfpVbT0toTLJvYIuUAP+sb1OB2II+U8HnviqEdzdjTriC5UrLayKEYnqh5B/U/rUllBNcLKA+wiRSse7aWPPI+gzWLtKadi18NmZevQ3UVraXenBZ7qM5eINgSLuwR7Hb0+grRRw6qIRvnlbnevLLgcexzTkiEdlkBSWVhtbr1xk/TtS2E8UWGIHmK2AynkkdSDVa21MdE7olt2l8t4xM6QN8m1pCN+P4W9Bn9aq+GbEx6zfMZSsV4EBQgHYwG0nJPQ8fQ1pWBAldplMqyB2Vd3K9ec/Wi0t9zlZCruFVUQHAYHP/wBbNYuDTTQ3Z7mfbwLDJK6BUdRtZh1PYc9yMnipZ51sL5N4MiYKIynhT1z7/wCRWlHtt55IVKybAiq4HU56/UZ/Sor+zjhl8t1EqSIRsY/e5JwD2rSCaV0ZyabsZWpK0dv8pI2oXAU+46exyahWRLyJXgTiaPYoxnyznkZ9hVqVmWAqcmNsLkdsfw+3eqWl2aWU1zPCxTzWE6RE8IR95l9GPGfpQ5Ijld7jLZEisltinKPy7fwqO2O3WpTB5s0ceMF2+UfqDVuwi/euxkBMiF2Y/wAAzkk+pqSWNCUZCvlSAvvTkpnomOxPWs1C7uU5dCD+z7n/AJ7yf99Ciqfnt/zxT8zRWvPEz5WZ6IIrxI0IkAYdOhb/AAp9z5hv3XasW4ncp9c9/T6UWcYCCdlII+ZvY5+UCkPK5GPP3licEt+Vc9rHeldk6SNl0wGlLffP3ifapJpSJdjEMgAzjj8KjsAojaU8BWBdmPBHqPU0stxBExaXcDNkRtNwD7kjjOO2aWpS03JsmO1jaXcAy/Lj0zx9B/Os5LxVk+zHGC+7ceo+np71qpFvsphsLt5YcsMnZ/hWZBpiT3YNxOIUjVn3kFh0yFAHc1a3SNabjZ3N54x5Bw5jkROQTy/+yPT196LJ1MUMc2AgY9QSCf7uO5HrVm0uDLYCAIvzkfOVyV9SPftVaRRE6xxHHG05Oe/b61UtHdEptqxYmfEbB0kPzEjdjlD0BPrnv6UsrPGsqnCFHHzKeWOMAZ9OvSi2QytNArbIs7tznGxU6jHeqqsjMElxvdsAk4AB70dRpXLOxTZBN+N7bpAy4C89B+NSeQtwElkbdOSMj2H8I/D86RBJ5Es0zAsecMcnjq3vUhUCBSD5UTfKxOCVAGP1OT9Kqw9tiPz8WqMmVdpHk8w/ex0K49MYqWIpC7kMuxwBtU/Nz2+nHNQXMTxzny3HK59kx/Dz34yaR/3haYcKoBJPXGOtQ73KauXArMXhRiVMgUjPbPQH9adKTcLHEgKyuSCFOTt42n9Mn1plkX+zPAVCpIobcO4Byfc8+lOaUmOGKEnfjKMvy8dBn6YPFPoRYdOyyTsYe6ZljIzsA4AOeh6n8qS4glWRrKP554m80yZJUoOQ4/Dr61NcAR/ZntJDI7LslVxgf7v4c8mq91IJBJJI0jTDYA5baWUkjB9sdqtAmMSJZIA12Da23mbZig3LF6cfiD9DWZaSfZdQcxF8fdBb72CO46GtJZBJcXMigzW0cYaUY+VlxgMynsvfHNY94FSRJlX5JMImG+8p7nvilUdrWKSXU0LxBczOWw3yBsKoBwBjtTjIXs4GZFZI32lCeM4IyfwwfwqOzjkkibMjtMrhcdmQDr+BxVmeBYYvMhB8t1MYzkFWI4fjtgmqSvqirLYnlj+y29q5h2ywsqPDLyJEyOGX1B5z3zmm3zx6fOVmhEiu3zRrxjDHuOuR0x6VWu5I4ILa0EaCUqXabJYvkkYx6YH41m6jqjvpNxOIJHmgQzIYxksqjj3PA4qkkjNxaV2b1sgeR7G6GwAKVmI5jTnac+vOD7Gr9zNbvY+TC8RMsm4IGzudR3z644Nc5ot79rFvdzscSjDb2I4KggHFP1LTIdTmtZUuJ4AxKfu5MMpHX2wT2rVSVtDOV2WLm5NvPJKrAoJEcKWIzzkA464PX60+W/isZ7kZaIuoLRvzuPVlY9geD7cVXaKW1uxEJC0QxHudQTjHI+oyfyqeSzgvYDBIiyq7DDKTicchie+fp71DUk3YmotLlpbyOaKF4xG7OpyCufnJxjHpiuf1G+/sHV47ogizd/InZVOIC3HI7A/pVnQLa6sLNYL2MNIknl+W2cZBOPcfLtP4c1Nq8r/ZmnSJZyVcyoOdyp1JH8vXtRFtx13MpK2pu7TcSs9wImaNBOuRgSxg4z+HQ1WkDC3A3MV3jZHnPckjPYevr1qtp91Df2lrc2M4+ytEJFmBJ2nGACOwOMf/AF6t6Tcl5zZhRCSrN5OOApxwCewptpkxYksK3zX9xcxKYWjEMkJHGMfcbPt+dReHokt447RHWGBVEcTzMXMQ6AEnknBxz9KhubmSG5uLkgNFv2u5UlGK4GD6qfz/AAp8LrcKk0f7vzMDCnO9W756Z6c+1S3Z3LsrlfUbCW3zaylRPby5TnBIbqM+nPSi7hmhk8xypMQ87av3RhsFSOx46VpalK08X2y4wYpLjy2Y8vG6jABHv2+nrVdIDd+VLIwHmMY3GRgnB5z3/wDrU5K+iLWmpTtb8Ykcy/Kx+cdDHn1x9acsbGeeBGDxygSKfcjGffiq8tvDDDscjcuYZtvdHyMqf84IqDwLLc3Ph2wa+VkuI3khdmOPnViu72BAz75rOGnuy3Ik2pXWzLcrrMSJI2kkLBQoPG0dR/8AX7UkSyRXNoxVXhcsMehDcYPfj+VOhjECxzOWTduAkHHIHB+nNWmt4o7dZnDecNhjwwODjLZ9qa7ilqrEd7BHHHdSMGRX4ib2yTj1PGOfeuMt5vJ8StaTzMi3SbrffnBkHBTPYnOa7O7imaF3cFdo2kD+8eeffHSuevtAttW8hLxzHG7kGRSV8o44bI/TvxUVZEcrtpub7LGLfdvXzMjj/Zxyf6Y9aszbd0Zt0A2RhsN/dHJ/PP45qhNa3NlpEMF/Mk+oRgBpkTasgyfmP1GDx3JqxpcRmAjZ/wB2ytufHKledvtk45qYybfK9yrWVye7mt1mjk2lQQA5JwM8nA9hxWdcTGS4iAPzg5OB159D0qWzDLbzNMoEiHb8/QcjcD2JFULy8EOrNEVfzABJHvPO0HHT/ParS543MZWjKxa1Dy4ppIljJi43Bhg56/nmqql1T5vlMykb2GeCcEj0705J2kvvNJx5YL/MN25h0X8TSTz5aR3cEABkU+5ycVE21sPyJ4yypLObdGjxkDHygDgYH4ZqCItCgG8bHDBxkfL7H69fwqOGRWaGZ1PltkLkdeOtQM6TcEYX+EL69h70492QyHn++lFTfarz/nofzWinp5isZqOX/dJksBuOT1NRrI0cplT77qQW7qO5+tWYAYLiTDld3JJXBx3p95ALe8RIlZWJ3gNjcM9j2Fcrva56MWthdMWETqbu38+IDhGkKDPb5uwq7KWRZVSSP7PONsjKnyuM/dCnoP51Sg2iWZyiqWGBtOeRxgVYmkknj6nKD5hwAD34q1qtCmtSOMyaa076XIRHInNtIcq/+6f4T+n0pNMuIgFnC71VtrRv8pDd1YdjSsqiNXn3KrLkLHjJx/KoL5HZ45oFQXEUYTYfuzKOdre/PB7H2obY+W2xtSoIniMDDyyQNwzgN1br6ZwasX+1JYiIwuxOgJIbnG7Pcf4Vj2l6k7W8qPuRRhVkHCEcFSD3B659Ku3DFTCpkJVl3Ix+vXHpnOK1uug1HUmaP927MTgABQT05yc/496jSMyEIh6sWHOOQOPxqaN41gkC9ZmAPp6kU4MIVXzG+UbsheuOoP50dSl5jZuLe4KMibyFReTn1OT096ZBI1vtDJvI+ZVP8Rxjp6Ujy745HUNggIoJ4zjv+FWLQOBJEmZCw+cquWLDoB/XFNLW6K2Qp5Mq9EVVQ8/fIzlz7fTrVcXDwu4XpMmOUzwO314zVhwPtLyn5kyAq9N4Oc7fxourdZLSH98qyEyDBHQA9W/kMUmuw7IZa3RKwRxmQfe8sjGQD6ehqe2Q3EjhAqOrZbvhR3/Sks4VSwD+W5IXJXP1w2e5J/LFQqDB5G5l80AuxXpz6nvn0oWm4NJl2+luYppbPDlzIHZF/v47Dp/jVfyFu7oiaUoF+RcnHKjJYnt9OuRT7q6kll8yBixj+cv3xgD8xWXKR5agFnnJJfdyM9qV9bkpMuu1vDZS+YUW5f54niPEeTyMep6/iazizPL+627ySxHOCo5XHsD2qncB5AZGDB/MXJ3c9M807zpLd3mLZm77l4Gc549TWnNrqPlaNGO4kBRIt6XCrvkOen+17deldFY3VtcogmO1XBRh054HPp839K4+Oe51CS3kZwRbEGONj0Prj+I85rbkdrKR5zv8u4jk3sACQ/AYHuMnGauMra9Cb9GO8VW6288XG0mPAdRjp1PuT/OsuKR2GN37okELnA34/U4HSpPEF3JdXFhE85Eyvl1VQVSPH8Pux/lU9kjNbrENodssWI4B45PpgCsou832NY6xGpD9jjkJ2SoxG8MwGfQjv6g46itSKKNYoZ0lECXeULgZCYyRgfUYqtqEkNxPCmnxBPlbIY/dJ6n64GQKz9Qv/wCz7e4hhkY25A3OUJG49Rjr759a6E1EycWy8ymWxeEttydyoTlsEZ/DJ5qHSYGihaS+kLQeYSrjgxdiD+NVdH1EyrBCyKAhLrvXkE9SfUjHArWdrdbqANlZZDumR+T8vIHocihWkuYhx7kMpdmcbdhkVYssSTnqvJ65PeifUW0+0mdreW4kUgyfZwGcAcbgO4/2R6cUSRm9uLmS0PlI0g2b+mT0J9PaoLSMyyGYjynB/wCWYJUD1A649vrTWj0Mpx5tCxp6acqG/wBHkb7FeyjzISD5Y3DnHTHzc47Gpra/h1i4k+yXCfb7T5ZIgMMueAWXsCPqD+NVJ0aCaRYpVdMb2AbCkcYZff1po02zudQtr2aArdxowWVGwxGPmGf4jjkD1FRza7EKlazNmyMUsctq4LwPuE0QOGjydoP07/Ss3RLEWDGxSJIfJbsfkchskrk8D6etStBNAFbeFkdPNhY9Jo+x/wAQaq+IbtryCFgmJTlgT0cYxjPt0/Ks5t2u+g+XUn1oxCa+a2LKjSKQWyOc9WB7nJx9Kje422UMSKohYmNJAehB6N6ZxkGs/SNQk1hWeOYTGECBl65x8uD6EdM1cidZLS4sJXZjKGRlUADC8qwPqD2oU7FJ8yshblXkF1Gx/dIEMiBQrMBhfzGeo69atWytFZzLOGR0xmMDJB/l0x+dUbKeVbeK4u5d13bsI5Nw+/H2Y+jccitOPbGyK2MTAF4+24HIz9eMY4pq0pXQS2syGZkurERoTv5XB5CAHO0D0x2pYW8yzMbzKyKBsKj+JeNv1xzTLiOR3k8g/vEKo6Hu2SRn/GnQA3MX2iBUAlJWVBxgngEelVu7GbSRZM6xxSjO6RDtcj5gwA6j8D2qKCMCYWwGPNeN4xngMV4ye3XH41WjkW2KxzHbIy/u89CevT6Eg+op4dpWZ1UA7ck9gR6e3X8qma01M009i1JbsltMGyoZ1ZI3bdxnaeexDD8RinSTLHpjW8PlmBVOT0YS+u7rlgOh4qC9kkezW8VhjeVByCVPckd8+v0qpNdzSumdo2Lxx14xk/hUXS0Q9bFZrpibvBISR9zRZyCPX6j169qoakiS3ml3qx5lhLB+wkRlxgfofbFXLW2860Z42dmiJbkdPbj2qlZzx3oilU7o2fYEXopz0+lOHNy+pnNq5dCSWwDALkoCwbgbexH51VkKlCd5WQnYuB/njHSrd5I0xnPmK4jGA3pz2+vpWZZSfaraQtjzoXcS4OCpUA/qcU5RujJy1J7twkQjVtodNrgZI69R6dOai3sUQYG9k6kYzkn5j7msmC9S9vJ7OQ7byAZlQnkA9G+lbVgu+Nln6g5Yk8gdMCsU5OVkNNWuR/YU96K1d9t/cf8AOiuj2SJ9oyhLA1vIk8yf6sDC7shsjgf1xVKaRrqVpJiC7H71XZIjFoXnOQN2JUy2Bgkjp3PFUoACmW+70/HtXHKyfKejTelyZDFHZSvKH81jthC8Y9WJ9Pan224RvIqAsQEwVBHPQ89/eoHbey+Y2W6HHI9qs3EQwHYjDDjHTA/h/A013RtuV41zEQckZwT2+tX5Y459v3R5cYDSKvDHOAR7dKp24yGCkkkYOPSrc/7uytyhGMZJznn3q47XBuzMq8t/IvluEYmC4dUlI7P0D+wPT8jWu0cyahK7BzcRNtcYyYugBPv7dqbfWu7SkmmAWHO0qODIDnP4+ho0aWefSUjl3jNwRcMp4dh/M4559apKzKUiy4jj3ckxghVZuOn3jT7qMFCBvDKQGz0x1AH86itmjbeZ1aRI88g9Q3Q+3/66sLkFApDfJ949N3Qt+mKdixZYhGqn7qY87HUDjgfWpNME010VhcwsinDZxhz1JP5kmmABIgCobccKGzyOuf0xT7WQmTCbpP3e0L3Ld8/j+lUt0GyEijMjw+UBubqCentntTFkZ2aIny4kVs45xySc+tSBXRg2cSIhdSBjHH9MVDbqzQi6OcghnHYjPcfr+FFtTTl0Jp7l/syJDuMcalQCM7S3HPviprKwlvGM8zMI4lHzkcBFXoPx44qrKjbGRX37ckkZ65xk/wAqtJcTQRmJFPksCuD6HGcehNJL3rsiS00IZIWtXmTyiHYggHqO4PHrWgsFglm11F5j3W9TBtGQuBypXvnn8KXzxcaa7JEUkySkwPcdB+ArOnvLS2IkhjleUNuMecJvxjhupXPOO3SrfLT17kK7K4hjJtpZmOSHCAclWJz+RzWW1rLcuqwR+Ywxn5sZzwMn61bjLOsYkO4IvJxjHPU/nVvSoRJcggxxFz5Y3HABx1b9fxNEVzs2bsjJ8vaFkOWA6Y4KnPINWrm/aDLuXkXbkMM7WbGM49h1HfFa15DaxRk2yusvl4kVhjb6qPp096wmnmEOzkjIdVbncB0Yjse1E48uxmnzaklhcQsJnvI1n83GyUsc89xjq316VdjkMAWM+YvB3LIOfm7/AJAc1QhtnEkbXLiIE+YVK9PUgdPwp7OhmykheMk8uTl1HYcdM96i1hqyehtKEa6juXZTLK20DqA2MBj7dsVmxp80x3qFAJVmPyjsT9c8fjTtIkiaDUFuFbzVCrET0U7uc/UcCrWtpHGtjHI21xGuYQOUGMYP+PoRWqd1cpb2MnSVQapbFm2I7cN1/lWxrdjMk6SRJJtEfnIc5+XOCSfT0qGZB9mmtJ2UOh8+N06fieo6VsWE7SaXcLKxbzjwAM7Jh1Q+m4cgdDVxSUeUma+0SaUIY9HtXnRCRC+2NufOcvjB9COuO2BUcKJHeSW6qzSsGHmL/eHdSOmRwc9CAaLi/DSIsCGOORhJGQf+Ww4Lr6ZHBHY1stbRgzzW7qLkFLuJivPGcrx0zg5/GrvdWXQ5pJp69TEn09bxpoYI1SOO3ZxjoSOpHp0596oWm6VFR4yd7xjzWOApx8v59M1v6Zc2r3UN48/l+YMtG3IXcTuT2IyPqCan8Q2UFvbs1kY5okmB8scBWIwy/RgOB2I96nlUveFzWfKznNRSVXZLzakqnG1eDuxwwHbOMH3qvDGtxawrIm5HlO5c8k7cEj0IIBx61e1FYVv4ZLa4eWzlhOZHXc4Qtg8dcg8HvgVixJNHe/Z3cQrMwIZjhQM8OD6e/pUTVmWlpoZvh/RrnTPFt5PpTpJZaiu25gYkHzl+7Kp6DIxkHvXQGzM32dy4htJLlgrOwJBAAIz/AHgeR7GmQTPaLNcRq6zodjxk5Uqoww9cg4YH0p2qWIht5ZBPFKrjbIBkmI4BBB79MH61k9iErMZBaSahNIfJ+SKAZmHy5UH77e+Cee9W9UuozZW1tMvKTFZMDDRsBtA+mMGjQdVCRRXYiU3aS4lLD5ZojxtIz1BwRx61FN5l1qsQmxJHczPIgLAOCw2kE9Bg4OKiL9y6e42tdSWykKtJ9oCFokW4AYdSvbj6YNME32W1eKAg29y7hXI+6Q3G0+nIqtHIEuYGuZSrK3lu7ruBx0J9iR+Ip8SyGeW0ZAZHwETAKruYH8M9eKSm9iZRKviKwju7YrHcPa3SR5hnAyVmUjgeqnofUGrNski2Ed0XjBVgrIv8QI5I+hp8Ft5lzcoSzxAlY2PCg/XsMDp1qvpt4sIuklkIR+Ap4DFeAf8Aez+laOXNa5g4JaolMkYQPtJG77o7/Wq8MUiXdwJlAiYqyN12nrtx1xS27CSSW0kGZQ5AUemMkj3+tFzcJKyHb80RKvIn93tj+v0qVpuJiQuBDIkZKb3APcY9ffmsfSrWHTGuGs9/7+ZrjazZCuepX2PXHrWndSfZ7iGKUqoOCxTkK3Yj1BBwahRZFM8ZbhM/c6ZUkj8K0cXZGTtuNZVSJIVYmXh3z2b09+MfrUUUcSG5mSLE021SQcA7f6jOKp2lytzeTRSlleJldyvXaav3TC1s4pJhndltp4K84BNTqzNtENjY2huzcPAoumQxGfHzheoUe2ala3YXoaJsDBBU96u2E4hLHaGJQnJ4wTxn6e1VZmBLPGu7B3KSeV5/l2rJ+5G63GtWSeS/r+lFO+2z/wDPFfzoo9vAORlZzi0iVBztO7jkYJ/xqrJGtuhIXKllIUdenI9qjZpUI8xiwIGD7dqv2yh7e8ZnCt5R+Unr6AfjWUJKTt1PQS5VcrQqBEzLktvXbkZA69T61ZQl5EE/zoCeV4B7nFJb4GjTBky/njnOMZXv+XH406zcO0YfcSmchR1AH+NX2NdxJIXW1R1jCK5xg/ecYznHYDgZqWJo5dNCOP30f3W7FPQj1z3oUuypIXPlTJ5XynnA/h9v8Kqq8oWRl4LAow7Aen0obs7jim9zSmJe1guUG9kfaiuflzgknHfGPwxVFHxdMnzSBlVkAPyhzgMTj2qZITO9pEH2wbziVxwB3P6VXuHT+0LbyTti2vHGO7dxn3J/pVxd9R2saohWAshZXUEsrn/loVHQD6nip1lURSqy7VfmTAySOyfngmoLiSDy438iQRhdo+bJLA8nPbp+lPldhCAhIYupAUc4z39OuRWjXYpK+pPaGVdolx8jAYJwTzkjHoKZAQsitESGAJ3Y68+ntzUtyqwiC1jaOQEhvMBOSzH7rH27mo54hBcNHL8yopBVG/iHQH155os0UiG+IXCfMBIeWY5INSSTwI0whiZbc4RCepHbP05qOdC8IeUEtgM3HK4PB/GlkeJ0lRlVpWlVEO7ay7s84/ixjr9KEab7DorkI8aeYEiL/O6jnAbINOkuVSQRp0kIfd6AknGPXHJFUbmFZLR5UB45QDggg4IP4c1LKtv9mjnDYZ0J5P3jnGMe39aauOyNCw1c2gkify9j5y2Mlhjj6Gs11SQh9uCRuIzgCnRabcO6tzFNksqkc+ox+dO+wSrF++5dugBzge9O03o9iWop3KwA3iRlO0cgH17Vf0+1ka1iaePIcmVhnG7H8zR5D201vLhW2uTxyMD61L9vfyIHgkRgD8qqOUGc7T/OrilHcmTvsUHSSb7SgdmRf3zsp42j1PU/hUNrY/ZZWdgGjcKWZwRsJ6NitOWdDE0zQrHlCmCxy25snHuBjjp1ou7+P7A0W1pnBEfmFeCq9s+h/OhRXUh36GXqEsisUUvtmkMqlWG1/Qkdsdvao4lV5WLPmRVOduSp9h7d6nmjsltcPIVuAdyocDcM/KM9aknGLgB7d0cEYwfbGD64Hep5bsd7KwanamztbK9iOUmj3uQfusOm4djj+VVFu/MmDSsQxPzuf0pb6aaKwaLcghMpdVxuOemM+mKzLX55wHHyKctjuKGveLhqrs6w2sD2rXO49wJAMru67G9MjP6VFotyIYZrmdTLBAAlwinlR/BMB6r0zVa5ie1tvtFq7PZzMQAW+9jjcR/eH8qXw1ey22uC3iMey8Ty5FYAo3opz6/pmtZOzVxJ3iyTW1u7DUHhlCF0O9ZU/iB5yD34IqD7eiQh45gkxXynjQk8ZzvDdOT27VsZgeza2cOJLYMYkfIZ0xnIPPIGRj2rnp/n8ySIqYQQBGRuGPb/ABrnnByd0VG0ty/Y3kasGljeVHcAjeA0gJ3H8D610rXAubCOS4lUyq8e8IvEUXzc7epZRgCuJ05C16scLfOuSm3v3IB/X8K7KTZbWsT+esTXEeJnlXdvRvuuR/dDcEjkAjNaUdjKrT1My18yz1i4sJ8s7A3FuM8Tp1BBHqvOPb1FT3toPKvljjExAS6t5tuPMGcMgX+6en1qzPHa6jp5McQtriBCylWOVZT8yt6KOuR1BrG0C+mk1CNI5GEtkh8sswBCZyRj+IYJ4+lWmotRexjytq5kXl0trqKtPcpEFwYp2wFIx8uS3pnac+lakrIbaVbWQPBPas8IU5wDjcue4yMj2rHvFt5zN9piimClgqugkDMSSpYHgHn8K1Y7hrb+z422iOJDGTgELGxI2sO2O1YK2opJ3MbSJ5oL17W4gkiGN8M4PyvzyPYjnI78Yro7iB9KvLNrtVkD/vE2tknBwQf0P0qpewLJEXRPlikIVzkbs/xYPQZH/j1WtSw9lD5iFpIQHDc/xAfP7nOD+lZSjKN7FJXsR6ynnzzyK6up+ZzERhSeVA+nPFTSl7S2tbreUlZo5VZDweMZx2wcfhmprCa1mee0lKiLdiJSe+c7ie/Jz/SsmSWVBbW8Y3Ou6FyBw24njn2NRKX2hPsXdUWZdZ1JofK8oSAnymzFkjIx6j7x9qqR28l9YSBVCmJZWTA+Zyfm3H3GOlLA5habeC6I3lMynno2QPYcc+lT2RSCKeESM7hwIkxjcuBn8/StqbTldmNRWVjCt7oahbQXSnypgWjdy20hlyM/T3qeEtDLHGpY7k2zRtxg5wQfSqPzm5DrEcSOWCdM89AB71aihYzGT59pOAc8E1FSetxctlYXxlcfbcC0jKSRoRCufm45C8etUNOuBeaXa3EPmLHOgmAYfdyPun3HIzW3eQeXcxSKwEhXAUtuxxjk/jUE9sII0VCCsMSg46ZJOQParlK9zFRS2KtnpyJqs2ob9rLamEqp4LbtwY+uBkY96kuy95ERO5OY+CeTWj9nKxsWCpld23kZGP5VhWFzIt/eWT/62NVkG4dVOcY9s01ojJ2uXtOM8FpA2or+8aExnHQgdD9emabZkhpQ564ANGq3CqlrbwKS0joqu5GS2MMfoe1LbofMaGIHAwWPv6+1TUTjYmDvck8uP0T8zRUXmt/zxT9f8aKjkXYu4W0XnXDRtl8IdiEZ3elSXE22YKufL8sxDdznjBz/AJ4pk1zC17cNAiwo0RChMnYeoAP6VVfb+7KN97nnkjnv9ah2SsjsSZatQTbyFgPLQgEZxknoT/Km4KxI5TMZOJSDjgevtSygEYAKqDkgc1ZV2ayjfEaMibQOgcZ/VqpdjVaD1KyQBGUKkO7bgcDJz0/IY61EkYWDO/cZAGODyGPQH6daZdko8ioW8uT5lb8Of14p9nCEQPIcJzkH1HP51bd3axpHRDpJGTTBb7yTLKZCfTjFZ5hxLHvOyVZABxnAIOT7Vo4MscEZGRDIeR1OeSPf+lVdQffPbTYB4Z3Uc8443D2/rTUUX0si7MS6P5g2OxChT6cc4HtVyyt3lVy7eXJ8zbmzkYGAc/marzyDdCUQs8hYAsvzHH8Xpycgj2pwuZWna3tRg3DKzleSAOijPbPNaq3UpK6G3UvmAIhJx0bOCT/SrL7RFFgK0rYzk8CqmoeXayL84kC7OQ2c+uD9c1DEZJwGkGWLBV3dCMdvpUtalKN9S6+QR5iGTMPHPI4/yaq2sZFrdEF0kiK5buijnj0qWKVRIkkkjFmBO3HVcf54qESGSR0G/ZJ8pCnk4HANUUn0Fik3WZDED5iTxz0z/P8AnTYpDvt45I9oX5+vqOcfUgGmwyDaoOMMfmfPRtpXp9cUzTDFHFEjB5J1cL83JIHJx6UkP4TfjufNV7ti7eVAHdlP8XIC89vUVXuL/FokaIrXc2C7E84/ug/3azNRvFSMJE7Yf95MvQFu2P5VmLIWbzS3Pp6fQ1fN0J5E1dl5nllDSeYEIPTOMH1p6AxOVDA9AFU45PXNUbW7RA0c2TGeWxyT9PTmpIrtg2GdQp5ViM8/7XrQrbiaHtvgmPmN8u7B3j8vrS/aYIgmx3ZX4kUH88etR3wN43mx4QAqoH8/wqta2wu5WTD5ztyOg9M0Ws9CJSS1Zp29p/aDlbUqRGuVAGc/h71aS8BLCaJorlcKqpwFxxg03w2Xs7gSJIIpLeQ5VurAfXtVLULs77h1AEjMWB7gZ6CrSS97qYylrYjmnUu6vuKgncR93nsBVW1QQ3SskuASUz6A8HNOsiSHWRCXlXaOO/pViCFmVUSMBw21lbAOR6Ukm9SvaJbHROkMWn267WIaMpcKTgMwBwy/59a5K5kMcqPC7ApgBl4I98+tehXulG98MwXke4IkSSrH975G4znt7/SuFubGZITvYM6uyNt6EdQa0qwuiaNRO9y7b+I7pLJbVMYV/wC6CNp5C49iTz74ra8OSRtZTQ3COZLtzDGiKDjI7c8Nn9K5S1jxbOXjYsh5XHIXPJrR0+4FvcR+V8hK7wx5VTnA/HnFZQunqbNq1kRzkW8shjkJkgYhSgx0PX/61dGdQhvPC9rDbwuL21clWYrtUnqpGMsrDgg1ka0Xm8iGYMn3mQIuAwLckfQ8VVjf7LaSRq3mBjgkfxAc9eoOe/1FRGLjNroW2pxRt+G57e41i3mvoy8TEBgOArjhcnvxxj2FP8YWf9neJEviVMdw3zRwtgxjoFB9e9YOk6gbKedAqG2uYSmWGdv+0PVgeKveItRlvkUTW6IwREY4HDY9Rxz149aFOKi4sylF8/kYN5IIDKmFwJSDxgsCfT+fpWlY3BeFmcfKgAZSPkI7Ejue/wCFY15G1zIYFOGl4PY7sYBz2/8ArVDompLc6Rvl3Lf2kjW11Gw4Vh0PtxyPXNYXabJno0jq5fLi0R0STzLmV/3vXAC9P84plvIZNPbc25VAZh0I6AD+XHtVHT0a5VTIwhgYE+cUJ6DsBzV28mKWiwxRt5EgEgZwMg9GxjoCaOa/vCS6IWxZPMZ5ju25dI+gc+hPapNbiMaQzKmySWCN0K54k5JyD0P+FRac6tE+HVZkwVPRjzk4P+Par17OskttGqqkbo0ZZtxw55BI7nPQe9ZwpqcW2TN6lWERXEMksMaR+fI7EM2TEAAMH2Lcio5Fia9CKXAaPkt1ORnkjqeT+VY63Sw3C+cWWN2xJgZxj1rX1RUiQSIQXcB14wQvQcemB096Slp6Gc072MrW5FgkW5YOqbgVPoAcZx26Zqx9rQvckZAkORj+IH+neqWolrh3+04YuTvXHHNOlijtdHhT95I8aHbg7y3oCfYZz6cCqS527GUk4rU0owVjXe+11+6x6EHtVjhbkiRwN8xTZ1PTgg9PYU3Ub+C90y1axWM20ahd6fe3Hkn39PbpUYHnPIZEJfyyM9QGOAprRx5fdI3VyxPKDCkIVw0TGMgtnbznFZD20X9ofanBW4UNECP4lPUH1/pV2KUxmSPG5g2RkdSOMZ7Cq2ulbK6ZVYSxqwTf0ByOSD9aFrqYzVit4h0641PToYrV1hkhnjuEkfJC7GGQe/I4xV1jMJZGjbaz4U/TsKeBLJbDeAC3tw2Kns0ZZ1O4DAOWPbjFJ8zkkJWSuZ32aT/n4X86Kk+zr6UU+WX9MdyKe2ktZrcSIUW4VWXcOQpPaopIDHLJDjLqxAA65qa6Lz+U0zbpCgAYDHA4H4VIFSO7wTjDfOy84OBkAis2k3Y7ldCvvFvZsFCOAYnYcbweQT+v5VeurZ7V7e2Dgyhg6vjIAxwPwqjvDQM7li3BHp9fypDO6XZt/JcBYvMFwXyuT1A/2ulVomUh9yVkmXbxG5yAO2OMn3PWp7eYrZSWzBP3jKQT2APWogm2MyAklmyo7dev4HNKFUllUBsHJIOQciri7amy1RK5xtQ5UE4O0cjJxge+Kp3zZvpGJLAxKuAfvDPf8MVel2rGpZQMBWZgcgHHXP6mqoJltRJtLMp3qzDGFPAGPoByfWiRUdWieOUzva207M7pvw+7gIVyAB/ePGT7URTyW8iiBAk0tuAGPZsZY+xxxiqVmrC7RnbGxweWxn6VKJpftE155jNO+5pM/wAQOMfy/SrT0ua8ttCbWUCw28aocJyrk5POOPpj+dW7BvtNu6SMvlxB9gxyTgfj+FQXa77B5A5aJZlG3oVBXKn8ai0y5MV1byZXerhdp/jB/wA4zTi0pBb3S1qEcMV95cQISMBc57k9qjithFLGNwfAZ5PYI3P6VDdlnigxtEzSvGFDZwB6/jSCfEUbHhwGDHPYgg1VwtoMkYvLfj5Avmbx6DntVeaRRcl1K8fNkdD71HCzMx2sdxwCxHTAouGXDLGB0weODUXKbs7BMFmkkbPLcqnf8KpowOc7lyT3qS3DTArycn7mOSf8KiEJa98veAmODT8yXNbF2C0Uxb3BJHIx938f/rU+S2ACu6l1bIx3+v510GjwwWFlM+olNrAFcgEkE4wBUfiR7aWbTm06Nlt5P3SFhtL7SByOx56VuoK1zkda7OfsjNCm8ZK8gD1rV0Uvd6vBE6qiy+vRT61qXWi+WnmB/IfeVbzE2gr6+xHcVraV4bhW+ea9VzaQALlBkbzjvVwotWRhOsmjktVtzZ3MyLIJC7cEc5FYeoSZKHJ3fcx6e1dfr8GNWleGJ40lG6JHGGKZwCP881m/8IxfX5uljgY3FtGJGj6HBPp3ODmidN3shRqpK7Mq5mtYo9Ptx5kV5N/qnx8jkc7Sezccetbeml5tZtJUZFaYg5k4wyjnJ9/WruqW1vceFJdK1FIbCZLlFjuWjCSKcgq+T0IPP4VoeKdCt7W1tZbecxxiYJcyEABSy4yvsTzj3rVU7amHtOhJBqxa01DTwRFa3LF4IyPlilVgZIuOMEHcCOMUr2sNnaLNdwwzQyu9qkMZBZH25VvoSMc9sGuC1jUr7w7faU07rCFmEAeSPcv3SFyp68Ej8q0LjW76K1nkE9rFDBMGjkjj3eZLjhdvYEdM0nUSun0HBPoLqVjcRqZ0BZEYQyOEOCwXpjqR1GehqrPKd0fyAQyYUKp7dcr7V0X9rCfQTeTQy2jYAEySFtqY249QD2A7k1zD3Qna4sr2Ix3sTpNGNvSPGSMD0GM+vWspRi/mdEKjej6GtqVxLIbaXylUI23Gc84+b/H61m3hQzRog2rLhx32nvx/Stu4tkuNPEw2eW7L5A4yAcKT7gtXP6oCjwCRguVCLzxuXgjPbnvRUhZXKpVTQ+xOtu7MgEiHzkCnIcDIYL+WQPr6VDclfIWAAls+ZGehZTyVJ/VT9RWlZymexfyfl8vieQdMfwkH6/rn1rnLi5Y28kOcrHwufTOQR9DWU4pLQunVcnqDSL9oMwBeJW3Env35+orN1x47PWZNWgVvIvwYrwZyBzmOT6qcg/WrtzG0LxyggNIu/CHOAcc/jmpLUW1wJ7e8jUxvExCn5QWH8JPbIzz2rlW9mb1I80boTwrqNuNRm0rVmYRkCezVCR9qTP7yIEfxDqM9a39SkkXUJEugY3UZKNzg4BHTjkYNcFPZzYfTrxpLa7tGDwyY+ZO6OvqMY57g109tqFxdMr3oA1FSizhT8rccMvqCOh/DtStZWMIvW66/1YvWrmCNpFwZGY478dx9D0qW4uxJJ+83uSwcs3dhzyPXt9KrzSFEliU4yVyduN46/wA6mkEaqPNBLnBAH3SCOo9v8KxUpQduhpa+pmXYV5GYpiN23YPT6U55Sf3hySQBnPXHStCK3W4kgiD/AC8hmJ6DqOOg9KphUG3H3GLADqVP+1U8jUnJPRik9LFeItJPvlZs8nA6n2q0VZ1TZng7QB/Dk1Umsp7NvnMoilG5FYccHGQe/pTIpZeHVvkBVSvfJ6H3p86hozneuqNmPSbKwe5isp3KyMJJIiPkibaNxUjsTk4/KltNobfK5MaksxXrx904/XFTwA3Nmz7CzRDkBuo7ceuaazNbIsflhDIvzZGQ2Tx+VbufNaRkkkrFYMwvPmHlnqARjB6jiq+sW5vrK8gxsd4yitjkOehPvmpr3aAY05cAMzEeg5/Cm20sn2guCdrbZDuOe/B98HnFUr3M5WZaaSRbe2W42rI6KWdR0IGG2598nHvToDLHaiZ1LQFjGr+46g+/eofMMrSCVnkVciPjHVuTj9avWLpbyqjlvslxg/MAORnDc1Dbve+hDVkQ71/uf+OUVP5tv6f+PmiunlZBhWO8jzWQsF3BTuwE4ycUlsVjYu7leCFPfdjipkmMHn2zJzKm0q2MKcghge3FRr89m8K8kOJVwvI7EZ+lcytfQ9Nd2XICkbKXXeAnQ8fNjj8KkmUSWsQjXLEAMO+c8fnUOnsskriXKxB8MWG44YHjHfkCnRqfm3YJHzbieijr9e1W3dDS1HKxMcqQlfMOF49PT9KbMFO/bu3FNwHGOvA/nUUF01vNHJGTkAgsONhIxS3BigYSyK2wBVAH3nyOMe5pL3jRNobJIhlaEAvFKoLbSRhf4gPrwKnnYxW7pJlDxuUDjPX+oqEQJFKRI0qvIFMgK52vjoo9AMc98k0+7fyxtljbLJjLE8jPT8/Sql7u5pC7dxsyDOcnLRAqB6+v0qIFlSOVQSJUYDjp2/yanuBMIEmYKpYsqEADPHIx2oaXc4dTiNo87RgDd3x6A4FVZmyehOQsVu0C7nUgFpcnO49M9jzxVAjypojJkKRub2PNWbqQW/7olgckgf3gSMcf56U248u3+0QyNumjdcOvP+ev6U7CWisRoGeJ9/ymJfN56tngYqm8vnSAMxAYk56mnSB9xD8nGFPsDUGPm3E5AIzjgn6Un2HsW1VvKbaPnHBI7g1WunAZcdO3ua0IbufyWktsZiUs+QDlc4yfXGaxJrk7xGp7HDNzxVNWWhhzNvU1NFlWWcKzCMj7jbclqu69pV3aSxzTYYYzuQcEVzryPYXFsssTweY5bMg2ZX0+vQ88V08XiKC6t7aK4mZRDJlQV5Ibluf7oxnGO9bwScbSOapJp3WxRW/to7q2a6CNGq5USMSo9R9e1PTVbe71BmhEaL9pFxFFg5Qjn8j3Htmue1K3e7nl+zt5ttAAQWXbuBJG4H8jUMeuSwxabb3v2eVdLl32527WZd27YzDqufx5NK7i9ES0nG6Z6Ta61cvBfm9QXgmJmcSOP3RJPC4/hIOOe4FK/imzsxdR25kW3naEsGJwoByRj6d/auCk1s3FzL5ucSu0mY145OSMemegrJvphC8lws8jbwVRHwOTwcn0xW3tGloc/Im9Tu/FWox3GsIbm+8+OWAGKRfl2sD8o/lWq3jC20aNJJLgs99Evmyp87HbwvHGO4PrXmp1qIaNLbSGzWcJgSuu5gB2B9T6jtiuWNxPdok6xlLVHI89kKKST0x6/wBKJTktYrUIwjLST2PVdQ8Ri9RpRcwiVEdWeSMlZkZcZwehwcdPpWNf6zcT6P8AZLjUg62soW3gYks4xkOewxjufauTsbG8vprib7dbWthaY868nlO0Z/uY5b2xSWcM9pqEk9pqETwqp2XOzzUfg/Kw7Z9DUP2knqhr2cVoza8TSNqXhySF3L3MQFypkO5gVwQPocYosLyDULqzkjh+yW5TzZRF8qYUZHU88jofpWIZEtrlIy6XMcsBmyV2KjEY78cGpLrxVZJY2VjqVuotbdikUUA2vtYAkFuu3OTg+2DSjFyVpaEOfK/d1TOx0hbnVi98s8VvZMC8bvKN7tzgt2B6444ppka28V2t7fTC5SMhJUC+WrQMuAw/2Pr1FcFqd3pcsYXRrma9LZkFuUZREe4PYkDBz70y01i6hs2uLgPINyRmaUtlxg7YwM8r6AccUPTS3zNYpy1T+R6hfamtxq1lqU0CwaetufLjHyfaMfdGOwyBis7Wpn02K2imbbepEoVQM/M/zPuz04I4965yyVtWjt7WWG6lggjFzvifLYzj5gc7cHjPpjjmqF5dambzU1vZlFyAZ3eRwrImeWkBBwfyrVJuN7XuQpxi7N7HXaNq0X9kNbKPOZdyzhW5ZSe30IBzVOwU3Fy6O7FY/vvjG0E4BNcLBLMro988kE29GRXQxvNC3SRD3HHB7da9A8H3kF5MDMpzJbypIwGScAlCcdW4Gcd6wlFyajI3TUU5RdzVvyo3RRKsbpGG3nkuSO/YYHpWUU/eKqbmfICjqSatQTLcKhZizSQ/Ox/vZGD/ACqbylFujcK6xyAHHVkb9TzWFSnzam9Op0M/UGER89iDgYlwM7VHp3O3n68+1XrRYJLFsuBNEcNKDnfG/wB0Y9MgHPvUaxGWRUTcUKnB7Ecc/wA6q2wOlzopI+yzu1vE2P8AVuPm2fQjJHsSO1TTvJWZU4qLv0f5/wBafcaz3r3CjcD+4HCHn/ez60W8okKBTukyMAHJVf7v1qq0n2C+nMaAqQ0S7uAARx+OCKi0aUxanbNkqrsFPswB2k/yrCcbysynoro13eRJNmzasbZKgZIz6mluo4VtbV4s+ZIXaTJyM5+UAew4rUuY7eO5KXkxUMNrSQrllfrkj+Ic8kHpWRgBAULbscBlKjOeoPvinblvBmTbepfuP9M09GdxI1vCqKWOAoOTgD+9nv3rm7wvBO0oXcUXIAPUitgySnT5kCExsyhiQM+qgH2NM/s4GURtJtlbBQ4OW4zwPYjGfesqkOdKxnaxp6fNHfwma0YbvK81dhAycAkADrnmo7u8N7el5/ny43FR6DsPwrG8EWs+nTaoltOTYYaa3RVG6HeMumD1G7p354qYtsnUtnK4JHQ+9aOa5V5nOo66jriNyX2upDEDcD6jIBqj4ZlM+mJM5/ebpIpFYYKsrkEVcldoppAW27854/HH8qj02x/s+x2wTtJFPcS3TBgB5W89B68/zreCtcye5P0lUg7ccZHb0p0kjzrGiZYRKVBPAJzmopAVxt9dw9se1OLhoUDDAHOQOSalK7ZT0IfOb0/SioPm9RRRygWrsSMY7ry9m1E3Nn7x5GQPrxjtU0cnlFgki/vPvAdj1xVSxuI3F3HNcoo243b1wGPYgnocdaVrmERKPPiDocBQwzWKdtTsXY0MMgMfTzNpJH8QzkVJbNuleOQqoMbLuI4z2+lM3wSwbUlneQNlVijLfOcdTwAOveq8bXDz72K243ckgO35dB+taapjWq0IH222DNuJlYhI4+XkHsPb3qaK2l86OW9ZMquxArZWIegPcn1/KpEtwyqsUYDKCDIeWk74Ld+KliiMkAGAWzge2ecUo2T901W12W5AGbPBV8Kx9wP0qtdH7R5e7IK4XLHPbg/jWlIBIYNsWJG5K+uBj+fOay7tR9likAAyT/h/Ot5amkGOVZtn2V1w2zzlyfvrtzkH3qnFvSBJVUMmdw46Y68fWr6lo7WKWIL58SszMef3eMZA9utQ2ReDypI13IZNjKeQu4YHPuKrqaXSRZ1ONbhYpyw8thvjYdFB6jHU4IOfrWS/GoGC4wmxtuew561du4zFEY0yyxMfLUnoh/8Ar5BqK5RSlvO/DNEI5gTgN1AP6c0pbjVrWIXjaVHi2jfE7YyeoPb8P61SYlRgjr69qlRvKZopFYMpOSRz+NWdQjjmtRNAF+VAsgB5PPDY/n+dK19TOUmnZmXFNN5yJbOBLLlFDEBcnjBqC2WazJvA0QurSYHys9R0wOx5zg1Dc7VZcKWwcginahayai6y2hl3iIqqqOm0fN060qd2zObsbOq+IBqkO27VZlI5OzDJg8Z9eD1zXLal9oOZreB8r8pOOMdu/esd55YpXQzBj9wI4wox64/LFPeR4wzM+xiocRjO4L35Pr6da6ruW5zStDYZF9vmSScrO0acMApOPw7VRu9RhzFDJMfLON6x/fH0B4zWvEtxdyxTRsYYSCyb5cEY4J46/jU+rWkQMEK35ZXRpnDIGVXH90nq2e1aKn2OadVrQwheyQ5NuzyJyMqMke/19aqald3EcbRX00UMLryZMnP0Uc5q5qcDyT273V9e/Z3XEJkiaJWwPmO4A7gPzrAfS72/vYhpQ+1neEEk7AKT3Bye2e9Hs7kqslq2WNPtJLiJ5LSOS6dcgO6ERrgjBIPy8+laWqX2sMbRLgSmKxLeXHKUZQeCRtTggE5DH1xWXeSTaTKbK1knlQyfLEsg8xHX73KZGODj2rntT1m+uFa3eVIup2IvzsSeQ56ZFWoJLUlzlJ3jZo6zVfFnnTwO7Jc3GD5ikDyWzwDtHQgdjVW21uNLoFra23LIJ1t1BETAdAUB6Z5+o9K4ex822mRVlizI2HWTIwcdWyMY9xWnJI+5isaSFcAyW+dgPoTUSUlsbQVO1md9qHimHxBcy/bo8SB9yBlVGZiuDygAA4Hy4xWNdSWzxuLiaRZoYxs2sNgfORn2/Ouejiea1klkmjRxJt2k4HTP3umfbrVmGGIW8Ur3aTQKrfJtDbR1yR1z/hRzN6yE4wjpHY0Ir+G3tXMs8bSq4aLCYy4/vEHhSD7/AM6hti99febYEJsYbbVvmG/PzA+3pj34qK3YCUT4HlRbRm4QAjrjIHcnP8q6HQSU1eO7YXMVwN7C7hZIcMAMIjDjJQnA4yc8mtIxUrXMKtRwbsV7QeIdCvv3KzBZRuWGWMosinPALYx0JH0pLW8gvtTWbUYbiW4llLFR83mMB1bPJ246Hj61vXTQRJcwJcz3d2zrLNFc5mUQ9FSRgOvK4CjqT70s0OiXAdbe0ey1JSreX5YaNM/dSQ9CreoPHetVG2i2OedRSu2tX1RyZvX1TX/tCyC1t7VkjiaWQmRAATwDnr37DpXd+BJ2bWJbkPHbaVHMZIwylCny7jjPY4IA561w0d1b6Xr0F3qT+aRG8wiVQVcEkFd3rwOeldwfENpfaJbzXcjyam0zzmSaMmKeNk2hQRjZt7cHJArnqNOWp1UfdpqKVzXtLkNGflxv5POOvat26ZJNIiZJsMHLmPup6Hn1wa4zSNfjureLS9QQw/ZpmZiYwtw+TwH/AA4AFdPYXUT6c8RgZi8z4jL4KKRjBPfpnFYb6HVrEWGPFsUjlILZKnvuz29Mjg1FPHDeWrWs29UlQt8pKlZB91gT0x+uakaMusH7xWlWMcDgAAZzkdDVWWYtdIkGAyjORySTyefWudv2bsjrhLnVmQW73LRJ9tMbSmLbIUJCkgYzg9D0zWhZS/ulaXBjizGwI48tjkg+ozUd2qIxljyI5AQO2B3oi2loTjYsqEdcZ6/1FZyfvG0bNWNu8klgURzk/aYf3eEUEBe2fXj8xio42EkSH5mJG5iTnI9PaqEN44UKMphQHIPUjv8ArVyEbY2w4G1ipOev4enasPtaGclZFox77GQZjJz5u4tyO23HrzRbXEbSQMzJ5cm1WYclSueR6ZPaoYWdorhVJII2kIf6+lNj2xSmby4guSNoX5d+3pj+vrVPS0jnaL9qyRaYrKpjukm+Vh0dCOQfcEZ+hqqwzIsztmHfsLH1Iz26mqbtLCjSM7vvbcGPPQdKliXZcxWsjhDt3sSeAxGefpUtqTSRE421KmtO4t3Zgw2lnUHrz0P6VaWN2s7ZlPzu4GPQkdfpVe+YTRFJAXzncSeoIxUHhq4kufD1lMzMZo1aGQ9QGUlf5CulSTRzWtI1J2RnfYSVCAFvU+n50jSJsYqNgBIUZ/Ede1KIh9ml2sr4dUyO+fT1qncEp5Ltk70646YOOPyp30uVy8xY8mX+435UVH/aR9W/76NFVaPcjkZXjYXbsVtwH6Esobj61bRdrZdIxvPzBVA5HSpIbRRDIy7hLuxhT1Bqe6824DSOQZ8YY4+924HqK8ym5RT5j0tGO0+fc0gbGQhICjqw5FTSRkRR3OB+9BbAHG3pnP14NVLeGWBzLKFRw+CqD5l9QV7etXYA7QxzbDJCjbSmfvKeo/LBrohUukibWYyIF4tmSAFIyDxu9cfSp7EQtalWHzkjr2yeaitIyG+ykhVDs8ZJHccZP6VHCxikG4A+W2euf8itYvqXvsXWkdoVJjkW4jyhyQSwPIx6cCqpAMTSqodHTa6norZzn6E8fWnTytJJ+5Ub0kJUjptOSFx6elSabLA08sF0THbzLs3DgxEkn+ZFbJ8zsaR0RWjDRqked0sWDH/dweqsPf8AQ0jxFbSKRXyhkDlCe+0dfY8ikgDRXUizrkhtjNjkZ4B/rU0rtGiBo9o2FCOxIOT+H9KaWly2Pvw9wzXFio2NGZwgTIjHfj06g/Sqt3aRnbOnmSxBAXDHdxjk/n29BmrunSi2jjy4CEldw+XAb7ykeh5FXtdtVt5GlsomTbFmZCfvRnHb1XjnvmiUbq5ClZ2OUSFppGG5jGQCGzk46DP44zUUryQOVOQc4Ydc+o+hrWgtvs/2e4mKNaSbSwC7iitn5sZ7c8daqa2hN+WxHJG6/LLEMLJjjIHY+1THRalN8zsY94FCSeQH2HnA5Mf1PtWNPPcMbiSXylQRBS5XAPYYx0c56+1bjP8AZJAzByHHOD1HpTRpyX4P2fb5THZICcKR6H0+tUlzbES93dGE8D3WmG82oXhRWdWI6Ho49z/Ws6yitpo7gXUaKJFJ3Eksr9iTW+LaFEmtvtSWrxrvCSKxMyd9uB2757VRbT7qxvYo9gDylWIBDBkI46eo5rohK1jhqq6fQq2c6RRSeYEN0Now3yZbpgdj25rM8VvaRaIsktxIb1ldAF4jZgR9zn5Rj73161o38FsIXZ2VUjHztKOdynI2+mRwfXpWLdG2uJ5rwQQDcpihUnCIcZLfN+BHqeK3ucj30Mae4u7zabXUmMe3y4oVDqUyACUJzyecj8R1rRtbeOCxWBUN/J55iS0iGw52cuSPTg4PvVJp5baNJNOgKwW0Kz3Ch1XKhsOwz9Rt7896t6fYG+uDLP5cFzNOWjMkhSQnGQWHZGyNoPeuiFmcFa8fQehBLRahcCzk2mOCKONf9ZtxvYDnGABnrk8d6vpp+i2FrdS/bIXvhHGslvJES0bfe+4P4j36jmlj03UbaBBd3AtLRVZzHIFkwrHGwjk5Y98/nWXpc1x5epxeWbO4GN08hJbaTyCo5Y88HrnvxitbWdmjm5rptMoJaW9xqemXlxbi2s7i6e3uYZSqqmDuYJ34Xv2JwKq64kQ1C0g0q1ktvNV2RGlBV9rMM/UqOp9OKWJVk1JHvprlrhZXgYxDeGGB83Pc8cD0rPtrJJ4E1K8uJm+x3IhmU/KUyflVOck98AcYNZTimjqpTad77FaIRNGNwL5OFDZG38PWr8qxWsUTeRAJgMEbSzN6E9hx0xXRaTp9jLp9xIdl1HA/kNKZdpiCgcIDweo9+p9aW10jTNssst7vjbO1HTnzMcbgPfv0rl5Wnodv1iLRh3v7wvOGWNJkQtGHB2g8bxjIznseR161s3rIIooZnEMlsWaJEkUptjIIOOVYElsHnqc1g2bIdVkyPtSOSJYtuA5xw4/vEH9RV77H9s0y0852mEcXk7pAAtu2flQY55zkt7VpFmFTW12dRPDPLJDP/aHk3sRaRbwShjuPKxNEOMd93I4zxWTBNFfRyeTYRx3MO/7VDO4VF6Kdo6ls9D1PpSafZajp0yafp2oafEVJkzKoWVsjk7jyFx06fgaqeILm6tvEha6lgW9vAokls5FkWVgCEkUjPJ6FR1zXQu7OZq/upkGro4vN08g1CW4ChrmY4AjUA8Afd4G3OB696Wz1m88QTW9jC0Men2kWERvlEKDJ+9269e9Tahtht7iOdUtZGQvIsrByH28DIPAAPp1rF8PCz0y0EuqWIuFMmZVZnHyAEKSo7B++RnNZVYpnVh5NLa7R13hy4a38Qi+hFvcy+S0U0t6PPVvV0B5zjAFdfYtK0kMJX9+RkNvy3P8AF7cda5fRtGvbfwdb6xLpd+tvLKC8+F8h48n5APvMenJwOOatT3Nxcwrf2ZvAy5g2qAqop5K8ckkc/wBa45RcV7x6MZqb09DsoJA1jO5aNGguUVWTq4Knp6jI5pLRkWa8uI1/dR7cAjactwcHt34rM0SZZ9sMcZzJtB53bGAxuBPrWhuEcbWQJMhkd3JP3iBtA/nWekveNovldiG5uWuWYRqQhOdvQZI5x6Vr3F1HN4fs2WBFnhnZjKDgg8fIF6YOAfY59awzIFMXllcKMcd8Hv6mrsl3/wASya2CqVDCRWPBx0I+nf61i9G79TovtYTz/tFw5VP9Yxk9W+lTQXLIm0n5TzxWVazlomkDYkD4GBzgg9KuCUeXGAeUO3j0rmmk35m26N+zkHkB8MqvnkHr9R2pTBvnRMEqdpyPTGP61V02dREF2k7WADDgkdaElleSXy2KhvmGOM4OQAe3/wBaqaXLY45p3LV3IzSOkrgNGNu2TrxxiqT3McWpWD3MRkEzupXp0HB9xUk7EDMZcs5zlhywqpPCGngm3BtqPgejEgdO3H86xhHqjGRbk2u1x5WQF5jBwcc9KTTbeCztFgso/JjXLMBzuYnLP+JNFq+2KXOOoBPpVosImKkg7UAA9e5FXF9SWhpn+zzNGDhsYLEdG7kDsaz7nzHTYSNm7cB74qVEV50VmKqTglRyailkP2iRRh+CuTWildWBq2xUyfb86Kdtb0f9KKLiujpplJZnjATI5VeARSIxW3Lop3od3px0q1alZ1bkFQBhRyT2J9uxqS4RfspmYAq52Agcrgc/WsHFS96LOmMujKrRG3KSxPGzNGruFOcHPQ/lzUkco/0hwv31Z02cbCfQU23MkTxkDncDk8blPfNXbiEW2oFHjwRuSVFbBB/vDPr1q4qyK8ioEDyw4ZSxxjdwvrzU/lxzrKwUxThi6AjAdSeV+oqCAiaDYW+dj949B6VZId99vIrfaFYqwJ5wMcfXHSqg7IopNI2BwgZioWX7oUj1/KmR9Z/ODIyEBkI5IzyB7jrU93CHeQqpCrwwPcdM49R3pspbzFZgWdW57gqBjP4d60jKzuzZEsIW4lQyN5hAKkd3AJ4z64OR9Kgjbzdm5sgtscg87sHB/HH51GNwfdGG+9uUD+X4GpZ50kvnukTarYeRU6K3fj61upXGyPTpWtbu2kuE8yFSJghHDj1+ldL4hkSVobuzikfytrYIzlMZG7t69K511RIEI+cA/KCevPI9jU8FwBbphnJi5RWPByeVb2PYjoa1jorGUo3fMWblYY4EYRxfYbsbyyDLwkclB9T0NU9Z02exhy0Zlt2RZw47ZGN3tn+dWI7thutk3LC7AqjdRtYkKfQ8kZ+lbPhjVI5Y4o5EUNArxS+dgqYTnAbPYH8aVlJ2Ik5Q1POrhCVYnLDIAB6knv8AWm2gkV5IYyQW4ZQPvVs+IrK2t7hHs3P2eQbxGeTHz6+h7VS0y0kmMkkLZlQEhW71nFWlY0lJOFyvexzi3EoHlmAglgu0rn0bPf0xVdrgyTiK9fzHuFA8zb/q93GMdsYFaNxdlnU3A+cv88p529jx/Ss97YJer58ZaBTyoPatG+qORq61MObS5Xufs5ljwrkM0uAqHsGNZEumC6voxOYvKZtrr90sPTJ428cmu5je3bTrsqjpqIRiCoLCTJwWPpj+oriL92W4tlSCW4LhkeBGwZTzkDjg4Gce1bU5JOxyTUmc14h0qBrl3kX9xvCNJFGGIXHOD/s9vUVXsm060lSG58yS6IEccltKSJcdA+en+6P16VvQwy3OlTpJL9mt3V2zcKcvjjaQOjHHT2rBuLC1mtHvVeedyNjoFAaN1HYjg/zrVSad0ZVIqUbSex1NxeWREumzXT3SzRCVI1XDFh/CrH0x0Poax9X/ALYvLWQoiqo2wL9lGPNYnODnBAA4B781mTGBY7ZbOFppG4zdMEeLkYZf7pPXJzVicwyzTRSxt9odg32gZIfoQxHbn04/lXQqjejPNdLk1Rj3kkolcEbrqJjgQNvToPkCgYG3k59azFma3tIbWIRyyFiwkcdO2wY68nrXRXcYlmltpZSku9ZjDCvyuW4cuw5AxztrLSxjvDcsgLW73HkxhO2cH5fbGB+NTJm1LXc6mwt4o7bbezW+oTyDdItrhckL/f4XeOhTrWfE4l3y+VJGASpbOCM9MKfvDAIFRxXwtrMWSIIz5hMjMQQi4A2n+8cDBqxPdyLD9quEguWDKwWHIKg91UDoMVnKxVNNPUqvb2zNJ5R2b8BEaUmTP94D1HTFSQPHB5d0koDQZ2B5tkqMPugAdT1/E0Rwpc2bTLI7PbKfMIHyh85UeoJ9elZU+1YRcQlHByzr5Z3Fc/3vUHp+lZq6NZR5la5ciEktzHc2tp5ZuTsedpQFOCSRlumR9efrVkQIt28f2jYZW2+WuCCeu3BHJzj5hgGqE960MzGBWeXht8h27xgHBB/E565/CpNJtcPJcm3uJyx3Mk3Kheo5JH689a1T5tjJwsrsralLYw3csNs0kiMFWW3C5Vzj5iuPukH9aVNQns7C7GnoSs7LDOzIXaIfU8+uB9avpHp0t+bmSYsFYwxrsG0djkdAOep/CpLix3WM6xov7txsbAVXUHBDnIIx246g+tBqvdSt+J1Eep6nJ4fs9NsLa5f7KzSBhnaBxiJsHBBAzg8iiLTdXl1B57G3e8WWVlNxbA+Wz5yQT2HpnHFc9ovnNoFlCtviSQyLlCTmEnPnEDklcYHHTNdFo91qMGpGaG7IdDCZHhPlJ5bjClhnAPc8flWdWKcVc3oNxm7WL1mt5pLMZFQGQg+Yr7lx12+575rQjaUf6Wsu4vkpjqMd8VnXEcC6jN9kd5o2LBZJUxk55bA4rR0aNEuGuLmZ5OQiKB8qgc/mcda81txlZHe5O3MOubaa0n+zzBVc4YhTnGR0P50bwGdJSpQKTjH3/YHt9afMTPK0+3DuST689qbDGWnG0cAZbI+6B1pVH1RspXWpFbJ5UKxq2QW8wkDpxgAHr+FThvmLgYAA+g9KAiRX7RTK+9mCQqq53Sk/cb0yM49+KlYJBBdRyxkSu2B6qynp/PPvWPK2rmsKi2LumNiCUgjKMNwxyAeMj+X41ceRAr5TAAwHXsf/AK+aydMjDFw3y7l+Uk4GeuPerrt5jMxIbcAT/hSivcsRUjrce/yqhnV3QoQAHwQfr+OaqWUc0atDISVHzRuTkyL6H/aHT34q8InaFSwYqy5UjH48dqdbBdyoXKndk5HQ/wBalRaSRztK9x9sWixHLuCseAR6ipJH3K+xQMkZGOntmnzJ+6yTgjpnkk+9SwbVgCD5kYh29z6fgKrltoYykRhGXaAOUXnaOQO/86oTFYwyIhGTz61pXLosayMWM7Pz1GUx0zWbt81p5pJPnzwnd8+n0oUbaIzc31IfP/2Ifyopnlt6H8jRRaQuY6Wz2xTAOgbaGfLHGRjkZ/l71biJ2fMhMjAEA9Dn+VUzE0oLAkyK5AGOoq5FK08RRSPNGDn1XHIHvxmlTszsWmw0qhVYmPIOA+eAp6D86kuXeZiLhd0yx7Bk9QPX1yO9SS/6VGWI3OCV3ADlQO49ajh4t/tIyDH8qscHnr0+lF7aM0TQsYeO4RmA3t8jKTkcjG7P0NOMEbb/AJm+0xEKrMcbiDjaR7jv7VYtI1mt5Y7mM+aqBoJCcCMZ/lyeKjuY2jvGtpEKz5KOG559M9+1UVHVlSZykiNs2yIxLA8555/LpSRtIlyBDu2uDtQnG5Seme4PSp5f3loigkXEZIwB98Y9fUDiqqpllBYqo+6390GmpWZqhbgRFxglcAMrjt9R+hrPclZjjrnkZ/GtSdxcW0kFyTDOD5kTqM5foR7KcVWljJeNJPknT5QmOf8AJ6itHJ9DSJCjbpsqVUHBK479v8KmlURrErL+7bKujcMPfJ9Kp7CG3KTgHqas5S4jMbAtKq785wQuepPse/pWsJ6EyAvt+UhRcAh0PQSDGM+5z19KtzxLeKt9aHZcxjEoc4Lvn06A4qpBH9pkjt7h1iJf93JjPlv7+qnjOPXNWPKktWilLlF+5vJzu56fzrTchhNfI2biZfOIIWeKQcgDggHspB49DWTBeHTtVWfTZXQRvvhd+T1yAw/nW6bRVdb2zJ8hTsOCCRnttPYjpmsLVNPNvG9wgXyw4XaDng9DUy5lqTHl2JTdW8k91JeQvcPMhZvn2CN853D1+n+FVtVeCOESwu8lmw3OVTc6/h7fyqICQxgswZSMEjr9akjBlAjZRvIwGPRx2FVGV1YzlBJ3M64eVZWkgcCV49ym1PbH88dR65rmdS0u5EfnwLL50LI2VyMZBO7cf4u1dffRQeaYx5iOuMyKSCAOoHYH61jaqCPMYxO0SR+YioSxX+67dv8A9VJe6zBrsc1IJtgiW4e6tpUEkcqDEqNjkN34PFVtXSDRre3to3jU4LkKxJQgc5HYknBPfp2rR8PG/mie2s4zumkIjJ58sHl5Oe+AKj1W1Sz1ZDdSQP8AZ0jaMxHzQCOQSp+9nPI9a6lrFSRyyilNxkcnMoa5a6kkT7Kr4WZhy4xnG71PbNWIIre4kUQtJJbMcyeTGGeE57AnkY/nXStAV8RLMStpZXqvEy4EiwybMFmA43kHoPu5xWdFodjd6bbWaCSW83nzo0yVjC8sQemSOe/AqotxlZmFSCmk9jCnlufPi3rLZagkke1FI2uc58xT6jrg/wBKivbgRJHaadI6w+c8rchZF9QGHcn6dMV0HiCzvdJtnijuYtQspYRNHcHAkGDjap7dB1HPNTaXp8NzZPqUUEdxa+SiqdvMcucFd3fHP61slfRnNfkV+hzORctNJvhiuFZYgpXbtTBO/uGY8ZNdbZSy2NvHMbZbx5Y0JaSMMWLcFVxyuOefpWH4nszFNJeWYjurSSUJJDGojaAKANhTqBknJHXir139ht5Ing+128MsSllfDZyMEL7eh/Op5bMbkppE17A0F5eXOmzQyabvxAp2mVvQMO4Bzk8+1cwy/ar13lt5FcjdJEWKru5Jx+HOTxXVz6ZFp0aRrdNDPGnzCOPMiPjoTxtyDgYz3rDv0eCxtry5hYLIGQRgksCOQeOQv8uc1LjylQaZm6vaiwtrW70iR7i3kPzbs5jI4KnHQZpk7qsS3MqGSSaQH/VB1fbj74PTnr7Vq6fdvZaiUgllNpLE2Ld1VoVdz92TPJUZJzzyBVOaCYWzGz6DJkjjfDgDI3ZP8OP04rRRM/aWdmR6fc3KFnSeO2ViYyJNpWQ9G+Q989M+lN1AwgSukM2JgcGV+Hb+E/RQCffPpTbDT2e0+0Ppst3Ox2ooBJI65XjHsfUfjUFlJAJJpdSini8iOVvJVCeWGB7jtknp7Ck10Zqp32NzTJtXnsoZES7uUhRY4LiBVTaXXLIWHVdoOATV3RL/AFLWJ7OWCFWNpCQ1x5ChUQD5S5x83GBz+VY8kMtxZWy2mYjJEJNgJBmkwFwcnt6D1zjFafg1tTW2uIbfYfs7eZIA2H3L8oUHt/EePTNY1L3sdtG3K5aXN2K9urzUZpbidA5bOI2woJHO3HArchbbtVGBU9MjGPVqzFW+1DV4X8hhfK5U24QAbFHLlhwT6mruUglJU4cgrtPO0/8A1ueK4ZxSvc61Z7F+M7Z87gDtJJJ6Goix81mXnJzz/P61HaMJJnDMeQdxx7f41HKWjQZB+Y9fasZRuawVmaDR+bPKEjV1VGdcNkfLzuyTnjrVJmYgA9Sc5Pep9Mu1hgviQPOkh8pOM9WGce+BUNuDLdwROActsAJwMH3/AFpuKtoNaPU0IcLEHYbiy+WnzfdOeTjvxx+NTK6gvkDkhQB/Oq/+ruMbh5aHblRknA/WlUjcNxG0EFiDnI74rN9irmysYNu0hLBIxtB7FuDj8qLA7r5A/wAquxOcZIz0NU4bhinl+Y/lsclQfy/Gr1qo/dHdxkZI65/+tWjsYSiT3SAlUAO5R8w6lm74pvmRqFzzGOOOv0oHmA71YhwTyOv1rN1ac2uj3N0+BFCMsfTjgUlq9DmnotSW6klfAOANu8ZPUE1QecJdRxsf9YCFOePXH5VLHHKltC8pDPJGrHac4yOmfaqWoWL3IiEMjRSxSLKsiDldp/ryPxoas9TJq6LPmD2/M0VD50P/ADwP/fVFLmiHIju7aPzRMrECVcjr196jnjOEniQJ6rnuOKbFKpMbOcHruPRvartrk/KMOsnBB4KnqazvzI6U+Uh6OWO7e3zgKON2efwp8UKut0C6rI0ZIXHB5yQD2NPvLY28SOjfu+Sjk4257H0pY4sMqqcIV3oRztbuprKzvZm0WnqNVpo4mTcwBQE8cMh7j+oomtjMFMLqZlXOVJ+bjOMnuMcH3pJZSpWRhh0bbgdhjofzqUoHGYcB4wGZRk7lH8Q+g61qlG1jaJEygqZdgVoyC+T8wPQHB5+o/GnNCsls0m3ZMzjYq9H9ffI61IrCeZX5eVWJc4/1iDpjPOcdfaks7YyTsAVB6oM9ieCDT0uWUpVUxhxgFjhT/dP9R2PpUbILiBoplJKqNknVo/QH2/8ArVoptS7uI8JskU5DcjOOQMevrVCaNoJEO0vFIMq+fvg9vrRGS+RafYo3KPFMyzfeHJbOQf8APrTYtqOAvzKx5z1GP6+lX5pVeBI54i6BRyvUDsQexqi0ZgUqTvRuQw6H0NaqVmUtVqQu/lqiHgCQlZNuCh7EH0rZNxE0EcUyiTztzYz8oc87ifrmsy4VGtxlcODyfQ+lJBdEWstq38ZB346EdOfTGa0VS2hLjfYnlY2E4IzJE4wWz98Z/mKZdSCfe6hQSS2G53f/AFzVgRq9qG3gxOxVk3ZKsBndz2NUHR4F2tkiQ5yehAPUe4qyOW/qZ6v5UhwPkbhQeRj/AD3pkYRBKW3grnIXkk49KlnPlqSMOnVc9B/hUBleERvDtK7skMOD7GsnK24SiOvJftNnE8QUlF+cA/e9cj1z+lULWaAXbQTyG0jKtG8ucZBGQMeoNWJr5JCmIYlkQ53BfToPeqlw5tZILqSNWjJ+bI3Y7g0KezMJw0sc5pkBll2xI0ojn8zEeQWAH3sjp0p90ry6VdeHmsIV1iKQzi9VlUtuG7BbPJI4GOhHSty/vgqvqFoLldTlUC0aNNqwEHKkHvk5B9faotZ0ie9T+1bsRLqDbZTKUMW6ToFYEY3E55X2rtoySjZM5Kqcndr/AIf/ACOS8P6pdsYprmQtDghVRNm3ou7PrkDP511UNrb2elLNcyllkkaSB4n8vKt985POc+vUcVV1vT4r/TZtTiZoovMDXCKxUxz5AZ2GPlPUFh171gXEr2a27ai0F1Z4WATQHG0djgfe46ngmru4u97mTgqmi08itqcsk8rIG/0d0Z0jeP8Ai6lsDuM5GemabqJBljurGL7NuBBihXy4nXaAOD1YNzuPXpW5fBftMkSwieG1MgkaAEmTcAVBP9zpk9c8ViapHdX9pFNcsWimbIkYcxSL0BUc7cggY5yaq7ezM3FWSaLer30jyxXTExvIn31XmZv7wXrk/wAVV7ZbC6i2lZAkjeavlkblJ7r3Xaece5q/ol/Hc2l1GkJhbHlyxNh5I19VGMkDBzn1qhq32sMVMnlRZC28u9E81fcKOtapyaucUocrtsWLoyrp726W5jj+VPt2CrPjkMT2b8ulM1UPc6RbRXhjhfaev93PPfPzdePSrPh8wXN80ICMWKRzLMd5A5J6fwjg5rO8WRw6dqUDSTve2cp3Ws6klVyDnIOc4PYdKhVkp8kiOWTehWmt7n7NFbtE7LATJ9ohcOcFOTn0x2PSs6yl8uYWFxau0BJIITkoVxuHdVOc9+K6PSNKk1eO4nuLlUYSHzZduPMAHDKvQ/N64HtRcaPph8+1e6kshIPMe5ky7DAHpydxPY4oeIXNyx3J9np7xmwXKrcXRt5/sJMuIY7iUqsUPHJOPmJGfepPGmoWz6DY6Z9ogmvbmbe0sXztEp42+oJAUe/fFcz4h0g6fam4EiTgvskbfuGc4wh+nPPrViC3F1rkbzmC1htYlt1ZycO+3OBxyxHH9a2cm00zSnBKSkmaltZGaybzLZZ7eF/3geb50+XIcY5+Xnn8Ki8Li4TZ9jiillgnLGTA/eHGeQT2B4x61Ydb2C22QSKBcNsnjPykqTkBj/CDjqMmpPD8UU2s5IUW6xFdkXCx7jwuepx61yTdkepS1u+h0txfXd7cx3FzaxRkp5TbchTgYIIHJPTj1q5olv5kBklAUsxCuedoHfHr7077LAJhcT/OVI+WJsq3uM/19alikIiGVZH3btpxwOg6Vyy1leR0w0jaJN5XkuykEsPlKjg/jSampIjXH3V2H+uPX60+3kEZnZiN+w9ec1Tmk3PtUA54Ht61hKW9jaC1uEMbmOUxHkIcEnHODipNPj8izsIbrJljUCVu7GpY1WOBlR3O5sc9Co7/AJ0p2+YHJIU8gnnOKS0VhtXdyzNhiWCYTrtU849jUyshaZtu08BEHIA9P5VXR1DAthjjAFW1VVtpQeXbBB74/wAKpRM3Kw+ImNNzD7wJbtitCMovlqHIVQNxIxyecfhxVG7lSGGGYFWWBUYl+OevSpIpmzL5snzt85zznPJNVyJIy57l9GyrcgY5J6HmsHxNBPeaM1naxjdNLGGJOAIw4LEn6D9a2AWHygYJAyBVeWVi5JbaDwc+lR8OonFSJYiWjaRR8xc4GOAKjjz5ZABMmTgdAPqatRsqQeWrjJGSfSqqklN56HIJx933/pQ17quc8tSPbcf3Yf1/wopd0n979aKnUm3mdNZwrNA8O1jM53xuThSB1H1q5buzltrZZ1+bsMjv/wDWrNdTEm1s4B3oenBq3buRBNFKAVZQySrwVP8A9esb9DpSNIpDNbNviSWEjLwuMhsdfrTp447iItCRFMMERL0Ix1BqtbM8LpG0qiR1DxEHcCPr2z0IqRWV7ohTtw52exP+eKXN3LRXMZuDkZMpAx/tHoR9algYlGdEBuFYDaRzx1+lWrwRlGlhyhUBZUPByepA+tNiQuJSZCtwoUoAPlkHqT2PvRszeMtCvKiFFktmJYAlyOAAD1A7fSpJd6GOSTCgfMFB42E5zj+6fSnzIUQyo2Nzg47qcc5HpU9nMto6ylTJEVaMcg4B69aE+5reyKUixtgBgDy0Yz6nofrVV5HkjW3xGpicuu5fvEjBBP4Zq7LCkTBX2vEQUUqx3QnOQfemG0+0qWXy1ZI84Jx5h7/j6UXvojRNGVJtUlU3bv4kbrkf5/rUKTSp5wVMQk5zuBDDOSGHb2NXxEFmVukoOT5g6Y7GoZAjFpUG0qcMo9+4Hp6irTtqUU5ED7ijNsOQueWx/dPrUL2+5A0bc4ywPVas48oKY+jnkKcYPoDStK8PllcAHBViBn0P1+lDlbUfoZ++RJGPO/GDj09KVZtwIfB5+70K/SrVwI7hyQoRz0Abg1QlUrIwLZIzzg/lWnNfcejC7RCF8pt5x9B9KoT7wTheM5HGfwq6ku3DbeRwQRmoJMnBwP55pvuCj0ZVEYQbgwVySdoHAqKWKF/uB4zt6A5XP0q1KqMny5ByMg01U65zkLwcd6pGUkKDFOnkTh2g27QA2wN35x6HmpbS9YCG31K7jNrGcu80ZlTOCPr6Y9zVNlRREVYuz8yRvwEb2Pcd6ZJcymU7iNp4yq57YxVxnbVHNOlfQjvNOjhklnSQmJ8SGOFSeOuMc+g6njNcnFBHbXStLCkkCP5kqKSFXvgH06Z963cvp3nBBKI5I2jZEcqcHrzWxaeGftKI0c1s8ewSuxcERJ78jnuQK2pzbehlKCgtWcpA1xa3Zt1iWRHwiQCTC7WPQH1B6/hUd5pkt3Ba+YJFZXY2jhuIuScHHbr+NdHqGhINWWHTLnzITGXjeMbs7h3A6dPwrNlgmtrn+yS8OYzvO4DcWx0z2GD/AJNdMV0ZyT11W5hPoRuXv5dP1WV74QmV8HIkfaPMXcD3J2g89Oay7bQdXn8yV5vs724UmJ+HcEDGxepPI6VuaUjteSXFvbCNInYfK24glT91eyH2HWr13qdzcXkF3dtFPqk0Yj81kJ2qFwoyOhxgkjkYo0tcl3XumJH4UuLVJ7y2uJFWEkTBTgMMfMFPc5x7jFdLHo0baTFZagE+2Tp9stZ0GfMfB25J+UkqCCB1PuKxhNdm9kmtZD9pDBH81PM8zkYVhwoTPQ46E5rWuXeNLHSdQhikkhjM8coJPlktuZUAPIz368USpKa0WvcwnJ3V2Y9w+saQSLyQLbyp5KXHkN5VtuHYjgMR2PIJovvD76hqds0oP2Z1jxHHJgyYPynnqnoVx1rZ8cXBl0q3ms2heCeBUubdhxGxON4PqM8jpz7VyKW+pW4K28L6hHaxiVgCRkDgkMD8oBwCV69amjKL95LciVJ8u5T8R2l3DawLJN5NjdXu6WOFAsAYHAcKB04IznBINc9pFlcXVs10kcxQyktJGo+Qk/KxJ984A9K7CfXHTQ7iK882W4ERjtxJGDErscfKP4fY98Gks9Nj0rw7YKrRjU/Ndxbux3qBzux6L1966rKREZSgrHKXmr3rxrHNK7+UpIIwAQT/ABD1z69M11PgyewdZ5NTuZhcn/Vssf7vdxgHvz04q1rNjYWVilpe2l5c6xqoVjcT/JEqucM6qvTHAHqSTV/xLLodnq9pY6RFIbWzj8oELtMkh+8WzzgHgE8msK0Ulud2Fk5e7y2v1RvW8QVGd5YfJ3DescikDnr1z+GKgtwZGMvJJJG5zwTnqPT6VHb3PmwLAqxgBR0XKqeuWIHP0qz+7EQYugjThIwcux/vY6Ba86Vr6HdFMWf5XMRUFlPzMPWoFIjnVyMgHOBUykk5PX370x4i0yhDwTyewNI1jpoTRyCV2bACkYAH8PtU7ruZAqqNibmI9PUn1qrEMZG0cZ+761cXBhEjbOmMA8nB6kfX+VCV9QloOZEGxpCTL9593bngfl/Op5DkK8a4Vix6/wCelROTNuY/xAA5649KQzRwwnJ4IAII6DqcfyqmYy7jNaR7vSJ0V2EkkTqpHUMBkD6dqn00StawPOSrlE8wDkZx0ogi8wgMpAC72wOinkU+2nUJtBwVbdx3/wD1UWfUyTW6NAyYhG4MX55B5JzUKgeaSyg7evp7VGWOEZc4ycH196lU5kVBnaRuJ9x0qJCbsTJ8yyKAdxGMnt61XLu8ZUE7UGAR9afNLGLOQb9v82/+tUVirtC2Oh+aq5dDnciTCf3hRRmL/aopE3R1TLtQiXJkDE9Qc56g+9FpG0c6qdzKwyV67l9h61IcOo3IFOPkI/vdf1pYgY8+YmZCc7un5VytanbF6ak9rEHfyy4yWwOg28dc/wBKuQss2nOjLDvhbDSAYdl9D2xVS1tyVImyhDYY45AJ6geoNWFHm4S5JA3NiZRznryKB6B5LOwRcCRU3xuOjr/jUzNDcgTbNlwv+tVRhZB647H1qRNwgaK4KsUUJHIjZVQf5gnNRTRrASkpMdwOcjoGA6fQ8HNFmtUaKzHRbbpj5n7tRnEqfej/ANr3FFtAy4kWU5HBOPl+hHoR+HNOhRrmR5beMiVcCRFbJJPcexp4/wBGaG6hWTySpjcg7drHqAe+Bzj61lOXKuZmq7IYbRJkLWrMeeIv4uf7vqPbtVJYUZGKny0HDLydvufatV4oXuEWyeVlJAjLLty3f6H09adK0dxOieUkFySFZixAY9w3saElJXRSlZmNco8u2OQf6R1ErNkSLj5Vz6+9Z7ApP5hykgOckfoa6KazUo0AVo33sVaRsKB/cB6HNV5LVbmCNFYGckqN7D5h6E+1X7yNIzRhvKBc+b5Sq4yxX+B/oPpVZm5GFDryCrKTg1seQzDyyNzJxsYEHH/1utVzZsTvRvnBBKngnPcVbuzRNGe1t5pBVP3Z/hH9KqvErAqXHB+XOfm/wxWi/mQAsW/ixtbjH4VSkj8yYbA2wnG3OCc9gaItbDVyrtWMukx3IASGUZ57fh71UdM465JO0etauxCrllIC5AX0PoargKchiRH2xyw9K0QX1uZzRNg44wOcGmgFR8pwcc5rQliZCgO14ycBuufbNQyxAAsMEZ6DnFXclvuZ865kOV2NjB78/hUT7vNTyl2KOG5+8O5+tXWiyDkcevpULoMHIJB6mhOxLRUuhDKihM7wepP3R9KyprEFlBB2E7gjfdPtW02ZJvlQfKuAMcmozGHJJO4jqppbmdrFfQtXuNBdntoJHuogTC+cpn+6y91x26VTiEj3EF/cxxMyTSIzGMFAZQW+51x1HP4VZlMu4+VhXYbSegxSWdv5Xmzsym4jYMqsuVz6k/yrSFZppGM6as3bcwNetyklnKso8zbJ5uRnzQT2UY4UdAe3Ws6K4EFhNbws8t0WBEgdUWMEgnbu5ZuCMiul1O7XWdQMsk7m6YbVz8qkHqP9n3NZ0EFvYvNZ3BV555hGJGUvHAOSCD3Iz+tdcaqb3OWdJpK6ILe1vbKFJ4715o5TLG64zJ8hyQxHQEcEjmovDzWscvn6naxTRSH7OWgnbzFVxkYDcemcdamv7Z4LZoo7rT5Z0fZHGsjFvUkKAMg9MnGDxWTJqk1rLfrOYbie4BDy3EYbY2AMqB0bt7CuhTSOV0pTNO/s7m68K3GoxmZhbT7C82S5wcBsDg8D8hWf/aNtHdwwwTTSplSdowGB5ODj5ueeMDAra8D3U80Fxo0yyQaXqeY/POT5cpX5XBznORgjoc1nXtlqqXM8EcEEdvp7Mbh4EAPHHX3zkD3xXNTmoylF+o/ZyenYtf2ZHdSJLc3NvFGXYg+XtBdRgBhyccn25NS2+nPcy3N9JHFbRMgMqqDnywQDgt2Hr3xTNLgjutOnkgiuEhMu15ZH+YpxldvXdmtKHQbqSISmC5upC6xR+e+EJ6hSPQDnHar57aJD9grasZfv9uk/tHU7V5ri9hEVg24AKiNtQhR/CFXGD1JzVBbOSOe71vVrfzJpBttI1+XfJnByOuAO/rWhLZ3lhqDxyzR3VxC3nSeVgIO2B07cU681C71S+gmmMVsFUqEiHEQPXaPf0rn9rZtvc7YUtLR2FigF3bQxuzIQ22Rs5UZxj6/SlCeRJ5e8OOOR0pYFKkKgLZBAx/F7ketSvbpBgEklchiVxz6VzybbvY3StoKGC8E8n3pyMTlVfAPXimoFdWViFI6E02NXeQjduKjn29ae+g0i7ZR7CGRQ21SQp5APY06FQ0Y3HA6En27Uy3JUKMHay564x7mnERFF2CQtyTyPwqlorCZKMBG2Y44qPUbb7RpVxbKT508LqGzwueF/xqeMKsW1vvDng81LD+8cYAQHt245powm7leMww6fMbhn+0CILC0fAZlAHI9O/wCFcHYeLLm71hLPTbYyhpR5krZIRM/MeOnsa6nxLZT6lZPDbSmLOFYgfw+gqh4e8N2uiZeDzDJOMPKx+9jsAOgFaNxcTKzWzOoicSM7E7VAyCR1x2qePls9gOcVC2xIFTgSbgGPXipxyCqDaFPGeTWaTIkzH8S3BeXTLCHO65nUylf+eKcsSe3YfjW2Jklldo1CxnhV9KwJlebxSZBHkpb4LkELGpP3R6knk/SteJWRRt7mqlc52lqT+Wf8iip8n+8PzoqfZsi51EOJIpNxG7sc85q9bCKQm3unWP5C0TtkqG9eP51CcS2+1IUSRT8zDqwqO5DLsibbgYGc54+vpXHsdy1LlsWSRysgDqOQejinMvmQNNGu2IMAyK2dp9cenpU2pShvnUIxUbW2rgdODTIoWaFbvAOHw+TwR6mk97Fp9SVg1vHCwwyt/q5QeMZ5BFQeZDqMVwYTiaNtrRgdugxWparFPp7W8o2jdxKVztPOAfQHNZi6Z9lllltAd4GHj+nORjtQ216AnfYtCHdaQFTvaMqrfwsoP8Ge4/lWi0cTRzJaLKwZ8SW8q8N/dbPY1Cwj1C0Cjy47lV+UAcTD0/3gaa4kLKJ8pJFhDkEOmOx9qu6NE2RpGBKYZAYi3D5U7lI7Yp8kErh/tiux2+YlwB8xGcZPqM4GOtOkVJ72Lc7I5wvm7s7xnhsnv/hUt+7wPLFIySuTlbgN8u31wOlZ2tvsXzalSOaeJJ7d1DqylGSTp9R6NTfKgjePz5Bcxt8zGMHcjdAfwOPar2pNaXTrcr5iOAEZCcsDj09O+e9Q3HmxiXzIlaMgLIyKAMdsHtVbPuWmmroqTI8t0i3cwt7tVwsrDjB7H6dKZNYSKxWd0jnXjawyjZ9x2PXNOkQ71iZtx4Cvnt2z/WrcCxPBJE0bFc/umHLZHYH09qpWkWm07nPX0cu4R36lZFAVJWXGQOgJ7j3rPvbaWE+VJHszk4XkEA9jXaRttkW31V8xY/dqfmQjHXPX/Csq7sxbzPbySedasxMbDjJ9j2/kcUuTrcuNTWxzLbniVXVVIGd+eT7H1qusO8OCwjKjOCeD7Vsy28caLljuyRjuo+vrVJo5JQkcv3xxHwOnck96pNGqZRjZw3lsjFOrA8Z9P/11EFJd+C5XnBH86vpNxsdVDY2s5UsSvb8v5VE1q4djCd7L12nk56YrTR7CvrYznAZiABg89ajaPOTjgdj1rQnwzjeMSLxIFXp/nvVZE+fdnk1LE0UDEVwy8HqD3FQuiYLEsJFPHbitYx4X5lOW6Z4zVSSEjkA8dPalfsJq5mkEnDEf41XnLeSYiFKHnPf6VclUr1/KojGz4+XcOnHBpv3kQ4mXFYKjo5iwzEleMkjHX6+lSae8NkhS4Z44MlywQNISRggH0PpV2TO8/LjAxiqs8YkC55xkcinG8NjOUebcXUpbGWyK6NpIW7ddryu3zN2yq5wB369ao6V4NZFmudQiIgxhmJHB5IbHp6j3qy6KSvmgAgfKFXj8atf62NnkkD7EAVWj+VfYr0P1raFZ9UYSptbMp6FbC1uIpPtAtrdGR0Z+oOcbgfTrg1q+LFiN9dzRwhVvfmREb5cA9fcnAIrLubh58RMqhAAnAyMDsB6Vqa6FS202MF/lUjIACn0A/XNZSqXasRKm+deZkR3Ign322POb725eeO59/epb/V9QuUSW6m3THJhZWAEI6HCjjJx1NU4l2Eqd3Geep/8A1VYaHMSOxRtxJJXt7Gn7ST6m/s4p6ogtUdp2cH5mHzZ5yasKgUAlAW7Z7fjTwNzcqBn5eOMVIyFWKg9uf8aEtCrCwl15jwrevQj6elJvEkARgmU/jyc49KCGXkHkVHGrEHGW2jJz2qrlKHUYV3Ejb9M0+NW2lDtI+8cjkU+NSCzBsHHHFSKh25IOM4yRjmlexRYYq8SRlgASCWPU+x+ntU6qJGOSC2R0GOKgQIw6c8fh/jVgBYVHRnIyRjoPSlzX2MZeQ1gQ+3bk9wTimEbUDZUlug6EfhVhbcyMR5ikbN746IPQ5/pVW6Jmu3upiWdkWMcYwq9AK0Vupzyb6CSbjE6xtgsMA+hqWFlSMgoOFAzjOMfyyeacsb+T5u5UDMV2DkjikdCPnKYXouD3oTIdrjnWIyLkqVXDkYOCRUwYrCrhlyXPH9f6VDArKgLgFSc8jrTlUGZWkAKLkkY600ZyJY5MSorAkMeR71KFMc8iOACT0P8AD61Xt7oWszOyKSAcZ5A4qvp1y935c0qGJXJZRJ1x6mqjaxzzepo7oP8AaorK/tNP+eUv/fuinYk9LsZTOPMHyBehP8qWUACVcFS3zAY5+ntRp7BIlYMY5lIKt2DZ4yPT3q7dxxyNcSGRjLkuzgZO49R+dcUo3jc7tmU4QykgqZEC5Ue3vV7Cpt2sfLK/ue+D/daq9q25REyjzU4VjxxjkGrEcrJbBpUYQToQxC8Nj09xWaWg76jrV5ba4G4Ha3BU8hvUfhWiip5sToCsLAK/OWAHUj/CqEqGAKkgDx5DiVDkH29jj+VWEkUQq0jBomPylRjOO/1/nR8JT7kwT7LAl0se+3kY4b+72IP86kt4pbmRBGSbmXJy38adQc+o71BGzRMwYCSFuoJwrDv+NRCGW2lU7sheVJPUex9aLq+uw0yzFC8LyWuohvLcF4yi5LMe4PpTZYzEp4CzIeCvzLKPepZJGmiJklkdt5Iy3MTdv/rmks0N9Evzbb1XIRegZfr65zzTau7Irm6srwR7JC8TbSV+dANxCnsM1bt7mOOFAQJI4926HGNyk9DUAlVrmPzwDLkrknAyeBn2FOlt3EknmRlJU5ZQcBx0ytCuti37w5pbeUTx4/cEKEDffiGc5H9aq3KvauDI3YNEyjAcevsauRyxGPAtonwfnz97pyfXHt61E/lGIxKDNEylQjnDx/Ru/tTtdDTcSCdg7ZkiUeZtb/d9x/Wkubd1hfe4dnURor/NlT3HoQBVZvtESokroy/eXA5Xtg+h9am+0SIqqit8v3WJwBn3pQs2ax11M0WhFxiYEK58sv2HfI9Tiob61ETOsSO6M5WOY8ZX0x0zV8BYomB+a3fgjPAbqOPUdRUUInmhK584A52rneoHPHpTSS0NOZmPLFA7bZd0IAwrqMrn0PfFVXMsSqAwEakgFf1xW1PFvbbBhxGcgyDsex9/aojbBY84Abdht64GT2A/rVJ2KizK+zmVZXYYlYjEZHPTr9KkigW6lfEexiAGcdFP09DVv7M0DIrlllIJAAz+veh8c8kSrwCox+HvVXBu5kTJJuKycleBUHltklV3EZ+Uit2GFZLjbcq7b/vPjPXsB61U8lFIEzFY2B2leuQehpNCutjBntiVPXceoPXPf8KpMHQ4JKgdu1dC8XykKNy54wOfrVSeBWiz/HnoeapDuYbRkMDnOON1QyRNnIXvWtJCdpOf9kCoDCXcjr/T2oJcTNeP5Ble/HFDZCj5ucYA9avNHgnjP9ahKk4BHvVIlxGJIDCI9q7o/mVvpyVx3o0zWoZHa01K2T7NIcLK44Rj0JA/DpQA0TBscqeMjNcrfyXCXtwGt0jWNxIsak/vFzww+npWU4cxzVo2szo9SsGtZQrMrbgSjocqRnHB71XZSFABynfiriSi609djMylhIoP8JPBH41CkTH88YrSKdjoiroaQVAUjJx19fepIhlkBPGevap0jUx/Ngk/p704w+U3coO9UPQYyK8bZHzdQSetRxIVxwPU4/rVuGEl/lOGPTA6U7yCuCAACcgjvikGmxXk2BmCRhGztz1AH+NPe3bCgkhRg8+lP8hthdupbPrmrKndbYO5nyArM3CjvxSau9SJabFREKysVX5RyR6CrJQYLHvjj2p6KUmGzCjOPUsDxipHhLhxGp2qTgd+v86cVYynIpNPhWWLC7jz6nFPWEi38zeEBB2qereuKhFt/pzSueAgVVHPOck1OkAmk+diqAFn4zwOwFXF3MRkAChC5O0ckdwPSpC5uSyoFUk7QD+p+tNklLKm8EMRjkc4qBgxUnBAA4/GjYzl3GzOEJCFiq8A5zzVq3lLIFYZz04qlDAGYhFwzYJNSujKSp4x8oIPJ9fpTTMpaoJ9nm+WDwDnIOean8sGPAHzDr3yKp2VhBbqY7ZcLnJ5J59Sa0TtjXCNnd19qp2MLvqVvKT0X86KnzH/AHf1FFKy7iudzbqzzFTtLOvy55DCtDSEW5huVJKyQrlUXq/rWcsTxoiSHY0bcHHJB75q0IWguiYXaF3XrnhhXKnY9CWuxfuUimjieIoswUH5TkMP8fUVUmmJtfIYuIsltmc7W9vSonJzhFxtcAsD2P8AWr91p6PbNNp5aVeQdwwwwOSR/WotJ3kgVloxdOa6u9JnS3TcFwrdlZRyFHv/APXq5o14LbTBHMYJ7aQkFSvzRHIyW/Lg1z0Nxc29u0aSFFZhnPGDnrWtGzRTvISGLYEwHQg98VMKik01uOUe5Y1QrDDIkOcsThG52+h/LvU1pew3VtFbGLH7vMhIwQwP3s980xIBOGkA2JnBYdAD0NWrO2Vt/wA6G6YbfmxscfXsfQ96pJ83kS2rFeaykhyJTjbzHIp+Vj3APvTZIFgmUbmizhlBPB9s9jVueSJrcQnMUZHO5jhXHaqthdxvCbe6i3KW3K4OGA6dT+eKLJOxcW2tRZiJozDcqwKfckC5ZQT3A6irBiSaIxyTyJLb8+XIdylT/dbtn0NRygCd4ZZX2ogEU4HBXv8AXjqKit5FhnMcwVyvCuOePUU1vqWu6Fh8pFyEIuFztZuhXoQT6+9RoFj5llYocq6Y+ZR6c0tzefOIinlzqcB85B9//r1bjZbi3upSEedSMh+CVxyf896Gk9i+Z9ULAkkOx4RDcBgW5H3gOxJ6HuKrXxt3jMunh1Ix50Tj5RnuPbNOtrqKF0eNWeBTuaJmIMPqPcUlwkbP5tmsjuo3OjjAIzxj8e1NXtoC0ZAkaSxrImxjnEiNxu9xSnbFMsdoXZF5jIG0knqpqt80auzINpbHln37gdqtXCwyW6NbOI2IyyA8bs9AOoov1Rom+pDcqk1wgnZIp48KZI15OOhx3NVpIfLufKmKpIc7Wk43DoTn0/rVsyPJGIWRVuAzLJK74JHbP8uKrz2UzorF4JYDIUWSOQFS3cine407kM8McRSOFZNsigqhx8x7kH0psqoYi6OSpb5Uz8yEf561YKNECkgDKRtYhdzJg84qQW0E8WY1HnHPzBsIBjOf/retUk3sFzMKvGszQtwTyw6H3/OqBtpTtBAAc7vn9jzWz5ibRGisW2+nzY9BUMgSXIhBCsQOTzj3pDTM57UZleKMi2Vs7T1Uds+1VJYsZ2gc4PA6D0FbBBhTj50YYPow/wAaihsmZgURk+Q53HAPcAH1xzinvsPmtuYctmDEr7dw65zg/Q1XNsqsuMEdDjqfWt28RfMkIOCWzx/EfTH9aptGHCAHbgEk9TVW7ApXMO4gMrhdmCo6CmfZiCFkBBB/AityK2YskfCDG5vXpUK2wk/eehO0DGDQh3srGM0GWK4OMc561WlsoZwBKqsqnKNtyV7ZHvWuyfM+5cHrjPWofKLtHk54Oe1JMVrmPYRmSO4SJf3ULeWp6eac9cVYS1KZ3Ag9eRWgEGAeCqDJx/Ee1PmZp3YjJfAHJzx3NOKsrCgmlYzxGdp4APXnmkW3cnOSI1+YjsPrWh5WdpwMk596k+U4GCxJyV7E09xvQqCA9D1PJpnk/Mq5OOmDWrBFvyZnAEYIAJ6VFjexdTwOBnufQU7EuWpRIJYBgNvYCl2jagRTmrj2hXaGPXsOMn0oRWRh5eN/IOB0pWsZya3RRHyrM4P7zgAU9m2Qx4YMxOG4qZoSrEHBPovP5VA8ZLHLDcBxQZSaEuCESJADuHzHPTdS3WzyQQV8x+SF/hHofeqFpZNbyvPcXFxczSdGcgBfZVHAFaMMTQp5ucMx474PrWl7HPdrczbnKSBchvU5zVWaKddUJgkZrJ4h5kbHO1x/EK0p4syYjxtBzu701I1LYAIC/nUqRM3dEcSsiBzwpOCRVZ7pUuYYWBYzFgp6bcc1rTLiFIgOnftVK7tozNblQd0eTknrnqapeRg5ixSOqlVAUdwBTXASIucnAyfpU6w5jZwOBxnPGajki8z5S3AprUiUih/aDf8AQPn/AEoq7hqKLkXZ3yXQltmin2jYoCsev/6qnaeSS08mf7yYKZGCn0+oqqfKeOVo1jSNhgDPJx0NTWmbpo0RgZuoL87sdq4VLm0PVempbLcguoWZMBAByfarscpSHzo3bc4IYHv9R6VTu3eWSObBWRQC/OORxkUumT3KfaSUt5ImYMQeWI74FPmd7C6E80IktIpJcNbFsNtHKn1otWC3KQAqZDJsZ93DKelT3CIkD/ZC5jkHmIp9uCDWbb2Mg/0tHDoxC+Wz8qR7dv60pLkknFDTui558lldhmXEeTG8bnn3yKvz7UJjdWIiJKyAZ25HAPtVCWczOZJEzI/Lh+d3+NXYJY7OGVpIzLbzABGY4xzkrn1o06PQRYvADCIbmDZMI8lz1GPXsf51VtbZEmxMRLCVwrJztY9KTT75YixZgVJwO+0ev1qw/kh1eIv5Uo2Occde1N6vmQ12IZt1iyxtMXRTuCngoe/0pZHjmtITKFfClSRww5yDn6cYp1wkscTwXBSWJn5mPzFWHr7dqkfToxZ+bayokoA3Qk5OPUeopJPWxaaRDLBttwkhUsfuE8EjGdw9R2qOBY3mRJA0bD7uefz9RSxT74TBP5heM7k2Lzn/AA+lOkWaWywxRohlomPBBzzg+ntVb6lxl0GTXUkh/wBJRTkEMpABHoy0sDm3Ecr/AL63jIkBRsHPox64/lVgXjXNnHHKI1dHVTkfM49vpUbSCzuJPKiVogf3g27lf/aHpTt1uO91YmkgWVBd2yArEA5BPEhzyFHtVOdI55E2MvmMNzsn3Tjoc9j71FaqxkL2bbYlblG6Bjx/9bNSTNLZ3GXt2jDcsrDg+49RT0auCuiG6SOWyVJgMtkBjlSPf1OfWmROljbSab5W1clU8sZ3EfdGfTPNaLuj6dI5uI3EY2xxnlmUnJycetZ93teFVZB1BDoflbj9PrSemoJgWljt0lLImw7WGfmOec49Kpm5uXiIktxbyO5BiQ5VlzwR6Z9KsxyPJcq1wcuCNpI3AkdM+oHpSzxMtwyBNsg+Y4POPamtVoX6kaSq5MpGJVGSD6dP5UskaeXvkUo2OAB09Cfb2qURMYEnuAEhU7UkBG4nPce1R3MytLiYF2yPnB4ZfWm0BAmRIFkRMkqzZ6EemadLM0kDxpu+zswyWPK45Az/AFqSYRiNo3TDtllYHJwP5mifz7N2UyI42FSGHTI/X61drBYoSQqzAgEMTtyT93/GqixswBIymeT6gVauSqhTGWKMRn6/WmRSARsVyy5w3rz/AEoHfQZLHudTOSXPJYj8vwqF41eNVUARgg/XuassrF2QljtB4HOPpUUyhwoU5UDJz6d6pC1IZohMHlmyoZcRcDgD1/WqkqmMiMKhZMlSo657+4rSknZ4NohVcYKHH3SP61VYFwZFA/d/MzcA/QUS8hpjItMeSd4PulBukI4wewqvHAVEpPJDbSRWlufzZGWciRgCHweSeDmqKiQ7YYycHO4/3j2FDFdldo1JG5hnG5vr6CmYaJSSOcYGR096uSp+9/djdgcj09ajljLNwAPrSGmVFVgCp+6pA3HoCaspBtSMnheTz2HrUsQwm3GFJ5B5+tLJJhTxnPShImTZErBmJbc2OnPNRseMKNoPpUrcRsoHGeWx19qQ7YEj3LkMe/XFO2pjJETpGkO8EtJuy3HT2qmoUM5Y5Pr2p+qXItrZCkLvKzBCi9Rn+I+wqvHuJGTk9DVtbGCldtD1VS4yRx2NLcvH8qwsxXA3Z9aRU2OEfIDcn1xT7tosDZhQMcf4mpIkV7mYwxLHFbtO8p2uVOPLHrSWBBWVG4yQc47VGZVCNufYWOFH971qaxTeWH3eCQfWnvYzkrXJA6yEqF5z970FRuiscrj5s5ok5YKpwOmaxWuJtQ8RbImK2tlFhgOjO3b8BVWOdmv1XaW2qOc1Qtb1p7y7tPIIWEKfNPcntUzSnBUA59apGaO2SWWUhFzl2JqooiVzQ3D+4KKzPtkH/PSX/vk0UrE6nozxgjdCylA+7BAznHPHpVuy5c3EY2bG5UHkZ9KgjiiS5MUshjjILB1Gc+hoX7o2bljzjfjmvOd07ntaM1Vd7lnaFh9oIIkzj5vpS26Is0QhOHY/KpGSr/3fxqnAmySREA2xnc5zzj2qw0TxxC4iZcbtwGfmUev/ANeqTe4nZaFx2bc7iLYY2LPCufl4wTn607/R1uhIiDypUwUkHC/j39RVe3uGkmUxKpbliAf9YOpU1LDLFJOFkcrDMSY+c+Q2ehq0xNWLU9hEr28SMHVztjmZ8Zz6+hH5Gqz2xtbhklDGLnMUjHbn+8B6+9TTSTCWSG8GwsVyyjpj7pHtWgsqzpKl6zG8AAjLdNoGc575PFPlUmTdoyorUGceTKrHGckdfUGtCGX7PcwmNEaAsfMgJO2PHXI6471mmRJbktE2wOO64BP07VcjjkeYRqji9XBjYYH5+tEfIpj5JxJcuqzIIZCY8r0bHIXP9abJBLGsIhaNpCx8skEOR3A9celQQNF5zwOGjLKd6qOje47fWpFu1hjdLkeZIVBik3Z249PSh2eo07D4l81XjuA8FwgJVtuMn3P0o8x7gSLcsN3XP3QOMZx0rRFgsl1HDveWWUCSKQNgOgHPPqOlMuIzcEiIyF4BsDMvvnDHuaai0h8yuZTCSEFWCSIpA4GVb0+hqaJ5TD5VoJVfpJnkgdNo9R7UhEWAU80TnIliYbfm7fhSXKLKEnsjMZIxmZSM7AO+R1FCui7oUr863FuqrsGWVDlVHTFTXl6jQxwxFpAo2xq3O0HqMnr/AIVFbXKSReZv2TDnYi/63Pc064tdsZ+VQDgqyjO4nsPr70Xa2Fe71MmZfKlY225E4yhOcHuPpVmGRXQuiqQ3yCNjyrE46VNKszBQ8ewrxv2jnHr74qvc3EVw0SpD5Lr8pZRnd7n3qY6Ft3WhNd2v2YvGqec7f7PTA6fUVSTbKR5j7JGblz0UelXbS4JJW4cA7s+awJ+h/ClVy6p5agbhtO8csecHnuau3YSfcqPceYnlyLtc4HTjI7gCmIhy7jLRhcjI4Pam3K+azcYaMFjJjaTx0/Cmw+eiuZRKyTYLbuVAx+lHUvYUAxSmPcpXAG8ds+9RXEQilEQ/eRRk4lVckr7+1WW8uJFVnG0nc4H3SOwqr5jGRjCuIs8kdcelK+lg5xsiux2IfMOSy7enH9aYyoplNvjYFBPPU9yKuyqY1ZiGI2jcpHAzVON0tmVxGrbTyrc5zTvqCl2IyitG2w7WXBCnjINRxkNkLwTxnv7098FkEh2ox7cjH0pzxq6kjqg44xxVKQmyo+54sKGwTgAGooU3cMpCtzux2zzVw74juQspxtKkYyPTNUXdkd1DFlfBcDocdPwqeawJj5mVZpGtnZ1B2q7DgDHJxSiJFh/cszogLFjwSf8ACjGIy2MsTgYPAHenO3kQlfk/epgDHI9/atF3G3YIo8yW5b5TIc7icAAev1qGX95JmEZ68HtzTYwyBRwzHIXd2+lSLAfKbA3Ig5YdifWjV6CbsMDoik53H+72/CoywLZI7cZqQFcbmA3Hr7Co9hDl85Y8qP73NIhjrsFIUJAOeAc5qC5b7u4/MPujv9aVSWckuVIPPfFRmLBdsn0Gad7mb8ytLjGeR29abaohlALbR0LYzx/jU11Pb20aSzkICwjRP7xxmqscm8lm5L56cVT01MnJbEt2wcgooXb8pP8Ae96rtFuAJHGN31FTqgX767l+uOaYVclSpwPug0t3dmd7GZqyC5hTLYlhcNGw4CeoH1qwsmVRTwAMnvnPaopI0JyhyO+asQgxqrMoHZQR+ZNVe5DRC6sIy4yCT1pIYvJSVsBRJjPqf/r1bPzIMc7Rnnp9arXLZkUAHapwOauNkYyVxoQbT3x296yLu0F3extMwMEI37B/E/bP0rQulklvUjU+UucsB6U1UAcgkEZxxT5ktDNxK+4/3v0oq3gf3T+dFToI7m0IvJPs7nDAfIfp61PDLMobIXzF+Rg/T2JqOBUE8Nxb4iAIDFvmCv7+xpZbmSO8lMgXe7YbjIPr/wDrrzr2Wp6/UvRIzAPAQUChmDdcdDipSyqEkt8ug+8PQHt9KzmmYOihyyEBos9K0pAiDzIm3Bx+8AHyqT0pryBschksLtJ7TaEb7u4ZGPQ02/j3znyTsLMJPQfX25qYBmgklji3RjAKryAf4sj0pyqhVNzEwA7YywxweoPqaLdATvqOt55biSC2v5pAmcK7DIQfz61a2o1tEJvkdS22TPIPYfTvUKK85jtBhmHyx+YcYH1pdOLTo0O3IVsBsZKHnJ+nWtYoTMvURPA6KMiN5CZSeTntg1ZsbqW4tlMiknnDc8fSrZmS2QpNAjq5KMTyHXpn6jqKggkmt5XtDGRGCXQMNu7jp/8AWoUdR8rRYwzqZGAaX7rseQV9z61HJbZZZUjwEfHJyAfQ+1XFt2trSC4Uq7AgOo6AY7j0qtcWUzyNc2xVINnMBJJUevuP1ocWguWWlXcqRSLCXIaOIN8qMfQn7oNTXmo4Ns1shiuoRiSNW4DDuc9frVDiSOKGdg4jXIlCfN9BUyadO0otpVUS7QyksBuX3qrvoKyHzXAvJXmLLFdQhdqM2fMT056/4Gktme7uGESmGfb86A7Q/wDkdqWS1vbkbXj3SrkI4xuH+IqG2feWa8fEqELuIO4D1H0pPzKi+xdEEYEiXkQRofkQhh8vfBPrUMi3Fmg85Q1vLwrZyMH0qzJKDFLBctEjyrhpTk+aByGHueB7VXlL29lGVxJE+DsY559CO3fGKoV7hNLPCVYb2hQbNpOPl67TVcjz5JJIIykQBA2HpxkjJ/OlhSYSExrKYiC0gAztHTOPpUEgFuvnQky2rkDr36/nSHexWeKSWSOBG3jqSB278Vagtd0zI8i5U7fJd8Ng9xVj7XbyW+yFVDluD3QDrg+9VZoTCj/dKn5hJg8n19aGralcwskkAG8ocqQrb+S2O4/Kn25niHnxykSMhByvysD2P4cUyeeK7VCYgjKowVPGfxpPtEmwwtKTHztIHJ9qaauTzaFeOLMCvCwMpODGwyc9cj0FJHKZFZNyxsOOcAEd81PPIpd3VBvICDbggjjj602WPFmztD94gK4IPPpU+hSZXaMtA8skmYWJJAPQDufaq85SSJvKG+NTvz7eprTaOSOMCVgsUilAwGRjuMVWit40xFBuSNOFX+9j3oaYlOzMceapYtg4GQduMCrMcLMGcEuT1J71qTxQwTspDkMD+B/rUCxmJtx/1e0N3oSsU5pkLiaeRsZdyPmGM5x6+lUns3G5mXBXn6CtlUcEgZJK5+U8Nn6fyqK/SGLy/LkZmkwW4xg9+KfL1ZCnZ6GWWywOFQKuMLUMsYzksFDcnI5FWp9on/cqCCfqfr7UixGX5pGVO+4gn8MVabK5ilGrQospUCN84749j6UQsHLKzMiH72BzipDgj+Ly+uD6+tMDOAxUbQ/BJ5pJjuM/gJOUViQpPBplug2nJbIHy+9PlRl+YE49TRJLsQ7BnIBye1WiZPQizbpG7MNr7+PpUMrZCFW/2iD60R7GWTfk574qMKY22sMbfXrU+ZmyKezjebz2G9wuAxH3R7UwIoCgKFAPJqzJcZg8sp8x5z3plxLDDbqWAkd8Z/2D/hTtcxem5DcSR4PlAsD/AHhyKjKM68fTjtT1IZTkZbrSx3Bh6AZA7ii93qQVoQsT7gAxHTI707ymkWSRtxx1Ppn/ABodkEYIKhyeSe9Qtc/IRnA6EHvVR03Jd90LJuWDABLN+tZGoO8l5a2NsxWa4b5nAzsQfeatRrhwSdp4GB7VSt3dLuSYbQ23BbGcCtI23ZjK7JZVCXMghJZV4DetRuNhLDkYpnmlWfYeCeBSMWdTg4A461O70Bj8N6UVDiT1X86KrlFoejSDHmhMFXIDr0ORzkCpII181EjcsC4KOBlh7Yp0MyGVJkT/AFUmWwM5XoeaPKPniPzNluHJUjkqetee+56SZJJChXMgChmOGH8HP3cdj3oiQWyNFllGcMucgj1FAMnkRwuf9VISYz1y3f3qW6jjiZfKl3lUAdgOEJ7VLX2kNFo+ZaJKsc2HOFIQ8SL1zViPypbqNSY/s9xnluAh7nHb+tVhFHcaVFMszm43GHaBwQBxz780CD7RZi4t/LWWBlDwk8sT0YfTvVoFYfdAiNFfIGcJLjk4NU5kkF27wqIbq2Y5CyEb0I+7+HWthTHeF5JHYxFerDnd6D0Gay54/KklRCMrkbiOCeoFN6alws9GOhmiktUVw3lSbQWC7myM/IPQmp7dJEuSZ4nuUhYOwJyVXv8Azqvas8cxvIVWTzF2yxn+Bj39vXNNM7sY5wSzx4UMpwAnv7mtk1Y3a6I0pkwrSQzsbdpMKV7A9BUcExSbymYpKo3RsTkMD6H0p1vF5BjubY5jdmCiQZDkfw/X+dU9Snle2t8Kglt5D14YAnkY7ilLTU52jaX5IIgVKW83z5zkL7D8eac4VVjjm3KqNgNnO3PIYH0PXFZ6O32PdGwe2ZslM/cY96nspTBKZlxLDykiN1wR6envRe7M3dFrzd0B3zf6QoMkLDjep6jP5/jTLmMMSud87IGjk6bgfX86gWQQ2gW4hLxnLRsvUc/yognE2y1j8tmClI2YY3ZOevQU+lmXHQjgsWuZVV5SJVbABGR/9arGGh3LE4fadrwsOQ3fFDlpQixgtcKCWKHG4DofwxVeSYS/ZjEY0lGd47kjo2Pf9alRKWrFtmZZPMilkSUDaAp2lh6ZpkuwBEVNvPzjtu9voanvY41WF45cu67hxy57/TmmwzloZFkDPtUg47e+PWnqtBFYRpCxuIVHlMdxH93noat2zGXc6ldpONpbJAAz06496ggke3mkfb5nylVWT7rBuuR61XneK3uvMsmZo1OMZ5IxSTsS2WZ7dfMBhCMCAx4OFz2qnfq5DLEBtGFLDkH8asWd6wkkVcqjYJXr37/Sp4XRI/l2iNyShIyx5xg+9Frgn3KtpEI5ofNgJIKkNnb79e2fWiYpCWkT96A2GVuQp9Qe4zUzk2xa3mO/qSp53H1+nao4rRiEAfYSu4qcYAPQVdh2uCSyi2LE7lDfKD90+o/I1Qtbp4dxCFgVK89gasIvkBCcPGWyBnpUjCMyuYhhcdAvy/jUkuIszxsluITuZhmQnt7U90RY1bOCOBt7+pNEFplw21kSVflZhU96UKKiw7HRtpCnOapRepm5WdigQ9vLJEwAJAw5PT3+tRmJ/tCTPtbBzgHpx1Navk/arBpFjP7ofMx/qaqJt8lXCndn72ePxpcuo+dbmVtjWQlJCS3BAHanfZy4YwlQVBOC2OO5+tSPbOGEsQww+bH061WkCqCN4ctySvFLbcq99mRxKkkYCjgAknPJ9sUiBChLfLGzbcnqO/SpkicFj5e5QASMdf8ACoZogsILEMx6e1UkNPuVp9otztPzZ79/SoLhVYKqnAOBz2q5KgwPf7pNRMBtGCRHkde9MdyuxFu6I3zKM5GOp9arXMn2m7znbnAy386t3kY25XB+Y4x2FUiCVZlyWGc47Ck3rYjchuGy56tzjNRSxtjcCDx61KwLnJAGTTH+Vv3Y+tHW5DGW65PJ5xnpnNJOG5AHJPQVIrspbA68H3qEznzP3TYYdBVaMyehh61ePbXdhb2wBe4l2tkdFxzVmVliIbkbDkg98d6R4Uk1GKd13GMHbnsfao7olvMPHzHoK1skjPmvcTSGku4DNO20yszgt2XtTyEA65UdvWoUdvLCc4AxT1Un0z1obItYr3kvkwl0Tc/UAd6zrK1uEuvtN3cNJM64Ea8JGPYevvW20DPluOOp7LVOVUU5Z1UdCxNHQi92Myf75/Oinb4/+ei/lRS1C56am9bmQbAySdMHAye9aMMECeZHKy+W43Ie4I6is9ZsusmcKSFfjge9WJMm3KMxLq5CydRzXnrRaHo6ku1JoyzNt2D5JCMEn0Jp0c3nXjF13eaNjKp79jUloQtiIroCSIHcCjfd/wDr1EymRgixHzQufl7qO9HVNGifcWJjEQQCJImDtEejY6mppwbaYyRMQGByOcjPalcC5RCSCy/KWIwR6VcmupJbeO3uI12xqSpPUZ7Z/DvVJFX7EEMxK5jVvMU5eEjgDH3v/rU533wFsBoG4AP3l57n1oeB/OSW1l8xcD5u/wDut70k6N500jxqkgbDw4Kgg9DSu7D0bKrRpChTiWNm+8j4yM9MdjUqeTBMjFSQW5UH7p9cdCKkidJFOFXaq4dVHJx0J/xocQPHEjMVDEhZDzgY+6fxq4u2xd7EyA2LzoE+0xqWXBz8p/vY7fWn3EaSBN7bnOGVzyGU+3qDUUM8i24geOQ3e/53B42gY/EYqfywUlcBQueUBwQfatG77GbfVk+nQTTXUqKsfmSIQ6H5V2/3sfyqOTTJYJA8OJDGof5Tnj+tEAkuVXe22eABTyQwXPH4CrEV3PFMqIyxpBITE4PGT1Gf4smmtdyLvoQQzwkBbkySJgIMcCME8j6VG1tHEol5kgIOSCMp25HY1oahD9qSWRVijvIzteFOrHufcYrAW4ltNUaG6hZLNkw0hGcH8KJLuCZangmkgM0Zyqr8rD7wHqf61TVGkZGJHmKMlx1OPenWF2JpZooSUCMMuw4J7D8e9aVy0DZkXZ9qRvnQrtRz6DFSrPUpSsV9k0d2XbENzGMkdM+/1qvNeSfa/NtlMeRhhmtMRwXNpczTsI7xBuSEcZXuD3qlNHEGG9GUKoygOM+tU0O99CexlWS2mRJP9IkYBAehH8Wfr6UyeEOfNSARxjkKw/Djv1qtKFhkVrZgT94FedvcZ96mtmN09wZpBI0pL+mDjJI+tFr6EtdRNkcaPLHH97gEnp/9epL6eG1B+zqCjxjfu7N6g9iKiiBGIyqyLIcBAcH1BqKRA+zzAyxkEqdv3vUU0mtgaJVdpLZPN+bILpIP4ifU+lW54o5YbiZCsX7sNj1IwML+dUDI6COGNdyY+TK4wPT2qybgQThIJY3tpRwhHzAnqp96a8xN22IdsYmiS6YiMLhlC8+2aitbmW3LGJjtycDOcfhU00qzPNuBMueBjJIHc+9UprR7e9iuIpJBhGVo92FcHGNw9e4pO62ByL7sI1V2cOGYcE57cnFVtrvPuX73qD1FMj82HAIBMg4LD7oz1qRlDkLETlnIxjGf8KDNosZdYSonysw+6B396hKlYyIhjafmyevpkUfaPMmB2quBsII+8fWiOMkhQyh+SWPTH1pPUi1iKOWSJmbnG3JquVAXzNqtGTu2j+HP9K0LmMQSxPF+943YYenqKqTTuUkCqrNK28bB+n0oemjKT7DY5UlLMxKqACUHUkcfhVeaONgHD/Nz8rCjyxkSKwLD7yZppZWiY7s5O3B9Kd2UVpHLyoXHA9earSkO4GMDPGKskFQQFznqT3qOaHa7JuGV59OKEmxpohuFPJ4K9M1WRVyXb7pH3fWrE+VJjOAO/NV1A3qCrM5OFVRkn6DuaGkgK7RMCGJYJ3HtSPhy4XjNbM2j3UcRa+ltdPTpi5lAcn/cGTSN4duo8EXVmxI4VmaPORngsMZx70+V9iLmHJGAy7GGRyTnvVV1Ayu05Y5JP8q0L20uLKQw3UDwyYyFYfeHqD0I+lUXR2AY4xnmqXkjJsi8nLZHDetVpoPXgk4z7VYOVG7nP8qgnkKsTwwxitFruY6rYzLa4juPNeL/AFccpjLf3sd6uxOAQ2ASf0qtbolvF5MaYQsW9+ascSTNtwigdDSlvoK91qSSTMAUjPB6j1rKaK3bc0sXmTluGboo9hWghGTuGKbKiqRuAODnHrRzO2hjZXKmf9gflRV/ePSOiiz7hzLsegOxgZJNvzEbiF+6pNW/KCpEpXByGB7EVXhkLWsybm8s4/76HrVyEBUELjezd88Y7EH+lcdj0biNErRExYVifnQnI47inWu0NHPASk8beuA2Owp6NJ5bK0mBgY9Djp+NNQ7y0qrllOSOhB7Ee1LlS1NEyxLkyTPGgVX3ZRT1X8fSkt4p5rFb2Ly2RDsZM/Mx9dv9ajwRcRvESZOvTgEjnipbcAAS2zFQSPMUHkH1+lHmUWbaWGF284yS2c6YCqMEMP6g00s5upo7phK8/wAqzls/N25+nFMW3MqbNrbWY7SDksfTFMtk/eC2lfYG6l/4PemrjVtxpglt5YriNVbJ5BOQO3NRyhYxIqJiNhgDOcfQ/WrKTbTMhQ7TwVzkce9Sz27whVMivaOu9HAz25A9DQl2KUnfUpwTBIcI7LMflKjgFPQ1OjByZ9wRhgBMdf8A62KrxboSrlN9ufbox96lAcKl1HH/ALLgjADe31FUtUU0mW4pIZsJO5RkB2Sn7pH90gdfSpWIuY2QkRLGn+qX/lp759elVoWtms3iCnzxIHR8fwnqPzqeKSAhGkcwMsn+r252jHDZ9M8U0zNqxWjuHtpraWNyWdSASOnqCeh9asz35kiKSwpIgO4sANxB7fSofPldjCjKyjcIxjIIPJx+VV5CfMD7eeGCnt+HpT5mgtfUeUNkjptjaCXnco4P49jUkTNPsRNizqQAdo4Hp/8AXptvM1vb3SQFZoWH3ZE55/iHoR0rK1CGaSzkWzuXtndlxLgMR6oR6HpR1uJsuXl5cCUumEuF+Vmxw6+h/wAalW5nura2t2iCoDiJsc8nuaJfJcmRNvyoD5bHOOcY+venyzyXwit2eNIUU8Hjp3z60/mDZFIHt0cblt2Y5ZD/ABpngio5IGERe3AMQw7kHJQH19qkmvbe+iCkqGiVYtpOWyDgn2GO3vTZbZ7dpAh4Vtr4PPPfHpQ0UndFlAn2hHbuuTu5DL7Uy4Q3ds9v5zRJ963lAyy454/rUY3W4lWM5SQbPmGcDrjHamTXTR7fsZLBDwr8c4559Kq9iGKkjNLm6clGUbivHIHWhkjGx4kUPzvQjJz65qOK5il2rIoCynnBJ2cYHPehGaFMqBgjnjOBnH4UkVuT2N6kVyjyqzNErAbBjk9Dmq0sjPOzZJKEbR1yeuB609xHJABGSZehUHjHpUcayJ/qPlkJyTn7o9qeuxLSepYllaaQvMfKMgBz1+X0H40ICYk8vny23bm5AH0qKGRI4pANzMSVAY9PQ/rTbpo4xG8Lbin7t1P8X+1R0uS0W7loGlRQrMApMnb5sdvaqnmOogEwLE/dwOtS20puZgqoiJxvOPTvmo9++XDN8qnAY+gpbkW7k1yJ1mRgfnZflwedvSqThkuB5EbrHkDB6596mjO5CGBBPRs9BTAywS75WkbackL60aAlYimkTzpGIBHdRxzVPeCjbflUHIHrV5pQd7LHlm+8CM8eufWqtzskKtEgVf4h2z2ptdUCdtwZluFDocOB84PGKp+Zt3Ern0J9aeA7DHY8EJUUgJXB+VSfwFLzKK4826u1AjZyzBFVByxPAH412enadFpyskbt9scBZLmEfN15SNzwqLggnqcZ6VjeGov9LnuVGWtYiU9Q7HapHuMk1b1658mxitoN22fO8lNu5F6gqOmSeR6CrglFczJfkNmNhqs4tLSxW9eFWwUl8mFVyfl3tyR/P3xVmR9QtraSdrI+TAd8jWd2JzGSMZKt1GB/Ce1RaVau+nW4tLGO6sE3XMvmIGJnUFSjEHIDA/KMdxXQeFbeTT7SU3dmYpxC00Wnpj90u7K9+PfPStYpvcls56D7HcWQXEc9hIxZV3bUGB823PKSZ559e4rk9XsmsbuS28zzImHmRy4++hzz7EYII7EVupapo+qx2ZvoZJLziWKJTsjPJjkVu4zgdOhIPFU9V+1S6FI+oqqXEE6tHtxho5OCAAeAGUHnrQpXRmzjNSnaG0ZiSSBhR6E9KS3t5ESGJwzeWgznnmrV5GB5WQDhg2Per+r6LrFpA15faXd2cBIDO6fLz0zjpTS0Mm3cxGgYsWJVQD681WvryG0jLNvbd91VXJY+1WtF0TXdQ0281NNPvJdNWRvLlWPI2jhiO7DIPIFIbCdLa1u5LeTyrkkW8pGVlIOCF/EgU2iW2VbCeW5tzJLAYechDyfqadK5EDbT8xNWb21n06ea31OCS1uEwzxSDDKCMj86zLy4+UPGmd3AFZ2sTYh3z+n60UZf+9+lFHOLkZ6vbykRhmQeW3Bb0arQBjmigmyhBJD/AMJXHb61SCmOaSJlDxbhvCnqOxBrR4W3LXKs+zhSDk49PauSysd4lu0Ty3EJZ1wd0aE8t+PTNOgYRyN5hZOPl28ZqNV4Xe25T8ydtpqaFNyykjegGWA6r7/SpNETCFlvdsSmTcuR/n2qS3aRJWwQjnO854cf3TUFu7Rq3lsVkBBV88t7VoXZhu/LlsogpWPMy5zk9yaaQcxnI6byI2IOf3bDgg9x70qPINqbSJlPyydanaISbZ41wqYDjqM9sVL5kU0S+ZGscityy9x7j0FT5Mu6sI+YpVj+zzPMeHWFNwAA5J74PtmnQhAqqXP2RxhpE+YH/A01XkhmRgTHj7rIen0p1xGsiPNAGVhzJtbax989wffNaRtYi7TEiXYFtZFZ0bLAqeMemPWq8m+1kVlcyW4bKgnnPuKV4JJEyJoQzDcoYbeB9OM0kMrbPs8kccbseXY5wPen0NExzncWmhVgvUrjhfarUMDXqlfOiRt4KBhjk9TnsKqRXE0CSxKF2ueS3X6+1SvGrQhoSFcLhoye3+BoXcTkSmNQwjl3rLEeOeD64xRdFHXBi/0nfuRoz8pX+7ipUe4vpQjoqysFCOoChQtPt7IzoSXWFc4bJ+YHuQOoFPfYi5UuITHGs+DsZ9qt2JA54pEt4htczqofIIAJ2jHQ/wCNWoriOP7QhhDNJH5eSOgB4I9KpJEAC4LbU5IPYds09Ogcw+S1WIpK43ROB0PzKDwD9arXVu8TDcnyMxRCTwxFWYlLRvswXB3Bic7fXFQsrFBlwC2dqMc/iPSjRlKXcr2scHmklmWQ9c4wfr7Vcn33MZGSrqCVU9W9f8cmq7xAOJMnY/oPun0xTVmUFcbkf7vmBs4Hene2g+uhZ+zv5BIPyFed3ZiOo9j61QaNyuQRxxn+tWftk1tE4DKwxsLAZGPSq0M3yuH+4Rgk9QfUU7Jj16jACeVQEE7SAe/bipkkae6d1ILCMKE6AgDHNP8AJ3o1xGreVuwG/u+n0qC4Q3MhdNqs/wDCBgE+gpLQNHoQ5FteFJHAxwGU5BH9atKAYkmQgtg7h6Y4yaolWcKrqPKz8xI5HvmpgJIRKUYmJ8Lkd8cgUkxSZOIY1KhptzHpt/hPao43hWQhy5PTcD2706eP5VkRsjYGcDsx4xUSuZJZDGAHCqqhe/rVWsJO46ONipdc4ZiAh6n3q2gjZsRn50VQq46nuMVHElxbSJOGCyL82c8j3xUTuyyowfLk5O3jB+tCViXqWoJnaSUSglgGAAHWoGiLKpH3iMsMfrTtymZ5EyHYY256inzXZS3WKE7Y87jnnJFO3czdytIm9cxnHY89T61BJIIw7TAEEkE9Tn1pGfy4zkrhuD6ioy5aFAPmEYz0ouTa5BGQI8hWUbvvDvTZpFMbIofZuzzU0oYRkFSQfm4PQ1EkMh2kjO77vvS8i1Y0tFYLbatDDta4MUckaMu4NscEjHfr0qTWoLu4NmZYmjuCHR0Ixhi24fTIOazdPuTpt9FcKm8oSsi9nU8Mv4iupIW46ySSrPiaC4jBJIXo5/hUrwu3vyD61pH3lYl6EVlpgso3s7W423W8XEtwBtZtgyyoD6c4P1NI9/c2kd/qVjcKlyygxJtLttbsQR944GO3UntVv+39RiumkutMW8/dsDNbsWO7+H5DzGOuRyeetV38RX0jxS2Gk3Byvl3C3ihY2X/ewM887j06AcmtLxWxO5W8T3L6nf6DCI1js5M3KuVKyZX7+5T0HHH1rJ8TfPpdxJI55khBTepXcSThSo9Bkgkke1a1lBLue4u5Xvr6XbGXzuBXtGg67RjkjGcfU1y/ia6SQi2iZZo7cs0koORJM33iD3AACg9+TSb3bEc5dMC4QYJ3jntjNeheIStnr3ivVLm+tX06/s3t7eFLlZWuJGRVUBAeMEE57V56sZaMZ+UZzio5IVV/3cYXaOwxRGdjOXZHoNtm41/Qteg1S1h0ayt4VmD3Oxrby1IePy+pLdsDnP0p9hJpVzZ+G7y4eKLTdPl1C/lhLDcg83dGm3qSSRgd8V5ywV2DbRuA4JGSKbIAyqp2kjnIFXzmd7Gz4/e112z0XVrfUXvJYXazvjPEsM0h5eNzGCflwSufpXIXsis+UwFUYwO9WJ41eQyEDIHBxzj0qvHAXyCO1Ju4466sobx6mirX2Uep/Oio5WXdHrUcLSRjyhmWIZOe61Natvlyi7ipyVY8njkVDC84jMaPtfoh9vTNRyQ+WFkUsWP+swPu81ybanQtdy75kaXhaFWa3bOxX4P0qZ2WMs0bkAjEiZxxVSfzEcxtJ5hJBBHOOOuacrpORJv/AHrHBXHAx0OaLa2ZasWUA2fuHAQ9FbnB9KkgDqkckZCqz4Zc8j149KrrEvlCSN8gj5lHODnrVkKGIR/3bEBXOMZJ9aQFq3CxahIsEsZhZcGR04XI6Y7Gk8p2i37EQrwQW5cHvVOICNvLkZ15KsOzVO8KPGi7vmyDGQc7h7nsRRbyC9h0bxtlAGx3QDLD1Ip432wEi4kCHgg5AB7Gs9nK3BaQtuBIYqe1Wg72zoYmJtyAc7d3HqRTTKH7F+QyEfZ2OeDnbn+E1N9lgOMqdqDeXXJZkzzwfSo7c+cqySIiRSMVVyODTJZJUVdxYenPJHp9KNELmfQlkt47bDMBLC3fOWX2PuBUjiE7HMYQKcF0GQwPQGq7SxLJGsDsInGGBPKHvz6UsM3lgK582MEgbTx9SKvQV7ltXEUGJcSWp+7g/MjVXLyKJZLd2YOuHUn5mHU05oCil1G+ByMdyvv+FMu7Yuu6HITpnPIpO5ALcQ3YXCna2F385z6+/wBKfEZLW6kkkXdtIRkI4cH1FRqQoBt8q4AGAMA++OxpM+YSk7FS/YDkEnt6ChMaYspRpfLjCqCflweB7E1A4w5WWMMBnAbggnvU7MBI3mxl5EHlupbBIz1AptzAq2zSCUMFbCjPzjPr6iqsmVexXczNDbxkEuWBVPUeuaJYtvlmGM5fOApB+tPmmiuGgV4xEw4JQdvX601VMSlgSiZ4I747e1Iq4m9pSkYCkou0gnAx71AYGgSUlC6sAcE9s8frU149u8TGBZBLn5h2K+o/GoraUBszEkMAC3pjpQ33HzOwrb4oQFk+WUZZAeh96hhYxzF4+McYYZC5q3Jdm5upDMFAPzEgYUADsB3pPLSW3nkVhFImH2HjIHp6mmo32Jv1EkVdjXBCrCx2Inc4HWq5EfllR8ozu3ZPp0xUyAQmORjv53bT0ODUcs3zSykYSR92AOQaYxSwdJFZQjnaAV4AH+NRRxqkpVGYLk4I65qWZ2j8tmjBbq+R949h+FIjq0cgfuc7gO5/pV2C1h08LwwRPId6P3BznHamlkZJC6lSBhTjovr9ab8qPDFK54bDAjgg96rXcQiungRw2DjIP5UeYkTRHyZup3FPlz70BikabhkN1B9M9qhdPm27jlRySeAKY0oYgP8AMQcDNJaBuSzGKVlRgoDMTu9KgaU28BjK4U56dT6VAcmbnIT7xHpUzv8AvchiVHOSMnFDJsCDbC5BBUKAeehPpTJZ0UMYlYKMbR6Gkn8t4QiKQc5POCaktY/OlSOCMPJIdqg+tLXZEtEZQskalh67fSpbLVZ9LZli2zWbtue3ckLu9QRyre4696mkspftMUe6MliQro2RuA5U+hqmdPuJbeKaKFpImUOWU9Mk9ffg8Cm7rYS8zXbUbK+t3UXc9nM2NjTIWKc5wGT8vpTLa7gtYp2u9Xju5DgoFjkkK+o+bHBHvWS9jei68qG2lZxxgLx7Y+tRtpl28ayvbSbMj5zx1OB7/h1pKUuxLDWtduJFWHTklt4JCI5J5GBmkj/u5HCg98cnuaymA8spgAZxV+XT7m1Ytc27sir5pYcgKMdx06jj3pt9od1Hs2xM8kieYojUjjbuzuIAwAecGqV3qRrczlyY1BICg8E1AJA/mjcMkdfU1LPpepnCfZXcbzGGQjazAHPPbgE5OOhqA6PqYZWFjOMsUwQByM+/HQ8njg8002ug3C5UlPlsOQGXgjPWoY/utluSelWbzTr2KNri6tZIId23cwAO7njHXsfyrOHyvuUce9DbTM3GxO4DKyn73YCoGPysoOCB1qRmBztyGPrTGUZxkHHJNVuSVMn0/SipN0fqfzopWfcD1ZcK0aNxCx+Vj2BNWCojnZ4JGaDO1t3JPv8ASoXRnPlyMGTII+bj8KfBPtkZJRkEFQzc49D9ax2ep1JDFzbTKwAKg5GOQRRer9pG6JAtxgtx91h6Y9asy24RWEbgocMkrd/VaiSSQQlgGUxnGTxt9fzqXpoyvNCW1wy+WNox90bRjcO/5VcVlmiaLaW2YEbgfN9D6/WqMkkNt5eXJ8zhgB0PXitGdnVUljYERqFDoMD/AD71PcL6hH5eAH4zgbj1UjvUjxxyI3mqUdjlTjGT3x6VXj2zLJMq7wcK0ecEf7VDv5cklt5nnHd+7Zeh9aOgE24wyRO6xyrt2cdCPQ+4p+37M6JGSI2Ulc4PB7Gms1zHbRblR7Pnll+UE9feqjNLb/ImWiyWTnj8apjSuTxxEoDEGKryqnpnuatXLRzuSCTGVX943HPcYqCO7VfKeDIBHO7saY5jKSB2Ajkf58DLL7ineyFZ31K06sky4KhD3JxVuKTckgWABW+Y5PpUc1wJY0jZeVJAVRnIP8qdAyR+XuUhkbcre3bikkkU3oSBnR91vv8AK+8Ae/19qmcQDbJG7tnAk+UKQT149KLaR7iSSLYBI5LIyngAck//AFqUwl0eTZtZPlYFuef8abj2M+ZdSWOMFYyriMkdWON/tTGja5EkwjMhU/Oy+vYVEsglOwjBByg68+hqyJTA8bW5EckfztnhQ3+eKFZiemxEkW+3Dqy784wR1/GqtxGJLgtGjCRl2hSeM9+Kdcyu0hlUBctvK44JPcD0qeNkkjSMRtLPuOd/AK09L2QJsz3hlgTcpBHAO3+H606C4LszMwCBfnTGQR2471KA5WfymxE42svXJ64/CqghESBsnPTJ7etLbY0umtR7W4ERdDxx06/hUiRKJDHES+EG75epJ6UsCB+JJGVT0IXOD2p7sBEVUMDkZ55bHfNNJMTkNeCW2iYBlMZJyV6q3vVfl0haKNtyDDN1FWGaVklZSTuwHX1+tVIwY1kaGXYp+Rs9QDQwTEkkVYGXcrMDvJ56+3tTJgzQROMbJBv6ZwR/KnXNu0XkmXpjoOeP602RwqSGNiynseM+9UvMv0GlzKYgSd4G3B9KL+ZIZxCX/dx44YYyvpx71WP3pJEYKY1B5PJ+lZ2oTNcFnkJaT1Pf0p3sjWKuXJ7tLmRTGCp24JJ/lTrSdbcuDGHMgwd3VR61lxLMsRcYLtxyOQPary7gwYYYoPmI6UJt6lSgkrF2aSJyzAcDgj0HrVZI1eXAkGc5qrvJkY8BfQGgNnheAe9Nu5lyNFmUOLgoMhjywxiq8jNHKPlIUnIxTXcjhiScYJPpTWlZgysQeABxQxpaE0rOvzrkbuCe7VNaiUeQ1s4WTcAhBwc545qoZmEaq4BABx7VJEWjnh2EGRGDqvUEjnHFBDuaNzPqIeOXMUhjJeN7ZQ0Y2nDfU9jmmTzamDEEtjCqKJVRIcBVAIyB6YY/nUiaxdQCZYYUhgZThERsBjlicnnPOfpinXGs3MMjXENqkYcfKrqSegyxPuPoMYpXXczYx5dYEcEjQyGF2do0Mf8ArCSHJx7HBH6VTkudUhjE8UEgSRFzK8GcAEAc/lzVmPU7+2aKcWgbOZo2aNskKEBI/wBn5V5+vNQLqmphjcRW7+cSNpWBiOQAMD6LTfqyBskuqT2VxZm0l2zTRiVlTALDhQe2TuGT9KrXMup3TyRpbB2UfZJWWLnnCbSemeAM1Nf6zqEkcUrxgRL0O07RkDAJ/AVTj1C7tA7R2xUuz3CFon+QHG8r6rgAZOcU7q9hWJZl1a6W7t5HscLKbST5lVpZMN8in+I4Len8qbNqOqzQjbZF7iaMGWYxFvNiAZQpGOF+fGPpioHvrmxkmgurSIzPP9rKzocpIVOGAzyMNkA57U258R38sUKP5b+UyPnByzIVIJ5/2Bn8armSEytfDV2lWG5sJZVcbfLeAjdt3MOfbcT+VZh0nUUjgYWk22ZY3Vyvy4c4Qk9sn16Vpp4lvbSYyCO3Ykh1LKTggnGOf9o1Qi8X3k5CpBCBbsVSXB6n72BnByOP/r1WhDZFcaZqLXCIllO0r71QJGW37DhseoB71lvHMqu7xuq5CklSBkjOPrjmunt/FMguJZNSt0lhd1llSL5TLIpGwnJ4AAxxj15rB1TVnvls4G3rHbhyc4+Z3ct27KCFGecUnbcRQ8w/3D+VFS5/2qKQuY9RkLQokchDJztK9cehpzRsIkl3h2ZchAeRg9KKK57XujdPS5Y3bo0jdfLwdxBPPvU7bvM8+Ilzu2Mp5DDH60UUirkUMKqwMuDkZHPf0+tS58ggqCUB5yOg7g0UVKDcmKw48xI/3TsQeeV+nqKbDGkR2bgVcZVjwaKKtjXYmt55thiuDkKMRgrkNnqAP61Fs+zzyC4XMH3WCt0HpRRQNCBRCjFNjI/K+qEHpUjeWhLOh2uM5I+8PbHvRRRfoVLYS3lMUymdWDbcIyDGfTPr6VIiMAY5E3g8q+efpRRTS6EPQdFGIZSkoYA4+6cEfj6VblYBY9iM4jwschHBB6g/j3ooq12M33Km1V2ySYwMh8dV56+9WnBjCtbrskbgqwyCP7wJ9aKKhbjuVc5YI4fg84GcD0FNeXymV0x8/wDCegI/h96KKm4xXeOXLBVjwNzBTkn3xSyTr5cvKlZFG4ehHAIooqr2EyntcKQwO1T/AE61WEhEwRpSFHIyKKKh6MqOqLkhMqsYnDYbHTGRVafam5skSZGVIzRRWm40ODmYokKHAGfXn/CoGjYqZjGfKzhh6GiimtVcq9nYr3Ckuwxye2M5HYVTvYyAsgOJM4JHbFFFN9zaDYyFWOwA/P8AdXNSrIscTqFGACAcd80UUJlS1GTJ5ZhkZSokGRkdabJjkouEQdKKKvrYV7kOd2WkON3THaoJFk4CkbR82R0IoopLVjQpdWOFz0wDUsE5F1FJGcPGwI7Zx2/pRRS62FJaG4fEdw1wGMERjK+X5POAN389vyZ/u1Bda1O1m9nNCjRuMMQxDEZzjPbjC/RRRRQ5NM5Zb2Hp4guU3/uF3SIQzec3Xg5Gfujj7o4qoNfvAX2E/vBtIEjADAQf+yD8zRRTuySnea09xYT2lxbxvA8gfiRhtI7Advr+nepofE97EGURK+4cEyEFeBjB544+73zRRUuTuNmRqd4b26N1Km2V1VXAJIO1QuRnpnGcdqzpXJiKrgGiikmSU7kqVK456bqr26qkKxIB8hOBiiitEzJrUVgWjwTznpiqsigvwOPWiirtoA3En94flRRRU2A//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Primary cutaneous anaplastic large cell lymphoma on the neck of a 24-year-old man.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37658=[""].join("\n");
var outline_f36_49_37658=null;
var title_f36_49_37659="BP cuff sizes";
var content_f36_49_37659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended dimensions for blood pressure cuff bladders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Width, cm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Length, cm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum arm circumference, cm*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Newborn",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infant",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small adult",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Large adult",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thigh",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Calculated so that the largest arm would still allow the bladder to encircle arm by at least 80 percent.",
"    </div>",
"    <div class=\"reference\">",
"     Fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National Heart, Lung and Blood Institute. National Institutes of Health. May 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37659=[""].join("\n");
var outline_f36_49_37659=null;
var title_f36_49_37660="Causes of syncope children";
var content_f36_49_37660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of syncope in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <span class=\"red\">",
"         Primary electrical disturbances",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Long QT syndrome",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Brugada syndrome",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Familial catecholaminergic polymorphic ventricular tachycardia",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Short QT syndrome",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Preexcitation syndromes (such as Wolff Parkinson White)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bradyarrhythmias (complete atrioventricular block, sinus node dysfunction)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <span class=\"red\">",
"         Structural abnormalities",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Hypertrophic cardiomyopathy",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Coronary artery anomalies",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Arrhythmogenic right ventriclular dysplasia/cardiomyopathy",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Valvar aortic stenosis",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Dilated cardiomyopathy",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Pulmonary hypertension",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Acute myocarditis",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Congenital heart disease",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"green\">",
"         Vasovagal (neurocardiogenic) syndrome, including situational syncope (cough, micturation, hair combing)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"green\">",
"         Breath holding spell",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"green\">",
"         Orthostatic hypotension (hemorrhage, dehydration, pregnancy, anorexia nervosa)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug effects or toxic exposure (eg, clonidine, typical antipsychotic agents, carbon monoxide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Conditions that mimic syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Seizure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Migraine syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hysterical faint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyperventilation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Causes listed in",
"    <span style=\"color:#ff0000\">",
"     red",
"    </span>",
"    are life threatening. Causes listed in",
"    <span style=\"color:#008000\">",
"     green",
"    </span>",
"    are common.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37660=[""].join("\n");
var outline_f36_49_37660=null;
var title_f36_49_37661="Contents: Gynecologic disease";
var content_f36_49_37661=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?43/6/44141\">",
"       Geriatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gynecologic disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gynecologic disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/33/40473\">",
"           An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/54/8039\">",
"           Clinical manifestations and diagnosis of vaginal atrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/8/20618\">",
"           Differential diagnosis of vulvar lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/6/37992\">",
"           Endometrial carcinoma: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/27/18874\">",
"           Endometrial carcinoma: Epidemiology and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/7/9337\">",
"           Pelvic organ prolapse in women: Choosing a primary surgical procedure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/46/8937\">",
"           Pelvic organ prolapse in women: Diagnostic evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/37/43607\">",
"           Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/50/6954\">",
"           Treatment of vaginal atrophy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-27B9093734-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f36_49_37661=[""].join("\n");
var outline_f36_49_37661=null;
var title_f36_49_37662="Reitan Test - part B";
var content_f36_49_37662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reitan Test for hepatic encephalopathy (part B)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 708px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Reitan Test (number connection test) is a commonly used bedside test that is useful for screening for hepatic encephalopathy. Part B of the test may follow completion of part A but is not used by all clinicians.",
"    <br>",
"     <br>",
"      Step 1: Make sure that the patient is alert enough to cooperate for this test, can see adequately, has a writing surface, is able to count, and can hold a pen or pencil.",
"      <br>",
"       <br>",
"        Step 2: Demonstrate to the patient how to connect the numbers and letters&nbsp;on the sample for part&nbsp;B (lower box), alternating between the numbers and letters (ie, 1-A-2-B-3-C, etc.).",
"        <br>",
"         <br>",
"          Step 3: Inform the patient that you will be timing&nbsp;the test&nbsp;and to complete the number-letter connections from 1 to&nbsp;L as fast as the patient can without lifting the pen or pencil from the paper.",
"          <br>",
"           <br>",
"            Step 4: If an error occurs, point it out immediately and allow the patient to correct the error. The total elapsed time to&nbsp;complete the test, including the time spent corrrecting errrors, is the score.",
"            <br>",
"             <br>",
"              Step 5: Record the time spent to complete the test. An average score is 75 seconds, while &gt;273 seconds is considered deficient.",
"              <div class=\"footnotes\">",
"              </div>",
"              <div class=\"reference\">",
"              </div>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37662=[""].join("\n");
var outline_f36_49_37662=null;
var title_f36_49_37663="TEE longitudinal view aortic rupture";
var content_f36_49_37663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiography longitudinal view of a traumatic rupture of the aortic isthmus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thick \"medial flap\" (arrow) was almost perpendicular to aortic walls because the injury was confined within a few centimeters.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of P Vignon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_49_37663=[""].join("\n");
var outline_f36_49_37663=null;
